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Supplementary Table III Proxy variants for the single nucleotide polymorphisms 
not available on the Metabochip array. 
SNP Proxy LD (R2) 
LDL-cholesterol   
rs12711751 rs10186133 0.65 
rs340005 rs340025 0.80 
rs2287921 rs676388 0.68 
HDL-cholesterol   
rs10761731 rs10761741 0.97 
rs9378212 rs12194148 1.00 
Triglycerides   
rs10435719 rs11998678* 0.51 
rs12755606 rs16842484* 0.57 
rs4660808 rs4660293* 1.00 
rs571312 rs523288* 1.00 
rs13409360 rs6731551* 0.70 
rs11208722 rs7539471* 0.90 
Total cholesterol   
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Background: C-reactive protein (CRP) is associated with immune, cardiometabolic 
(somatic) and psychiatric traits and diseases. Yet it is inconclusive whether these 
associations are causal.  
Methods: We performed Mendelian randomization (MR) analyses using two 
genetic risk scores (GRS) as instrumental variables (IVs). The first consisted of four 
single nucleotide polymorphisms (SNPs) in the CRP gene (GRSCRP), and the second 
of eighteen SNPs that were significantly associated with CRP levels in the largest 
genome-wide association study (GWAS) to date (GRSGWAS). To optimize power we 
used summary statistics from GWAS consortia and tested association of these two 
GRSs with 32 complex somatic and psychiatric outcomes comprising up to 123,865 
participants per outcome from populations of European ancestry. We performed 
heterogeneity tests to disentangle pleotropic effect of IVs. A Bonferroni corrected 
significance level of less than 0.0016 was considered statically significant. 
Results: The strengths (F statistics) of IVs were between 27.6-2527.8 and 83.4-
6519.2 for GRSCRP and GRSGWAS, respectively. CRP GRSGWAS showed a statistically 
significant protective relationship of a 10% genetically elevated lnCRP levels with 
the risk of schizophrenia (OR 0.86 [95% CI 0.79-0.94]; P<0.001). CRP GRSGWAS 
showed nominal association with risk of knee osteoarthritis (1.17 [1.01-1.36]; 
P<0.04), bipolar disorder (1.21 [1.05-1.40]; P<7.17x10-3), with an increase of 0.72 
(0.11-1.34; P<0.02), and 0.39 (-0.01 - 0.78; P<0.05) mmHg in systolic and diastolic 
blood pressure, respectively. After adjustment for heterogeneity when necessary, 
none of the GRSs showed a significant effect on any of the other 27 studied 
complex diseases.  
Conclusions: Genetically elevated CRP levels showed a significant potentially 
protective causal  relationship with risk of schizophrenia. We observed nominal, yet 
to be confirmed, evidence for a causal relation between elevated CRP levels and 
SBP, DBP, knee osteoarthritis and bipolar disorder. Our analyses did not support 
any causal effect of CRP on 27 other common somatic and neuropsychiatric 
outcomes investigated in the present study. This implies that interventions lowering 
CRP levels are unlikely to result in decreased risk for the majority of common 
complex outcomes. 
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Emerging evidence suggests that the persistent dysregulation of the inflammatory 
response is linked to a plethora of complex somatic and neuropsychiatric 
disorders(1–18). Epidemiological studies have shown that C-reactive protein (CRP), 
a well-studied biomarker of inflammation, is associated with and exhibited a reliable 
predictive value for cardiovascular disease(19, 20), type 2 diabetes(21), and 
immunity-related disorders such as inflammatory bowel disease (IBD)(22), 
rheumatoid arthritis(23) and all-cause mortality(20, 24). Nevertheless, the evidence 
for a causal involvement of CRP from traditional experimental or observational 
studies remains controversial(25, 26), fuelling the debate whether CRP contributes 
to the chain of causality in disease mechanisms(27). The use of genetically informed 
instrumental variables (IVs) termed Mendelian randomization is a complementary 
approach to epidemiological observations and allows investigating whether the 
effect of an exposure (i.e. CRP levels) on observed outcome phenotypes is likely to 
be causal(28). 
Recent large-scale Mendelian randomization studies, focussing mainly on 
cardiovascular disease and metabolic traits, failed to show a causal association 
between CRP and these outcomes (Supplementary Table S1). This has led to the 
notion that elevated CRP levels do not causally contribute to these traits and 
disorders. However, these studies have used either a single CRP-associated single 
nucleoid polymorphism (SNP), or a very limited set of CRP-associated SNPs 
(Supplementary Table S1). Common SNPs serving as proxies for CRP levels 
represent only a small effect on CRP levels per se requiring a large enough sample 
size to detect causal effects on the outcome. Moreover, most studies have generally 
included a limited range of common, complex diseases, often not more than two or 
three outcomes, or they have been performed in a single or small population 
yielding inadequate study power (Supplementary Table S1). In other words, existing 
evidence for a causal relationship between CRP and a broad range of common 
traits or diseases remains inconclusive. This is mostly due to the lack of well-
powered Mendelian randomization studies that use optimally informative genetic 
IVs for CRP. Here, we sought to comprehensively examine the hypothesis that 
genetically increased CRP levels directly contribute to common somatic and 
psychiatric outcomes. To optimize IV power, we applied a Mendelian 
randomization approach using summary statistics of outcomes data from large-scale 
genome-wide association study (GWAS) consortia for the largest known set of 
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independent SNPs known to be associated with CRP and for the four variants 
representing 98% of the common variation in the CRP gene. 
Methods 
Study design and rationale 
The present Mendelian randomization study consists of two key components: first, 
we used established variants associated with CRP levels, and combined them to 
build two genetic risk scores (GRS) for CRP: The first one consisted of only four 
SNPs in the CRP gene (GRSCRP) selected from the largest recent Mendelian 
randomization study of CRP(29), and the second of eighteen SNPs that were 
genome-wide significantly associated with CRP levels in the largest GWAS to date 
(GRSGWAS)(30). Second, we obtained summary association statistics from GWAS 
consortia for a panel of 32 common somatic and psychiatric outcomes (Table 1). 
The corresponding authors have selected the studies, and contacted each 
consortium with a standardized data request for study data, including the name of 
study/consortium, number of cases and controls, number of available CRP SNPs 
for GRSCRP and GRSGWAS, and the estimated effects for each SNP (or its proxy) on 
outcome, i.e. per allele regression coefficient with standard errors or odds ratio and 
corresponding 95% confidence interval. 
Data were available for 32 different outcomes in five broad disease classes, 
(i.e. auto-immune-inflammatory, cardiovascular, metabolic, neuro-degenerative and 
psychiatric), including at least 2,525 up to 123,865 participants per outcome from 
populations of European ancestry (Table 1). These outcomes were selected based 
on the following two inclusion criteria: (i) having been associated with CRP levels 
in epidemiological studies and (ii) availability of large meta-GWAS analyses for the 
outcome, as our study design relies on summary association statistics of GWAS 
level data (Table 1). 
Genetic instruments  
Weak IVs yielding insufficient statistical power may have hampered estimation of 
causal effects of CRP on the outcomes in previous analyses (Supplementary Table 
S1). Our Mendelian randomization approach, by using GWAS data, and combining 
multiple independent SNPs into a GRS (i.e. IV), has the potential to greatly increase 
power. These IVs were used to test the combined effect of the associations of CRP 
level influencing alleles with the outcomes. The selected SNPs have been described 
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elsewhere(30–32), and are further detailed  in Supplementary Tables S2 and S3. Our 
approach was implemented in such a way that both the effects of independent 
SNPs in the CRP gene (GRSCRP)(31, 32) and independent SNPs known to be 
genome-wide significantly associated with CRP levels (GRSGWAS)(30), as well as 
pleiotropic effects of SNPs could be discriminated(33). Pleiotropy exists if CRP 
SNPs influence exposures (risk factors) other than CRP levels and therefore would 
violate Mendelian randomization assumptions. We selected all independent SNPs 
for GRSCRP and assessed if they influenced outcome risk only via changes in CRP 
levels. 
 
Table 1 Diseases and traits included in this study. 
Disease / Trait Class Abbre-viation Cases Controls Total 
Refe- 
rence 
Autoimmune/Inflammatory      
Celiac Disease CED 4533 10750 15283 (34) 
Inflammatory Bowel Disease (all types) IBD 13020 34774 47794 (35, 36) 
Crohn's Disease CD 6333 15056 21389 (35) 
Ulcerative Colitis UC 6687 19718 26405 (36) 
Psoriasis Vulgaris#  PSV 4007 4934 8941 (37, 38) 
Psoriatic Arthritis# PSA 1946 4934 6880 (37, 38) 
Psoriasis Cutaneous# PSC 1363 3517 4880 (37, 38) 
Rheumatoid Arthritis RA 5538 20167 25705 (39) 
Systemic Lupus Erythematosus SLE 1311 3340 4651 (40) 
Systemic Sclerosis SSC 2356 5187 7543 (41) 
Type 1 Diabetes T1D 9934 16956 26890 (42) 
Knee Osteoarthritis KOA 5755 18505 24260 (43) 
Cardiovascular      
Coronary Artery Disease CAD 22233 64762 86995 (44) 
Systolic Blood Pressure SBP ─ ─ 69368 (45) 
Diastolic Blood Pressure DBP ─ ─ 69372 (45) 
Ischemic Stroke (all types) IS 3548 5972 9520 (46) 
Ischemic Stroke (Cardioembloic) IS (CS) 790 5972 6762 (46) 
Ischemic Stroke (Large Vessel) IS (LVS) 844 5972 6816 (46) 
Ischemic Stroke (Small Vessel) IS (SVD) 580 5972 6522 (46) 
Metabolic      
Body Mass Index BMI ─ ─ 123865 (47) 
Type 2 Diabetes T2D 6698 15872 22570 (48) 
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Disease / Trait Class Abbre-viation Cases Controls Total 
Refe- 
rence 
Chronic Kidney Disease CKD 6271 68083 74354 (49) 
eGFR for creatinine eGFR ─ ─ 74354 (49) 
Serum Albumin Levels SA ─ ─ 53189 (50) 
Serum Protein Levels SP ─ ─ 25537 (50) 
Neurodegenerative      
Amyotrophic Lateral Sclerosis ALS 4133 8130 12663 (51) 
Alzheimer's Disease ALZ 4663 8357 13020 (52) 
Parkinsons's Disease PKD 5333 12019 17352 (53) 
Psychiatric      
Autism AUT 90 1476 1566 (54) 
Bipolar Disorder BPD 7481 9250 16731 (55) 
Major Depressive Disorder MDD 9240 9519 18759 (56) 
Schizophrenia SCZ 34241 45604 79845 (57) 
#results from individual cohorts combined in meta-analysis, which is, yet 
unpublished data. 
 
Statistical analysis  
All analyses were done using the GRS function implemented in the grs.summary 
module as part of the Genetics ToolboX R (version 2.15.1 for Windows; Vienna, 
Austria). The grs.summary module approximates the regression of an outcome 
onto an additive GRS, using only single SNP association summary statistics 
extracted from GWAS results. The method is described in more detail 
elsewhere(58). In brief, we performed Mendelian randomization analyses using 
GRS IVs in two steps: first, we used individual CRP gene SNPs (i.e. IVs) associated 
with CRP levels(32, 59) (Supplementary Tables S2 and S3) to create a weighted 
GRS, named  GRSCRP, corresponding to the joint effect of four SNPs within the 
CRP gene(31). We extracted ω (the estimated coefficient or weight) for individual 
SNPs from the association results as reported by the CRP Coronary Heart Disease 
Genetics Collaboration (CCGH)(31), which represent one unit (in mg/L) increase 
of the natural log of CRP (lnCRP) per dose of the coded allele. These four tagging 
SNPs represent 98% of the common variation in the CRP gene assuming minor 
allele frequency ≥0.05 and an r2 threshold of ≥0.8, and aggregately explain ~2% of 
the total variation (i.e. phenotypic variance) in serum CRP levels in populations of 
European descent(31, 59). Second, we constructed a multilocus GRS, named 
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GRSGWAS, that combined 18 SNPs associated with serum CRP levels at genome-
wide significance (P<5×10-8; Supplementary Tables S2 and S3), derived from a 
large meta-GWAS analysis for CRP conducted by the CHARGE consortium(30). 
This multilocus GRS explains approximately ~5% of the total variation in serum 
CRP levels(30). 
We integrated ω for each CRP SNP from the reference data of CCGH(31) 
or meta-analysis of GWASs(30) for CRP levels with the summary association 
statistics extracted from GWAS consortia for each outcome. This Mendelian 
randomization approach using meta-GWAS summary statistics data is equivalent to 
an inverse-variance weighted meta-analysis and has previously been validated in 
comparison to individual level data(33, 60). To estimate the causal effect of CRP on 
an outcome, we obtained the β values (estimated effects from regression analysis) 
for CRP SNPs on the outcome with standard errors of seβ from the corresponding 
discovery GWAS results. When no summary statistics for the SNPs of in genetic 
instruments were available in the look-up dataset, we chose a proxy SNP that had 
the highest  linkage disequilibrium (LD) with the initial SNP (r2>0.9 in HapMap 
release 22). If several proxy SNPs had the exact same r2 values, we chose the proxy 
nearest to the original SNP in the instrument. Separate regressions of outcomes on 
GRSs were performed to calculate αIV estimators (causal IV estimator) for each 
outcome. Correspondingly, the value of a GRS is the sum of the ω values, which is 
multiplied by the allele dosage (i.e. 0, 1 or 2) for each CRP SNP in the CCGC or in 
the CHARGE CRP consortium(30, 31). For uncorrelated SNPs, when maximizing 
the likelihood function, the αIV value and its standard error, seα , can be 
approximated with the formula: {α≅ (Ʃω × β × seβ-2 )/(Ʃω2 × seβ-2)} with its 
{seα≅√1/ Ʃω2× seβ-2}. Since lnCRP was used as the outcome in reference 
studies(30)(31), to obtain the ω values (i.e. effect sizes) for each of the CRP SNPs, a 
unit increase in lnCRP equals to a 10 symmetric percentage (s%) increase in CRP 
levels, which corresponds to a unit change in level of a continuous outcome or logit 
of risk-estimate (i.e. beta coefficient) for a dichotomous outcome(61). The αIV value 
(i.e. causal estimate) for each CRP SNP was, therefore, presented for each outcome 
as corresponding to a 10 s% increase in actual CRP levels.  
To assess which SNP might have violated one of the main Mendelian 
randomization assumptions of pleiotropy, we performed goodness-of-fit tests to 
correct both GRSs for heterogeneity of effects on outcome. Heterogeneity, which 
indicates potential presence of pleiotropy, was measured using Q statistics, and was 
considered statistically significant at a conservative uncorrected P value <0.05. 
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Although heterogeneity could be an indicator of pleiotropy; there are other factors 
that could introduce heterogeneity in the analyses. Therefore, even though the 
adopted adjustments for heterogeneity that we have taken could be 
overconservative, we have taken this method in order to minimize false positives. 
After stepwise removal of SNPs with potential pleiotropic effects, we repeated the 
analyses until significant heterogeneity was no longer observed.  
To further ensure the strength of these two GRSs as IVs, we generated an 
F statistic for each outcome. We used variance in lnCRP levels explained by each 
set of CRP SNPs (2% and 5% respectively for GRSCRP, GRSGWAS), to calculate F 
statistics using the formula as F-statistic=(R2×(n−1-K))/((1−R2)×K), where “R2” 
represents proportion of variability in the CRP that is explained by GRS, “n” 
represents sample size, and “K” represents number of IVs included in model (i.e. 
for this study K=1) (62). As a rule of thumb, an F value above 10 indicates that a 
causal estimate is unlikely to be biased due to weak instruments(33). 
Multiple testing. The present study included 32 independent sample-sets. Per each 
sample-set, we did one statistical test, for which a global nominal significance level 
of 0.05 would be considered as satisfactory to derive conclusions. The need for 
correction for multiple testing is debatable. Nevertheless, to ensure the validity of 
our conclusions, we took a conservative approach, and applied a Bonferroni 
corrected significance threshold calculated as 0.05 divided by 32 (i.e. 0.0016). We 
present our results and discussion at three different levels of confidence for 
corresponding causal estimates; we considered a statistical test with an observed P 
value more than 0.05 as a definite non-significant result yielded no association; an 
observed P value equal or less than 0.05 as nominal significant evidence for a 
potential causal association but yet to be confirmed; and an observed P value equal 
or less than 0.0016 as statistically significant evidence for a causal association. 
Results 
Using the GRSCRP, we first tested whether a CRP gene determined increase in 
lnCRP levels was associated with the outcome risks. In Table 2, the causal effects of 
lnCRP estimated for each outcome are summarized. We found no heterogeneity in 
the IV analyses (Pheterogeneity≥0.11 for all outcomes) while the GRSCRP was a strong 
instrument (F≥31). IV analyses provided nominal evidence for potential causal 
relationships of lnCRP with risk for Crohn’s disease (odd ratio [OR] 0.78 [95%CI 
0.65-0.94];P<0.009), psoriatic arthritis (1.45 [1.04-2.04];P<0.03), schizophrenia 
(0.90 [0.82-0.99];P<0.03), and increase in SBP (mean increase 1.23 
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(0.45─2.01);P<0.002), and DBP (0.70 (0.20─1.19);P<0.006) in mmHg per 10 s% 
increase in CRP levels. The GRSCRP showed no significant effect on any of the 
other outcomes (Table 2, Supplementary Figure S1). 
 
Table 2 The effect of the CRP Genetic Risk Score instrument of four SNPs in CRP 
(GRSCRP) with somatic and neuropsychiatric outcomes. 





Autoimmune/Inflammatory       
Celiac Disease 3 15283 0.96 (0.77-1.21) 0.750 0.19 311.86 
Inflammatory Bowel Disease (all) 3 47794 0.97 (0.84-1.13) 0.700 0.30 975.35 
Crohn's Disease 4 21389 0.78 (0.65-0.94) 0.009 0.25 436.47 
Ulcerative Colitis 4 26405 1.10 (0.92-1.31) 0.290 0.92 538.84 
Psoriasis Vulgaris# 4 8941 1.23 (0.96-1.57) 0.110 0.95 182.43 
Psoriatic Arthritis# 4 6880 1.45 (1.04-2.04) 0.030 0.92 140.37 
Psoriasis Cutaneous# 4 4880 1.10 (0.76-1.59) 0.620 0.60 99.55 
Rheumatoid Arthritis 4 25702 0.94 (0.77-1.15) 0.550 0.17 524.55 
Systemic Lupus Erythematosus 3 4651 1.20 (0.80-1.81) 0.380 0.19 94.88 
Systemic Sclerosis 3 7518 1.07 (0.78-1.45) 0.680 0.85 153.90 
Type 1 Diabetes 2 26890 1.15 (0.90-1.47) 0.260 0.34 548.73 
Knee Osteoarthritis 4 24260 0.94 (0.78-1.13) 0.500 0.23 495.06 
Cardiovascular            
Coronary Artery Disease 4 86995 1.07 (0.95-1.20) 0.280 0.41 1775.37 
Systolic Blood Pressure ** 4 69372 1.23 (0.45-2.01) 0.002 0.51 1415.63 
Diastolic Blood Pressure  ** 4 69368 0.70 (0.2-1.19) 0.006 0.68 1415.71 
Ischemic Stroke (all types) 4 9520 1.19 (0.93-1.53) 0.160 0.93 194.24 
Ischemic Stroke (Cardioembolic) 4 6762 1.02 (0.65-1.58) 0.940 0.96 137.96 
Ischemic Stroke (Large Vessel) 4 6816 1.44 (0.93-2.21) 0.100 0.31 139.06 
Ischemic Stroke (Small Vessel) 4 6552 1.18 (0.71-1.95) 0.520 0.36 133.06 
Metabolic            
Body Mass Index *** 4 123864 -0.017 (-0.06-0.02) 0.410 0.50 2527.82 
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Neurodegenerative            
Amyotrophic Lateral Sclerosis 2 12263 0.79 (0.60-1.04) 0.090 0.23 258.39 
Alzheimer's Disease 2 13020 1.26 (0.89-1.78) 0.200 0.11 265.67 
Parkinsons's Disease 3 17352 1.00 (0.85-1.17) 0.960 0.33 354.08 
Psychiatric            
Autism 3 1566 1.02 (0.97-1.07) 0.380 0.69 31.92 
Bipolar Disorder 4 16731 1.17 (0.97-1.42) 0.110 0.49 341.41 
Major Depressive Disorder 3 18759 0.98 (0.81-1.18) 0.810 0.86 382.80 
Schizophrenia 3 79845 0.90 (0.82- 0.99) 0.030 0.79 1629.45 
Abbreviations: M: number of markers used in the genetic instrument; N: number 
of samples in the disease/trait meta-analysis; Effect size (95% CI): Effect size (95% 
CI) per mg/L increase in lnCRP serum levels; P-value: P-value of goodness of fit 
test; P-het: P-value of heterogeneity of effect test; F-value : F-statistic value for 
the used genetic instrument; 
* For risk of disease, effect size is given in odds ratios, otherwise in the specific 
units in which the outcome was measured. Derived from the IV causal estimator α. 
** Effect size unit is mm Hg per increase in ln serum CRP (mg/L). 
*** Effect size unit is 1 standard deviation per ln mg/L increase in serum CRP (the 
BMI results were inverse normal transformed to a distribution with μ = 0 and σ = 1). 
**** Effect size unit is ml per min per 1.73 m2, per ln mg/L increase in serum CRP. 
***** Effect size unit g/dL, per ln mg/L increase in serum CRP. 
#results from individual cohorts combined in meta-analysis which is yet 
unpublished data 
 
Second, the GRSGWAS showed a statistically significant protective effect of 
lnCRP on the risk of schizophrenia (OR 0.86 [95%CI 0.79-0.94];P<0.0010) per 10 
s% increase in CRP levels (Figure 1, Table 3). The GRSGWAS also showed moderate 
but nominally significant effects of lnCRP on the risk of IBD (OR 0.85 [95%CI 
0.74─0.98];P<0.03), Crohn's disease (0.81[0.70─0.94];P<0.005), psoriatic arthritis 
(1.36 [1.00-1.84];P<0.049), knee osteoarthritis (1.17 [1.01-1.36];P<0.04), coronary 
artery disease (CAD) (0.86 [0.79-0.95];P<0.002), and bipolar disorder (1.21 [1.05-
1.40];P<0.007) (Table 3, Figure 1, Supplementary Figure S1). GRSGWAS revealed a 
nominally significant increase of 0.72 (95%CI 0.11-1.34;P<0.02), and 0.45 (0.06-
0.84;P<0.02) mmHg in SBP and DBP respectively (Table 3; Supplementary Figure 
S1). Likewise, genetically 10 s% increase in CRP levels was nominally associated 
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with a 0.01 ml/min/1.73m2 (0.003-0.02;P<0.005) higher estimated glomerular 
filtration rate from serum creatinine (eGFRcr),  0.01 g/dl (0.0004-0.02;P<0.04)  
higher albumin, and 0.03 g/dl (0.008-0.05;P<0.009) higher serum protein levels. 
The remaining outcomes tested for causal associations using GRSGWAS did not 
reach statistical significance, though the corresponding GRSGWAS proved to be a 
strong IV with F values ≥82 (Table 3, Supplementary Figure S1). 
 
 
Using the GRSGWAS, there was no significant evidence of heterogeneity of 
the effect sizes for knee osteoarthritis, bipolar disorder, schizophrenia, and SBP, 
Figure 1 Genetic Risk Score GRSGWAS for bipolar disorder (A) and schizophrenia 
(B). Genetic risk score plots for bipolar disorder and schizophrenia. Horizontal 
axes: effect size for up to 18 SNPs comprising the GRSGWAS influencing levels of 
CRP, with corresponding standard error bars. Vertical axes: Log odds ratio for the 
GRSGWAS SNPs in bipolar disorder (A) or schizophrenia (B) with corresponding 
standard error bars. The effect estimate of CRP levels on disease risk or trait level 
is represented by a red solid line with gradient ?. The 95% CI of this ? estimate is 
represented by grey dashed lines. 
The included SNPs are shown by Arabic numbering as: #1 rs2847281 (gene:PTPN2; 
chr:18;basepair position:12811593); #2: rs340029 (RORA;15;58682257); #3: 
rs6901250 (GPRC6A;6;117220718); #4 rs10745954 (ASCL1;12;102007224); #5: 
rs4705952 (IRF1;5;131867517); #6 rs12037222 (PABPC4;1;39837548); #7 rs12239046 
(NLRP3;1;245668218); #8 rs6734238 (IL1F10;2;113557501); #9 rs13233571 
(BCL7B;7;72609167); #10 rs9987289 (PPP1R3B;8;9220768); #11 rs1260326 
(GCKR;2;27584444); #12 rs4129267 (IL6R;1;152692888); #13 rs1800961 
(HNF4A;20;42475778); #14 rs4420065 (LEPR;1;6;5934049); #15 rs10521222 
(SALL1;1;6;49716211); #16 rs1183910 (HNF1A;12;119905190); #17 rs2794520 
(CRP;1;157945440); #18 rs4420638 (APOC1;19;50114786).
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while the heterogeneity test was statistically significant for psoriatic arthritis, IBD, 
Crohn's disease, CAD, DBP, eGFRcr, serum albumin and serum protein. These 
heterogeneities in the effects of GRSGWAS may be attributable to pleiotropic effects 
of SNPs used to build the GRSGWAS. We subsequently performed a stepwise 
removal of SNPs from GRSGWAS until no significant heterogeneity remained and 
presented the results in Table 4. This adjustment in the GRSGWAS resulted in the 
removal of three SNPs from the GRSGWAS  for IBD (in GCKR, IRF1, PTPN2), five 
SNPs for Crohn's disease (in GCKR, IL6R, IRF1, PABPC4, PTPN2), one SNP for 
psoriatic arthritis (in GCKR), five SNPs for CAD (in APOC1, ASCL1, HNF1A, 
IL6R, IL1F10), one SNP for DBP (in PABPC4), two SNPs for eGFR (in LEPR 
and GCKR), eight SNPs for serum albumin (in APOC1, BCL7B, GCKR, IL6R, 
LEPR, PPP1R3B, PTPN2, SALL1), and one SNP for serum protein levels (in 
GCKR). After removal of these variants from the GRSGWAS, we found no 
significant association between genetically increased lnCRP levels and any of these 
outcomes (Table 4). However, for DBP, 17 SNPs remained in the GRSGWAS and 
yielded a slightly lower causal estimate (when compared to the values before 
adjustment) of 0.39 mmHg (-0.01 to 0.78) increase in DBP per 10 s% increase in 
lnCRP levels with a nominal significance of P<0.05.  
 
Table 3 The effect of the CRP Genetic Risk Score instrument of 18 SNPs associated 
to CRP (GRSGWAS) with somatic and neuropsychiatric outcomes. 
Disease / Trait Class M Effect size (95% CI) * 
P-
value P-het F-value 
Autoimmune/Inflammatory      
Celiac Disease 18 0.99(0.85-1.16) 0.930 7.2x10-4 804.26 
Inflammatory Bowel Disease (all) 15 0.85(0.74-0.98) 0.030 1.4x10-5 2515.37 
Crohn's Disease 17 0.81(0.70-0.94) 0.005 4.4x10-7 1125.63 
Ulcerative Colitis 17 1.05(0.91-1.21) 0.490 0.01 1389.63 
Psoriasis Vulgaris# 17 1.12(0.90-1.40) 0.310 0.19 470.47 
Psoriatic Arthritis# 17 1.36(1.00-1.84) 0.049 0.04 362.00 
Psoriasis Cutaneous# 17 1.00(0.72-1.39) 0.990 0.16 256.74 
Rheumatoid Arthritis 18 0.93(0.80-1.08) 0.350 1.8x10-6 1352.79 
Systemic Lupus Erythematosus 11 1.06(0.71-1.58) 0.780 0.27 244.68 
Systemic Sclerosis 11 0.84(0.62-1.14) 0.280 0.63 396.89 
Type 1 Diabetes 15 1.10(0.92-1.31) 0.310 3.47x10-3 1415.16 
Knee Osteoarthritis 18 1.17(1.01-1.36) 0.040 0.10 1276.74 
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Disease / Trait Class M Effect size (95% CI) * 
P-
value P-het F-value 
Cardiovascular          
Coronary Artery Disease 18 0.86 (0.79-0.95) 0.002 2.08x10-8 4578.58 
Systolic Blood Pressure ** 18 0.72(0.11-1.34) 0.020 0.14 3650.84 
Diastolic Blood Pressure ** 18 0.45(0.06-0.84) 0.020 0.02 3651.05 
Ischemic Stroke (all types) 18 1.06(0.87-1.29) 0.570 0.37 500.95 
Ischemic Stroke (Cardioembolic) 18 0.98(0.69-1.39) 0.920 0.35 355.79 
Ischemic Stroke (Large Vessel) 18 1.30(0.92-1.82) 0.140 0.97 358.63 
Ischemic Stroke (Small Vessel) 18 0.85(0.58-1.25) 0.420 0.76 343.16 
Metabolic          
Body Mass Index *** 18 -0.005(-0.03-0.02) 0.740 0.11 6519.11 
Type 2 Diabetes 18 1.090(0.95-1.24) 0.210 1.8x10-3 1187.79 
Chronic Kidney Disease 18 0.960(0.84-1.09) 0.500 0.07 3913.26 
eGFR for creatinine **** 18 0.011(0.003-0.02) 0.005 7.2x10-9 3913.26 
Serum Albumin Levels ***** 18 0.011(0.0004-0.02) 0.041 2.3x10-18 2799.32 
Serum Protein Levels ***** 18 0.031 (0.008-0.05) 0.009 0.03 1343.95 
Neurodegenerative          
Amyotrophic Lateral Sclerosis 8 1.01 (0.79-1.29) 0.960 0.56 666.37 
Alzheimer's Disease 11 1.26 (0.99-1.61) 0.060 0.23 685.16 
Parkinsons's Disease 10 1.06 (0.90-1.25) 0.500 0.50 913.16 
Psychiatric          
Autism # 9 0.89 (0.70-1.13) 0.350 0.99 82.32 
Bipolar Disorder 18 1.21 (1.05-1.40) 0.007 0.15 880.47 
Major Depressive Disorder 15 1.14 (0.96-1.36) 0.140 0.84 987.21 
Schizophrenia 15 0.86 (0.79- 0.94) 0.001 0.66 4202.26 
Abbreviations: M: number of markers used in the genetic instrument; Effect size 
(95% CI): Effect size (95% CI) per mg/L increase in lnCRP serum levels; P-value: P-
value of goodness of fit test; P-het: P-value of heterogeneity of effect test; F-value: 
F-statistic value for the used genetic instrument 
* For risk of disease, effect size is given in odds ratios, otherwise in the specific 
units in which the outcome was measured. Derived from the IV causal estimator α. 
** Effect size unit is mm Hg per increase in ln serum CRP (mg/L). 
*** Effect size unit is 1 standard deviation per ln mg/L increase in serum CRP (the 
BMI results were inverse normal transformed to a distribution with μ = 0 and σ = 1). 
**** Effect size unit is ml per min per 1.73 m2, per ln mg/L increase in serum CRP. 
***** Effect size unit g/dL, per ln mg/L increase in serum CRP. 
# results from individual cohorts combined in meta-analysis which is yet 
unpublished data. 
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Table 4 The effect of the CRP Genetic Risk Score instrument of 18 SNPs associated 
to CRP (GRSGWAS) with somatic and neuropsychiatric outcomes after correcting for 
heterogeneity. 
Disease / Trait Class M Effect size  (95% CI)* 
P-
value P- het 
Autoimmune/Inflammatory     
Celiac Disease 16 1.05 (0.90-1.23) 0.56 0.10 
Inflammatory Bowel Disease 12 0.92 (0.79-1.06) 0.24 0.14 
Crohn's Disease 12 0.93 (0.79-1.08) 0.34 0.12 
Ulcerative Colitis 16 1.11 (0.96-1.28) 0.16 0.12 
Psoriatic Arthritis 16 1.25 (0.91-1.72) 0.16 0.07 
Rheumatoid Arthritis 12 0.98 (0.81-1.19) 0.85 0.09 
Type 1 Diabetes 14 1.06 (0.89-1.27) 0.52 0.07 
Cardiovascular     
Coronary Artery Disease 13 1.03 (0.91-1.18) 0.55 0.07 
Diastolic Blood Pressure ** 17 0.385 (-0.008-0.78) 0.05 0.09 
Metabolic     
Type 2 Diabetes 17 0.95 (0.82-1.10) 0.52 0.09 
eGFR for creatinine **** 16 0.001 (-0.007-0.01) 0.74 0.11 
Serum Albumin ***** 10 -0.005 (-0.02-0.01) 0.49 0.15 
Serum Protein ***** 17 0.021 (-0.002-0.05) 0.07 0.31 
Abbreviations: M: number of markers used in the genetic instrument; Effect size 
(95% CI): Effect size (95% CI) per mg/L increase in lnCRP serum levels; P-value: P-
value of goodness of fit test; P-het: P-value of heterogeneity of effect test. 
* For risk of disease, effect size is given in odds ratios, otherwise in the specific 
units in which the outcome was measured. Derived from the IV causal estimator α. 
** Effect size unit is mm Hg per increase in ln serum CRP (mg/L). 
**** Effect size unit is ml per min per 1.73 m2, per ln mg/L increase in serum CRP. 
***** Effect size unit g/dL, per ln mg/L increase in serum CRP. 
 
Likewise, we hypothesized that a non-significant effect of CRP using 
GRSGWAS on celiac disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes 
and type 2 diabetes can be to some extent explained by significant heterogeneity 
observed for these outcomes (Table 3). This adjustment in the GRSGWAS resulted in 
the removal of two SNPs from the GRSGWAS for celiac disease (in PABPC4, 
PTPN2), one SNP for ulcerative colitis (in GCKR), six SNPS for rheumatoid 
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Likewise, we hypothesized that a non-significant effect of CRP using 
GRSGWAS on celiac disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes 
and type 2 diabetes can be to some extent explained by significant heterogeneity 
observed for these outcomes (Table 3). This adjustment in the GRSGWAS resulted in 
the removal of two SNPs from the GRSGWAS for celiac disease (in PABPC4, 
PTPN2), one SNP for ulcerative colitis (in GCKR), six SNPS for rheumatoid 
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arthritis (in APOC1, GCKR, HNF4A, IL6R,  PPP1R3B, SALL1), one SNP for type 
1 diabetes (in PTPN2), one SNP for type 2 diabetes (in APOC1). However, after 
adjusting for heterogeneity, the association of GRSGWAS with these outcomes 
remained non-significant (Table 4). 
Discussion 
In this large scale cross-consortia Mendelian randomization study of 32 complex 
outcomes, we provide evidence for a potential causal relationship between elevated 
CRP levels, and schizophrenia in both genetic IVs (i.e. GRSCRP and GRSGWAS). We 
found nominally significant evidence for a causal association of CRP levels with 
knee osteoarthritis, SBP and DBP and bipolar disorder in GRSGWAS. The initial 
finding of a causal association between CRP and Crohn’s disease, and psoriasis 
arthritis in GRSCRP was not further confirmed using GRSGWAS. After adjustment for 
heterogeneity when necessary, we found no further causal association of CRP with 
other common somatic and psychiatric outcomes, including celiac disease, IBD, 
ulcerative colitis, psoriasis (all types), rheumatoid arthritis, systemic lupus 
erythematosus, systemic sclerosis, type 1 and 2 diabetes, CAD, stroke (all types), 
BMI, chronic kidney disease, eGFR, albumin, serum protein, amyotrophic lateral 
sclerosis, Alzheimer’s disease, Parkinson’s disease, autism, and major depressive 
disorder. 
Strikingly, as opposed to current literature, our study shows that genetically 
elevated levels of CRP are not predisposing but in fact protective for schizophrenia. 
Others have previously shown that CRP levels are significantly elevated in patients 
with schizophrenia(63, 64). Furthermore, evidence for involvement of 
inflammatory pathways comes from recent large scale GWAS studies that 
corroborate previous findings(65) that variants in the major histocompatibility 
complex (MHC) region on chromosome 6p21, harboring many cytokine genes, are 
involved in the development of schizophrenia(57, 66–69), but not of bipolar 
disorder. In addition, other recent studies indicated an important role for 
inflammatory genetic variants in schizophrenia, and bipolar disorder, which 
includes variants in the IL10 promoter(70), TNF promoter(71) and IL-1B(72). 
Nevertheless, for variants in CRP either no association with schizophrenia was 
found(73), or the results were inconclusive(74), and so was a previous IV 
analysis(75). Therefore, the manner by which CRP impacts susceptibility to 
schizophrenia remains unclear. Our observation that a genetically determined 
marginal increase in the levels of CRP is likely to be protective for schizophrenia, 
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may fuel the debate about whether the observed elevated levels of CRP in 
schizophrenia are a by-product of the pathogenesis of schizophrenia or directly 
contribute to the clinical manifestations of the disorder(6). This finding may also 
point out potential biases in previous studies regarding the causes of elevated CRP 
levels in patients with schizophrenia such as reverse causality and/or pleiotropic 
effects within chosen instruments. As for bipolar disorder, though the nominal 
predisposing effect needs to be confirmed, our finding corroborates 
epidemiological observations suggesting that higher levels of CRP are associated 
with the disease(76). In bipolar disorder, our findings support a potential causal 
predisposing association between this disorder with inflammation in general. Our 
results failed to pass a multiple testing correction, though they may be biologically 
sensible, nevertheless independent confirmations on cohort level, and by functional 
follow-up analyses and with the use of a stronger CRP GRSGWAS from upcoming 
studies are required to make a factitive conclusion. 
We found nominally significant evidence for up to ~0.70 mmHg increased 
blood pressure for a 10 s% increase in CRP levels and no evidence for 
heterogeneity for SBP. Additionally, there was nominally borderline evidence of a 
causal association for DBP after we adjusted for heterogeneity. These nominally 
significant findings, on the one hand, are in line with numerous epidemiological 
studies that have highlighted an association between higher CRP levels and 
increased risk of hypertension. For instance, one study found an association 
between CRP loci and hypertension in Asians(77). An additional line of support for 
a possible causal association of CRP and blood pressure comes from an 
experimental study where the authors found that when in mice CRP gene 
expression increased, and subsequently, CRP protein levels, this led to a rise in 
particularly SBP (78). Moreover an ex-vivo study by Zhou et al. has shown that 
combining IL-6 treatment and mechanical strain has led to a consistent increase in 
CRP expression at protein and mRNA levels in smooth muscle cells(79). Both 
inflammatory factors and local mechanical strains are abundant in blood vessels and 
are well known risk factors for high blood pressure. However, on the other hand, 
our finding did not reach a statically significant level after correction for multiple 
testing; thus it may echo previous Mendelian randomization studies which have 
failed to find a causal relationship between CRP levels and blood pressure or 
hypertension in Europeans(80, 81). However our systematic review showed 
previous studies had some limitations (Supplementary Table S1). For instance, no 
study used a refined GWAS set of 18 CRP associated SNPs rather they tested single 
or a limited set of CRP SNPs. Using such instruments might have led to biased 
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estimates as their corresponding effects on CRP levels have been found to be 
small(30, 33). A combination of weak instruments and low sample sizes might lead 
to type II error(28, 33), and hence to a conclusion of no causal association between 
CRP and blood pressure traits in previous studies. Taken together, a direct link 
between CRP and blood pressure remains to be elucidated, though our nominal 
association between GRSCRP, GRSGWAS and blood pressure do add to a line of 
findings from experimental studies suggesting a potential causal relationship 
between CRP and blood pressure. 
Our nominally significant findings that CRP might be a potential causal 
factor for knee osteoarthritis (using GRSGWAS), should be interpreted with caution. 
In line with our findings, we have shown earlier that the levels of CRP were higher 
in women with early radiological knee osteoarthritis (i.e. Kellgren-Lawrence grade 
2+), and in women whose disease progressed(82). Additionally, another study 
showed that genetically elevated CRP levels contribute to osteoarthritis severity(83). 
However, other studies found contrasting results(84),(85). One systematic review 
provided evidence that the relationship between CRP and osteoarthritis does exist, 
but is dependent on BMI(85). It remains to be further investigated whether weight 
gain over the lifetime mediates the potential causal association between genetically 
elevated CRP and knee osteoarthritis. 
The present study was able to calculate nominal causal estimates for IBD, 
Crohn’s disease, psoriatic arthritis, CAD, eGFRcr, serum albumin or protein using 
a CRP GRSGWAS; but they were altered by removal of SNPs from GRSGWAS based 
on heterogeneity tests resulting in non-significant associations. These outcomes 
appeared therefore to have heterogeneity in causal estimates suggesting these 
observed estimates were biased likely due to pleiotropic effects of CRP loci. These 
results corroborate negative findings of previous studies (Supplementary Table S1), 
suggesting a causal role of CRP in these traits and diseases is unlikely. 
A detailed evaluation of pleiotropic SNPs in our study showed that our 
applied method to identify heterogeneity sources was able to indicate and exclude 
several already known pleiotropic loci from the GRSGWAS IV. For instance, the use 
of a SNP in IL6R (rs4129267) amongst others resulted in heterogeneity of effects 
on CAD risk. The same variant contributed to heterogeneity of effects for Crohn’s 
disease and serum albumin levels in our study, and it has been shown that this SNP 
is associated with levels of biomarkers other than CRP[56]. Further, a Mendelian 
randomization study found that IL6R SNPs, specifically, the non-synonymous SNP 
rs8192284, are associated with CAD risk and CRP levels(86). Our selected IL6R 
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SNPs, namely rs4537545 or rs4129267, are in extremely high LD with rs8192284 
(r2≥0.96 for both SNPs). Carriers of the risk allele of rs8192284 have higher CRP, 
IL6 and fibrinogen levels(86). Fibrinogen is also a well-known risk factor for CAD. 
Therefore, it is unclear so far which biomarker(s) mediates the effect of IL6R SNPs 
on CAD. Besides the IL6 locus, APOC1 and PABPC4 have been indicated as 
pleiotropic in three, and PTPN2 in four and GCKR in six out of 32 our investigated 
outcomes. Taken together, we were able to disentangle at least part of the 
pleiotropic effect on the causal estimates of CRP with outcomes. Again, we found 
no significant association of CRP GRSGWAS after adjustment for heterogeneity.  
Even though our results were mostly based on very large sample sizes of 
GWAS consortia and therefore much better powered than most previous 
Mendelian randomization studies investing causal involvement of CRP, we found 
that genetically elevated CRP levels approximated by powerful instruments appear 
not to contribute directly to most of the studied somatic and psychiatric outcomes. 
It is of utmost interest whether the observed effect of CRP as a risk predictor is 
causal and thus whether reduction of CRP levels will lower the risk of disease. Our 
findings are consistent with previous Mendelian randomization studies that suggest 
null associations of genetically elevated CRP levels with inflammation-related 
outcomes including CAD(32, 59, 87), type 2 diabetes(88), BMI(89), Alzheimer’s 
disease and depression(90). All previous Mendelian randomization studies were 
substantially limited to a single or a few outcomes, used only SNPs in the CRP gene 
or had sample sizes much smaller than the present study (Supplementary Table S1). 
In addition to these studies, the use of current GWAS data do not corroborate 
epidemiological observations suggesting that elevated CRP levels are associated 
with amyotrophic lateral sclerosis(91), Alzheimer’s disease(92), Parkinson’s 
disease(93), and major depressive disorder(94). Furthermore, patients with 
immunity-related disorders frequently have a very high CRP level (as high as 100 
mg/L) due to their disease status. Our findings may therefore more favorably 
indicate reverse causality. Taken together, we showed that CRP is highly unlikely to 
contribute causally to most of the major common somatic and neuropsychiatric 
outcomes that are investigated in the present study. 
Strengths and limitations of the study 
Results presented in table 2 show that our GRSCRP is not a weak instrument, as 
indicated by its high F values owing to the available large sample sizes of outcomes 
from GWAS consortia. The strength of our instruments increased considerably in 
all disease classes when we used variants of multiple loci associated with CRP in 
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GWAS. However, the variants comprising the CRP GRSGWAS explain on average 
only a moderate ~5% of the total variance in baseline CRP levels(30). Moreover, 
the possibility of effect modification by non-genetic CRP related factors on the 
outcomes remains to be investigated. We may be able to create even stronger 
instruments based on ongoing efforts to identify additional variation influencing 
CRP levels. Even if larger sample sizes and stronger instruments can be realized, 
the overwhelming lack of causal effects observed for most of outcomes in our 
current study also implies that CRP specific lowering therapies will not directly 
result in decreased risk of the investigated outcomes, or a better efficacy(95, 96). 
Here we used summary associations statistics obtained from previously conducted 
meta-GWASs in order to maximize our study power. One may argue this may 
induce bias, compared to when one uses the individual level data. Nevertheless, 
several studies showed a high agreement in results for both the GWAS summary 
data and individual level data Mendelian randomization methods(60, 97). 
Conclusion 
We showed that elevated CRP levels driven by genetic factors are causally 
associated with schizophrenia. We observed nominal evidence that genetically 
elevated CRP is causally associated with SBP, DBP, knee osteoarthritis and bipolar 
disorder. Our analyses did not support any causal effect of CRP on the other 27 
common somatic and neuropsychiatric outcomes investigated in the present study. 
Therefore, disease associated rise in CRP levels in these 27 outcomes may be 
interpreted as a response to the disease process rather than a cause for it.  This 
implies that interventions lowering CRP levels are unlikely to result in decreased 
risk for the majority of common complex outcomes. 
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Genetics ToolboX R (version 2.15.1 for Windows; Vienna, Austria): http://cran.r-
project.org/web/packages/gtx/index.html 
Publicly downloaded GWAS summary statistics 
1. GIANT BMI summary statistics:  
www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files 
2. CARDIoGRAM CAD summary statistics: www.cardiogramplusc4d.org 
210204-L-bw-Vaez
Chapter 6  
136 
 
3. Rheumatoid arthritis summary statistics:  
www.broadinstitute.org/ftp/pub/rheumatoid arthritis/Stahl_etal_2010NG/ 
4. PGC consortium (psychiatric) summary statistics:  
www.med.unc.edu/pgc/downloads 
5. Systemic Lupus Erythematosus 
Data was download through dbGaP: http://www.ncbi.nlm.nih.gov/gap 
Study name : Whole Genome Association Study of Systemic Lupus Erythematosus  
dbGaP Study Accession: phs000122.v1.p1  
Analysis Name and Accession 
Name: Whole Genome Association Study of Systemic Lupus Erythematosus  
Accession: pha002848.1 
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genes Findings Notes / Study Conclusions 
Cardiovascular                
Blood pressure 15731495 2005 >3500 
women 
─ rs1800947 CRP The polymorphism was associated with a robust 
difference in CRP, but the predicted causal effects of 
CRP on blood pressure, pulse pressure, and 
hypertension using instrumental variables methods 
were close to nill, although with wide Cis. 
CRP levels are associated with blood 
pressure, pulse pressure, and 
hypertension, but adjustment for life 
course confounding and a Mendelian 
randomization approach suggest the 
elevated CRP levels do not lead to 
elevated blood pressure. 





CRP With the instrumental variable approach, we noted no 
association between plasma CRP concentration and 
any of the metabolic syndrome phenotypes assessed  
The main study was regarding 
metabolic syndrome (phenotypes), 
but they included also systolic 






















CRP variants were each associated with up to 30% per 
allele difference in concentration of C reactive protein 
(P<10(-34)) and were unrelated to other risk factors. 
Risk ratios for coronary heart disease per additional 
copy of an allele associated with raised C reactive 
protein were 0.93 (95% confidence interval 0.87 to 
1.00) for rs3093077; 1.00 (0.98 to 1.02) for rs1205; 
0.98 (0.96 to 1.00) for rs1130864; and 0.99 (0.94 to 
1.03) for rs1800947. In a combined analysis, the risk 
ratio for coronary heart disease was 1.00 (0.90 to 1.13) 
per 1 SD higher genetically raised natural log (ln) 
concentration of C reactive protein. The genetic 
findings were discordant with the risk ratio observed 
for coronary heart disease of 1.33 (1.23 to 1.43) per 1 
SD higher circulating ln concentration of C reactive 
protein in prospective studies (P=0.001 for difference). 
Human genetic data indicate that C 
reactive protein concentration itself 
is unlikely to be even a modest 
causal factor in coronary heart 
disease. 
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genes Findings Notes / Study Conclusions 
Coronary Artery 
Disease 










SNP rs7553007 and published data for SNPs 
rs1130864 and rs1205 for 18 cohorts. SNP rs7553007 
was not significantly associated with CHD; estimated 
OR was 0.98 (95% CI, 0.94-1.01) per 20% lower CRP. 
For rs1130864, OR was 1.00 (95% CI, 0.86-1.15) and 
for rs1205, OR was 1.03 (95% CI, 0.99-1.07). There 
was no association of CHD with CRP variants (per 
20% lower CRP) when results for all three SNPs were 
combined, OR 1.00 (95% CI, 0.97-1.02) 
The lack of concordance between the 
effect on coronary heart disease risk 
of CRP genotypes and CRP levels 
argues against a causal association of 
CRP with coronary heart disease. 
Coronary Artery 
Disease 




─ rs1130864 CRP An instrumental variables analysis by rs1130864 
suggested that circulating CRP was not associated with 
CHD: the odds ratio for a doubling of CRP level was 
1.04 (95%CI: 0.61, 1.80). No association of this SNP, 
which is known to be related to CRP levels, and 
having CHD. 
 These findings do not support a 
causal association between circulating 
CRP and CHD risk, but very large, 
extended, genetic association studies 
would be required to rule this out. 
Coronary Artery 
Di ease 
16565153 2006 6201 for 
MR 
─ rs1130864 CRP A difference in CRP of 0.68 mg/l (95% CI 0.31–1.10) 
would confer an OR for non-fatal MI of 1.25 (95% CI 
1.09–1.43) or 1.20 (95% CI 1.07–1.38) using data from 
a meta-analysis of prospective cohort studies. 
However,  for men with the TT genotype, the point 
estimate of the OR for non-fatal MI was 1.01 (95% CI 
0.74–1.38).  
The null association of CRP variant 
with coronary events suggests 
possible residual confounding (or 
reverse causation) in the CRP–
coronary event association in 
observational studies, though the 
confidence limits are still compatible 
with a modest causal effect. 
Ischemic Heart 
Disease 












 Genotype combinations of the four CRP 
polymorphisms were associated with an increase in 
CRP levels of up to 64%, resulting in a theoretically 
predicted increased risk of up to 32% for ischemic 
heart disease and up to 25% for ischemic 
cerebrovascular disease. However, these genotype 
combinations were not associated with an increased 
risk of ischemic vascular disease. 
Polymorphisms in the CRP gene are 
associated with marked increases in 
CRP levels and thus with a 
theoretically predicted increase in the 
risk of ischemic vascular disease. 
However, these polymorphisms are 
not in themselves associated with an 
increased risk of ischemic vascular 
disease. 
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predicted increased risk of up to 32% for ischemic 
heart disease and up to 25% for ischemic 
cerebrovascular disease. However, these genotype 
combinations were not associated with an increased 
risk of ischemic vascular disease. 
Polymorphisms in the CRP gene are 
associated with marked increases in 
CRP levels and thus with a 
theoretically predicted increase in the 
risk of ischemic vascular disease. 
However, these polymorphisms are 
not in themselves associated with an 
increased risk of ischemic vascular 
disease. 
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genes Findings Notes / Study Conclusions 
Metabolic                
Body Mass 
Index 
20714329 2011 37 027 ─ rs3091244 CRP Observational analyses showed change in BMI of 
1.03 kg m−2 (95% CI: 1.00, 1.07), P<0.0001), for a 
doubling in logCRP. Analysis using rs3091244 CRP to 
re-estimate the causal effect of circulating CRP on 
BMI yielded null effects (change in BMI for a 
doubling in logCRP of −0.24 kg m−2 (95% CI: −0.58, 
0.11), P=0.2) 
These data suggest that the observed 
association between circulating CRP 
and measured BMI is likely to be 
driven by BMI, with CRP being a 
marker of elevated adiposity. 
Body Mass 
Index 




With increasing CRP allele score, there was a stepwise 
decrease in CRP levels (P for trend < 0.0001) and a 
1.98 mg/liter difference between extremes of the allele 
score distribution, but there was no associated change 
in BMI or leptin levels (P >or= 0.89). Adiposity allele 
score was associated with  increased CRP levels (1.24 
mg/liter difference between extremes; P for trend 
0.002). 
Greater adiposity conferred by FTO 
and MC4R SNPs led to higher CRP 














Log-transformed CRP explained by the rs7553007 
CRP gene was significantly associated with BMI 
[regression coefficient: 1.22 (0.18; 2.25), P = 0.02] and 
fat mass [2.67 (0.65; 4.68), P = 0.01] but not with lean 
mass in women, whereas no association was found in 
men. Log-transformed CRP explained by this 
combined CRP-LEPR instrument  was significantly 
associated with BMI [0.98 (0.32; 1.63), P = 0.004], fat 
mass [2.07 (0.79; 3.34), P = 0.001], and waist [2.09 
(0.39; 3.78), P = 0.01] in women but not men. 
CRP is causally and positively related 
to BMI in women and that this is 
mainly due to fat mass. Results on 
the combined CRP-LEPR instrument 
suggest that leptin may play a role in 
the causal association between CRP 
and adiposity in women. Results in 
men were not significant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
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The associations of CRP with HOMA-IR and HbA1c 
were all null when examined using instrumental 
variables analysis, with genetic variants as the 
instrument for serum CRP. Instrumental variables 
estimates differed from the directly observed 
associations (p = 0.007-0.11). Pooled analysis of CRP 
haplotypes and diabetes in Whitehall II and 
Northwick Park Heart Study II produced null findings 
(p = 0.25-0.88). Analyses based on the Wellcome 
Trust Case Control Consortium (1,923 diabetes cases, 
2,932 controls) using three SNPs in tight linkage 
disequilibrium with our tagging SNPs also 
demonstrated null associations. 
Observed associations between 
serum CRP and insulin resistance, 
glycemia, and diabetes are likely to be 
noncausal. Inflammation may play a 
causal role via upstream effectors 
rather than the downstream marker 
CRP. 












Elevated CRP was associated with increased risk of 
depression in individuals in the general population, 
but genetically elevated CRP was not. This indicates 
that CRP per se is not a causal risk factor for 
depression 
There is no evidence for a causal 
association between CRP and Major 
depression.  








The instrumental variable analysis resulted in a causal 
risk estimate with an OR of 1.40 (0.46–4.25) 
(observational vs causal model: P = .89).  
Data cannot exclude a causal 
association between CRP and 
schizophrenia, but  the data need to 
be verified by others.. 
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Supplementary Table 2 CRP lead variants used in the genetic risk score as instrumental variables 
A) CRP gene genetic risk score (ie. GRSCRP) 

















rs3093077 1 157946260 G/T 0.0500 CRP 0.207 0.033 5.40E-35 21325005 
rs1205 1 157948857 C/T 0.6667 CRP 0.169 0.016 1.00E-40 21325005 
rs1130864 1 157949715 T/C 0.3091 CRP 0.127 0.014 1.00E-40 21325005 
rs1800947 1 157950062 G/C 0.9333 CRP 0.232 0.030 1.00E-40 21325005 
 
B) CRP multilocus genetic risk score (ie. GRSGWAS) 
















rs12037222 1 39837548 A/G 0.2373 PABPC4 0.045 0.007 6.40E-11 23034020 
rs4420065 1 65934049 C/T 0.6500 LEPR 0.090 0.005 3.50E-62 23034020 
rs4129267 1 152692888 C/T 0.6583 IL6R 0.079 0.005 2.10E-48 23034020 
rs2794520 1 157945440 C/T 0.6667 CRP 0.160 0.006 2.00E-186 23034020 
rs12239046 1 245668218 C/T 0.6500 NLRP3 0.047 0.006 1.20E-15 23034020 
rs1260326 2 27584444 T/C 0.4000 GCKR 0.072 0.005 4.60E-40 23034020 
rs6734238 2 113557501 G/A 0.4167 IL1F10 0.050 0.006 1.80E-17 23034020 
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rs4705952 5 131867517 G/A 0.1638 IRF1 0.042 0.007 1.30E-08 23034020 
rs6901250 6 117220718 A/G 0.3276 GPRC6A 0.035 0.006 4.80E-08 23034020 
rs13233571 7 72609167 C/T 0.8833 BCL7B 0.054 0.009 3.60E-09 23034020 
rs9987289 8 9220768 G/A 0.9250 PPP1R3B 0.069 0.011 3.40E-13 23034020 
rs10745954 12 102007224 A/G 0.4833 ASCL1 0.039 0.006 1.60E-11 23034020 
rs1183910 12 119905190 G/A 0.7083 HNF1A 0.149 0.006 2.00E-124 23034020 
rs340029 15 58682257 T/C 0.6417 RORA 0.032 0.006 4.10E-09 23034020 
rs10521222 16 49716211 C/T 0.9167 SALL1 0.104 0.015 8.50E-13 23034020 
rs2847281 18 12811593 A/G 0.6271 PTPN2 0.031 0.006 2.20E-08 23034020 
rs4420638 19 50114786 A/G 0.8167 APOC1 0.236 0.009 9.00E-139 23034020 
rs1800961 20 42475778 C/T 0.9500 HNF4A 0.088 0.015 2.20E-09 23034020 
SNP indicates single nucleotide polymorphism; Chr, chromosome; Alleles, raising/lowering alleles respectively; AF, allele 
frequency of raising Allele in European populations; and CRP, C-reactive protein.  
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Supplementary Table 2 CRP lead variants used in the genetic risk score as instrumental variables 
A) CRP gene genetic risk score (ie. GRSCRP) 

















rs3093077 1 157946260 G/T 0.0500 CRP 0.207 0.033 5.40E-35 21325005 
rs1205 1 157948857 C/T 0.6667 CRP 0.169 0.016 1.00E-40 21325005 
rs1130864 1 157949715 T/C 0.3091 CRP 0.127 0.014 1.00E-40 21325005 
rs1800947 1 157950062 G/C 0.9333 CRP 0.232 0.030 1.00E-40 21325005 
 
B) CRP multilocus genetic risk score (ie. GRSGWAS) 
















rs12037222 1 39837548 A/G 0.2373 PABPC4 0.045 0.007 6.40E-11 23034020 
rs4420065 1 65934049 C/T 0.6500 LEPR 0.090 0.005 3.50E-62 23034020 
rs4129267 1 152692888 C/T 0.6583 IL6R 0.079 0.005 2.10E-48 23034020 
rs2794520 1 157945440 C/T 0.6667 CRP 0.160 0.006 2.00E-186 23034020 
rs12239046 1 245668218 C/T 0.6500 NLRP3 0.047 0.006 1.20E-15 23034020 
rs1260326 2 27584444 T/C 0.4000 GCKR 0.072 0.005 4.60E-40 23034020 
rs6734238 2 113557501 G/A 0.4167 IL1F10 0.050 0.006 1.80E-17 23034020 
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rs4705952 5 131867517 G/A 0.1638 IRF1 0.042 0.007 1.30E-08 23034020 
rs6901250 6 117220718 A/G 0.3276 GPRC6A 0.035 0.006 4.80E-08 23034020 
rs13233571 7 72609167 C/T 0.8833 BCL7B 0.054 0.009 3.60E-09 23034020 
rs9987289 8 9220768 G/A 0.9250 PPP1R3B 0.069 0.011 3.40E-13 23034020 
rs10745954 12 102007224 A/G 0.4833 ASCL1 0.039 0.006 1.60E-11 23034020 
rs1183910 12 119905190 G/A 0.7083 HNF1A 0.149 0.006 2.00E-124 23034020 
rs340029 15 58682257 T/C 0.6417 RORA 0.032 0.006 4.10E-09 23034020 
rs10521222 16 49716211 C/T 0.9167 SALL1 0.104 0.015 8.50E-13 23034020 
rs2847281 18 12811593 A/G 0.6271 PTPN2 0.031 0.006 2.20E-08 23034020 
rs4420638 19 50114786 A/G 0.8167 APOC1 0.236 0.009 9.00E-139 23034020 
rs1800961 20 42475778 C/T 0.9500 HNF4A 0.088 0.015 2.20E-09 23034020 
SNP indicates single nucleotide polymorphism; Chr, chromosome; Alleles, raising/lowering alleles respectively; AF, allele 
frequency of raising Allele in European populations; and CRP, C-reactive protein.  
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rs4705952 5 131867517 G/A 0.1638 IRF1 0.042 0.007 1.30E-08 23034020 
rs6901250 6 117220718 A/G 0.3276 GPRC6A 0.035 0.006 4.80E-08 23034020 
rs13233571 7 72609167 C/T 0.8833 BCL7B 0.054 0.009 3.60E-09 23034020 
rs9987289 8 9220768 G/A 0.9250 PPP1R3B 0.069 0.011 3.40E-13 23034020 
rs10745954 12 102007224 A/G 0.4833 ASCL1 0.039 0.006 1.60E-11 23034020 
rs1183910 12 119905190 G/A 0.7083 HNF1A 0.149 0.006 2.00E-124 23034020 
rs340029 15 58682257 T/C 0.6417 RORA 0.032 0.006 4.10E-09 23034020 
rs10521222 16 49716211 C/T 0.9167 SALL1 0.104 0.015 8.50E-13 23034020 
rs2847281 18 12811593 A/G 0.6271 PTPN2 0.031 0.006 2.20E-08 23034020 
rs4420638 19 50114786 A/G 0.8167 APOC1 0.236 0.009 9.00E-139 23034020 
rs1800961 20 42475778 C/T 0.9500 HNF4A 0.088 0.015 2.20E-09 23034020 
 
SNP indicates single nucleotide polymorphism; Chr, chromosome; Alleles, raising/lowering alleles respectively; AF, allele 
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Supplementary Table 3 Proxy SNPs of CRP lead variants used in the genetic risk scores as instrumental variables. 
A) CRP gene genetic risk score (GRSCRP)- proxy SNPs of CRP lead variants. 
CRP lead 
SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs3093077 1 157946260 rs3093075 157946537 277 1 
rs3093077 1 157946260 rs16842568 157942844 3416 1 
rs3093077 1 157946260 rs16842559 157942795 3465 1 
rs3093077 1 157946260 rs12068753 157959161 12901 1 
rs3093077 1 157946260 rs16842599 157964099 17839 1 
rs3093077 1 157946260 rs11265260 157966663 20403 1 
rs3093077 1 157946260 rs16842502 157920487 25773 1 
rs3093077 1 157946260 rs12081252 157973137 26877 1 
rs3093077 1 157946260 rs12081264 157973184 26924 1 
rs1205 1 157948857 rs2794520 157945440 3417 1 
rs1205 1 157948857 rs2808629 157943420 5437 1 
rs1205 1 157948857 rs2808628 157942635 6222 1 
rs1205 1 157948857 rs1341665 157958183 9326 1 
rs1205 1 157948857 rs7553007 157965173 16316 1 
rs1205 1 157948857 rs2027471 157956012 7155 0.963 
rs1130864 1 157949715 rs1417938 157950810 1095 1 
rs1130864 1 157949715 rs3116656 157958996 9281 1 
rs1130864 1 157949715 rs12741825 157936769 12946 1 
rs1130864 1 157949715 rs3116653 157963534 13819 1 
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Supplementary Table 3 Proxy SNPs of CRP lead variants used in the genetic risk scores as instrumental variables. 
A) CRP gene genetic risk score (GRSCRP)- proxy SNPs of CRP lead variants. 
CRP lead 
SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
3093077 6260 3 930 5 4 537 277 1 
3093077 6260 6842568 42 44 3416
3093077 6260 16842 59 427 5 3465
3093077 6260 068753 591 1 01
3093077 6260 16842 99 4099 7 3
rs3093077 1 157946260 rs11265260 157966663 20403 1 
rs3093077 1 157946260 rs16842502 157920487 25773 1 
rs3093077 1 157946260 rs12081252 157973137 26877 1 
rs3093077 1 157946260 rs12081264 157973184 26924 1 
rs1205 1 157948857 rs2794520 157945440 3417 1 
rs1205 1 157948857 rs2808629 157943420 5437 1 
rs1205 1 157948857 rs2808628 157942635 6222 1 
rs1205 1 157948857 rs1341665 157958183 9326 1 
rs1205 1 157948857 rs7553007 157965173 16316 1 
rs1205 1 157948857 rs2027471 157956012 7155 0.963 
rs1130864 1 157949715 rs1417938 157950810 1095 1 
rs1130864 1 157949715 rs3116656 157958996 9281 1 
rs1130864 1 157949715 rs12741825 157936769 12946 1 


































































































































































































































































































































































































































































































































































































































































SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs1130864 1 157949715 rs3116651 157965109 15394 1 
rs1130864 1 157949715 rs12727021 157969111 19396 1 
rs1130864 1 157949715 rs12754915 157927493 22222 1 
rs1130864 1 157949715 rs12739022 157926055 23660 1 
rs1130864 1 157949715 rs12749227 157925733 23982 1 
rs1130864 1 157949715 rs12093699 157914612 35103 0.927 
rs1130864 1 157949715 rs12755606 157936960 12755 0.926 
rs1800947 1 157950062 ─ ─ ─ ─ 
 
B) CRP multilocus genetic risk score (GRSGWAS)- proxy SNPs of CRP lead variants 
CRP lead 
SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs12037222 1 39837548 rs2293476 39809434 28114 1 
rs12037222 1 39837548 rs17513135 39808273 29275 1 
rs12037222 1 39837548 rs17264866 39795364 42184 1 
rs12037222 1 39837548 rs4660808 39791096 46452 1 
rs12037222 1 39837548 rs4660293 39800767 36781 0.955 
rs4420065 1 65934049 rs6588158 65933209 840 1 
rs4420065 1 65934049 rs2889195 65929318 4731 1 
rs4420065 1 65934049 rs2211651 65928609 5440 1 
rs4420065 1 65934049 rs4655585 65928215 5834 1 
Mendelian randomization of CRP in 32 somatic and psychiatric outcomes 
153 
 
CR  lead 
SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs1130864 1 157949715 rs3116651 157965109 15394 1 
rs1130864 1 157949715 rs12727021 157969111 19396 1 
rs1130864 1 157949715 rs12754915 157927493 22222 1 
rs1130864 1 157949715 rs12739022 157926055 23660 1 
rs1130864 1 157949715 rs12749227 157925733 23982 1 
rs1130864 1 157949715 rs12093699 157914612 35103 0.927 
rs1130864 1 157949715 rs12755606 157936960 12755 0.926 
rs1800947 1 157950062 ─ ─ ─ ─ 
 
B) CRP multilocus genetic risk score (GRSGWAS)- proxy SNPs of CRP lead variants 
CRP lead 
SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs12037222 1 39837548 rs2293476 39809434 28114 1 
rs12037222 1 39837548 rs17513135 39808273 29275 1 
rs12037222 1 39837548 rs17264866 39795364 42184 1 
rs12037222 1 39837548 rs4660808 39791096 46452 1 
rs12037222 1 39837548 rs4660293 39800767 36781 0.955 
rs4420065 1 65934049 rs6588158 65933209 840 1 
rs4420065 1 65934049 rs2889195 65929318 4731 1 
rs4420065 1 65934049 rs2211651 65928609 5440 1 
rs4420065 1 65934049 rs4655585 65928215 5834 1 
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A) CRP gene genetic risk score (GRSCRP)- proxy SNPs of CRP lead variants. 
CRP lead 
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SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs1130864 1 157949715 rs3116651 157965109 15394 1 
rs1130864 1 157949715 rs12727021 157969111 19396 1 
rs1130864 1 157949715 rs12754915 157927493 22222 1 
rs1130864 1 157949715 rs12739022 157926055 23660 1 
rs1130864 1 157949715 rs12749227 157925733 23982 1 
rs1130864 1 157949715 rs12093699 157914612 35103 0.927 
rs1130864 1 157949715 rs12755606 157936960 12755 0.926 
rs1800947 1 157950062 ─ ─ ─ ─ 
 
B) CRP multilocus genetic risk score (GRSGWAS)- proxy SNPs of CRP lead variants 
CRP lead 
SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs12037222 1 39837548 rs2293476 39809434 28114 1 
rs12037222 1 39837548 rs17513135 39808273 29275 1 
rs12037222 1 39837548 rs17264866 39795364 42184 1 
rs12037222 1 39837548 rs4660808 39791096 46452 1 
rs12037222 1 39837548 rs4660293 39800767 36781 0.955 
rs4420065 1 65934049 rs6588158 65933209 840 1 
rs4420065 1 65934049 rs2889195 65929318 4731 1 
rs4420065 1 65934049 rs2211651 65928609 5440 1 
rs4420065 1 65934049 rs4655585 65928215 5834 1 
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CR  lead 
SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs1130864 1 157949715 rs3116651 157965109 15394 1 
rs1130864 1 157949715 rs12727021 157969111 19396 1 
rs1130864 1 157949715 rs12754915 157927493 22222 1 
rs1130864 1 157949715 rs12739022 157926055 23660 1 
rs1130864 1 157949715 rs12749227 157925733 23982 1 
rs1130864 1 157949715 rs12093699 157914612 35103 0.927 
rs1130864 1 157949715 rs12755606 157936960 12755 0.926 
rs1800947 1 157950062 ─ ─ ─ ─ 
 
B) CRP multilocus genetic risk score (GRSGWAS)- proxy SNPs of CRP lead variants 
CRP lead 
SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs12037222 1 39837548 rs2293476 39809434 28114 1 
rs12037222 1 39837548 rs17513135 39808273 29275 1 
rs12037222 1 39837548 rs17264866 39795364 42184 1 
rs12037222 1 39837548 rs4660808 39791096 46452 1 
rs12037222 1 39837548 rs4660293 39800767 36781 0.955 
rs4420065 1 65934049 rs6588158 65933209 840 1 
rs4420065 1 65934049 rs2889195 65929318 4731 1 
rs4420065 1 65934049 rs2211651 65928609 5440 1 



































































































































































































































































































































































































































































































































































































































































SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs4420065 1 65934049 rs4655584 65928103 5946 1 
rs4420065 1 65934049 rs4655582 65925951 8098 1 
rs4420065 1 65934049 rs11208711 65920434 13615 1 
rs4420065 1 65934049 rs12042807 65906640 27409 1 
rs4420065 1 65934049 rs12042779 65906538 27511 1 
rs4420065 1 65934049 rs10789192 65898358 35691 1 
rs4420065 1 65934049 rs1938492 65890417 43632 1 
rs4420065 1 65934049 rs7531867 65880134 53915 1 
rs4420065 1 65934049 rs1805096 65874845 59204 1 
rs4420065 1 65934049 rs7524581 65939087 5038 0.964 
rs4420065 1 65934049 rs1892534 65878532 55517 0.964 
rs4420065 1 65934049 rs7541434 65941087 7038 0.928 
rs4420065 1 65934049 rs12753193 65942267 8218 0.928 
rs4420065 1 65934049 rs7516341 65860731 73318 0.928 
rs4420065 1 65934049 rs10889569 65858782 75267 0.928 
rs4420065 1 65934049 rs4655557 65853375 80674 0.928 
rs4420065 1 65934049 rs6678033 65850212 83837 0.928 
rs4129267 1 152692888 rs4537545 152685503 7385 1 
rs4129267 1 152692888 rs8192284 152693594 706 0.964 
rs4129267 1 152692888 rs4845623 152682401 10487 0.964 
rs4129267 1 152692888 rs4453032 152680710 12178 0.964 
rs4129267 1 152692888 rs4393147 152680661 12227 0.964 
rs4129267 1 152692888 rs4845622 152678043 14845 0.964 




SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
4655584 92 103 594  1 
82 925951 98 1 
11208711 92 434 1 615 1 
4 00 5 6 934049 12042807 6 90664  27409 
4 00 5 6 934049 1204 779 6 906538 27511 1 
4 00 5 6 934049 10789192 6 89 358 35691 1 
4 00 5 6 934049 193849 6 890417 43632 1 
4 00 5 6 934049 753186 6 880134 53915 1 
4 00 5 6 934049 1 0 096 6 874 45 59204 1 
rs4420065 1 65934049 rs7524581 65939087 5038 0.964 
rs4420065 1 65934049 rs1892534 65878532 55517 0.964 
rs4420065 1 65934049 rs7541434 65941087 7038 0.928 
rs4420065 1 65934049 rs12753193 65942267 8218 0.928 
rs4420065 1 65934049 rs7516341 65860731 73318 0.928 
rs4420065 1 65934049 rs10889569 65858782 75267 0.928 
rs4420065 1 65934049 rs4655557 65853375 80674 0.928 
rs4420065 1 65934049 rs6678033 65850212 83837 0.928 
rs4129267 1 152692888 rs4537545 152685503 7385 1 
rs4129267 1 152692888 rs8192284 152693594 706 0.964 
rs4129267 1 152692888 rs4845623 152682401 10487 0.964 
rs4129267 1 152692888 rs4453032 152680710 12178 0.964 
rs4129267 1 152692888 rs4393147 152680661 12227 0.964 








































































































































































































































































































































































































































































































































































































































































































SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs4129267 1 152692888 rs7518199 152674043 18845 0.964 
rs2794520 1 157945440 rs2808629 157943420 2020 1 
rs2794520 1 157945440 rs2808628 157942635 2805 1 
rs2794520 1 157945440 rs1205 157948857 3417 1 
rs2794520 1 157945440 rs1341665 157958183 12743 1 
rs2794520 1 157945440 rs7553007 157965173 19733 1 
rs2794520 1 157945440 rs2027471 157956012 10572 0.963 
rs12239046 1 245668218 rs4925546 245669591 1373 1 
rs12239046 1 245668218 rs10157379 245672222 4004 1 
rs1260326 2 27584444 rs780094 27594741 10297 0.932 
rs1260326 2 27584444 rs780093 27596107 11663 0.932 
rs1260326 2 27584444 ─ ─ ─ ─ 
rs6734238 2 113557501 rs10176274 113557046 455 0.933 
rs6734238 2 113557501 rs6722922 113557986 485 0.933 
rs6734238 2 113557501 rs6750559 113558003 502 0.933 
rs6734238 2 113557501 rs10188292 113556914 587 0.933 
rs6734238 2 113557501 rs6743171 113556529 972 0.933 
rs6734238 2 113557501 rs13398728 113558977 1476 0.933 
rs6734238 2 113557501 rs13410964 113559754 2253 0.933 
rs6734238 2 113557501 rs6741180 113560855 3354 0.933 
rs6734238 2 113557501 rs4496335 113560946 3445 0.933 
rs6734238 2 113557501 rs12328766 113563209 5708 0.933 
rs6734238 2 113557501 rs12329129 113563478 5977 0.933 




SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
4129 67 1 52692888 751819 52674 4 18845 64
2 9 520 1 57945440 280 6  57943420 2020 1 
2 9 520 1 57945440 2808628 57942635 2805 1 
2 9 520 1 57945440 205 5794 85 3 17 1 
2 9 520 1 57945440 665 579 8183 1 743 1 
2 9 520 1 57945440 7553007 579 5173 19733 1 
2 9 520 1 57945440 2027471 57956012 10572 6
12239046 1 245668218 492554  2456 9591 1373 1 
12239046 1 245668218 015737 245672222 4004 1 
rs1260326 2 27584444 rs780094 27594741 10297 0.932 
rs1260326 2 27584444 rs780093 27596107 11663 0.932 
rs1260326 2 27584444 ─ ─ ─ ─ 
rs6734238 2 113557501 rs10176274 113557046 455 0.933 
rs6734238 2 113557501 rs6722922 113557986 485 0.933 
rs6734238 2 113557501 rs6750559 113558003 502 0.933 
rs6734238 2 113557501 rs10188292 113556914 587 0.933 
rs6734238 2 113557501 rs6743171 113556529 972 0.933 
rs6734238 2 113557501 rs13398728 113558977 1476 0.933 
rs6734238 2 113557501 rs13410964 113559754 2253 0.933 
rs6734238 2 113557501 rs6741180 113560855 3354 0.933 
rs6734238 2 113557501 rs4496335 113560946 3445 0.933 
rs6734238 2 113557501 rs12328766 113563209 5708 0.933 
rs6734238 2 113557501 rs12329129 113563478 5977 0.933 
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SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs4420065 1 65934049 rs4655584 65928103 5946 1 
rs4420065 1 65934049 rs4655582 65925951 8098 1 
rs4420065 1 65934049 rs11208711 65920434 13615 1 
rs4420065 1 65934049 rs12042807 65906640 27409 1 
rs4420065 1 65934049 rs12042779 65906538 27511 1 
rs4420065 1 65934049 rs10789192 65898358 35691 1 
rs4420065 1 65934049 rs1938492 65890417 43632 1 
rs4420065 1 65934049 rs7531867 65880134 53915 1 
rs4420065 1 65934049 rs1805096 65874845 59204 1 
rs4420065 1 65934049 rs7524581 65939087 5038 0.964 
rs4420065 1 65934049 rs1892534 65878532 55517 0.964 
rs4420065 1 65934049 rs7541434 65941087 7038 0.928 
rs4420065 1 65934049 rs12753193 65942267 8218 0.928 
rs4420065 1 65934049 rs7516341 65860731 73318 0.928 
rs4420065 1 65934049 rs10889569 65858782 75267 0.928 
rs4420065 1 65934049 rs4655557 65853375 80674 0.928 
rs4420065 1 65934049 rs6678033 65850212 83837 0.928 
rs4129267 1 152692888 rs4537545 152685503 7385 1 
rs4129267 1 152692888 rs8192284 152693594 706 0.964 
rs4129267 1 152692888 rs4845623 152682401 10487 0.964 
rs4129267 1 152692888 rs4453032 152680710 12178 0.964 
rs4129267 1 152692888 rs4393147 152680661 12227 0.964 
rs4129267 1 152692888 rs4845622 152678043 14845 0.964 




SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
4655584 92 103 594  1 
82 925951 98 1 
11208711 92 434 1 615 1 
4 00 5 6 934049 12042807 6 90664  27409 
4 00 5 6 934049 1204 779 6 906538 27511 1 
4 00 5 6 934049 10789192 6 89 358 35691 1 
4 00 5 6 934049 193849 6 890417 43632 1 
4 00 5 6 934049 753186 6 880134 53915 1 
4 00 5 6 934049 1 0 096 6 874 45 59204 1 
rs4420065 1 65934049 rs7524581 65939087 5038 0.964 
rs4420065 1 65934049 rs1892534 65878532 55517 0.964 
rs4420065 1 65934049 rs7541434 65941087 7038 0.928 
rs4420065 1 65934049 rs12753193 65942267 8218 0.928 
rs4420065 1 65934049 rs7516341 65860731 73318 0.928 
rs4420065 1 65934049 rs10889569 65858782 75267 0.928 
rs4420065 1 65934049 rs4655557 65853375 80674 0.928 
rs4420065 1 65934049 rs6678033 65850212 83837 0.928 
rs4129267 1 152692888 rs4537545 152685503 7385 1 
rs4129267 1 152692888 rs8192284 152693594 706 0.964 
rs4129267 1 152692888 rs4845623 152682401 10487 0.964 
rs4129267 1 152692888 rs4453032 152680710 12178 0.964 
rs4129267 1 152692888 rs4393147 152680661 12227 0.964 
rs4129267 1 152692888 rs4845622 152678043 14845 0.964 




SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs4129267 1 152692888 rs7518199 152674043 18845 0.964 
rs2794520 1 157945440 rs2808629 157943420 2020 1 
rs2794520 1 157945440 rs2808628 157942635 2805 1 
rs2794520 1 157945440 rs1205 157948857 3417 1 
rs2794520 1 157945440 rs1341665 157958183 12743 1 
rs2794520 1 157945440 rs7553007 157965173 19733 1 
rs2794520 1 157945440 rs2027471 157956012 10572 0.963 
rs12239046 1 245668218 rs4925546 245669591 1373 1 
rs12239046 1 245668218 rs10157379 245672222 4004 1 
rs1260326 2 27584444 rs780094 27594741 10297 0.932 
rs1260326 2 27584444 rs780093 27596107 11663 0.932 
rs1260326 2 27584444 ─ ─ ─ ─ 
rs6734238 2 113557501 rs10176274 113557046 455 0.933 
rs6734238 2 113557501 rs6722922 113557986 485 0.933 
rs6734238 2 113557501 rs6750559 113558003 502 0.933 
rs6734238 2 113557501 rs10188292 113556914 587 0.933 
rs6734238 2 113557501 rs6743171 113556529 972 0.933 
rs6734238 2 113557501 rs13398728 113558977 1476 0.933 
rs6734238 2 113557501 rs13410964 113559754 2253 0.933 
rs6734238 2 113557501 rs6741180 113560855 3354 0.933 
rs6734238 2 113557501 rs4496335 113560946 3445 0.933 
rs6734238 2 113557501 rs12328766 113563209 5708 0.933 
rs6734238 2 113557501 rs12329129 113563478 5977 0.933 




SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
4129 67 1 52692888 751819 52674 4 18845 64
2 9 520 1 57945440 280 6  57943420 2020 1 
2 9 520 1 57945440 2808628 57942635 2805 1 
2 9 520 1 57945440 205 5794 85 3 17 1 
2 9 520 1 57945440 665 579 8183 1 743 1 
2 9 520 1 57945440 7553007 579 5173 19733 1 
2 9 520 1 57945440 2027471 57956012 10572 6
12239046 1 245668218 492554  2456 9591 1373 1 
12239046 1 245668218 015737 245672222 4004 1 
rs1260326 2 27584444 rs780094 27594741 10297 0.932 
rs1260326 2 27584444 rs780093 27596107 11663 0.932 
rs1260326 2 27584444 ─ ─ ─ ─ 
rs6734238 2 113557501 rs10176274 113557046 455 0.933 
rs6734238 2 113557501 rs6722922 113557986 485 0.933 
rs6734238 2 113557501 rs6750559 113558003 502 0.933 
rs6734238 2 113557501 rs10188292 113556914 587 0.933 
rs6734238 2 113557501 rs6743171 113556529 972 0.933 
rs6734238 2 113557501 rs13398728 113558977 1476 0.933 
rs6734238 2 113557501 rs13410964 113559754 2253 0.933 
rs6734238 2 113557501 rs6741180 113560855 3354 0.933 
rs6734238 2 113557501 rs4496335 113560946 3445 0.933 
rs6734238 2 113557501 rs12328766 113563209 5708 0.933 




































































































































































































































































































































































































































































































































































































































































































































SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs6734238 2 113557501 rs12328368 113563615 6114 0.933 
rs6734238 2 113557501 rs6730516 113565432 7931 0.933 
rs6734238 2 113557501 rs6738239 113567263 9762 0.933 
rs6734238 2 113557501 rs1446509 113567630 10129 0.933 
rs6734238 2 113557501 rs1446510 113567988 10487 0.933 
rs4705952 5 131867517 ─ ─ ─ ─ 
rs6901250 6 117220718 rs6924002 117220916 198 0.962 
rs6901250 6 117220718 rs615199 117220346 372 0.962 
rs6901250 6 117220718 rs993394 117223836 3118 0.962 
rs13233571 7 72609167 rs17145738 72620810 11643 1 
rs13233571 7 72609167 rs13232120 72621246 12079 1 
rs13233571 7 72609167 rs13244268 72549779 59388 1 
rs13233571 7 72609167 rs12056034 72516581 92586 1 
rs13233571 7 72609167 rs2074755 72515102 94065 1 
rs13233571 7 72609167 rs714052 72502805 106362 1 
rs13233571 7 72609167 rs13231516 72501185 107982 1 
rs13233571 7 72609167 rs2240466 72494205 114962 1 
rs9987289 8 9220768 rs4841132 9221006 238 1 
rs9987289 8 9220768 rs4841133 9221074 306 1 
rs9987289 8 9220768 rs4240624 9221641 873 1 
rs10745954 12 102007224 rs7972145 102001606 5618 1 
rs10745954 12 102007224 rs4584635 101999174 8050 1 
rs10745954 12 102007224 rs7295481 102016298 9074 1 




SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
6734238 2 113557501 12328368 113563615 6114 0.933 
6734238 2 113557501 6730516 113565432 7931 0.933 
6734238 2 113557501 6738239 113567263 9762 0.933 
6734 38 2 113557501 14 6509 113567 30 10129 0.933 
6734 38 2 113557501 14 6510 11356 988 1 487 0.933 
4705952 5 131867517 ─ ─ ─ ─ 
6901250 6 17220718 6 24002 1722091 198 0.962 
6901250 6 17220718 615199 17220346 372 0.962 
6901250 6 17220718 993394 17223836 3118 0.962 
rs13233571 7 72609167 rs17145738 72620810 11643 1 
rs13233571 7 72609167 rs13232120 72621246 12079 1 
rs13233571 7 72609167 rs13244268 72549779 59388 1 
rs13233571 7 72609167 rs12056034 72516581 92586 1 
rs13233571 7 72609167 rs2074755 72515102 94065 1 
rs13233571 7 72609167 rs714052 72502805 106362 1 
rs13233571 7 72609167 rs13231516 72501185 107982 1 
rs13233571 7 72609167 rs2240466 72494205 114962 1 
rs9987289 8 9220768 rs4841132 9221006 238 1 
rs9987289 8 9220768 rs4841133 9221074 306 1 
rs9987289 8 9220768 rs4240624 9221641 873 1 
rs10745954 12 102007224 rs7972145 102001606 5618 1 
rs10745954 12 102007224 rs4584635 101999174 8050 1 































































































































































































































































































































































































































































































































































































































































































SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs10745954 12 102007224 rs1588886 101971777 35447 1 
rs10745954 12 102007224 rs2222044 101982079 25145 0.967 
rs10745954 12 102007224 rs10778212 101979690 27534 0.967 
rs1183910 12 119905190 rs2244608 119901371 3819 0.96 
rs1183910 12 119905190 rs1169288 119901033 4157 0.96 
rs1183910 12 119905190 rs11065385 119907769 2579 0.921 
rs340029 15 58682257 ─ ─ ─ ─ 
rs10521222 16 49716211 ─ ─ ─ ─ 
rs2847281 18 12811593 rs12971201 12820538 8945 1 
rs2847281 18 12811593 rs2852151 12831176 19583 1 
rs2847281 18 12811593 rs674222 12838349 26756 1 
rs2847281 18 12811593 rs4797709 12872359 60766 0.965 
rs4420638 19 50114786 ─ ─ ─ ─ 
rs1800961 20 42475778 ─ ─ ─ ─ 
 
SNP indicates single nucleotide polymorphism; Chr, chromosome; CRP, C-reactive protein; bp, base pairs; and LD, linkage 
disequilibrium (r2) with lead SNP. 
  




SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs10745954 12 102007224 rs1588886 101971777 35447 1 
rs10745954 12 102007224 rs2222044 101982079 25145 0.967 
rs10745954 12 102007224 rs10778212 101979690 27534 0.967 
rs1183910 12 119905190 rs2244608 119901371 3819 0.96 
rs1183910 12 119905190 rs1169288 119901033 4157 0.96 
rs1183910 12 119905190 rs11065385 119907769 2579 0.921 
rs340029 15 58682257 ─ ─ ─ ─ 
rs10521222 16 49716211 ─ ─ ─ ─ 
rs2847281 18 12811593 rs12971201 12820538 8945 1 
rs2847281 18 12811593 rs2852151 12831176 19583 1 
rs2847281 18 12811593 rs674222 12838349 26756 1 
rs2847281 18 12811593 rs4797709 12872359 60766 0.965 
rs4420638 19 50114786 ─ ─ ─ ─ 
rs1800961 20 42475778 ─ ─ ─ ─ 
 
SNP indicates single nucleotide polymorphism; Chr, chromosome; CRP, C-reactive protein; bp, base pairs; and LD, linkage 
disequilibrium (r2) with lead SNP. 
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SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs6734238 2 113557501 rs12328368 113563615 6114 0.933 
rs6734238 2 113557501 rs6730516 113565432 7931 0.933 
rs6734238 2 113557501 rs6738239 113567263 9762 0.933 
rs6734238 2 113557501 rs1446509 113567630 10129 0.933 
rs6734238 2 113557501 rs1446510 113567988 10487 0.933 
rs4705952 5 131867517 ─ ─ ─ ─ 
rs6901250 6 117220718 rs6924002 117220916 198 0.962 
rs6901250 6 117220718 rs615199 117220346 372 0.962 
rs6901250 6 117220718 rs993394 117223836 3118 0.962 
rs13233571 7 72609167 rs17145738 72620810 11643 1 
rs13233571 7 72609167 rs13232120 72621246 12079 1 
rs13233571 7 72609167 rs13244268 72549779 59388 1 
rs13233571 7 72609167 rs12056034 72516581 92586 1 
rs13233571 7 72609167 rs2074755 72515102 94065 1 
rs13233571 7 72609167 rs714052 72502805 106362 1 
rs13233571 7 72609167 rs13231516 72501185 107982 1 
rs13233571 7 72609167 rs2240466 72494205 114962 1 
rs9987289 8 9220768 rs4841132 9221006 238 1 
rs9987289 8 9220768 rs4841133 9221074 306 1 
rs9987289 8 9220768 rs4240624 9221641 873 1 
rs10745954 12 102007224 rs7972145 102001606 5618 1 
rs10745954 12 102007224 rs4584635 101999174 8050 1 
rs10745954 12 102007224 rs7295481 102016298 9074 1 




SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
6734238 2 113557501 12328368 113563615 6114 0.933 
6734238 2 113557501 6730516 113565432 7931 0.933 
6734238 2 113557501 6738239 113567263 9762 0.933 
6734 38 2 113557501 14 6509 113567 30 10129 0.933 
6734 38 2 113557501 14 6510 11356 988 1 487 0.933 
4705952 5 131867517 ─ ─ ─ ─ 
6901250 6 17220718 6 24002 1722091 198 0.962 
6901250 6 17220718 615199 17220346 372 0.962 
6901250 6 17220718 993394 17223836 3118 0.962 
rs13233571 7 72609167 rs17145738 72620810 11643 1 
rs13233571 7 72609167 rs13232120 72621246 12079 1 
rs13233571 7 72609167 rs13244268 72549779 59388 1 
rs13233571 7 72609167 rs12056034 72516581 92586 1 
rs13233571 7 72609167 rs2074755 72515102 94065 1 
rs13233571 7 72609167 rs714052 72502805 106362 1 
rs13233571 7 72609167 rs13231516 72501185 107982 1 
rs13233571 7 72609167 rs2240466 72494205 114962 1 
rs9987289 8 9220768 rs4841132 9221006 238 1 
rs9987289 8 9220768 rs4841133 9221074 306 1 
rs9987289 8 9220768 rs4240624 9221641 873 1 
rs10745954 12 102007224 rs7972145 102001606 5618 1 
rs10745954 12 102007224 rs4584635 101999174 8050 1 
rs10745954 12 102007224 rs7295481 102016298 9074 1 




SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs10745954 12 102007224 rs1588886 101971777 35447 1 
rs10745954 12 102007224 rs2222044 101982079 25145 0.967 
rs10745954 12 102007224 rs10778212 101979690 27534 0.967 
rs1183910 12 119905190 rs2244608 119901371 3819 0.96 
rs1183910 12 119905190 rs1169288 119901033 4157 0.96 
rs1183910 12 119905190 rs11065385 119907769 2579 0.921 
rs340029 15 58682257 ─ ─ ─ ─ 
rs10521222 16 49716211 ─ ─ ─ ─ 
rs2847281 18 12811593 rs12971201 12820538 8945 1 
rs2847281 18 12811593 rs2852151 12831176 19583 1 
rs2847281 18 12811593 rs674222 12838349 26756 1 
rs2847281 18 12811593 rs4797709 12872359 60766 0.965 
rs4420638 19 50114786 ─ ─ ─ ─ 
rs1800961 20 42475778 ─ ─ ─ ─ 
 
SNP indicates single nucleotide polymorphism; Chr, chromosome; CRP, C-reactive protein; bp, base pairs; and LD, linkage 
disequilibrium (r2) with lead SNP. 
  




SNP ID Chr 
Position 




lead SNP (bp) 
LD with 
lead SNP 
rs10745954 12 102007224 rs1588886 101971777 35447 1 
rs10745954 12 102007224 rs2222044 101982079 25145 0.967 
rs10745954 12 102007224 rs10778212 101979690 27534 0.967 
rs1183910 12 119905190 rs2244608 119901371 3819 0.96 
rs1183910 12 119905190 rs1169288 119901033 4157 0.96 
rs1183910 12 119905190 rs11065385 119907769 2579 0.921 
rs340029 15 58682257 ─ ─ ─ ─ 
rs10521222 16 49716211 ─ ─ ─ ─ 
rs2847281 18 12811593 rs12971201 12820538 8945 1 
rs2847281 18 12811593 rs2852151 12831176 19583 1 
rs2847281 18 12811593 rs674222 12838349 26756 1 
rs2847281 18 12811593 rs4797709 12872359 60766 0.965 
rs4420638 19 50114786 ─ ─ ─ ─ 
rs1800961 20 42475778 ─ ─ ─ ─ 
 
SNP indicates single nucleotide polymorphism; Chr, chromosome; CRP, C-reactive protein; bp, base pairs; and LD, linkage 
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Supplementary Table 4 Individual association summary statistics of CRP lead SNPs and / or proxies with traits and diseases. 














N Controls N Total 
Autoimmune / Inflammatory 
CD rs3093077 T/G 1 CRP rs3093077 A/C 0.997 (0.91-1.093) -0.003 (0.047) 9.55E-01 6333-15056 21389 
CD rs1205 T/C 1 CRP rs1205 T/C 0.96 (0.916-1.007) -0.04 (0.024) 9.45E-02 6333-15056 21389 
CD rs1130864 C/T 1 CRP rs1130864 A/G 1.072 (1.022-1.125) 0.07 (0.025) 4.44E-03 6333-15056 21389 
CD rs1800947 C/G 1 CRP rs1800947 C/G 0.985 (0.883-1.098) -0.016 (0.056) 7.79E-01 6333-15056 21389 
CED rs3093077 T/G 1 CRP rs3093077 C/A 0.968 (0.872-1.074) -0.033 (0.053) 5.40E-01 4533-10750 15283 
CED rs1205 T/C 1 CRP rs1205 T/C 1.009 (0.958-1.063) 0.009 (0.027) 7.45E-01 4533-10750 15283 
CED rs1130864 C/T 1 CRP rs1417938 T/A 0.95 (0.896-1.008) -0.051 (0.03) 6.18E-02 3796-8154 11950 
CED rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs3093077 T/G 1 CRP rs12068753 A/T 0.967 (0.902-1.036) -0.034 (0.035) 3.33E-01 13020-34774 47794 
IBD rs1205 T/C 1 CRP rs1205 T/C 0.997 (0.963-1.032) -0.003 (0.018) 8.54E-01 13020-34774 47794 
IBD rs1130864 C/T 1 CRP rs1130864 A/G 1.023 (0.988-1.06) 0.023 (0.018) 2.00E-01 13020-34774 47794 
IBD rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PSA rs3093077 T/G 1 CRP rs3093077 A/C 1.097 (0.925-1.301) 0.093 (0.087) 2.89E-01 1946-4934 6880 
PSA rs1205 T/C 1 CRP rs1205 T/C 1.085 (0.992-1.187) 0.082 (0.046) 7.52E-02 1946-4934 6880 
PSA rs1130864 C/T 1 CRP rs1130864 G/A 1.024 (0.935-1.121) 0.024 (0.046) 6.16E-01 1946-4934 6880 
PSA rs1800947 C/G 1 CRP rs1800947 G/C 1.071 (0.898-1.277) 0.069 (0.09) 4.44E-01 1946-4934 6880 
PSC rs3093077 T/G 1 CRP rs3093077 A/C 1.133 (0.948-1.355) 0.125 (0.091) 1.72E-01 1363-3517 4880 
PSC rs1205 T/C 1 CRP rs1205 C/T 1.02 (0.925-1.125) 0.02 (0.05) 6.89E-01 1363-3517 4880 
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Supplementary Table 4 Individual association summary statistics of CRP lead SNPs and / or proxies with traits and diseases. 














N Controls N Total 
Autoimmune / Inflammatory 
CD 3093077 T G 3093077 A C 0 997 1-1.093) -0.003 (0.047) 9 55 6333 15056 21389 
CD 2 5 T C 2 5 T  0 96 (0.916-1.00 ) -0.04 (0. 24) 9 5 2 6333 15056 21389 
CD 1130864 C T 1130864 G 072 1 022 12 07 (0.025) 4 44 3 6 3 1 056 21389 
CD 8 0947 C G 8 0947 G 0 985 (0.883-1.098) -0.016 ( .056) 7 7 6 3 1 056 21389 
CED rs3093077 T/G 1 CRP rs3093077 C/A 0.968 (0.872-1.074) -0.033 (0.053) 5.40E-01 4533-10750 15283 
CED rs1205 T/C 1 CRP rs1205 T/C 1.009 (0.958-1.063) 0.009 (0.027) 7.45E-01 4533-10750 15283 
CED rs1130864 C/T 1 CRP rs1417938 T/A 0.95 (0.896-1.008) -0.051 (0.03) 6.18E-02 3796-8154 11950 
CED rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs3093077 T/G 1 CRP rs12068753 A/T 0.967 (0.902-1.036) -0.034 (0.035) 3.33E-01 13020-34774 47794 
IBD rs1205 T/C 1 CRP rs1205 T/C 0.997 (0.963-1.032) -0.003 (0.018) 8.54E-01 13020-34774 47794 
IBD rs1130864 C/T 1 CRP rs1130864 A/G 1.023 (0.988-1.06) 0.023 (0.018) 2.00E-01 13020-34774 47794 
IBD rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PSA rs3093077 T/G 1 CRP rs3093077 A/C 1.097 (0.925-1.301) 0.093 (0.087) 2.89E-01 1946-4934 6880 
PSA rs1205 T/C 1 CRP rs1205 T/C 1.085 (0.992-1.187) 0.082 (0.046) 7.52E-02 1946-4934 6880 
PSA rs1130864 C/T 1 CRP rs1130864 G/A 1.024 (0.935-1.121) 0.024 (0.046) 6.16E-01 1946-4934 6880 
PSA rs1800947 C/G 1 CRP rs1800947 G/C 1.071 (0.898-1.277) 0.069 (0.09) 4.44E-01 1946-4934 6880 
PSC rs3093077 T/G 1 CRP rs3093077 A/C 1.133 (0.948-1.355) 0.125 (0.091) 1.72E-01 1363-3517 4880 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
PSC rs1130864 C/T 1 CRP rs1130864 G/A 1.004 (0.911-1.106) 0.004 (0.049) 9.36E-01 1363-3517 4880 
PSC rs1800947 C/G 1 CRP rs1800947 G/C 1.031 (0.841-1.264) 0.031 (0.104) 7.68E-01 1363-3517 4880 
PSV rs3093077 T/G 1 CRP rs3093077 A/C 1.079 (0.954-1.22) 0.076 (0.063) 2.25E-01 4007-4934 8941 
PSV rs1205 T/C 1 CRP rs1205 T/C 1.026 (0.961-1.095) 0.026 (0.033) 4.40E-01 4007-4934 8941 
PSV rs1130864 C/T 1 CRP rs1130864 G/A 1.026 (0.961-1.096) 0.026 (0.034) 4.37E-01 4007-4934 8941 
PSV rs 800947 C/G 1 CRP rs1800947 G/C 1.04 (0.913-1.185) 0.039 (0.067) 5.56E-01 4007-4934 8941 
RA rs3093077 T/G 1 CRP rs3093077 A/C 0.962 (0.875-1.057) -0.039 (0.048) 5.46E-01 5537-20164 25702 
RA rs1205 T/C 1 CRP rs1205 C/T 1.004 (0.954-1.056) 0.004 (0.026) 6.50E-01 5537-20155 25691 
RA rs1130864 C/T 1 CRP rs1130864 G/A 0.944 (0.887-1.006) -0.057 (0.032) 2.62E-02 3497-18025 21522 
RA rs1800947 C/G 1 CRP rs1800947 G/C 0.937 (0.845-1.038) -0.066 (0.053) 8.72E-01 4013-9560 13573 
SLE rs3093077 T/G 1 CRP rs3093077 C/A 1 (0.836-1.196) 0 (0.091) 6.56E-01 1311-3340 4651 
SLE rs1205 T/C 1 CRP rs2794520 C/T 0.911 (0.827-1.005) -0.093 (0.05) 2.28E-01 1311-3340 4651 
SLE rs1130864 C/T 1 CRP rs12093699 G/A 0.961 (0.871-1.059) -0.04 (0.05) 4.48E-02 1311-3340 4651 
SLE rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs3093077 T/G 1 CRP rs3093077 C/A 1 (0.887-1.18) 0.023 (0.073) 7.51E-01 2340-5178 7518 
SSC rs1205 T/C 1 CRP rs1205 T/C 1 (0.944-1.092) 0.015 (0.037) 6.89E-01 2342-5163 7505 
SSC rs1130864 C/T 1 CRP rs1130864 A/G 0.982 (0.911-1.057) -0.019 (0.038) 6.26E-01 2322-5136 7458 
SSC rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs3093077 T/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs1205 T/C 1 CRP rs1205 C/T 0.991 (0.941-1.044) -0.009 (0.026) 7.35E-01 9934-16956 26890 
T1D rs1130864 C/T 1 CRP rs1130864 G/A 1.039 (0.986-1.095) 0.038 (0.027) 1.51E-01 9934-16956 26890 
T1D rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
UC rs3093077 T/G 1 CRP rs3093077 A/C 1.046 (0.953-1.148) 0.045 (0.047) 3.48E-01 6687-19718 26405 
















N Controls N Total 
P 1130864 C T 1130864 G  .0 4 (0.911-1.106) 04 49 9 36 1 63 3517 4880
P 8 0947 C G 8 0947 G  .031 (0.841-1.264) 31 104 7 68 1 63 3517 4880
P V 3093077 T G 3093077 C 1 079 54 22) 0.076 (0.063) 2 5 4007 49 4 8941
P V 2 5 T C rs1205 T C 1.026 (0.961-1.095) 0.026 (0.033) 4.40E-01 4007-4934 8941 
PSV 1130864 C T rs1130864 G A 1.026 (0.961-1.096) 0.026 (0.034) 4.37E-01 4007-4934 8941 
PSV 8 0947 C G 8 0947 G C 1 04 (0.913-1.185) 0.039 (0.067) 5 56 4007 4934 8941 
RA 3093077 T G 3093077 A C 0 962 875 57 -0.039 (0.048) 5 46 55 7 20164 5702
RA 2 5 T C rs1205 C T 1.004 (0.954-1.056) 0.004 (0.026) 6.50E-01 5537-20155 25691 
RA 130864 C T 1130864 G A 0 9 4 887 006 -0.057 (0.032) 2 62 2 349 8025 1522
RA rs1800947 C/G 1 CRP rs1800947 G/C 0.937 (0.845-1.038) -0.066 (0.053) 8.72E-01 4013-9560 13573 
SLE rs3093077 T/G 1 CRP rs3093077 C/A 1 (0.836-1.196) 0 (0.091) 6.56E-01 1311-3340 4651 
SLE rs1205 T/C 1 CRP rs2794520 C/T 0.911 (0.827-1.005) -0.093 (0.05) 2.28E-01 1311-3340 4651 
SLE rs1130864 C/T 1 CRP rs12093699 G/A 0.961 (0.871-1.059) -0.04 (0.05) 4.48E-02 1311-3340 4651 
SLE rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs3093077 T/G 1 CRP rs3093077 C/A 1 (0.887-1.18) 0.023 (0.073) 7.51E-01 2340-5178 7518 
SSC rs1205 T/C 1 CRP rs1205 T/C 1 (0.944-1.092) 0.015 (0.037) 6.89E-01 2342-5163 7505 
SSC rs1130864 C/T 1 CRP rs1130864 A/G 0.982 (0.911-1.057) -0.019 (0.038) 6.26E-01 2322-5136 7458 
SSC rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs3093077 T/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs1205 T/C 1 CRP rs1205 C/T 0.991 (0.941-1.044) -0.009 (0.026) 7.35E-01 9934-16956 26890 
T1D rs1130864 C/T 1 CRP rs1130864 G/A 1.039 (0.986-1.095) 0.038 (0.027) 1.51E-01 9934-16956 26890 
T1D rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
UC rs3093077 T/G 1 CRP rs3093077 A/C 1.046 (0.953-1.148) 0.045 (0.047) 3.48E-01 6687-19718 26405 
210204-L-bw-Vaez
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Supplementary Table 4 Individual association summary statistics of CRP lead SNPs and / or proxies with traits and diseases. 














N Controls N Total 
Autoimmune / Inflammatory 
CD rs3093077 T/G 1 CRP rs3093077 A/C 0.997 (0.91-1.093) -0.003 (0.047) 9.55E-01 6333-15056 21389 
CD rs1205 T/C 1 CRP rs1205 T/C 0.96 (0.916-1.007) -0.04 (0.024) 9.45E-02 6333-15056 21389 
CD rs1130864 C/T 1 CRP rs1130864 A/G 1.072 (1.022-1.125) 0.07 (0.025) 4.44E-03 6333-15056 21389 
CD rs1800947 C/G 1 CRP rs1800947 C/G 0.985 (0.883-1.098) -0.016 (0.056) 7.79E-01 6333-15056 21389 
CED rs3093077 T/G 1 CRP rs3093077 C/A 0.968 (0.872-1.074) -0.033 (0.053) 5.40E-01 4533-10750 15283 
CED rs1205 T/C 1 CRP rs1205 T/C 1.009 (0.958-1.063) 0.009 (0.027) 7.45E-01 4533-10750 15283 
CED rs1130864 C/T 1 CRP rs1417938 T/A 0.95 (0.896-1.008) -0.051 (0.03) 6.18E-02 3796-8154 11950 
CED rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs3093077 T/G 1 CRP rs12068753 A/T 0.967 (0.902-1.036) -0.034 (0.035) 3.33E-01 13020-34774 47794 
IBD rs1205 T/C 1 CRP rs1205 T/C 0.997 (0.963-1.032) -0.003 (0.018) 8.54E-01 13020-34774 47794 
IBD rs1130864 C/T 1 CRP rs1130864 A/G 1.023 (0.988-1.06) 0.023 (0.018) 2.00E-01 13020-34774 47794 
IBD rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PSA rs3093077 T/G 1 CRP rs3093077 A/C 1.097 (0.925-1.301) 0.093 (0.087) 2.89E-01 1946-4934 6880 
PSA rs1205 T/C 1 CRP rs1205 T/C 1.085 (0.992-1.187) 0.082 (0.046) 7.52E-02 1946-4934 6880 
PSA rs1130864 C/T 1 CRP rs1130864 G/A 1.024 (0.935-1.121) 0.024 (0.046) 6.16E-01 1946-4934 6880 
PSA rs1800947 C/G 1 CRP rs1800947 G/C 1.071 (0.898-1.277) 0.069 (0.09) 4.44E-01 1946-4934 6880 
PSC rs3093077 T/G 1 CRP rs3093077 A/C 1.133 (0.948-1.355) 0.125 (0.091) 1.72E-01 1363-3517 4880 
PSC rs1205 T/C 1 CRP rs1205 C/T 1.02 (0.925-1.125) 0.02 (0.05) 6.89E-01 1363-3517 4880 
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Supplementary Table 4 Individual association summary statistics of CRP lead SNPs and / or proxies with traits and diseases. 














N Controls N Total 
Autoimmune / Inflammatory 
CD 3093077 T G 3093077 A C 0 997 1-1.093) -0.003 (0.047) 9 55 6333 15056 21389 
CD 2 5 T C 2 5 T  0 96 (0.916-1.00 ) -0.04 (0. 24) 9 5 2 6333 15056 21389 
CD 1130864 C T 1130864 G 072 1 022 12 07 (0.025) 4 44 3 6 3 1 056 21389 
CD 8 0947 C G 8 0947 G 0 985 (0.883-1.098) -0.016 ( .056) 7 7 6 3 1 056 21389 
CED rs3093077 T/G 1 CRP rs3093077 C/A 0.968 (0.872-1.074) -0.033 (0.053) 5.40E-01 4533-10750 15283 
CED rs1205 T/C 1 CRP rs1205 T/C 1.009 (0.958-1.063) 0.009 (0.027) 7.45E-01 4533-10750 15283 
CED rs1130864 C/T 1 CRP rs1417938 T/A 0.95 (0.896-1.008) -0.051 (0.03) 6.18E-02 3796-8154 11950 
CED rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs3093077 T/G 1 CRP rs12068753 A/T 0.967 (0.902-1.036) -0.034 (0.035) 3.33E-01 13020-34774 47794 
IBD rs1205 T/C 1 CRP rs1205 T/C 0.997 (0.963-1.032) -0.003 (0.018) 8.54E-01 13020-34774 47794 
IBD rs1130864 C/T 1 CRP rs1130864 A/G 1.023 (0.988-1.06) 0.023 (0.018) 2.00E-01 13020-34774 47794 
IBD rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PSA rs3093077 T/G 1 CRP rs3093077 A/C 1.097 (0.925-1.301) 0.093 (0.087) 2.89E-01 1946-4934 6880 
PSA rs1205 T/C 1 CRP rs1205 T/C 1.085 (0.992-1.187) 0.082 (0.046) 7.52E-02 1946-4934 6880 
PSA rs1130864 C/T 1 CRP rs1130864 G/A 1.024 (0.935-1.121) 0.024 (0.046) 6.16E-01 1946-4934 6880 
PSA rs1800947 C/G 1 CRP rs1800947 G/C 1.071 (0.898-1.277) 0.069 (0.09) 4.44E-01 1946-4934 6880 
PSC rs3093077 T/G 1 CRP rs3093077 A/C 1.133 (0.948-1.355) 0.125 (0.091) 1.72E-01 1363-3517 4880 
PSC rs1205 T/C 1 CRP rs1205 C/T 1.02 (0.925-1.125) 0.02 (0.05) 6.89E-01 1363-3517 4880 
















N Controls N Total 
PSC rs1130864 C/T 1 CRP rs1130864 G/A 1.004 (0.911-1.106) 0.004 (0.049) 9.36E-01 1363-3517 4880 
PSC rs1800947 C/G 1 CRP rs1800947 G/C 1.031 (0.841-1.264) 0.031 (0.104) 7.68E-01 1363-3517 4880 
PSV rs3093077 T/G 1 CRP rs3093077 A/C 1.079 (0.954-1.22) 0.076 (0.063) 2.25E-01 4007-4934 8941 
PSV rs1205 T/C 1 CRP rs1205 T/C 1.026 (0.961-1.095) 0.026 (0.033) 4.40E-01 4007-4934 8941 
PSV rs1130864 C/T 1 CRP rs1130864 G/A 1.026 (0.961-1.096) 0.026 (0.034) 4.37E-01 4007-4934 8941 
PSV rs1800947 C/G 1 CRP rs1800947 G/C 1.04 (0.913-1.185) 0.039 (0.067) 5.56E-01 4007-4934 8941 
RA rs3093077 T/G 1 CRP rs3093077 A/C 0.962 (0.875-1.057) -0.039 (0.048) 5.46E-01 5537-20164 25702 
RA rs1205 T/C 1 CRP rs1205 C/T 1.004 (0.954-1.056) 0.004 (0.026) 6.50E-01 5537-20155 25691 
RA rs1130864 C/T 1 CRP rs1130864 G/A 0.944 (0.887-1.006) -0.057 (0.032) 2.62E-02 3497-18025 21522 
RA rs1800947 C/G 1 CRP rs1800947 G/C 0.937 (0.845-1.038) -0.066 (0.053) 8.72E-01 4013-9560 13573 
SLE rs3093077 T/G 1 CRP rs3093077 C/A 1 (0.836-1.196) 0 (0.091) 6.56E-01 1311-3340 4651 
SLE rs1205 T/C 1 CRP rs2794520 C/T 0.911 (0.827-1.005) -0.093 (0.05) 2.28E-01 1311-3340 4651 
SLE rs1130864 C/T 1 CRP rs12093699 G/A 0.961 (0.871-1.059) -0.04 (0.05) 4.48E-02 1311-3340 4651 
SLE rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs3093077 T/G 1 CRP rs3093077 C/A 1 (0.887-1.18) 0.023 (0.073) 7.51E-01 2340-5178 7518 
SSC rs1205 T/C 1 CRP rs1205 T/C 1 (0.944-1.092) 0.015 (0.037) 6.89E-01 2342-5163 7505 
SSC rs1130864 C/T 1 CRP rs1130864 A/G 0.982 (0.911-1.057) -0.019 (0.038) 6.26E-01 2322-5136 7458 
SSC rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs3093077 T/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs1205 T/C 1 CRP rs1205 C/T 0.991 (0.941-1.044) -0.009 (0.026) 7.35E-01 9934-16956 26890 
T1D rs1130864 C/T 1 CRP rs1130864 G/A 1.039 (0.986-1.095) 0.038 (0.027) 1.51E-01 9934-16956 26890 
T1D rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
UC rs3093077 T/G 1 CRP rs3093077 A/C 1.046 (0.953-1.148) 0.045 (0.047) 3.48E-01 6687-19718 26405 
















N Controls N Total 
P 1130864 C T 1130864 G  .0 4 (0.911-1.106) 04 49 9 36 1 63 3517 4880
P 8 0947 C G 8 0947 G  .031 (0.841-1.264) 31 104 7 68 1 63 3517 4880
P V 3093077 T G 3093077 C 1 079 54 22) 0.076 (0.063) 2 5 4007 49 4 8941
P V 2 5 T C rs1205 T C 1.026 (0.961-1.095) 0.026 (0.033) 4.40E-01 4007-4934 8941 
PSV 1130864 C T rs1130864 G A 1.026 (0.961-1.096) 0.026 (0.034) 4.37E-01 4007-4934 8941 
PSV 8 0947 C G 8 0947 G C 1 04 (0.913-1.185) 0.039 (0.067) 5 56 4007 4934 8941 
RA 3093077 T G 3093077 A C 0 962 875 57 -0.039 (0.048) 5 46 55 7 20164 5702
RA 2 5 T C rs1205 C T 1.004 (0.954-1.056) 0.004 (0.026) 6.50E-01 5537-20155 25691 
RA 1130864 C T 1130864 G A 0 9 4 887 006 -0.057 (0.032) 2 62 2 349 8025 1522
RA rs1800947 C/G 1 CRP rs1800947 G/C 0.937 (0.845-1.038) -0.066 (0.053) 8.72E-01 4013-9560 13573 
SLE rs3093077 T/G 1 CRP rs3093077 C/A 1 (0.836-1.196) 0 (0.091) 6.56E-01 1311-3340 4651 
SLE rs1205 T/C 1 CRP rs2794520 C/T 0.911 (0.827-1.005) -0.093 (0.05) 2.28E-01 1311-3340 4651 
SLE rs1130864 C/T 1 CRP rs12093699 G/A 0.961 (0.871-1.059) -0.04 (0.05) 4.48E-02 1311-3340 4651 
SLE rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs3093077 T/G 1 CRP rs3093077 C/A 1 (0.887-1.18) 0.023 (0.073) 7.51E-01 2340-5178 7518 
SSC rs1205 T/C 1 CRP rs1205 T/C 1 (0.944-1.092) 0.015 (0.037) 6.89E-01 2342-5163 7505 
SSC rs1130864 C/T 1 CRP rs1130864 A/G 0.982 (0.911-1.057) -0.019 (0.038) 6.26E-01 2322-5136 7458 
SSC rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs3093077 T/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs1205 T/C 1 CRP rs1205 C/T 0.991 (0.941-1.044) -0.009 (0.026) 7.35E-01 9934-16956 26890 
T1D rs1130864 C/T 1 CRP rs1130864 G/A 1.039 (0.986-1.095) 0.038 (0.027) 1.51E-01 9934-16956 26890 
T1D rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
UC rs1205 T/C 1 CRP rs1205 T/C 1.018 (0.974-1.063) 0.018 (0.022) 4.36E-01 6687-19718 26405 
UC rs1130864 C/T 1 CRP rs1130864 A/G 0.992 (0.949-1.037) -0.008 (0.023) 7.35E-01 6687-19718 26405 
UC rs1800947 C/G 1 CRP rs1800947 C/G 0.999 (0.901-1.108) -0.001 (0.053) 9.87E-01 6687-19718 26405 
KOA rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.015 (0.05) 7.63E-01 5755-18505 24260 
KOA rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.022 (0.025) 3.69E-01 5755-18505 24260 
KOA rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.034 (0.025) 1.87E-01 5755-18505 24260 
KOA rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.073 (0.05) 1.41E-01 5755-18505 24260 
Cardiovascular 
CAD rs3093077 T/G 1 CRP rs3093077 A/C 1.026 (0.968-1.088) 0.026 (0.03) 3.90E-01 22233-64762 86995 
CAD rs1205 T/C 1 CRP rs1205 T/C 1.024 (0.995-1.054) 0.024 (0.015) 1.04E-01 22233-64762 86995 
CAD rs1130864 C/T 1 CRP rs1130864 A/G 1.002 (0.97-1.035) 0.002 (0.016) 9.00E-01 22233-64762 86995 
CAD rs1800947 C/G 1 CRP rs1800947 G/C 1.028 (0.961-1.101) 0.028 (0.035) 3.44E-01 22233-64762 86995 
DBP rs3093077 T/G 1 CRP rs3093077 A/C ─ (─-─) 0.076 (0.128) 5.52E-01 ─-─ 67321 
DBP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.158 (0.065) 1.53E-02 ─-─ 68822 
DBP rs1130864 C/T 1 CRP rs1417938 A/T ─ (─-─) -0.108 (0.066) 9.82E-02 ─-─ 68689 
DBP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.036 (0.147) 8.09E-01 ─-─ 43686 
IS rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.033 (0.068) 6.29E-01 3548-5972 9520 
IS rs1205 T/C 1 CRP rs1205 T/C ─ (─-─) 0.047 (0.033) 1.61E-01 3548-5972 9520 
IS rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.011 (0.034) 7.50E-01 3548-5972 9520 
IS rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.022 (0.066) 7.34E-01 3548-5972 9520 
IS (CS) rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.021 (0.126) 8.65E-01 790-5972 6762 
IS (CS) rs1205 T/C 1 CRP rs1205 T/C ─ (─-─) 0.011 (0.059) 8.54E-01 790-5972 6762 
IS (CS) rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.012 (0.059) 8.42E-01 790-5972 6762 
















N Controls N Total 
UC rs1205 T/C 1 CRP rs1205 T/C 1.018 (0.974-1.063) 0.018 (0.022) 4.36E-01 6687-19718 26405 
UC rs1130864 C/T 1 CRP rs1130864 A/G 0.992 (0.949-1.037) -0.008 (0.023) 7.35E-01 6687-19718 26405 
UC rs1800947 C/G 1 CRP rs1800947 C/G 0.999 (0.901-1.108) -0.001 (0.053) 9.87E-01 6687-19718 26405 
KOA rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.015 (0.05) 7.63E-01 5755-18505 24260 
KOA rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.022 (0.025) 3.69E-01 5755-18505 24260 
KOA rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.034 (0.025) 1.87E-01 5755-18505 24260 
KOA rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.073 (0.05) 1.41E-01 5755-18505 24260 
Cardiovascular 
CAD 3093077 T G 3093077 A C 1.026 (0.968-1.088) 26 3) 3 90 22233-64762 86995 
CAD rs1205 T/C 1 CRP rs1205 T/C 1.024 (0.995-1.054) 0.024 (0.015) 1.04E-01 22233-64762 86995 
CAD rs1130864 C/T 1 CRP rs1130864 A/G 1.002 (0.97-1.035) 0.002 (0.016) 9.00E-01 22233-64762 86995 
CAD rs1800947 C/G 1 CRP rs1800947 G/C 1.028 (0.961-1.101) 0.028 (0.035) 3.44E-01 22233-64762 86995 
DBP rs3093077 T/G 1 CRP rs3093077 A/C ─ (─-─) 0.076 (0.128) 5.52E-01 ─-─ 67321 
DBP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.158 (0.065) 1.53E-02 ─-─ 68822 
DBP rs1130864 C/T 1 CRP rs1417938 A/T ─ (─-─) -0.108 (0.066) 9.82E-02 ─-─ 68689 
DBP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.036 (0.147) 8.09E-01 ─-─ 43686 
IS rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.033 (0.068) 6.29E-01 3548-5972 9520 
IS rs1205 T/C 1 CRP rs1205 T/C ─ (─-─) 0.047 (0.033) 1.61E-01 3548-5972 9520 
IS rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.011 (0.034) 7.50E-01 3548-5972 9520 
IS rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.022 (0.066) 7.34E-01 3548-5972 9520 
IS (CS) rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.021 (0.126) 8.65E-01 790-5972 6762 
IS (CS) rs1205 T/C 1 CRP rs1205 T/C ─ (─-─) 0.011 (0.059) 8.54E-01 790-5972 6762 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
IS (CS) rs 800947 C/G 1 CRP rs1800947 C/G ─ (─-─) -0.048 (0.112) 6.69E-01 790-5972 6762 
IS (LVS) rs3 93077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.197 (0.111) 7.67E-02 844-5972 6816 
IS (LVS) rs 2 5 T/C 1 CRP rs1205 T/C ─ (─-─) 0.09 (0.058) 1.23E-01 844-5972 6816 
IS (LVS) rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.04 (0.059) 4.95E-01 844-5972 6816 
IS (LVS) rs1800947 C/G 1 CRP rs18 0947 C/G ─ (─-─) 0.069 (0.114) 5.46E-01 844-5972 6816 
IS (SVD) rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.192 (0.146) 1.88E-01 580-5972 6552 
IS (SVD) rs1205 T/C 1 CRP rs12  T/C ─ (─-─) 0.034 (0.066) 6.13E-01 580-5972 6552 
IS (SVD) rs1130 64 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.078 (0.066) 2.32E-01 580-5972 6552 
IS (SVD) rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.062 (0.135) 6.48E-01 580-5972 6552 
SBP rs3 93077 T/G 1 CRP rs3093077 A/C ─ (─-─) 0.008 (0.2) 9.68E-01 ─-─ 67368 
SBP rs1 05 T/C 1 CRP rs1205 C/T ─ (─-─) -0.286 (0.103) 5.35E-03 ─-─ 68827 
SBP rs1130864 C/T 1 CRP rs1417938 A/T ─ (─-─) -0.187 (0.103) 6.97E-02 ─-─ 68692 
SBP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.2 (0.233) 3.90E-01 ─-─ 43480 
Metabolic 
BMI rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0 (0.01) 9.90E-01 ─-─ 123837 
BMI rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.003 (0.005) 5.34E-01 ─-─ 123864 
BMI rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.011 (0.007) 1.19E-01 ─-─ 67240 
BMI rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.006 (0.011) 6.20E-01 ─-─ 110634 
T2D rs3093077 T/G 1 CRP rs3093077 A/C 1.08 (0.99-1.177) 0.077 (0.044) 8.14E-02 ─-─ 22570 
T2D rs1205 T/C 1 CRP rs1205 T/C 1.019 (0.976-1.063) 0.019 (0.022) 3.91E-01 ─-─ 22570 
T2D rs1130864 C/T 1 CRP rs1417938 A/T 1.002 (0.961-1.045) 0.002 (0.022) 9.27E-01 ─-─ 22570 
T2D rs1800947 C/G 1 CRP rs1800947 G/C 1.006 (0.898-1.128) 0.006 (0.058) 9.19E-01 ─-─ 13971 
CKD rs3 93077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.007 (0.044) 8.84E-01 6271-68083 74354 
















N Controls N Total 
IS (CS) rs 800947 C/G 1 CRP rs1800947 C/G ─ (─-─) -0.048 (0.112) 6.69E-01 790-5972 6762 
IS (LVS) rs3 93077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.197 (0.111) 7.67E-02 844-5972 6816 
IS (LVS) rs 2 5 T/C 1 CRP rs1205 T/C ─ (─-─) 0.09 (0.058) 1.23E-01 844-5972 6816 
IS (LVS) rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.04 (0.059) 4.95E-01 844-5972 6816 
IS (LVS) rs1800947 C/G 1 CRP rs18 0947 C/G ─ (─-─) 0.069 (0.114) 5.46E-01 844-5972 6816 
IS (SVD) rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.192 (0.146) 1.88E-01 580-5972 6552 
IS (SVD) rs1205 T/C 1 CRP rs12  T/C ─ (─-─) 0.034 (0.066) 6.13E-01 580-5972 6552 
IS (SVD) rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.078 (0.066) 2.32E-01 580-5972 6552 
IS (SVD) rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.062 (0.135) 6.48E-01 580-5972 6552 
SBP rs3093077 T/G 1 CRP rs3093077 A/C ─ (─-─) 0.008 (0.2) 9.68E-01 ─-─ 67368 
SBP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.286 (0.103) 5.35E-03 ─-─ 68827 
SBP rs1130864 C/T 1 CRP rs1417938 A/T ─ (─-─) -0.187 (0.103) 6.97E-02 ─-─ 68692 
SBP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.2 (0.233) 3.90E-01 ─-─ 43480 
Metabolic 
BMI rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0 (0.01) 9.90E-01 ─-─ 123837 
BMI rs1205 /C 1 CRP rs1205 C/T ─ (─-─) 0.003 (0.005) 5.34E-01 ─-─ 123864 
BMI rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.011 (0.007) 1.19E-01 ─-─ 67240 
BMI rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.006 (0.011) 6.20E-01 ─-─ 110634 
T2D rs3093 77 T/G 1 CRP rs3093077 A/C 1.08 (0.99-1.177) 0.077 (0.044) 8.14E-02 ─-─ 22570 
T2D rs1205 T/C 1 CRP rs1205 T/C 1.019 (0.976-1.063) 0.019 (0.022) 3.91E-01 ─-─ 22570 
T2D rs1130864 C/T 1 CRP rs1417938 A/T 1.002 (0.961-1.045) 0.002 (0.022) 9.27E-01 ─-─ 22570 
T2D rs1800947 C/G 1 CRP rs1800947 G/C 1.006 (0.898-1.128) 0.006 (0.058) 9.19E-01 ─-─ 13971 
CKD rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.007 (0.044) 8.84E-01 6271-68083 74354 
210204-L-bw-Vaez
















N Controls N Total 
UC rs1205 T/C 1 CRP rs1205 T/C 1.018 (0.974-1.063) 0.018 (0.022) 4.36E-01 6687-19718 26405 
UC rs1130864 C/T 1 CRP rs1130864 A/G 0.992 (0.949-1.037) -0.008 (0.023) 7.35E-01 6687-19718 26405 
UC rs1800947 C/G 1 CRP rs1800947 C/G 0.999 (0.901-1.108) -0.001 (0.053) 9.87E-01 6687-19718 26405 
KOA rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.015 (0.05) 7.63E-01 5755-18505 24260 
KOA rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.022 (0.025) 3.69E-01 5755-18505 24260 
KOA rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.034 (0.025) 1.87E-01 5755-18505 24260 
KOA rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.073 (0.05) 1.41E-01 5755-18505 24260 
Cardiovascular 
CAD rs3093077 T/G 1 CRP rs3093077 A/C 1.026 (0.968-1.088) 0.026 (0.03) 3.90E-01 22233-64762 86995 
CAD rs1205 T/C 1 CRP rs1205 T/C 1.024 (0.995-1.054) 0.024 (0.015) 1.04E-01 22233-64762 86995 
CAD rs1130864 C/T 1 CRP rs1130864 A/G 1.002 (0.97-1.035) 0.002 (0.016) 9.00E-01 22233-64762 86995 
CAD rs1800947 C/G 1 CRP rs1800947 G/C 1.028 (0.961-1.101) 0.028 (0.035) 3.44E-01 22233-64762 86995 
DBP rs3093077 T/G 1 CRP rs3093077 A/C ─ (─-─) 0.076 (0.128) 5.52E-01 ─-─ 67321 
DBP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.158 (0.065) 1.53E-02 ─-─ 68822 
DBP rs1130864 C/T 1 CRP rs1417938 A/T ─ (─-─) -0.108 (0.066) 9.82E-02 ─-─ 68689 
DBP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.036 (0.147) 8.09E-01 ─-─ 43686 
IS rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.033 (0.068) 6.29E-01 3548-5972 9520 
IS rs1205 T/C 1 CRP rs1205 T/C ─ (─-─) 0.047 (0.033) 1.61E-01 3548-5972 9520 
IS rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.011 (0.034) 7.50E-01 3548-5972 9520 
IS rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.022 (0.066) 7.34E-01 3548-5972 9520 
IS (CS) rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.021 (0.126) 8.65E-01 790-5972 6762 
IS (CS) rs1205 T/C 1 CRP rs1205 T/C ─ (─-─) 0.011 (0.059) 8.54E-01 790-5972 6762 
IS (CS) rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.012 (0.059) 8.42E-01 790-5972 6762 
















N Controls N Total 
UC rs1205 T/C 1 CRP rs1205 T/C 1.018 (0.974-1.063) 0.018 (0.022) 4.36E-01 6687-19718 26405 
UC rs1130864 C/T 1 CRP rs1130864 A/G 0.992 (0.949-1.037) -0.008 (0.023) 7.35E-01 6687-19718 26405 
UC rs1800947 C/G 1 CRP rs1800947 C/G 0.999 (0.901-1.108) -0.001 (0.053) 9.87E-01 6687-19718 26405 
KOA rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.015 (0.05) 7.63E-01 5755-18505 24260 
KOA rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.022 (0.025) 3.69E-01 5755-18505 24260 
KOA rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.034 (0.025) 1.87E-01 5755-18505 24260 
KOA rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.073 (0.05) 1.41E-01 5755-18505 24260 
Cardiovascular 
CAD 3093077 T G 3093077 A C 1.026 (0.968-1.088) 26 3) 3 90 22233-64762 86995 
CAD rs1205 T/C 1 CRP rs1205 T/C 1.024 (0.995-1.054) 0.024 (0.015) 1.04E-01 22233-64762 86995 
CAD rs1130864 C/T 1 CRP rs1130864 A/G 1.002 (0.97-1.035) 0.002 (0.016) 9.00E-01 22233-64762 86995 
CAD rs1800947 C/G 1 CRP rs1800947 G/C 1.028 (0.961-1.101) 0.028 (0.035) 3.44E-01 22233-64762 86995 
DBP rs3093077 T/G 1 CRP rs3093077 A/C ─ (─-─) 0.076 (0.128) 5.52E-01 ─-─ 67321 
DBP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.158 (0.065) 1.53E-02 ─-─ 68822 
DBP rs1130864 C/T 1 CRP rs1417938 A/T ─ (─-─) -0.108 (0.066) 9.82E-02 ─-─ 68689 
DBP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.036 (0.147) 8.09E-01 ─-─ 43686 
IS rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.033 (0.068) 6.29E-01 3548-5972 9520 
IS rs1205 T/C 1 CRP rs1205 T/C ─ (─-─) 0.047 (0.033) 1.61E-01 3548-5972 9520 
IS rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.011 (0.034) 7.50E-01 3548-5972 9520 
IS rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.022 (0.066) 7.34E-01 3548-5972 9520 
IS (CS) rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.021 (0.126) 8.65E-01 790-5972 6762 
IS (CS) rs1205 T/C 1 CRP rs1205 T/C ─ (─-─) 0.011 (0.059) 8.54E-01 790-5972 6762 
IS (CS) rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.012 (0.059) 8.42E-01 790-5972 6762 
















N Controls N Total 
IS (CS) rs 800947 C/G 1 CRP rs1800947 C/G ─ (─-─) -0.048 (0.112) 6.69E-01 790-5972 6762 
IS (LVS) rs3 93077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.197 (0.111) 7.67E-02 844-5972 6816 
IS (LVS) rs 2 5 T/C 1 CRP rs1205 T/C ─ (─-─) 0.09 (0.058) 1.23E-01 844-5972 6816 
IS (LVS) rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.04 (0.059) 4.95E-01 844-5972 6816 
IS (LVS) rs1800947 C/G 1 CRP rs18 0947 C/G ─ (─-─) 0.069 (0.114) 5.46E-01 844-5972 6816 
IS (SVD) rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.192 (0.146) 1.88E-01 580-5972 6552 
IS (SVD) rs1205 T/C 1 CRP rs12  T/C ─ (─-─) 0.034 (0.066) 6.13E-01 580-5972 6552 
IS (SVD) rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.078 (0.066) 2.32E-01 580-5972 6552 
IS (SVD) rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.062 (0.135) 6.48E-01 580-5972 6552 
SBP rs3093077 T/G 1 CRP rs3093077 A/C ─ (─-─) 0.008 (0.2) 9.68E-01 ─-─ 67368 
SBP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.286 (0.103) 5.35E-03 ─-─ 68827 
SBP rs1130864 C/T 1 CRP rs1417938 A/T ─ (─-─) -0.187 (0.103) 6.97E-02 ─-─ 68692 
SBP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.2 (0.233) 3.90E-01 ─-─ 43480 
Metabolic 
BMI rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0 (0.01) 9.90E-01 ─-─ 123837 
BMI rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.003 (0.005) 5.34E-01 ─-─ 123864 
BMI rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.011 (0.007) 1.19E-01 ─-─ 67240 
BMI rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.006 (0.011) 6.20E-01 ─-─ 110634 
T2D rs3093077 T/G 1 CRP rs3093077 A/C 1.08 (0.99-1.177) 0.077 (0.044) 8.14E-02 ─-─ 22570 
T2D rs1205 T/C 1 CRP rs1205 T/C 1.019 (0.976-1.063) 0.019 (0.022) 3.91E-01 ─-─ 22570 
T2D rs1130864 C/T 1 CRP rs1417938 A/T 1.002 (0.961-1.045) 0.002 (0.022) 9.27E-01 ─-─ 22570 
T2D rs1800947 C/G 1 CRP rs1800947 G/C 1.006 (0.898-1.128) 0.006 (0.058) 9.19E-01 ─-─ 13971 
CKD rs3 93077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.007 (0.044) 8.84E-01 6271-68083 74354 
















N Controls N Total 
IS (CS) rs 800947 C/G 1 CRP rs1800947 C/G ─ (─-─) -0.048 (0.112) 6.69E-01 790-5972 6762 
IS (LVS) rs3 93077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.197 (0.111) 7.67E-02 844-5972 6816 
IS (LVS) rs 2 5 T/C 1 CRP rs1205 T/C ─ (─-─) 0.09 (0.058) 1.23E-01 844-5972 6816 
IS (LVS) rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.04 (0.059) 4.95E-01 844-5972 6816 
IS (LVS) rs1800947 C/G 1 CRP rs18 0947 C/G ─ (─-─) 0.069 (0.114) 5.46E-01 844-5972 6816 
IS (SVD) rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.192 (0.146) 1.88E-01 580-5972 6552 
IS (SVD) rs1205 T/C 1 CRP rs12  T/C ─ (─-─) 0.034 (0.066) 6.13E-01 580-5972 6552 
IS (SVD) rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.078 (0.066) 2.32E-01 580-5972 6552 
IS (SVD) rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.062 (0.135) 6.48E-01 580-5972 6552 
SBP rs3093077 T/G 1 CRP rs3093077 A/C ─ (─-─) 0.008 (0.2) 9.68E-01 ─-─ 67368 
SBP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.286 (0.103) 5.35E-03 ─-─ 68827 
SBP rs1130864 C/T 1 CRP rs1417938 A/T ─ (─-─) -0.187 (0.103) 6.97E-02 ─-─ 68692 
SBP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) -0.2 (0.233) 3.90E-01 ─-─ 43480 
Metabolic 
BMI rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0 (0.01) 9.90E-01 ─-─ 123837 
BMI rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.003 (0.005) 5.34E-01 ─-─ 123864 
BMI rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.011 (0.007) 1.19E-01 ─-─ 67240 
BMI rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.006 (0.011) 6.20E-01 ─-─ 110634 
T2D rs3093077 T/G 1 CRP rs3093077 A/C 1.08 (0.99-1.177) 0.077 (0.044) 8.14E-02 ─-─ 22570 
T2D rs1205 T/C 1 CRP rs1205 T/C 1.019 (0.976-1.063) 0.019 (0.022) 3.91E-01 ─-─ 22570 
T2D rs1130864 C/T 1 CRP rs1417938 A/T 1.002 (0.961-1.045) 0.002 (0.022) 9.27E-01 ─-─ 22570 
T2D rs1800947 C/G 1 CRP rs1800947 G/C 1.006 (0.898-1.128) 0.006 (0.058) 9.19E-01 ─-─ 13971 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
CKD rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.014 (0.022) 5.37E-01 6271-68083 74354 
CKD rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.007 (0.023) 7.68E-01 6271-68083 74354 
CKD rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.023 (0.046) 6.13E-01 6271-68083 74354 
eGFR rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0 (0.003) 8.75E-01 ─-─ 74354 
eGFR rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.001 (0.001) 6.25E-01 ─-─ 74354 
eGFR rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.001 (0.001) 3.29E-01 ─-─ 74354 
eGFR rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.001 (0.003) 8.69E-01 ─-─ 74354 
SA rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.001 (0.004) 7.73E-01 ─-─ 53188 
SA rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.001 (0.002) 6.04E-01 ─-─ 53189 
SA rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.001 (0.002) 5.44E-01 ─-─ 38231 
SA rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) 0.001 (0.004) 8.67E-01 ─-─ 49950 
SP rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.006 (0.008) 4.15E-01 ─-─ 25536 
SP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.002 (0.004) 7.04E-01 ─-─ 25537 
SP rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.013 (0.006) 3.30E-02 ─-─ 12156 
SP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) 0.007 (0.009) 4.08E-01 ─-─ 25537 
Neurodegenerative 
ALS rs3093077 T/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1205 T/C 1 CRP rs2794520 C/T 1.019 (0.961-1.08) 0.019 (0.03) 5.29E-01 ─-─ 12260 
ALS rs1130864 C/T 1 CRP rs12093699 G/A 0.943 (0.889-1) -0.059 (0.03) 4.87E-02 ─-─ 12252 
ALS rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs3093077 T/G 1 CRP rs11265260 G/A 0.888 (0.775-1.018) -0.119 (0.058) 8.79E-02 4663-8357 13020 
ALZ rs1205 T/C 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs1130864 C/T 1 CRP rs12093699 G/A 1 (0.943-1.06) 0 (0.029) 9.88E-01 4663-8357 13020 
















N Controls N Total 
CKD 2 5 T C 2 5 C T -0.014 (0.022) 5 37 6271-68083 74354
CKD rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.007 (0.023) 7.68E-01 6271-68083 74354 
CKD rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.023 (0.046) 6.13E-01 6271-68083 74354 
eGFR rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0 (0.003) 8.75E-01 ─-─ 74354 
eGFR rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.001 (0.001) 6.25E-01 ─-─ 74354 
eGFR rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.001 (0.001) 3.29E-01 ─-─ 74354 
eGFR rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.001 (0.003) 8.69E-01 ─-─ 74354 
SA rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.001 (0.004) 7.73E-01 ─-─ 53188 
SA rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.001 (0.002) 6.04E-01 ─-─ 53189 
SA rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.001 (0.002) 5.44E-01 ─-─ 38231 
SA rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) 0.001 (0.004) 8.67E-01 ─-─ 49950 
SP rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.006 (0.008) 4.15E-01 ─-─ 25536 
SP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.002 (0.004) 7.04E-01 ─-─ 25537 
SP rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.013 (0.006) 3.30E-02 ─-─ 12156 
SP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) 0.007 (0.009) 4.08E-01 ─-─ 25537 
Neurodegenerative 
ALS rs3093077 T/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1205 T/C 1 CRP rs2794520 C/T 1.019 (0.961-1.08) 0.019 (0.03) 5.29E-01 ─-─ 12260 
ALS rs1130864 C/T 1 CRP rs12093699 G/A 0.943 (0.889-1) -0.059 (0.03) 4.87E-02 ─-─ 12252 
ALS rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs3093077 T/G 1 CRP rs11265260 G/A 0.888 (0.775-1.018) -0.119 (0.058) 8.79E-02 4663-8357 13020 
ALZ rs1205 T/C 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
ALZ rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs3093077 T/G 1 CRP rs3 9 077 A/C 1.04 (0.969-1.118) 0.04 (0.036) 2.78E-01 5333-12019 17352 
PKD rs1205 T/C 1 CRP rs2794520 A/G 1 (0.963-1.038) 0 (0.019) 9.92E-01 5333-12019 17352 
PKD rs1130864 C/T 1 CRP rs12093699 A/G 1.02 (0.983-1.058) 0.02 (0.019) 3.04E-01 5333-12019 17352 
PKD rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
Psychiatric 
AUT rs3093077 T/G 1 CRP rs3093077 T/G 0.941 (─-─) -0.06 (0.117) 5.16E-01 90-1476 1566 
AUT rs1205 T/C 1 CRP rs7553007 C/T 1.03 (─-─) 0.03 (0.05) 5.87E-01 90-1476 1566 
AUT rs1130864 C/T 1 CRP rs3116651 C/T 1.003 (─-─) 0.003 (0.003) 9.55E-01 90-1476 1566 
AUT rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
BPD rs3093077 T/G 1 CRP rs3093077 C/A 0.965 (0.876-1.064) -0.035 (0.05) 4.79E-01 7481-9250 16731 
BPD rs1205 T/C 1 CRP rs1205 T/C 1.053 (1.004-1.105) 0.052 (0.025) 3.45E-02 7481-9250 16731 
BPD rs1130864 C/T 1 CRP rs1130864 G/A 0.999 (0.951-1.05) -0.001 (0.025) 9.77E-01 7481-9250 16731 
BPD rs1800947 C/G 1 CRP rs1800947 C/G 0.984 (0.868-1.116) -0.016 (0.064) 8.05E-01 7481-9250 16731 
MDD rs3093077 T/G 1 CRP rs3093077 C/A 0.999 (0.914-1.091) -0.001 (0.045) 9.77E-01 9240-9519 18759 
MDD rs1205 T/C 1 CRP rs1205 C/T 0.998 (0.955-1.043) -0.002 (0.023) 9.30E-01 9240-9519 18759 
MDD rs1130864 C/T 1 CRP rs1130864 G/A 0.986 (0.943-1.032) -0.014 (0.023) 5.51E-01 9240-9519 18759 
MDD rs 800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs3093077 T/G 1 CRP rs3093077 C/A 1.008 (0.967-1.051) 0.008 (0.021) 6.90E-01 34241-45604 79845 
SCZ rs1205 T/C 1 CRP rs1205 C/T 1.021 (0.999-1.043) 0.02 (0.011) 3.57E-01 34241-45604 79845 
SCZ rs 130864 C/T 1 CRP rs1130864 G/A 0.986 (0.963-1.008) -0.015 (0.012) 9.06E-01 34241-45604 79845 
SCZ rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
 
















N Controls N Total 
ALZ rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs3093077 T/G 1 CRP rs3 9 077 A/C 1.04 (0.969-1.118) 0.04 (0.036) 2.78E-01 5333-12019 17352 
PKD rs1205 T/C 1 CRP rs2794520 A/G 1 (0.963-1.038) 0 (0.019) 9.92E-01 5333-12019 17352 
PKD rs1130864 C/T 1 CRP rs12093699 A/G 1.02 (0.983-1.058) 0.02 (0.019) 3.04E-01 5333-12019 17352 
PKD rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
Psychiatric 
AUT 3 93077 T G 3093077 T G 41 ─-─) 6 (0.117) 5 1 90-1476 1566 
AUT 2 5 T C rs7553007 C T 1.03 ( -─) 0.03 (0.05) 5.87E-01 90-1476 1566 
AUT rs1130864 C/T 1 CRP rs3116651 C/T 1.003 (─-─) 0.003 (0.003) 9.55E-01 90-1476 1566 
AUT rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
BPD rs3093077 T/G 1 CRP rs3093077 C/A 0.965 (0.876-1.064) -0.035 (0.05) 4.79E-01 7481-9250 16731 
BPD rs1205 T/C 1 CRP rs1205 T/C 1.053 (1.004-1.105) 0.052 (0.025) 3.45E-02 7481-9250 16731 
BPD rs1130864 /T 1 CRP rs1130864 G/A 0.999 (0.951-1.05) -0.001 (0.025) 9.77E-01 7481-9250 16731 
BPD rs1800947 C/G 1 CRP rs1800947 C/G 0.984 (0.868-1.116) -0.016 (0.064) 8.05E-01 7481-9250 16731 
MDD rs3093077 T/G 1 CRP rs3093077 C/A 0.999 (0.914-1.091) -0.001 (0.045) 9.77E-01 9240-9519 18759 
MDD rs1205 /C 1 CRP rs1205 C/T 0.998 (0.955-1.043) -0.002 (0.023) 9.30E-01 9240-9519 18759 
MDD rs1130864 C/T 1 CRP rs1130864 G/A 0.986 (0.943-1.032) -0.014 (0.023) 5.51E-01 9240-9519 18759 
MDD rs 800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs3093077 T/G 1 CRP rs3093077 C/A 1.008 (0.967-1.051) 0.008 (0.021) 6.90E-01 34241-45604 79845 
SCZ rs1205 T/C 1 CRP rs1205 C/T 1.021 (0.999-1.043) 0.02 (0.011) 3.57E-01 34241-45604 79845 
SCZ rs 130864 C/T 1 CRP rs1130864 G/A 0.986 (0.963-1.008) -0.015 (0.012) 9.06E-01 34241-45604 79845 
SCZ rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
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N Controls N Total 
CKD rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.014 (0.022) 5.37E-01 6271-68083 74354 
CKD rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.007 (0.023) 7.68E-01 6271-68083 74354 
CKD rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.023 (0.046) 6.13E-01 6271-68083 74354 
eGFR rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0 (0.003) 8.75E-01 ─-─ 74354 
eGFR rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.001 (0.001) 6.25E-01 ─-─ 74354 
eGFR rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.001 (0.001) 3.29E-01 ─-─ 74354 
eGFR rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.001 (0.003) 8.69E-01 ─-─ 74354 
SA rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.001 (0.004) 7.73E-01 ─-─ 53188 
SA rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.001 (0.002) 6.04E-01 ─-─ 53189 
SA rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.001 (0.002) 5.44E-01 ─-─ 38231 
SA rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) 0.001 (0.004) 8.67E-01 ─-─ 49950 
SP rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.006 (0.008) 4.15E-01 ─-─ 25536 
SP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.002 (0.004) 7.04E-01 ─-─ 25537 
SP rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.013 (0.006) 3.30E-02 ─-─ 12156 
SP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) 0.007 (0.009) 4.08E-01 ─-─ 25537 
Neurodegenerative 
ALS rs3093077 T/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1205 T/C 1 CRP rs2794520 C/T 1.019 (0.961-1.08) 0.019 (0.03) 5.29E-01 ─-─ 12260 
ALS rs1130864 C/T 1 CRP rs12093699 G/A 0.943 (0.889-1) -0.059 (0.03) 4.87E-02 ─-─ 12252 
ALS rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs3093077 T/G 1 CRP rs11265260 G/A 0.888 (0.775-1.018) -0.119 (0.058) 8.79E-02 4663-8357 13020 
ALZ rs1205 T/C 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs1130864 C/T 1 CRP rs12093699 G/A 1 (0.943-1.06) 0 (0.029) 9.88E-01 4663-8357 13020 
















N Controls N Total 
CKD 2 5 T C 2 5 C T -0.014 (0.022) 5 37 6271-68083 74354
CKD rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) -0.007 (0.023) 7.68E-01 6271-68083 74354 
CKD rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.023 (0.046) 6.13E-01 6271-68083 74354 
eGFR rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0 (0.003) 8.75E-01 ─-─ 74354 
eGFR rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) -0.001 (0.001) 6.25E-01 ─-─ 74354 
eGFR rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.001 (0.001) 3.29E-01 ─-─ 74354 
eGFR rs1800947 C/G 1 CRP rs1800947 C/G ─ (─-─) 0.001 (0.003) 8.69E-01 ─-─ 74354 
SA rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) 0.001 (0.004) 7.73E-01 ─-─ 53188 
SA rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.001 (0.002) 6.04E-01 ─-─ 53189 
SA rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.001 (0.002) 5.44E-01 ─-─ 38231 
SA rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) 0.001 (0.004) 8.67E-01 ─-─ 49950 
SP rs3093077 T/G 1 CRP rs3093077 C/A ─ (─-─) -0.006 (0.008) 4.15E-01 ─-─ 25536 
SP rs1205 T/C 1 CRP rs1205 C/T ─ (─-─) 0.002 (0.004) 7.04E-01 ─-─ 25537 
SP rs1130864 C/T 1 CRP rs1130864 G/A ─ (─-─) 0.013 (0.006) 3.30E-02 ─-─ 12156 
SP rs1800947 C/G 1 CRP rs1800947 G/C ─ (─-─) 0.007 (0.009) 4.08E-01 ─-─ 25537 
Neurodegenerative 
ALS rs3093077 T/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1205 T/C 1 CRP rs2794520 C/T 1.019 (0.961-1.08) 0.019 (0.03) 5.29E-01 ─-─ 12260 
ALS rs1130864 C/T 1 CRP rs12093699 G/A 0.943 (0.889-1) -0.059 (0.03) 4.87E-02 ─-─ 12252 
ALS rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs3093077 T/G 1 CRP rs11265260 G/A 0.888 (0.775-1.018) -0.119 (0.058) 8.79E-02 4663-8357 13020 
ALZ rs1205 T/C 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs1130864 C/T 1 CRP rs12093699 G/A 1 (0.943-1.06) 0 (0.029) 9.88E-01 4663-8357 13020 
















N Controls N Total 
ALZ rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs3093077 T/G 1 CRP rs3 9 077 A/C 1.04 (0.969-1.118) 0.04 (0.036) 2.78E-01 5333-12019 17352 
PKD rs1205 T/C 1 CRP rs2794520 A/G 1 (0.963-1.038) 0 (0.019) 9.92E-01 5333-12019 17352 
PKD rs1130864 C/T 1 CRP rs12093699 A/G 1.02 (0.983-1.058) 0.02 (0.019) 3.04E-01 5333-12019 17352 
PKD rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
Psychiatric 
AUT rs3093077 T/G 1 CRP rs3093077 T/G 0.941 (─-─) -0.06 (0.117) 5.16E-01 90-1476 1566 
AUT rs1205 T/C 1 CRP rs7553007 C/T 1.03 (─-─) 0.03 (0.05) 5.87E-01 90-1476 1566 
AUT rs1130864 C/T 1 CRP rs3116651 C/T 1.003 (─-─) 0.003 (0.003) 9.55E-01 90-1476 1566 
AUT rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
BPD rs3093077 T/G 1 CRP rs3093077 C/A 0.965 (0.876-1.064) -0.035 (0.05) 4.79E-01 7481-9250 16731 
BPD rs1205 T/C 1 CRP rs1205 T/C 1.053 (1.004-1.105) 0.052 (0.025) 3.45E-02 7481-9250 16731 
BPD rs1130864 C/T 1 CRP rs1130864 G/A 0.999 (0.951-1.05) -0.001 (0.025) 9.77E-01 7481-9250 16731 
BPD rs1800947 C/G 1 CRP rs1800947 C/G 0.984 (0.868-1.116) -0.016 (0.064) 8.05E-01 7481-9250 16731 
MDD rs3093077 T/G 1 CRP rs3093077 C/A 0.999 (0.914-1.091) -0.001 (0.045) 9.77E-01 9240-9519 18759 
MDD rs1205 T/C 1 CRP rs1205 C/T 0.998 (0.955-1.043) -0.002 (0.023) 9.30E-01 9240-9519 18759 
MDD rs1130864 C/T 1 CRP rs1130864 G/A 0.986 (0.943-1.032) -0.014 (0.023) 5.51E-01 9240-9519 18759 
MDD rs 800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs3093077 T/G 1 CRP rs3093077 C/A 1.008 (0.967-1.051) 0.008 (0.021) 6.90E-01 34241-45604 79845 
SCZ rs1205 T/C 1 CRP rs1205 C/T 1.021 (0.999-1.043) 0.02 (0.011) 3.57E-01 34241-45604 79845 
SCZ rs 130864 C/T 1 CRP rs1130864 G/A 0.986 (0.963-1.008) -0.015 (0.012) 9.06E-01 34241-45604 79845 
SCZ rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
 
















N Controls N Total 
ALZ rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs3093077 T/G 1 CRP rs3 9 077 A/C 1.04 (0.969-1.118) 0.04 (0.036) 2.78E-01 5333-12019 17352 
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PKD rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
Psychiatric 
AUT 3 93077 T G 3093077 T G 41 ─-─) 6 (0.117) 5 1 90-1476 1566 
AUT 2 5 T C rs7553007 C T 1.03 ( -─) 0.03 (0.05) 5.87E-01 90-1476 1566 
AUT rs1130864 C/T 1 CRP rs3116651 C/T 1.003 (─-─) 0.003 (0.003) 9.55E-01 90-1476 1566 
AUT rs1800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
BPD rs3093077 T/G 1 CRP rs3093077 C/A 0.965 (0.876-1.064) -0.035 (0.05) 4.79E-01 7481-9250 16731 
BPD rs1205 T/C 1 CRP rs1205 T/C 1.053 (1.004-1.105) 0.052 (0.025) 3.45E-02 7481-9250 16731 
BPD rs1130864 C/T 1 CRP rs1130864 G/A 0.999 (0.951-1.05) -0.001 (0.025) 9.77E-01 7481-9250 16731 
BPD rs1800947 C/G 1 CRP rs1800947 C/G 0.984 (0.868-1.116) -0.016 (0.064) 8.05E-01 7481-9250 16731 
MDD rs3093077 T/G 1 CRP rs3093077 C/A 0.999 (0.914-1.091) -0.001 (0.045) 9.77E-01 9240-9519 18759 
MDD rs1205 T/C 1 CRP rs1205 C/T 0.998 (0.955-1.043) -0.002 (0.023) 9.30E-01 9240-9519 18759 
MDD rs1130864 C/T 1 CRP rs1130864 G/A 0.986 (0.943-1.032) -0.014 (0.023) 5.51E-01 9240-9519 18759 
MDD rs 800947 C/G 1 CRP ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs3093077 T/G 1 CRP rs3093077 C/A 1.008 (0.967-1.051) 0.008 (0.021) 6.90E-01 34241-45604 79845 
SCZ rs1205 T/C 1 CRP rs1205 C/T 1.021 (0.999-1.043) 0.02 (0.011) 3.57E-01 34241-45604 79845 
SCZ rs 130864 C/T 1 CRP rs1130864 G/A 0.986 (0.963-1.008) -0.015 (0.012) 9.06E-01 34241-45604 79845 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 4 Individual association summary statistics of CRP lead SNPs and / or proxies with traits and diseases. 














N Controls N Total 
Autoimmune / Inflammatory 
CD rs12037222 G/A 1 PABPC4 rs12037222 G/A 0.922 (0.874-0.972) -0.082 (0.027) 2.66E-03 6333-15056 21389 
CD rs4420065 T/C 1 LEPR rs4420065 T/C 1.024 (0.978-1.072) 0.024 (0.023) 3.07E-01 6333-15056 21389 
CD rs4129267 T/C 1 IL6R rs4129267 T/C 0.935 (0.894-0.979) -0.067 (0.023) 4.08E-03 6333-15056 21389 
CD rs2794520 T/C 1 CRP rs2794520 T/C 0.959 (0.914-1.005) -0.042 (0.024) 7.86E-02 6333-15056 21389 
CD rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.016 (0.968-1.066) 0.016 (0.025) 5.22E-01 6333-15056 21389 
CD rs1260326 C/T 2 GCKR rs1260326 T/C 1.09 (1.042-1.14) 0.086 (0.023) 1.92E-04 6333-15056 21389 
CD rs6734238 A/G 2 IL1F10 rs6734238 A/G 0.976 (0.933-1.021) -0.024 (0.023) 2.95E-01 6333-15056 21389 
CD rs4705952 A/G 5 IRF1 rs4705952 A/G 1.094 (1.032-1.16) 0.09 (0.03) 2.50E-03 6333-15056 21389 
CD rs6901250 G/A 6 GPRC6A rs6901250 A/G 0.974 (0.928-1.023) -0.026 (0.025) 2.92E-01 6333-15056 21389 
CD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.914 (0.851-0.983) -0.089 (0.037) 1.48E-02 6333-15056 21389 
CD rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
CD rs10745954 G/A 12 ASCL1 rs1588886 A/G 1.003 (0.959-1.049) 0.003 (0.023) 8.97E-01 6333-15056 21389 
CD rs1183910 A/G 12 HNF1A rs1183910 G/A 0.999 (0.952-1.048) -0.001 (0.025) 9.57E-01 6333-15056 21389 
CD rs340029 C/T 15 RORA rs340029 T/C 1.011 (0.964-1.06) 0.011 (0.024) 6.41E-01 6333-15056 21389 
CD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.119 (1.004-1.247) 0.112 (0.055) 4.31E-02 6333-15056 21389 
CD rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.079 (1.031-1.13) 0.076 (0.023) 1.19E-03 6333-15056 21389 
CD rs4420638 G/A 19 APOC1 rs4420638 A/G 1.03 (0.955-1.111) 0.03 (0.039) 4.48E-01 6333-15056 21389 
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4420065 T C  LEPR 4420065 T C 24 0 978 072) 24 3 07 1
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CD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.914 (0.851-0.983) -0.089 (0.037) 1.48E-02 6333-15056 21389 
CD rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
CD rs10745954 G/A 12 ASCL1 rs1588886 A/G 1.003 (0.959-1.049) 0.003 (0.023) 8.97E-01 6333-15056 21389 
CD rs1183910 A/G 12 HNF1A rs1183910 G/A 0.999 (0.952-1.048) -0.001 (0.025) 9.57E-01 6333-15056 21389 
CD rs340029 C/T 15 RORA rs340029 T/C 1.011 (0.964-1.06) 0.011 (0.024) 6.41E-01 6333-15056 21389 
CD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.119 (1.004-1.247) 0.112 (0.055) 4.31E-02 6333-15056 21389 
CD rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.079 (1.031-1.13) 0.076 (0.023) 1.19E-03 6333-15056 21389 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
CD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.994 (0.837-1.182) -0.006 (0.088) 9.50E-01 6333-15056 21389 
CED rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.103 (1.041-1.169) 0.098 (0.03) 9.34E-04 4533-10750 15283 
CED rs4420065 T/C 1 LEPR rs4420065 T/C 1.044 (0.993-1.098) 0.043 (0.026) 9.07E-02 4533-10750 15283 
CED rs4129267 T/C 1 IL6R rs4129267 T/C 0.966 (0.919-1.016) -0.034 (0.026) 1.85E-01 4533-10750 15283 
CED rs2794520 T/C 1 CRP rs2794520 T/C 1.007 (0.956-1.061) 0.007 (0.027) 8.01E-01 4533-10750 15283 
CED rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.046 (0.994-1.1) 0.045 (0.026) 8.16E-02 4533-10750 15283 
CED rs1260326 C/T 2 GCKR rs1260326 T/C 1.062 (1.01-1.117) 0.06 (0.026) 1.80E-02 4533-10750 15283 
CED rs673 238 A/G 2 IL1F10 rs6734238 G/A 1.001 (0.952-1.053) 0.001 (0.026) 9.78E-01 4533-10750 15283 
CED rs4705952 A/G 5 IRF1 rs4705952 G/A 0.995 (0.939-1.055) -0.005 (0.03) 8.64E-01 4533-10750 15283 
CED rs6901250 G/A 6 GPRC6A rs6901250 A/G 1 (0.949-1.054) 0 (0.027) 9.86E-01 4533-10750 15283 
CED rs13233571 T/C 7 BCL7B rs13233571 T/C 0.99 (0.918-1.068) -0.01 (0.039) 7.92E-01 4533-10750 15283 
CED rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.027 (0.946-1.115) 0.027 (0.042) 5.28E-01 4533-10750 15283 
CED rs10745954 G/A 12 ASCL1 rs10745954 A/G 1.018 (0.969-1.069) 0.018 (0.025) 4.85E-01 4533-10750 15283 
CED rs 183910 A/G 12 HNF1A rs1183910 A/G 0.969 (0.919-1.022) -0.031 (0.027) 2.45E-01 4533-10750 15283 
CED rs340029 C/T 15 RORA rs340029 C/T 1.035 (0.984-1.089) 0.034 (0.026) 1.80E-01 4533-10750 15283 
CED rs 0521222 T/C 16 SALL1 rs10521222 T/C 0.962 (0.854-1.084) -0.039 (0.061) 5.26E-01 4533-10750 15283 
CED rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.929 (0.884-0.977) -0.074 (0.026) 4.05E-03 4533-10750 15283 
CED rs4420638 G/A 19 APOC1 rs4420638 A/G 0.921 (0.853-0.994) -0.082 (0.039) 3.01E-02 3795-8153 11948 
CED rs1800961 T/C 20 HNF4A rs1800961 T/C 1.043 (0.909-1.196) 0.042 (0.07) 5.45E-01 4533-10750 15283 
IBD rs12037222 G/A 1 PABPC4 rs2293476 C/G 1.04 (1-1.081) 0.039 (0.02) 4.93E-02 13020-34774 47794 
IBD rs4420065 T/C 1 LEPR rs4420065 T/C 1.016 (0.982-1.051) 0.016 (0.017) 3.66E-01 13020-34774 47794 
IBD rs4129267 T/C 1 IL6R rs4129267 T/C 0.984 (0.951-1.017) -0.017 (0.017) 3.30E-01 13020-34774 47794 
IBD rs 79 520 T/C 1 CRP rs2794520 T/C 0.994 (0.96-1.029) -0.006 (0.018) 7.31E-01 13020-34774 47794 
















N Controls N Total 
D 18 961 T C 20 HNF4A 18 961 T C 0 994 837 1 2 -0.006 (0.088) 9 5 63 50 6 213 9
2037 G A  P BPC4 2037 A G 1 103 1 041 169 0.098 (0.03) 9 34 4
4420065 T C  LEPR 4420065 T C 1 044 993 1 098 0.043 (0.026) 9 7 2
1 9267 T C  IL6R 1 9267 T C 66 919 1 016 34 26 1 85 1 4533 10750 5283
2794520 1 CRP 2794520 07 56 061 07 27) 8 01
CED 2 9046 T C NLRP3 1 2 9046 T C 6 (0.994-1.1) 45 6) 8 16 4533-10750 15283
CED 126 326 C T 2 GCK 126 326 62 1 01-1.117) 6 (0.026) 1 80 2 4533-10750 15283
CED 6734 38 A G 2 1F10 6734 38 G A 1 001 2 53 0.001 (0.026) 9 78 4533-10750 15283
CED 4 05952 A G 5 IRF1 4 05952 G A 5 39-1.055) 5 3) 8 64 4533-10750 15283
CED rs6901250 G/A 6 GPRC6A rs6901250 A/G 1 (0.949-1.054) 0 (0.027) 9.86E-01 4533-10750 15283 
CED rs13233571 T/C 7 BCL7B rs13233571 T/C 0.99 (0.918-1.068) -0.01 (0.039) 7.92E-01 4533-10750 15283 
CED rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.027 (0.946-1.115) 0.027 (0.042) 5.28E-01 4533-10750 15283 
CED rs10745954 G/A 12 ASCL1 rs10745954 A/G 1.018 (0.969-1.069) 0.018 (0.025) 4.85E-01 4533-10750 15283 
CED rs1183910 A/G 12 HNF1A rs1183910 A/G 0.969 (0.919-1.022) -0.031 (0.027) 2.45E-01 4533-10750 15283 
CED rs340029 C/T 15 RORA rs340029 C/T 1.035 (0.984-1.089) 0.034 (0.026) 1.80E-01 4533-10750 15283 
CED rs10521222 T/C 16 SALL1 rs10521222 T/C 0.962 (0.854-1.084) -0.039 (0.061) 5.26E-01 4533-10750 15283 
CED rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.929 (0.884-0.977) -0.074 (0.026) 4.05E-03 4533-10750 15283 
CED rs4420638 G/A 19 APOC1 rs4420638 A/G 0.921 (0.853-0.994) -0.082 (0.039) 3.01E-02 3795-8153 11948 
CED rs1800961 T/C 20 HNF4A rs1800961 T/C 1.043 (0.909-1.196) 0.042 (0.07) 5.45E-01 4533-10750 15283 
IBD rs12037222 G/A 1 PABPC4 rs2293476 C/G 1.04 (1-1.081) 0.039 (0.02) 4.93E-02 13020-34774 47794 
IBD rs4420065 T/C 1 LEPR rs4420065 T/C 1.016 (0.982-1.051) 0.016 (0.017) 3.66E-01 13020-34774 47794 
IBD rs4129267 T/C 1 IL6R rs4129267 T/C 0.984 (0.951-1.017) -0.017 (0.017) 3.30E-01 13020-34774 47794 
IBD rs2794520 T/C 1 CRP rs2794520 T/C 0.994 (0.96-1.029) -0.006 (0.018) 7.31E-01 13020-34774 47794 
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Supplementary Table 4 Individual association summary statistics of CRP lead SNPs and / or proxies with traits and diseases. 














N Controls N Total 
Autoimmune / Inflammatory 
CD rs12037222 G/A 1 PABPC4 rs12037222 G/A 0.922 (0.874-0.972) -0.082 (0.027) 2.66E-03 6333-15056 21389 
CD rs4420065 T/C 1 LEPR rs4420065 T/C 1.024 (0.978-1.072) 0.024 (0.023) 3.07E-01 6333-15056 21389 
CD rs4129267 T/C 1 IL6R rs4129267 T/C 0.935 (0.894-0.979) -0.067 (0.023) 4.08E-03 6333-15056 21389 
CD rs2794520 T/C 1 CRP rs2794520 T/C 0.959 (0.914-1.005) -0.042 (0.024) 7.86E-02 6333-15056 21389 
CD rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.016 (0.968-1.066) 0.016 (0.025) 5.22E-01 6333-15056 21389 
CD rs1260326 C/T 2 GCKR rs1260326 T/C 1.09 (1.042-1.14) 0.086 (0.023) 1.92E-04 6333-15056 21389 
CD rs6734238 A/G 2 IL1F10 rs6734238 A/G 0.976 (0.933-1.021) -0.024 (0.023) 2.95E-01 6333-15056 21389 
CD rs4705952 A/G 5 IRF1 rs4705952 A/G 1.094 (1.032-1.16) 0.09 (0.03) 2.50E-03 6333-15056 21389 
CD rs6901250 G/A 6 GPRC6A rs6901250 A/G 0.974 (0.928-1.023) -0.026 (0.025) 2.92E-01 6333-15056 21389 
CD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.914 (0.851-0.983) -0.089 (0.037) 1.48E-02 6333-15056 21389 
CD rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
CD rs10745954 G/A 12 ASCL1 rs1588886 A/G 1.003 (0.959-1.049) 0.003 (0.023) 8.97E-01 6333-15056 21389 
CD rs1183910 A/G 12 HNF1A rs1183910 G/A 0.999 (0.952-1.048) -0.001 (0.025) 9.57E-01 6333-15056 21389 
CD rs340029 C/T 15 RORA rs340029 T/C 1.011 (0.964-1.06) 0.011 (0.024) 6.41E-01 6333-15056 21389 
CD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.119 (1.004-1.247) 0.112 (0.055) 4.31E-02 6333-15056 21389 
CD rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.079 (1.031-1.13) 0.076 (0.023) 1.19E-03 6333-15056 21389 
CD rs4420638 G/A 19 APOC1 rs4420638 A/G 1.03 (0.955-1.111) 0.03 (0.039) 4.48E-01 6333-15056 21389 
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CED rs10745954 G/A 12 ASCL1 rs10745954 A/G 1.018 (0.969-1.069) 0.018 (0.025) 4.85E-01 4533-10750 15283 
CED rs1183910 A/G 12 HNF1A rs1183910 A/G 0.969 (0.919-1.022) -0.031 (0.027) 2.45E-01 4533-10750 15283 
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CED rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.929 (0.884-0.977) -0.074 (0.026) 4.05E-03 4533-10750 15283 
CED rs4420638 G/A 19 APOC1 rs4420638 A/G 0.921 (0.853-0.994) -0.082 (0.039) 3.01E-02 3795-8153 11948 
CED rs1800961 T/C 20 HNF4A rs1800961 T/C 1.043 (0.909-1.196) 0.042 (0.07) 5.45E-01 4533-10750 15283 
IBD rs12037222 G/A 1 PABPC4 rs2293476 C/G 1.04 (1-1.081) 0.039 (0.02) 4.93E-02 13020-34774 47794 
IBD rs4420065 T/C 1 LEPR rs4420065 T/C 1.016 (0.982-1.051) 0.016 (0.017) 3.66E-01 13020-34774 47794 
IBD rs4129267 T/C 1 IL6R rs4129267 T/C 0.984 (0.951-1.017) -0.017 (0.017) 3.30E-01 13020-34774 47794 
IBD rs2794520 T/C 1 CRP rs2794520 T/C 0.994 (0.96-1.029) -0.006 (0.018) 7.31E-01 13020-34774 47794 
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CED rs4420638 G/A 19 APOC1 rs4420638 A/G 0.921 (0.853-0.994) -0.082 (0.039) 3.01E-02 3795-8153 11948 
CED rs1800961 T/C 20 HNF4A rs1800961 T/C 1.043 (0.909-1.196) 0.042 (0.07) 5.45E-01 4533-10750 15283 
IBD rs12037222 G/A 1 PABPC4 rs2293476 C/G 1.04 (1-1.081) 0.039 (0.02) 4.93E-02 13020-34774 47794 
IBD rs4420065 T/C 1 LEPR rs4420065 T/C 1.016 (0.982-1.051) 0.016 (0.017) 3.66E-01 13020-34774 47794 
IBD rs4129267 T/C 1 IL6R rs4129267 T/C 0.984 (0.951-1.017) -0.017 (0.017) 3.30E-01 13020-34774 47794 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
IBD rs12239046 T/C 1 NLRP3 rs12239046 T/C 0.986 (0.953-1.021) -0.014 (0.018) 4.31E-01 13020-34774 47794 
IBD rs1260326 C/T 2 GCKR rs1260326 T/C 1.066 (1.031-1.102) 0.064 (0.017) 1.81E-04 13020-34774 47794 
IBD rs6734238 A/G 2 IL1F10 rs6734238 A/G 0.988 (0.955-1.021) -0.012 (0.017) 4.64E-01 13020-34774 47794 
IBD rs4705952 A/G 5 IRF1 rs4705952 A/G 1.064 (1.021-1.109) 0.062 (0.021) 3.29E-03 13020-34774 47794 
IBD rs6901250 G/A 6 GPRC6A rs6901250 A/G 1.005 (0.97-1.041) 0.005 (0.018) 7.86E-01 13020-34774 47794 
IBD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.935 (0.888-0.985) -0.067 (0.027) 1.22E-02 13020-34774 47794 
IBD rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs10745954 G/A 12 ASCL1 rs1588886 A/G 1.004 (0.971-1.038) 0.004 (0.017) 8.33E-01 13020-34774 47794 
IBD rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs340029 C/T 15 RORA rs340029 T/C 0.992 (0.959-1.027) -0.008 (0.017) 6.58E-01 13020-34774 47794 
IBD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.051 (0.966-1.144) 0.05 (0.043) 2.53E-01 13020-34774 47794 
IBD rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.063 (1.028-1.099) 0.061 (0.017) 3.96E-04 13020-34774 47794 
IBD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.91 (0.811-1.021) -0.095 (0.059) 1.08E-01 13020-34774 47794 
PSA rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.007 (0.911-1.114) 0.007 (0.051) 8.94E-01 1946-4934 6880 
PSA rs4420065 T/C 1 LEPR rs4420065 C/T 1.015 (0.931-1.107) 0.015 (0.044) 7.44E-01 1946-4934 6880 
PSA rs4129267 T/C 1 IL6R rs4129267 T/C 1.072 (0.983-1.169) 0.07 (0.044) 1.14E-01 1946-4934 6880 
PSA rs2794520 T/C 1 CRP rs2794520 T/C 1.082 (0.989-1.183) 0.079 (0.046) 8.50E-02 1946-4934 6880 
PSA rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.026 (0.94-1.12) 0.026 (0.045) 5.69E-01 1946-4934 6880 
PSA rs1260326 C/T 2 GCKR rs1260326 C/T 1.111 (1.02-1.211) 0.105 (0.044) 1.59E-02 1946-4934 6880 
PSA rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.098 (1.009-1.195) 0.093 (0.043) 3.00E-02 1946-4934 6880 
PSA rs4705952 A/G 5 IRF1 rs4705952 G/A 1.133 (1.019-1.26) 0.125 (0.054) 2.17E-02 1946-4934 6880 
PSA rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.012 (0.922-1.111) 0.012 (0.047) 8.05E-01 1946-4934 6880 
















N Controls N Total 
IBD 2 9046 T C NLRP3 2 9046 T C 0 986 53 021 -0.014 (0.018) 4 31 3020-34774 47794 
IBD 126 326 C T 2 GCK 126 326 T C 66 1 0 2 64 17 1 81 4 3020-34774 47794 
IBD 6734 38 A G 2 1F10 6734 38 A G 0 988 55 021 -0.012 ( .017) 4 6 3020-34774 47794 
IBD 4 05952 A G 5 IRF1 4 05952 A G 64 1 021 09 62 21 3 29 3 3020-34774 47794 
IBD 6901250 G A 6 GP C6A 6901250 A G 05 7 041) 05 18 7 86 3020-34774 47794 
IBD 323 571 T C 7 B L7B 323 571 T C 0 935 0 888-0.985) -0.067 (0.027) 22 3020-34774 47794 
IBD 9987 89 8 PPP1R3B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD 10745954 G A 12 ASCL1 1588886 A G 004 0 971 038) 004 17 8 33 1 3020-34774 47794 
IBD 118391 A G 12 HNF1A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs340029 C/T 15 RORA rs340029 T/C 0.992 (0.959-1.027) -0.008 (0.017) 6.58E-01 13020-34774 47794 
IBD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.051 (0.966-1.144) 0.05 (0.043) 2.53E-01 13020-34774 47794 
IBD rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.063 (1.028-1.099) 0.061 (0.017) 3.96E-04 13020-34774 47794 
IBD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.91 (0.811-1.021) -0.095 (0.059) 1.08E-01 13020-34774 47794 
PSA rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.007 (0.911-1.114) 0.007 (0.051) 8.94E-01 1946-4934 6880 
PSA rs4420065 T/C 1 LEPR rs4420065 C/T 1.015 (0.931-1.107) 0.015 (0.044) 7.44E-01 1946-4934 6880 
PSA rs4129267 T/C 1 IL6R rs4129267 T/C 1.072 (0.983-1.169) 0.07 (0.044) 1.14E-01 1946-4934 6880 
PSA rs2794520 T/C 1 CRP rs2794520 T/C 1.082 (0.989-1.183) 0.079 (0.046) 8.50E-02 1946-4934 6880 
PSA rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.026 (0.94-1.12) 0.026 (0.045) 5.69E-01 1946-4934 6880 
PSA rs1260326 C/T 2 GCKR rs1260326 C/T 1.111 (1.02-1.211) 0.105 (0.044) 1.59E-02 1946-4934 6880 
PSA rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.098 (1.009-1.195) 0.093 (0.043) 3.00E-02 1946-4934 6880 
PSA rs4705952 A/G 5 IRF1 rs4705952 G/A 1.133 (1.019-1.26) 0.125 (0.054) 2.17E-02 1946-4934 6880 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
PSA rs13 33571 T/C 7 BCL7B rs13233571 T/C 1.078 (0.946-1.228) 0.075 (0.067) 2.60E-01 1946-4934 6880 
PSA rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.09 (0.931-1.277) 0.086 (0.081) 2.84E-01 1946-4934 6880 
PSA rs1 745954 G/A 12 ASCL1 rs10 5954 G/A 1.007 (0.926-1.095) 0.007 (0.043) 8.64E-01 1946-4934 6880 
PSA rs1 83910 A/G 12 HNF1A rs1183910 G/A 1.017 (0.929-1.113) 0.017 (0.046) 7.21E-01 1946-4934 6880 
PSA rs3 0029 C/T 15 RORA rs340029 T/C 1.093 (1.002-1.193) 0.089 (0.045) 4.48E-02 1946-4934 6880 
PSA rs105212 2 T/C 16 SALL1 rs10521222 C/T 1.197 (0.935-1.532) 0.18 (0.126) 1.53E-01 1946-4934 6880 
PSA rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.033 (0.948-1.126) 0.032 (0.044) 4.61E-01 1946-4934 6880 
PSA rs4420638 G/A 19 APOC1 rs 420638 A/G ─ (─-─) ─ (─) ─ ─-─ ─ 
PSA rs1800961 T/C 20 HNF4A rs1800961 T/C 1.096 (0.838-1.433) 0.092 (0.137) 5.04E-01 1946-4934 6880 
PSC rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.083 (0.97-1.209) 0.08 (0.056) 1.58E-01 1363-3517 4880 
PSC rs442006  T/C 1 LEPR rs 420065 T/C 1.017 (0.926-1.117) 0.017 (0.048) 7.23E-01 1363-3517 4880 
PSC rs412 267 T/C 1 IL6R rs 129267 T/C 1.027 (0.935-1.128) 0.027 (0.048) 5.79E-01 1363-3517 4880 
PSC rs2794520 T/C 1 CRP rs2794520 C/T 1.024 (0.929-1.129) 0.024 (0.05) 6.28E-01 1363-3517 4880 
PSC rs1 239046 T/C 1 NLRP3 rs12239046 C/T 1.042 (0.949-1.145) 0.041 (0.048) 3.89E-01 1363-3517 4880 
PSC rs1260326 C/T 2 GCKR rs1260326 T/C 1.014 (0.922-1.115) 0.014 (0.049) 7.69E-01 1363-3517 4880 
PSC rs6734238 A/G 2 IL1F10 rs6 3 238 G/A 1.048 (0.956-1.149) 0.047 (0.047) 3.20E-01 1363-3517 4880 
PSC rs4705952 A/G 5 IRF  rs 05952 G/A 1.103 (0.977-1.245) 0.098 (0.062) 1.13E-01 1363-3517 4880 
PSC rs69 1250 G/A 6 GPRC6A rs6901250 G/A 1.146 (1.034-1.271) 0.136 (0.053) 9.59E-03 1363-3517 4880 
PSC rs 3233571 T/C 7 BCL7B rs13233571 C/T 1.07 (0.929-1.233) 0.068 (0.072) 3.50E-01 1363-3517 4880 
PSC rs9 7289 A/G 8 PPP1R3B rs9987289 A/G 1.051 (0.885-1.248) 0.05 (0.088) 5.68E-01 1363-3517 4880 
PSC rs10745954 G/A 12 ASCL1 rs10745954 G/A 1.079 (0.984-1.183) 0.076 (0.047) 1.07E-01 1363-3517 4880 
PSC rs1183910 A/G 12 HNF1A rs1183910 A/G 1.018 (0.922-1.123) 0.018 (0.05) 7.29E-01 1363-3517 4880 
PSC rs340029 C/T 15 RORA rs 0029 C/T 1.011 (0.92-1.111) 0.011 (0.048) 8.18E-01 1363-3517 4880 
















N Controls N Total 
A 3 3 571 T C 7 B L7B 323 571 78 46 228 75 67 2 0 946 4934 6
A 998 89 8 PPP R3B 9987 89 A G 9 (0.931-1.277) 86 81 2 84 946 4934 6
A 1 745954 G A 12 ASCL1 10 5954 0 7 26 09 07 43 8 64 946 4934 6
A 1 91 A G 12 HNF1A 118391 017 0 929 113 017 46 7 21 1 946 4934 6
A 3 0029 C T 15 RORA 0029 T C 93 (1.002-1.193) 89 45 4 48 2 946 4934 6
A 10521222 T C 16 SALL1 10521222 C T 197 93 532 18 126 1 53 946 4934 6
A 2847281 8 PTPN2 2847281 33 48 26 32 4 4 61 946 4934 6
A 4420638 G A 9 APOC1 20638 ─ (─-─) ─ (─) ─ ─-─ ─ 
A 18 961 T C 20 HNF4A 18 961 T C 96 838-1.433) 92 137 5 04 946 4934 6
PSC rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.083 (0.97-1.209) 0.08 (0.056) 1.58E-01 1363-3517 4880 
PSC rs4420065 T/C 1 LEPR rs 420065 T/C 1.017 (0.926-1.117) 0.017 (0.048) 7.23E-01 1363-3517 4880 
PSC rs412 267 T/C 1 IL6R rs 129267 T/C 1.027 (0.935-1.128) 0.027 (0.048) 5.79E-01 1363-3517 4880 
PSC rs2794520 T/C 1 CRP rs2794520 C/T 1.024 (0.929-1.129) 0.024 (0.05) 6.28E-01 1363-3517 4880 
PSC rs1 239046 T/C 1 NLRP3 rs12239046 C/T 1.042 (0.949-1.145) 0.041 (0.048) 3.89E-01 1363-3517 4880 
PSC rs1260326 C/T 2 GCKR rs1260326 T/C 1.014 (0.922-1.115) 0.014 (0.049) 7.69E-01 1363-3517 4880 
PSC rs6734238 A/G 2 IL1F10 rs6734238 G/A 1.048 (0.956-1.149) 0.047 (0.047) 3.20E-01 1363-3517 4880 
PSC rs4705952 A/G 5 IRF  rs4705952 G/A 1.103 (0.977-1.245) 0.098 (0.062) 1.13E-01 1363-3517 4880 
PSC rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.146 (1.034-1.271) 0.136 (0.053) 9.59E-03 1363-3517 4880 
PSC rs 3233571 T/C 7 BCL7B rs13233571 C/T 1.07 (0.929-1.233) 0.068 (0.072) 3.50E-01 1363-3517 4880 
PSC rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.051 (0.885-1.248) 0.05 (0.088) 5.68E-01 1363-3517 4880 
PSC rs10745954 G/A 12 ASCL1 rs10745954 G/A 1.079 (0.984-1.183) 0.076 (0.047) 1.07E-01 1363-3517 4880 
PSC rs1183910 A/G 12 HNF1A rs1183910 A/G 1.018 (0.922-1.123) 0.018 (0.05) 7.29E-01 1363-3517 4880 
PSC rs340029 C/T 15 RORA rs 0029 C/T 1.011 (0.92-1.111) 0.011 (0.048) 8.18E-01 1363-3517 4880 
210204-L-bw-Vaez
















N Controls N Total 
IBD rs12239046 T/C 1 NLRP3 rs12239046 T/C 0.986 (0.953-1.021) -0.014 (0.018) 4.31E-01 13020-34774 47794 
IBD rs1260326 C/T 2 GCKR rs1260326 T/C 1.066 (1.031-1.102) 0.064 (0.017) 1.81E-04 13020-34774 47794 
IBD rs6734238 A/G 2 IL1F10 rs6734238 A/G 0.988 (0.955-1.021) -0.012 (0.017) 4.64E-01 13020-34774 47794 
IBD rs4705952 A/G 5 IRF1 rs4705952 A/G 1.064 (1.021-1.109) 0.062 (0.021) 3.29E-03 13020-34774 47794 
IBD rs6901250 G/A 6 GPRC6A rs6901250 A/G 1.005 (0.97-1.041) 0.005 (0.018) 7.86E-01 13020-34774 47794 
IBD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.935 (0.888-0.985) -0.067 (0.027) 1.22E-02 13020-34774 47794 
IBD rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs10745954 G/A 12 ASCL1 rs1588886 A/G 1.004 (0.971-1.038) 0.004 (0.017) 8.33E-01 13020-34774 47794 
IBD rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs340029 C/T 15 RORA rs340029 T/C 0.992 (0.959-1.027) -0.008 (0.017) 6.58E-01 13020-34774 47794 
IBD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.051 (0.966-1.144) 0.05 (0.043) 2.53E-01 13020-34774 47794 
IBD rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.063 (1.028-1.099) 0.061 (0.017) 3.96E-04 13020-34774 47794 
IBD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.91 (0.811-1.021) -0.095 (0.059) 1.08E-01 13020-34774 47794 
PSA rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.007 (0.911-1.114) 0.007 (0.051) 8.94E-01 1946-4934 6880 
PSA rs4420065 T/C 1 LEPR rs4420065 C/T 1.015 (0.931-1.107) 0.015 (0.044) 7.44E-01 1946-4934 6880 
PSA rs4129267 T/C 1 IL6R rs4129267 T/C 1.072 (0.983-1.169) 0.07 (0.044) 1.14E-01 1946-4934 6880 
PSA rs2794520 T/C 1 CRP rs2794520 T/C 1.082 (0.989-1.183) 0.079 (0.046) 8.50E-02 1946-4934 6880 
PSA rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.026 (0.94-1.12) 0.026 (0.045) 5.69E-01 1946-4934 6880 
PSA rs1260326 C/T 2 GCKR rs1260326 C/T 1.111 (1.02-1.211) 0.105 (0.044) 1.59E-02 1946-4934 6880 
PSA rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.098 (1.009-1.195) 0.093 (0.043) 3.00E-02 1946-4934 6880 
PSA rs4705952 A/G 5 IRF1 rs4705952 G/A 1.133 (1.019-1.26) 0.125 (0.054) 2.17E-02 1946-4934 6880 
PSA rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.012 (0.922-1.111) 0.012 (0.047) 8.05E-01 1946-4934 6880 
















N Controls N Total 
IBD 2 9046 T C NLRP3 2 9046 T C 0 986 53 021 -0.014 (0.018) 4 31 3020-34774 47794 
IBD 126 326 C T 2 GCK 126 326 T C 66 1 0 2 64 17 1 81 4 3020-34774 47794 
IBD 6734 38 A G 2 1F10 6734 38 A G 0 988 55 021 -0.012 ( .017) 4 6 3020-34774 47794 
IBD 4 05952 A G 5 IRF1 4 05952 A G 64 1 021 09 62 21 3 29 3 3020-34774 47794 
IBD 6901250 G A 6 GP C6A 6901250 A G 05 7 041) 05 18 7 86 3020-34774 47794 
IBD 323 571 T C 7 B L7B 323 571 T C 0 935 0 888-0.985) -0.067 (0.027) 22 3020-34774 47794 
IBD 9987 89 8 PPP1R3B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD 10745954 G A 12 ASCL1 1588886 A G 004 0 971 038) 004 17 8 33 1 3020-34774 47794 
IBD 118391 A G 12 HNF1A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs340029 C/T 15 RORA rs340029 T/C 0.992 (0.959-1.027) -0.008 (0.017) 6.58E-01 13020-34774 47794 
IBD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.051 (0.966-1.144) 0.05 (0.043) 2.53E-01 13020-34774 47794 
IBD rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.063 (1.028-1.099) 0.061 (0.017) 3.96E-04 13020-34774 47794 
IBD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
IBD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.91 (0.811-1.021) -0.095 (0.059) 1.08E-01 13020-34774 47794 
PSA rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.007 (0.911-1.114) 0.007 (0.051) 8.94E-01 1946-4934 6880 
PSA rs4420065 T/C 1 LEPR rs4420065 C/T 1.015 (0.931-1.107) 0.015 (0.044) 7.44E-01 1946-4934 6880 
PSA rs4129267 T/C 1 IL6R rs4129267 T/C 1.072 (0.983-1.169) 0.07 (0.044) 1.14E-01 1946-4934 6880 
PSA rs2794520 T/C 1 CRP rs2794520 T/C 1.082 (0.989-1.183) 0.079 (0.046) 8.50E-02 1946-4934 6880 
PSA rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.026 (0.94-1.12) 0.026 (0.045) 5.69E-01 1946-4934 6880 
PSA rs1260326 C/T 2 GCKR rs1260326 C/T 1.111 (1.02-1.211) 0.105 (0.044) 1.59E-02 1946-4934 6880 
PSA rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.098 (1.009-1.195) 0.093 (0.043) 3.00E-02 1946-4934 6880 
PSA rs4705952 A/G 5 IRF1 rs4705952 G/A 1.133 (1.019-1.26) 0.125 (0.054) 2.17E-02 1946-4934 6880 
PSA rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.012 (0.922-1.111) 0.012 (0.047) 8.05E-01 1946-4934 6880 
















N Controls N Total 
PSA rs13 33571 T/C 7 BCL7B rs13233571 T/C 1.078 (0.946-1.228) 0.075 (0.067) 2.60E-01 1946-4934 6880 
PSA rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.09 (0.931-1.277) 0.086 (0.081) 2.84E-01 1946-4934 6880 
PSA rs1 745954 G/A 12 ASCL1 rs10 5954 G/A 1.007 (0.926-1.095) 0.007 (0.043) 8.64E-01 1946-4934 6880 
PSA rs1 83910 A/G 12 HNF1A rs1183910 G/A 1.017 (0.929-1.113) 0.017 (0.046) 7.21E-01 1946-4934 6880 
PSA rs3 0029 C/T 15 RORA rs340029 T/C 1.093 (1.002-1.193) 0.089 (0.045) 4.48E-02 1946-4934 6880 
PSA rs10521222 T/C 16 SALL1 rs10521222 C/T 1.197 (0.935-1.532) 0.18 (0.126) 1.53E-01 1946-4934 6880 
PSA rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.033 (0.948-1.126) 0.032 (0.044) 4.61E-01 1946-4934 6880 
PSA rs4420638 G/A 19 APOC1 rs 420638 A/G ─ (─-─) ─ (─) ─ ─-─ ─ 
PSA rs1800961 T/C 20 HNF4A rs1800961 T/C 1.096 (0.838-1.433) 0.092 (0.137) 5.04E-01 1946-4934 6880 
PSC rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.083 (0.97-1.209) 0.08 (0.056) 1.58E-01 1363-3517 4880 
PSC rs4420065 T/C 1 LEPR rs 420065 T/C 1.017 (0.926-1.117) 0.017 (0.048) 7.23E-01 1363-3517 4880 
PSC rs412 267 T/C 1 IL6R rs 129267 T/C 1.027 (0.935-1.128) 0.027 (0.048) 5.79E-01 1363-3517 4880 
PSC rs2794520 T/C 1 CRP rs2794520 C/T 1.024 (0.929-1.129) 0.024 (0.05) 6.28E-01 1363-3517 4880 
PSC rs1 239046 T/C 1 NLRP3 rs12239046 C/T 1.042 (0.949-1.145) 0.041 (0.048) 3.89E-01 1363-3517 4880 
PSC rs1260326 C/T 2 GCKR rs1260326 T/C 1.014 (0.922-1.115) 0.014 (0.049) 7.69E-01 1363-3517 4880 
PSC rs6734238 A/G 2 IL1F10 rs6 3 238 G/A 1.048 (0.956-1.149) 0.047 (0.047) 3.20E-01 1363-3517 4880 
PSC rs4705952 A/G 5 IRF  rs 05952 G/A 1.103 (0.977-1.245) 0.098 (0.062) 1.13E-01 1363-3517 4880 
PSC rs69 1250 G/A 6 GPRC6A rs6901250 G/A 1.146 (1.034-1.271) 0.136 (0.053) 9.59E-03 1363-3517 4880 
PSC rs 3233571 T/C 7 BCL7B rs13233571 C/T 1.07 (0.929-1.233) 0.068 (0.072) 3.50E-01 1363-3517 4880 
PSC rs9 7289 A/G 8 PPP1R3B rs9987289 A/G 1.051 (0.885-1.248) 0.05 (0.088) 5.68E-01 1363-3517 4880 
PSC rs10745954 G/A 12 ASCL1 rs10745954 G/A 1.079 (0.984-1.183) 0.076 (0.047) 1.07E-01 1363-3517 4880 
PSC rs1183910 A/G 12 HNF1A rs1183910 A/G 1.018 (0.922-1.123) 0.018 (0.05) 7.29E-01 1363-3517 4880 
PSC rs340029 C/T 15 RORA rs 0029 C/T 1.011 (0.92-1.111) 0.011 (0.048) 8.18E-01 1363-3517 4880 
















N Controls N Total 
A 3 3 571 T C 7 B L7B 323 571 78 46 228 75 67 2 0 946 4934 6
A 998 89 8 PPP R3B 9987 89 A G 9 (0.931-1.277) 86 81 2 84 946 4934 6
A 1 745954 G A 12 ASCL1 10 5954 0 7 26 09 07 43 8 64 946 4934 6
A 1 91 A G 12 HNF1A 118391 017 0 929 113 017 46 7 21 1 946 4934 6
A 3 0029 C T 15 RORA 0029 T C 93 (1.002-1.193) 89 45 4 48 2 946 4934 6
A 10521222 T C 16 SALL1 10521222 C T 197 93 532 18 126 1 53 946 4934 6
A 2847281 8 PTPN2 2847281 33 48 26 32 4 4 61 946 4934 6
A 4420638 G A 9 APOC1 20638 ─ (─-─) ─ (─) ─ ─-─ ─ 
A 18 961 T C 20 HNF4A 18 961 T C 96 838-1.433) 92 137 5 04 946 4934 6
PSC rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.083 (0.97-1.209) 0.08 (0.056) 1.58E-01 1363-3517 4880 
PSC rs4420065 T/C 1 LEPR rs 420065 T/C 1.017 (0.926-1.117) 0.017 (0.048) 7.23E-01 1363-3517 4880 
PSC rs412 267 T/C 1 IL6R rs 129267 T/C 1.027 (0.935-1.128) 0.027 (0.048) 5.79E-01 1363-3517 4880 
PSC rs2794520 T/C 1 CRP rs2794520 C/T 1.024 (0.929-1.129) 0.024 (0.05) 6.28E-01 1363-3517 4880 
PSC rs1 239046 T/C 1 NLRP3 rs12239046 C/T 1.042 (0.949-1.145) 0.041 (0.048) 3.89E-01 1363-3517 4880 
PSC rs1260326 C/T 2 GCKR rs1260326 T/C 1.014 (0.922-1.115) 0.014 (0.049) 7.69E-01 1363-3517 4880 
PSC rs6734238 A/G 2 IL1F10 rs6734238 G/A 1.048 (0.956-1.149) 0.047 (0.047) 3.20E-01 1363-3517 4880 
PSC rs4705952 A/G 5 IRF  rs4705952 G/A 1.103 (0.977-1.245) 0.098 (0.062) 1.13E-01 1363-3517 4880 
PSC rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.146 (1.034-1.271) 0.136 (0.053) 9.59E-03 1363-3517 4880 
PSC rs 3233571 T/C 7 BCL7B rs13233571 C/T 1.07 (0.929-1.233) 0.068 (0.072) 3.50E-01 1363-3517 4880 
PSC rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.051 (0.885-1.248) 0.05 (0.088) 5.68E-01 1363-3517 4880 
PSC rs10745954 G/A 12 ASCL1 rs10745954 G/A 1.079 (0.984-1.183) 0.076 (0.047) 1.07E-01 1363-3517 4880 
PSC rs1183910 A/G 12 HNF1A rs1183910 A/G 1.018 (0.922-1.123) 0.018 (0.05) 7.29E-01 1363-3517 4880 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
PSC rs10521222 T/C 16 SALL1 rs10521222 C/T 1.125 (0.907-1.395) 0.118 (0.11) 2.83E-01 1363-3517 4880 
PSC rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.064 (0.97-1.167) 0.062 (0.047) 1.89E-01 1363-3517 4880 
PSC rs4420638 G/A 19 APOC1 rs4420638 A/G ─ (─-─) ─ (─) ─ ─-─ ─ 
PSC rs1800961 T/C 20 HNF4A rs1800961 T/C 1.157 (0.864-1.549) 0.146 (0.149) 3.29E-01 1363-3517 4880 
PSV rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.053 (0.978-1.134) 0.052 (0.038) 1.67E-01 4007-4934 8941 
PSV rs4420065 T/C 1 LEPR rs4420065 T/C 1.012 (0.95-1.078) 0.012 (0.032) 7.10E-01 4007-4934 8941 
PSV rs4129267 T/C 1 IL6R rs4129267 T/C 1.04 (0.977-1.108) 0.039 (0.032) 2.20E-01 4007-4934 8941 
PSV rs2794520 T/C 1 CRP rs2794520 T/C 1.021 (0.957-1.09) 0.021 (0.033) 5.30E-01 4007-4934 8941 
PSV rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.008 (0.946-1.075) 0.008 (0.033) 8.09E-01 4007-4934 8941 
PSV rs1260326 C/T 2 GCKR rs1260326 C/T 1.051 (0.987-1.119) 0.05 (0.032) 1.23E-01 4007-4934 8941 
PSV rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.019 (0.958-1.084) 0.019 (0.032) 5.54E-01 4007-4934 8941 
PSV rs4705952 A/G 5 IRF1 rs4705952 G/A 1.097 (1.014-1.186) 0.093 (0.04) 2.04E-02 4007-4934 8941 
PSV rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.053 (0.983-1.128) 0.052 (0.035) 1.42E-01 4007-4934 8941 
PSV rs13233571 T/C 7 BCL7B rs13233571 T/C 1.023 (0.93-1.126) 0.023 (0.049) 6.41E-01 4007-4934 8941 
PSV rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.051 (0.938-1.178) 0.05 (0.058) 3.94E-01 4007-4934 8941 
PSV rs10745954 G/A 12 ASCL1 rs10745954 G/A 1.043 (0.981-1.109) 0.042 (0.031) 1.81E-01 4007-4934 8941 
PSV rs1183910 A/G 12 HNF1A rs1183910 G/A 1.022 (0.957-1.091) 0.022 (0.033) 5.25E-01 4007-4934 8941 
PSV rs340029 C/T 15 RORA rs340029 T/C 1.036 (0.972-1.104) 0.035 (0.032) 2.72E-01 4007-4934 8941 
PSV rs10521222 T/C 16 SALL1 rs10521222 C/T 1.09 (0.925-1.285) 0.086 (0.084) 3.05E-01 4007-4934 8941 
PSV rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.038 (0.975-1.105) 0.037 (0.032) 2.37E-01 4007-4934 8941 
PSV rs4420638 G/A 19 APOC1 rs4420638 A/G ─ (─-─) ─ (─) ─ ─-─ ─ 
PSV rs1800961 T/C 20 HNF4A rs1800961 T/C 1.075 (0.888-1.302) 0.072 (0.098) 4.62E-01 4007-4934 8941 
RA rs12037222 G/A 1 PABPC4 rs12037222 G/A 0.996 (0.941-1.053) -0.004 (0.029) 8.27E-01 5538-20165 25703 
















N Controls N Total 
C 10521222 T C 16 SALL1 10521222 C T 125 07 395 118 (0.11 2 83 1363 3517 4880
C 2847281 8 PTPN2 2847281 64 7-1.167) 6 47 9 1363 3517 4880
C 4420638 G A 9 APOC1 4420638 A G ─ (─-─) ─ (─) ─ ─-─ ─ 
C 18 961 T C 20 HNF4A 18 961 157 864 549 146 149 3 29 1363 3517 4880
2037 G A  P BPC4 2037 A G 53 (0.978-1.134) 52 38 1 67
4420065 T C  LEPR 4420065 T C 12 5-1.078) 12 7 10
1 9267 T C  IL6R 1 9267 T C 1.04 (0.977-1.108) 0.039 (0.032) 2.20E-01 4007-4934 8941 
2794520 1 CRP 2794520 21 957 09) 21 33 5 30
PSV 2 9046 T C NLRP3 2 9046 T C 1 008 6 75 0.008 (0.033) 09 4007 4934 8941 
PSV rs1260326 C/T 2 GCKR rs1260326 C/T 1.051 (0.987-1.119) 0.05 (0.032) 1.23E-01 4007-4934 8941 
PSV rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.019 (0.958-1.084) 0.019 (0.032) 5.54E-01 4007-4934 8941 
PSV rs4705952 A/G 5 IRF1 rs4705952 G/A 1.097 (1.014-1.186) 0.093 (0.04) 2.04E-02 4007-4934 8941 
PSV rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.053 (0.983-1.128) 0.052 (0.035) 1.42E-01 4007-4934 8941 
PSV rs13233571 T/C 7 BCL7B rs13233571 T/C 1.023 (0.93-1.126) 0.023 (0.049) 6.41E-01 4007-4934 8941 
PSV rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.051 (0.938-1.178) 0.05 (0.058) 3.94E-01 4007-4934 8941 
PSV rs10745954 G/A 12 ASCL1 rs10745954 G/A 1.043 (0.981-1.109) 0.042 (0.031) 1.81E-01 4007-4934 8941 
PSV rs1183910 A/G 12 HNF1A rs1183910 G/A 1.022 (0.957-1.091) 0.022 (0.033) 5.25E-01 4007-4934 8941 
PSV rs340029 C/T 15 RORA rs340029 T/C 1.036 (0.972-1.104) 0.035 (0.032) 2.72E-01 4007-4934 8941 
PSV rs10521222 T/C 16 SALL1 rs10521222 C/T 1.09 (0.925-1.285) 0.086 (0.084) 3.05E-01 4007-4934 8941 
PSV rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.038 (0.975-1.105) 0.037 (0.032) 2.37E-01 4007-4934 8941 
PSV rs4420638 G/A 19 APOC1 rs4420638 A/G ─ (─-─) ─ (─) ─ ─-─ ─ 
PSV rs1800961 T/C 20 HNF4A rs1800961 T/C 1.075 (0.888-1.302) 0.072 (0.098) 4.62E-01 4007-4934 8941 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
RA rs4420065 T/C 1 LEPR rs4420065 C/T 1.05 (0.999-1.103) 0.049 (0.025) 1.43E-01 5536-20154 25690 
RA rs4129267 T/C 1 IL6R rs4129267 C/T 0.932 (0.887-0.979) -0.071 (0.025) 2.52E-02 5538-20165 25703 
RA rs2794520 T/C 1 CRP rs2794520 C/T 1.004 (0.955-1.057) 0.004 (0.026) 6.26E-01 5535-20158 25693 
RA rs12239046 T/C 1 NLRP3 rs 2239046 C/T 0.946 (0.9-0.995) -0.055 (0.026) 1.70E-01 5538-20164 25701 
RA rs1260326 C/T 2 GCKR rs1260326 C/T 0.944 (0.898-0.992) -0.058 (0.025) 2.13E-01 5533-20160 25693 
RA rs6 34238 A/G 2 IL1F10 rs6734238 A/G 1.045 (0.995-1.097) 0.044 (0.025) 3.91E-03 5537-20155 25691 
RA rs4705952 A/G 5 IRF  rs4705952 A/G 1.036 (0.979-1.097) 0.035 (0.029) 3.76E-01 5537-20165 25702 
RA rs6901250 G/A 6 GPRC6A rs6901250 G/A 0.997 (0.947-1.05) -0.003 (0.026) 8.72E-01 5537-20160 25697 
RA rs13233571 T/C 7 BCL7B rs13233571 C/T 0.996 (0.93-1.067) -0.004 (0.035) 9.73E-01 5538-20163 25701 
RA rs9987289 A/G 8 PPP R3B rs9987289 G/A 1.044 (0.968-1.127) 0.043 (0.039) 5.74E-01 5538-20166 25704 
RA rs1 7 5954 G/A 12 ASCL1 rs10745954 A/G 1.019 (0.971-1.07) 0.019 (0.025) 8.35E-01 5536-20155 25691 
RA rs1 391  A/G 12 HNF1A rs1183910 G/A 1.009 (0.959-1.062) 0.009 (0.026) 5.20E-01 5537-20159 25696 
RA rs340029 C/T 15 RORA rs 0029 T/C 0.959 (0.913-1.009) -0.041 (0.025) 2.35E-01 5537-20168 25705 
RA rs 0521222 T/C 16 SALL1 rs10521222 C/T 0.827 (0.718-0.952) -0.19 (0.072) 5.14E-02 3530-8111 11641 
RA rs2847281 G/A 18 PTPN2 rs2847281 A/G 0.938 (0.893-0.986) -0.064 (0.025) 5.37E-04 5538-20165 25703 
RA rs4420638 G/A 19 APOC1 rs4 20638 A/G 1.098 (1.02-1.182) 0.093 (0.038) 2.97E-02 4009-9549 13558 
RA rs1800961 T/C 20 HNF4A rs1800961 C/T 1.253 (1.083-1.449) 0.225 (0.074) 1.37E-01 4013-9561 13574 
SLE rs12 37222 G/A 1 PABPC4 rs4660293 G/A 1.014 (0.911-1.129) 0.014 (0.055) 7.76E-01 1311-3340 4651 
SLE rs4420065 T/C 1 LEPR rs2211651 G/T 1.037 (0.944-1.139) 0.036 (0.048) 4.94E-01 1311-3340 4651 
SLE rs4 29267 T/C 1 IL6R rs4129267 C/T 1.016 (0.927-1.115) 0.016 (0.047) 6.38E-01 1311-3340 4651 
SLE rs2794520 T/C 1 CRP rs2794520 C/T 0.911 (0.827-1.005) -0.093 (0.05) 2.28E-01 1311-3340 4651 
SLE rs12239046 T/C 1 NLRP3 rs10157379 C/T 0.939 (0.856-1.031) -0.063 (0.048) 7.42E-01 1311-3340 4651 
SLE rs1260326 C/T 2 GCKR rs 260326 C/T 0.944 (0.861-1.034) -0.058 (0.047) 8.29E-01 1311-3340 4651 
















N Controls N Total 
4420065 T C  LEPR 4 20065 C T 1 05 (0.99 -1.103) 0.049 (0.025) 1 43 1 6 54 690
267 T C  IL6R 1 9267 C T 0 932 0 887-0.979) -0.071 (0.025) 52 5538 20165 25703
27 4520 1 CRP 2794520 004 0 955 057 004 26 6 26 5535 20158 25693
RA 2 9046 T C NLRP3 2239046 C T 0 946 -0.995) -0.055 (0.026) 1 0 5538 20164 25701 
RA 126 326 C T 2 GCK 1 60326 C  0 944 898 0 992 -0.058 (0.025) 2 13 5533 20160 25693 
RA 6 34 38 A G 2 1F10 6734 38 A G 45 95 097 44 25 3 91 3 5537 20155 25691 
RA 4 05952 A G 5 IRF  4 05952 A G 1 036 979 97 0.035 (0.029) 3 76 5537 20165 25702 
RA 69 125  G A 6 GP C6A 6901250 G A 97 947 5) 0 26 8 7 5537 20160 25697 
RA 32 571 T C 7 B L7B 323 571 96 93-1.067) 04 35 9 73 5538 20163 25701 
RA rs9987289 A/G 8 PPP R3B rs9987289 G/A 1.044 (0.968-1.127) 0.043 (0.039) 5.74E-01 5538-20166 25704 
RA rs1 7 5954 G/A 12 ASCL1 rs10745954 A/G 1.019 (0.971-1.07) 0.019 (0.025) 8.35E-01 5536-20155 25691 
RA rs1 3910 A/G 12 HNF1A rs1183910 G/A 1.009 (0.959-1.062) 0.009 (0.026) 5.20E-01 5537-20159 25696 
RA rs340029 C/T 15 RORA rs 0029 T/C 0.959 (0.913-1.009) -0.041 (0.025) 2.35E-01 5537-20168 25705 
RA rs 0521222 T/C 16 SALL1 rs10521222 C/T 0.827 (0.718-0.952) -0.19 (0.072) 5.14E-02 3530-8111 11641 
RA rs2847281 G/A 18 PTPN2 rs2847281 A/G 0.938 (0.893-0.986) -0.064 (0.025) 5.37E-04 5538-20165 25703 
RA rs4420638 G/A 19 APOC1 rs4 20638 A/G 1.098 (1.02-1.182) 0.093 (0.038) 2.97E-02 4009-9549 13558 
RA rs1800961 T/C 20 HNF4A rs1800961 C/T 1.253 (1.083-1.449) 0.225 (0.074) 1.37E-01 4013-9561 13574 
SLE rs12 37222 G/A 1 PABPC4 rs4660293 G/A 1.014 (0.911-1.129) 0.014 (0.055) 7.76E-01 1311-3340 4651 
SLE rs4420065 T/C 1 LEPR rs2211651 G/T 1.037 (0.944-1.139) 0.036 (0.048) 4.94E-01 1311-3340 4651 
SLE rs4 29267 T/C 1 IL6R rs4129267 C/T 1.016 (0.927-1.115) 0.016 (0.047) 6.38E-01 1311-3340 4651 
SLE rs2794520 T/C 1 CRP rs2794520 C/T 0.911 (0.827-1.005) -0.093 (0.05) 2.28E-01 1311-3340 4651 
SLE rs12239046 T/C 1 NLRP3 rs10157379 C/T 0.939 (0.856-1.031) -0.063 (0.048) 7.42E-01 1311-3340 4651 
SLE rs1260326 C/T 2 GCKR rs 260326 C/T 0.944 (0.861-1.034) -0.058 (0.047) 8.29E-01 1311-3340 4651 
210204-L-bw-Vaez
















N Controls N Total 
PSC rs10521222 T/C 16 SALL1 rs10521222 C/T 1.125 (0.907-1.395) 0.118 (0.11) 2.83E-01 1363-3517 4880 
PSC rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.064 (0.97-1.167) 0.062 (0.047) 1.89E-01 1363-3517 4880 
PSC rs4420638 G/A 19 APOC1 rs4420638 A/G ─ (─-─) ─ (─) ─ ─-─ ─ 
PSC rs1800961 T/C 20 HNF4A rs1800961 T/C 1.157 (0.864-1.549) 0.146 (0.149) 3.29E-01 1363-3517 4880 
PSV rs12037222 G/A 1 PABPC4 rs12037222 A/G 1.053 (0.978-1.134) 0.052 (0.038) 1.67E-01 4007-4934 8941 
PSV rs4420065 T/C 1 LEPR rs4420065 T/C 1.012 (0.95-1.078) 0.012 (0.032) 7.10E-01 4007-4934 8941 
PSV rs4129267 T/C 1 IL6R rs4129267 T/C 1.04 (0.977-1.108) 0.039 (0.032) 2.20E-01 4007-4934 8941 
PSV rs2794520 T/C 1 CRP rs2794520 T/C 1.021 (0.957-1.09) 0.021 (0.033) 5.30E-01 4007-4934 8941 
PSV rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.008 (0.946-1.075) 0.008 (0.033) 8.09E-01 4007-4934 8941 
PSV rs1260326 C/T 2 GCKR rs1260326 C/T 1.051 (0.987-1.119) 0.05 (0.032) 1.23E-01 4007-4934 8941 
PSV rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.019 (0.958-1.084) 0.019 (0.032) 5.54E-01 4007-4934 8941 
PSV rs4705952 A/G 5 IRF1 rs4705952 G/A 1.097 (1.014-1.186) 0.093 (0.04) 2.04E-02 4007-4934 8941 
PSV rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.053 (0.983-1.128) 0.052 (0.035) 1.42E-01 4007-4934 8941 
PSV rs13233571 T/C 7 BCL7B rs13233571 T/C 1.023 (0.93-1.126) 0.023 (0.049) 6.41E-01 4007-4934 8941 
PSV rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.051 (0.938-1.178) 0.05 (0.058) 3.94E-01 4007-4934 8941 
PSV rs10745954 G/A 12 ASCL1 rs10745954 G/A 1.043 (0.981-1.109) 0.042 (0.031) 1.81E-01 4007-4934 8941 
PSV rs1183910 A/G 12 HNF1A rs1183910 G/A 1.022 (0.957-1.091) 0.022 (0.033) 5.25E-01 4007-4934 8941 
PSV rs340029 C/T 15 RORA rs340029 T/C 1.036 (0.972-1.104) 0.035 (0.032) 2.72E-01 4007-4934 8941 
PSV rs10521222 T/C 16 SALL1 rs10521222 C/T 1.09 (0.925-1.285) 0.086 (0.084) 3.05E-01 4007-4934 8941 
PSV rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.038 (0.975-1.105) 0.037 (0.032) 2.37E-01 4007-4934 8941 
PSV rs4420638 G/A 19 APOC1 rs4420638 A/G ─ (─-─) ─ (─) ─ ─-─ ─ 
PSV rs1800961 T/C 20 HNF4A rs1800961 T/C 1.075 (0.888-1.302) 0.072 (0.098) 4.62E-01 4007-4934 8941 
RA rs12037222 G/A 1 PABPC4 rs12037222 G/A 0.996 (0.941-1.053) -0.004 (0.029) 8.27E-01 5538-20165 25703 
















N Controls N Total 
C 10521222 T C 16 SALL1 10521222 C T 125 07 395 118 (0.11 2 83 1363 3517 4880
C 2847281 8 PTPN2 2847281 64 7-1.167) 6 47 9 1363 3517 4880
C 4420638 G A 9 APOC1 4420638 A G ─ (─-─) ─ (─) ─ ─-─ ─ 
C 18 961 T C 20 HNF4A 18 961 157 864 549 146 149 3 29 1363 3517 4880
2037 G A  P BPC4 2037 A G 53 (0.978-1.134) 52 38 1 67
4420065 T C  LEPR 4420065 T C 12 5-1.078) 12 7 10
1 9267 T C  IL6R 1 9267 T C 1.04 (0.977-1.108) 0.039 (0.032) 2.20E-01 4007-4934 8941 
2794520 1 CRP 2794520 21 957 09) 21 33 5 30
PSV 2 9046 T C NLRP3 2 9046 T C 1 008 6 75 0.008 (0.033) 09 4007 4934 8941 
PSV rs1260326 C/T 2 GCKR rs1260326 C/T 1.051 (0.987-1.119) 0.05 (0.032) 1.23E-01 4007-4934 8941 
PSV rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.019 (0.958-1.084) 0.019 (0.032) 5.54E-01 4007-4934 8941 
PSV rs4705952 A/G 5 IRF1 rs4705952 G/A 1.097 (1.014-1.186) 0.093 (0.04) 2.04E-02 4007-4934 8941 
PSV rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.053 (0.983-1.128) 0.052 (0.035) 1.42E-01 4007-4934 8941 
PSV rs13233571 T/C 7 BCL7B rs13233571 T/C 1.023 (0.93-1.126) 0.023 (0.049) 6.41E-01 4007-4934 8941 
PSV rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.051 (0.938-1.178) 0.05 (0.058) 3.94E-01 4007-4934 8941 
PSV rs10745954 G/A 12 ASCL1 rs10745954 G/A 1.043 (0.981-1.109) 0.042 (0.031) 1.81E-01 4007-4934 8941 
PSV rs1183910 A/G 12 HNF1A rs1183910 G/A 1.022 (0.957-1.091) 0.022 (0.033) 5.25E-01 4007-4934 8941 
PSV rs340029 C/T 15 RORA rs340029 T/C 1.036 (0.972-1.104) 0.035 (0.032) 2.72E-01 4007-4934 8941 
PSV rs10521222 T/C 16 SALL1 rs10521222 C/T 1.09 (0.925-1.285) 0.086 (0.084) 3.05E-01 4007-4934 8941 
PSV rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.038 (0.975-1.105) 0.037 (0.032) 2.37E-01 4007-4934 8941 
PSV rs4420638 G/A 19 APOC1 rs4420638 A/G ─ (─-─) ─ (─) ─ ─-─ ─ 
PSV rs1800961 T/C 20 HNF4A rs1800961 T/C 1.075 (0.888-1.302) 0.072 (0.098) 4.62E-01 4007-4934 8941 
RA rs12037222 G/A 1 PABPC4 rs12037222 G/A 0.996 (0.941-1.053) -0.004 (0.029) 8.27E-01 5538-20165 25703 
















N Controls N Total 
RA rs4420065 T/C 1 LEPR rs4420065 C/T 1.05 (0.999-1.103) 0.049 (0.025) 1.43E-01 5536-20154 25690 
RA rs4129267 T/C 1 IL6R rs4129267 C/T 0.932 (0.887-0.979) -0.071 (0.025) 2.52E-02 5538-20165 25703 
RA rs2794520 T/C 1 CRP rs2794520 C/T 1.004 (0.955-1.057) 0.004 (0.026) 6.26E-01 5535-20158 25693 
RA rs12239046 T/C 1 NLRP3 rs 2239046 C/T 0.946 (0.9-0.995) -0.055 (0.026) 1.70E-01 5538-20164 25701 
RA rs1260326 C/T 2 GCKR rs1260326 C/T 0.944 (0.898-0.992) -0.058 (0.025) 2.13E-01 5533-20160 25693 
RA rs6 34238 A/G 2 IL1F10 rs6734238 A/G 1.045 (0.995-1.097) 0.044 (0.025) 3.91E-03 5537-20155 25691 
RA rs4705952 A/G 5 IRF  rs4705952 A/G 1.036 (0.979-1.097) 0.035 (0.029) 3.76E-01 5537-20165 25702 
RA rs6901250 G/A 6 GPRC6A rs6901250 G/A 0.997 (0.947-1.05) -0.003 (0.026) 8.72E-01 5537-20160 25697 
RA rs13233571 T/C 7 BCL7B rs13233571 C/T 0.996 (0.93-1.067) -0.004 (0.035) 9.73E-01 5538-20163 25701 
RA rs9987289 A/G 8 PPP R3B rs9987289 G/A 1.044 (0.968-1.127) 0.043 (0.039) 5.74E-01 5538-20166 25704 
RA rs1 7 5954 G/A 12 ASCL1 rs10745954 A/G 1.019 (0.971-1.07) 0.019 (0.025) 8.35E-01 5536-20155 25691 
RA rs1 3910 A/G 12 HNF1A rs1183910 G/A 1.009 (0.959-1.062) 0.009 (0.026) 5.20E-01 5537-20159 25696 
RA rs340029 C/T 15 RORA rs 0029 T/C 0.959 (0.913-1.009) -0.041 (0.025) 2.35E-01 5537-20168 25705 
RA rs 0521222 T/C 16 SALL1 rs10521222 C/T 0.827 (0.718-0.952) -0.19 (0.072) 5.14E-02 3530-8111 11641 
RA rs2847281 G/A 18 PTPN2 rs2847281 A/G 0.938 (0.893-0.986) -0.064 (0.025) 5.37E-04 5538-20165 25703 
RA rs4420638 G/A 19 APOC1 rs4 20638 A/G 1.098 (1.02-1.182) 0.093 (0.038) 2.97E-02 4009-9549 13558 
RA rs1800961 T/C 20 HNF4A rs1800961 C/T 1.253 (1.083-1.449) 0.225 (0.074) 1.37E-01 4013-9561 13574 
SLE rs12 37222 G/A 1 PABPC4 rs4660293 G/A 1.014 (0.911-1.129) 0.014 (0.055) 7.76E-01 1311-3340 4651 
SLE rs4420065 T/C 1 LEPR rs2211651 G/T 1.037 (0.944-1.139) 0.036 (0.048) 4.94E-01 1311-3340 4651 
SLE rs4 29267 T/C 1 IL6R rs4129267 C/T 1.016 (0.927-1.115) 0.016 (0.047) 6.38E-01 1311-3340 4651 
SLE rs2794520 T/C 1 CRP rs2794520 C/T 0.911 (0.827-1.005) -0.093 (0.05) 2.28E-01 1311-3340 4651 
SLE rs12239046 T/C 1 NLRP3 rs10157379 C/T 0.939 (0.856-1.031) -0.063 (0.048) 7.42E-01 1311-3340 4651 
SLE rs1260326 C/T 2 GCKR rs 260326 C/T 0.944 (0.861-1.034) -0.058 (0.047) 8.29E-01 1311-3340 4651 
















N Controls N Total 
4420065 T C  LEPR 4 20065 C T 1 05 (0.99 -1.103) 0.049 (0.025) 1 43 1 6 54 690
267 T C  IL6R 1 9267 C T 0 932 0 887-0.979) -0.071 (0.025) 52 5538 20165 25703
27 4520 1 CRP 2794520 004 0 955 057 004 26 6 26 5535 20158 25693
RA 2 9046 T C NLRP3 2239046 C T 0 946 -0.995) -0.055 (0.026) 1 0 5538 20164 25701 
RA 126 326 C T 2 GCK 1 60326 C  0 944 898 0 992 -0.058 (0.025) 2 13 5533 20160 25693 
RA 6 34 38 A G 2 1F10 6734 38 A G 45 95 097 44 25 3 91 3 5537 20155 25691 
RA 4 05952 A G 5 IRF  4 05952 A G 1 036 979 97 0.035 (0.029) 3 76 5537 20165 25702 
RA 69 1250 G A 6 GP C6A 6901250 G A 97 947 5) 0 26 8 7 5537 20160 25697 
RA 32 571 T C 7 B L7B 323 571 96 93-1.067) 04 35 9 73 5538 20163 25701 
RA rs9987289 A/G 8 PPP R3B rs9987289 G/A 1.044 (0.968-1.127) 0.043 (0.039) 5.74E-01 5538-20166 25704 
RA rs1 7 5954 G/A 12 ASCL1 rs10745954 A/G 1.019 (0.971-1.07) 0.019 (0.025) 8.35E-01 5536-20155 25691 
RA rs1 3910 A/G 12 HNF1A rs1183910 G/A 1.009 (0.959-1.062) 0.009 (0.026) 5.20E-01 5537-20159 25696 
RA rs340029 C/T 15 RORA rs 0029 T/C 0.959 (0.913-1.009) -0.041 (0.025) 2.35E-01 5537-20168 25705 
RA rs 0521222 T/C 16 SALL1 rs10521222 C/T 0.827 (0.718-0.952) -0.19 (0.072) 5.14E-02 3530-8111 11641 
RA rs2847281 G/A 18 PTPN2 rs2847281 A/G 0.938 (0.893-0.986) -0.064 (0.025) 5.37E-04 5538-20165 25703 
RA rs4420638 G/A 19 APOC1 rs4 20638 A/G 1.098 (1.02-1.182) 0.093 (0.038) 2.97E-02 4009-9549 13558 
RA rs1800961 T/C 20 HNF4A rs1800961 C/T 1.253 (1.083-1.449) 0.225 (0.074) 1.37E-01 4013-9561 13574 
SLE rs12 37222 G/A 1 PABPC4 rs4660293 G/A 1.014 (0.911-1.129) 0.014 (0.055) 7.76E-01 1311-3340 4651 
SLE rs4420065 T/C 1 LEPR rs2211651 G/T 1.037 (0.944-1.139) 0.036 (0.048) 4.94E-01 1311-3340 4651 
SLE rs4 29267 T/C 1 IL6R rs4129267 C/T 1.016 (0.927-1.115) 0.016 (0.047) 6.38E-01 1311-3340 4651 
SLE rs2794520 T/C 1 CRP rs2794520 C/T 0.911 (0.827-1.005) -0.093 (0.05) 2.28E-01 1311-3340 4651 
SLE rs12239046 T/C 1 NLRP3 rs10157379 C/T 0.939 (0.856-1.031) -0.063 (0.048) 7.42E-01 1311-3340 4651 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
SLE rs6734238 A/G 2 IL1F10 rs13410964 G/A 0.968 (0.882-1.061) -0.033 (0.047) 4.90E-01 1311-3340 4651 
SLE rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs6901250 G/A 6 GPRC6A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs13233571 T/C 7 BCL7B rs714052 G/A 0.964 (0.834-1.115) -0.037 (0.074) 7.39E-01 1311-3340 4651 
SLE rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs10745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs340029 C/T 15 RORA rs340029 C/T 0.995 (0.907-1.093) -0.005 (0.048) 6.45E-01 1311-3340 4651 
SLE rs10521222 T/C 16 SALL1 rs10521222 C/T 0.806 (0.655-0.993) -0.215 (0.106) 7.02E-02 1311-3340 4651 
SLE rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs1800961 T/C 20 HNF4A rs1800961 C/T 0.998 (0.743-1.34) -0.002 (0.15) 2.06E-01 1311-3340 4651 
SSC rs12037222 G/A 1 PABPC4 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs4420065 T/C 1 LEPR rs4420065 T/C 0.986 (0.917-1.059) -0.015 (0.037) 6.90E-01 2324-5123 7447 
SSC rs4129267 T/C 1 IL6R rs4129267 T/C 0.931 (0.868-0.999) -0.071 (0.036) 4.80E-02 2355-5183 7538 
SSC rs2794520 T/C 1 CRP rs2794520 T/C 1 (0.941-1.088) 0.012 (0.037) 7.53E-01 2354-5185 7539 
SSC rs12239046 T/C 1 NLRP3 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs1260326 C/T 2 GCKR rs1260326 T/C 1 (0.963-1.106) 0.031 (0.035) 3.69E-01 2356-5129 7485 
SSC rs6734238 A/G 2 IL1F10 rs6734238 G/A 1 (0.944-1.085) 0.012 (0.035) 7.30E-01 2353-5180 7533 
SSC rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs6901250 G/A 6 GPRC6A rs6901250 A/G 1 (0.997-1.157) 0.071 (0.038) 6.09E-02 2307-5044 7351 
SSC rs13233571 T/C 7 BCL7B rs13233571 T/C 1.02 (0.913-1.139) 0.02 (0.056) 7.20E-01 2342-5140 7482 
SSC rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
















N Controls N Total 
LE 6734 38 A G 2 1F10 13410964 G A 68 82 1 061 33 47 9 1 1 11 3340 4651
LE 4 05952 A G 5 IRF1 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
LE 6901250 G A 6 GP C6A 
LE 323 571 T C 7 B L7B 714 5  G A 0.964 (0.834-1.115) -0.037 (0.074) 7 3 1 11 3340 4651
LE 9987 89 8 PPP1R3B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
LE 10745954 G A 12 ASCL1 
LE 118391 A G 12 HNF1A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
LE 340029 C T 15 RORA 340029 C T 0 995 (0.907-1.0 3) -0.005 ( .048) 6 45 1 11 33 4651
LE 10521222 T C 16 SALL1 rs10521222 C T 0.806 (0.655-0.993) -0.215 (0.106) 7.02E-02 1311-3340 4651 
SLE rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs1800961 T/C 20 HNF4A rs1800961 C/T 0.998 (0.743-1.34) -0.002 (0.15) 2.06E-01 1311-3340 4651 
SSC rs12037222 G/A 1 PABPC4 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs4420065 T/C 1 LEPR rs4420065 T/C 0.986 (0.917-1.059) -0.015 (0.037) 6.90E-01 2324-5123 7447 
SSC rs4129267 T/C 1 IL6R rs4129267 T/C 0.931 (0.868-0.999) -0.071 (0.036) 4.80E-02 2355-5183 7538 
SSC rs2794520 T/C 1 CRP rs2794520 T/C 1 (0.941-1.088) 0.012 (0.037) 7.53E-01 2354-5185 7539 
SSC rs12239046 T/C 1 NLRP3 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs1260326 C/T 2 GCKR rs1260326 T/C 1 (0.963-1.106) 0.031 (0.035) 3.69E-01 2356-5129 7485 
SSC rs6734238 A/G 2 IL1F10 rs6734238 G/A 1 (0.944-1.085) 0.012 (0.035) 7.30E-01 2353-5180 7533 
SSC rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs6901250 G/A 6 GPRC6A rs6901250 A/G 1 (0.997-1.157) 0.071 (0.038) 6.09E-02 2307-5044 7351 
SSC rs13233571 T/C 7 BCL7B rs13233571 T/C 1.02 (0.913-1.139) 0.02 (0.056) 7.20E-01 2342-5140 7482 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
SSC rs1 745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs340029 C/T 15 RORA rs340029 C/T 0.993 (0.925-1.066) -0.007 (0.036) 8.45E-01 2355-5150 7505 
SSC rs105212 2 T/C 16 SALL1 rs1 521222 T/C 1.03 (0.881-1.204) 0.03 (0.08) 7.12E-01 2356-5179 7535 
SSC rs2847281 G/A 18 PTPN2 rs2847281 G/A 1 (0.948-1.092) 0.017 (0.036) 6.32E-01 2310-5119 7429 
SSC rs44 0638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs1800961 T/C 20 HNF4A rs1800961 T/C 0.985 (0.801-1.211) -0.015 (0.106) 8.85E-01 2356-5187 7543 
T1D rs120 7222 G/A 1 PABPC4 rs12037222 G/A 1.061 (1.002-1.123) 0.059 (0.029) 4.38E-02 9934-16956 26890 
T1D rs4420065 T/C 1 LEPR rs 420065 C/T 0.987 (0.939-1.038) -0.013 (0.026) 6.19E-01 9934-16956 26890 
T1D rs4129267 T/C 1 IL6R rs4129267 C/T 0.953 (0.907-1.002) -0.048 (0.025) 5.95E-02 9934-16956 26890 
T1D rs2794520 T/C 1 CRP rs2794520 C/T 0.991 (0.941-1.044) -0.009 (0.026) 7.43E-01 9934-16956 26890 
T1D rs12239046 T/C 1 NLRP3 rs12239046 C/T 0.977 (0.93-1.027) -0.023 (0.025) 3.68E-01 9934-16956 26890 
T1D rs1260326 C/T 2 GCKR rs1260326 C/T 0.968 (0.921-1.017) -0.032 (0.025) 2.02E-01 9934-16956 26890 
T1D rs6734238 A/G 2 IL1F10 rs6734238 G/A 0.991 (0.943-1.041) -0.009 (0.025) 7.23E-01 9934-16956 26890 
T1D rs4705952 A/G 5 IRF  rs 705952 G/A 0.949 (0.89-1.011) -0.053 (0.033) 1.08E-01 9934-16956 26890 
T1D rs6901250 G/A 6 GPRC6A rs6901250 G/A 0.966 (0.917-1.018) -0.034 (0.027) 1.97E-01 9934-16956 26890 
T1D rs13233571 T/C 7 BCL7B rs13233571 C/T 0.928 (0.86-1.002) -0.074 (0.039) 5.68E-02 9934-16956 26890 
T1D rs9987289 A/G 8 PPP R3B rs9 87289 G/A 0.961 (0.879-1.051) -0.04 (0.046) 3.80E-01 9934-16956 26890 
T1D rs10745954 G/A 12 ASCL1 rs1 745954 G/A 0.987 (0.941-1.037) -0.013 (0.025) 6.08E-01 9934-16956 26890 
T1D rs1183910 A/G 12 HNF1A rs1183910 G/A 1.033 (0.981-1.088) 0.033 (0.027) 2.18E-01 9934-16956 26890 
T1D rs340029 C/T 15 RORA rs3 0029 C/T 0.978 (0.93-1.029) -0.022 (0.026) 3.98E-01 9934-16956 26890 
T1D rs 521222 T/C 16 SALL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs284728  G/A 18 PTPN2 rs2847281 G/A 1.091 (1.038-1.147) 0.088 (0.026) 5.93E-04 9934-16956 26890 
















N Controls N Total 
SSC 1 745954 G A 12 ASCL1 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC 118391 A G 12 HNF1A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC 34 029 C T 15 RORA 340029 93 925-1. 66) 07 6 8 45 1 2355 5150 7505 
SSC 10521222 T C 16 SALL1 1 521222 T C 1 03 (0.8 1-1.2 4) 0.03 (0.08) 7 12 2356 5179 7535 
SSC 2847281 8 PTPN2 2847281 1 (0.948-1.092) 0.017 (0.036) 32 2310 5119 742  
SSC 4420638 G A 9 APOC1 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC 18 961 T C 20 HNF4A 18 961 T C 85 801-1. 11) 15 10 8 85 2356 5187 7543 
20 7 G A  P BPC4 rs12037222 G A 1.061 (1.002-1.123) 0.059 (0.029) 4.38E-02 9934-16956 26890 
4420065 T C  LEPR 420065 C T 0 987 0 9 9 038 -0.013 (0.026) 6 19 1
T1D rs4129267 T/C 1 IL6R rs4129267 C/T 0.953 (0.907-1.002) -0.048 (0.025) 5.95E-02 9934-16956 26890 
T1D rs2794520 T/C 1 CRP rs2794520 C/T 0.991 (0.941-1.044) -0.009 (0.026) 7.43E-01 9934-16956 26890 
T1D rs12239046 T/C 1 NLRP3 rs12239046 C/T 0.977 (0.93-1.027) -0.023 (0.025) 3.68E-01 9934-16956 26890 
T1D rs1260326 C/T 2 GCKR rs1260326 C/T 0.968 (0.921-1.017) -0.032 (0.025) 2.02E-01 9934-16956 26890 
T1D rs6734238 A/G 2 IL1F10 rs6734238 G/A 0.991 (0.943-1.041) -0.009 (0.025) 7.23E-01 9934-16956 26890 
T1D rs4705952 A/G 5 IRF1 rs4705952 G/A 0.949 (0.89-1.011) -0.053 (0.033) 1.08E-01 9934-16956 26890 
T1D rs6901250 G/A 6 GPRC6A rs6901250 G/A 0.966 (0.917-1.018) -0.034 (0.027) 1.97E-01 9934-16956 26890 
1D rs13233571 T/C 7 BCL7B rs13233571 C/T 0.928 (0.86-1.002) -0.074 (0.039) 5.68E-02 9934-16956 26890 
T1D rs9987289 A/G 8 PPP R3B rs9 87289 G/A 0.961 (0.879-1.051) -0.04 (0.046) 3.80E-01 9934-16956 26890 
T1D rs10745954 G/A 12 ASCL1 rs1 745954 G/A 0.987 (0.941-1.037) -0.013 (0.025) 6.08E-01 9934-16956 26890 
T1D rs1183910 A/G 12 HNF1A rs1183910 G/A 1.033 (0.981-1.088) 0.033 (0.027) 2.18E-01 9934-16956 26890 
T1D rs340029 C/T 15 RORA rs3 0029 C/T 0.978 (0.93-1.029) -0.022 (0.026) 3.98E-01 9934-16956 26890 
T1D rs 0521222 T/C 16 SALL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.091 (1.038-1.147) 0.088 (0.026) 5.93E-04 9934-16956 26890 
210204-L-bw-Vaez
















N Controls N Total 
SLE rs6734238 A/G 2 IL1F10 rs13410964 G/A 0.968 (0.882-1.061) -0.033 (0.047) 4.90E-01 1311-3340 4651 
SLE rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs6901250 G/A 6 GPRC6A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs13233571 T/C 7 BCL7B rs714052 G/A 0.964 (0.834-1.115) -0.037 (0.074) 7.39E-01 1311-3340 4651 
SLE rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs10745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs340029 C/T 15 RORA rs340029 C/T 0.995 (0.907-1.093) -0.005 (0.048) 6.45E-01 1311-3340 4651 
SLE rs10521222 T/C 16 SALL1 rs10521222 C/T 0.806 (0.655-0.993) -0.215 (0.106) 7.02E-02 1311-3340 4651 
SLE rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs1800961 T/C 20 HNF4A rs1800961 C/T 0.998 (0.743-1.34) -0.002 (0.15) 2.06E-01 1311-3340 4651 
SSC rs12037222 G/A 1 PABPC4 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs4420065 T/C 1 LEPR rs4420065 T/C 0.986 (0.917-1.059) -0.015 (0.037) 6.90E-01 2324-5123 7447 
SSC rs4129267 T/C 1 IL6R rs4129267 T/C 0.931 (0.868-0.999) -0.071 (0.036) 4.80E-02 2355-5183 7538 
SSC rs2794520 T/C 1 CRP rs2794520 T/C 1 (0.941-1.088) 0.012 (0.037) 7.53E-01 2354-5185 7539 
SSC rs12239046 T/C 1 NLRP3 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs1260326 C/T 2 GCKR rs1260326 T/C 1 (0.963-1.106) 0.031 (0.035) 3.69E-01 2356-5129 7485 
SSC rs6734238 A/G 2 IL1F10 rs6734238 G/A 1 (0.944-1.085) 0.012 (0.035) 7.30E-01 2353-5180 7533 
SSC rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs6901250 G/A 6 GPRC6A rs6901250 A/G 1 (0.997-1.157) 0.071 (0.038) 6.09E-02 2307-5044 7351 
SSC rs13233571 T/C 7 BCL7B rs13233571 T/C 1.02 (0.913-1.139) 0.02 (0.056) 7.20E-01 2342-5140 7482 
SSC rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
















N Controls N Total 
LE 6734 38 A G 2 1F10 13410964 G A 68 82 1 061 33 47 9 1 1 11 3340 4651
LE 4 05952 A G 5 IRF1 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
LE 6901250 G A 6 GP C6A 
LE 323 571 T C 7 B L7B 714 5  G A 0.964 (0.834-1.115) -0.037 (0.074) 7 3 1 11 3340 4651
LE 9987 89 8 PPP1R3B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
LE 10745954 G A 12 ASCL1 
LE 118391 A G 12 HNF1A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
LE 340029 C T 15 RORA 340029 C T 0 995 (0.907-1.0 3) -0.005 ( .048) 6 45 1 11 33 4651
LE 10521222 T C 16 SALL1 rs10521222 C T 0.806 (0.655-0.993) -0.215 (0.106) 7.02E-02 1311-3340 4651 
SLE rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SLE rs1800961 T/C 20 HNF4A rs1800961 C/T 0.998 (0.743-1.34) -0.002 (0.15) 2.06E-01 1311-3340 4651 
SSC rs12037222 G/A 1 PABPC4 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs4420065 T/C 1 LEPR rs4420065 T/C 0.986 (0.917-1.059) -0.015 (0.037) 6.90E-01 2324-5123 7447 
SSC rs4129267 T/C 1 IL6R rs4129267 T/C 0.931 (0.868-0.999) -0.071 (0.036) 4.80E-02 2355-5183 7538 
SSC rs2794520 T/C 1 CRP rs2794520 T/C 1 (0.941-1.088) 0.012 (0.037) 7.53E-01 2354-5185 7539 
SSC rs12239046 T/C 1 NLRP3 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs1260326 C/T 2 GCKR rs1260326 T/C 1 (0.963-1.106) 0.031 (0.035) 3.69E-01 2356-5129 7485 
SSC rs6734238 A/G 2 IL1F10 rs6734238 G/A 1 (0.944-1.085) 0.012 (0.035) 7.30E-01 2353-5180 7533 
SSC rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs6901250 G/A 6 GPRC6A rs6901250 A/G 1 (0.997-1.157) 0.071 (0.038) 6.09E-02 2307-5044 7351 
SSC rs13233571 T/C 7 BCL7B rs13233571 T/C 1.02 (0.913-1.139) 0.02 (0.056) 7.20E-01 2342-5140 7482 
SSC rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
















N Controls N Total 
SSC rs1 745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs340029 C/T 15 RORA rs340029 C/T 0.993 (0.925-1.066) -0.007 (0.036) 8.45E-01 2355-5150 7505 
SSC rs10521222 T/C 16 SALL1 rs1 521222 T/C 1.03 (0.881-1.204) 0.03 (0.08) 7.12E-01 2356-5179 7535 
SSC rs2847281 G/A 18 PTPN2 rs2847281 G/A 1 (0.948-1.092) 0.017 (0.036) 6.32E-01 2310-5119 7429 
SSC rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC rs1800961 T/C 20 HNF4A rs1800961 T/C 0.985 (0.801-1.211) -0.015 (0.106) 8.85E-01 2356-5187 7543 
T1D rs120 7222 G/A 1 PABPC4 rs12037222 G/A 1.061 (1.002-1.123) 0.059 (0.029) 4.38E-02 9934-16956 26890 
T1D rs4420065 T/C 1 LEPR rs 420065 C/T 0.987 (0.939-1.038) -0.013 (0.026) 6.19E-01 9934-16956 26890 
T1D rs4129267 T/C 1 IL6R rs4129267 C/T 0.953 (0.907-1.002) -0.048 (0.025) 5.95E-02 9934-16956 26890 
T1D rs2794520 T/C 1 CRP rs2794520 C/T 0.991 (0.941-1.044) -0.009 (0.026) 7.43E-01 9934-16956 26890 
T1D rs12239046 T/C 1 NLRP3 rs12239046 C/T 0.977 (0.93-1.027) -0.023 (0.025) 3.68E-01 9934-16956 26890 
T1D rs1260326 C/T 2 GCKR rs1260326 C/T 0.968 (0.921-1.017) -0.032 (0.025) 2.02E-01 9934-16956 26890 
T1D rs6734238 A/G 2 IL1F10 rs6734238 G/A 0.991 (0.943-1.041) -0.009 (0.025) 7.23E-01 9934-16956 26890 
T1D rs4705952 A/G 5 IRF  rs 705952 G/A 0.949 (0.89-1.011) -0.053 (0.033) 1.08E-01 9934-16956 26890 
T1D rs6901250 G/A 6 GPRC6A rs6901250 G/A 0.966 (0.917-1.018) -0.034 (0.027) 1.97E-01 9934-16956 26890 
T1D rs13233571 T/C 7 BCL7B rs13233571 C/T 0.928 (0.86-1.002) -0.074 (0.039) 5.68E-02 9934-16956 26890 
T1D rs9987289 A/G 8 PPP R3B rs9 87289 G/A 0.961 (0.879-1.051) -0.04 (0.046) 3.80E-01 9934-16956 26890 
T1D rs10745954 G/A 12 ASCL1 rs1 745954 G/A 0.987 (0.941-1.037) -0.013 (0.025) 6.08E-01 9934-16956 26890 
T1D rs1183910 A/G 12 HNF1A rs1183910 G/A 1.033 (0.981-1.088) 0.033 (0.027) 2.18E-01 9934-16956 26890 
T1D rs340029 C/T 15 RORA rs3 0029 C/T 0.978 (0.93-1.029) -0.022 (0.026) 3.98E-01 9934-16956 26890 
T1D rs 521222 T/C 16 SALL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.091 (1.038-1.147) 0.088 (0.026) 5.93E-04 9934-16956 26890 
















N Controls N Total 
SSC 1 745954 G A 12 ASCL1 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC 118391 A G 12 HNF1A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC 340029 C T 15 RORA 340029 93 925-1. 66) 07 6 8 45 1 2355 5150 7505 
SSC 10521222 T C 16 SALL1 1 521222 T C 1 03 (0.8 1-1.2 4) 0.03 (0.08) 7 12 2356 5179 7535 
SSC 2847281 8 PTPN2 2847281 1 (0.948-1.092) 0.017 (0.036) 32 2310 5119 742  
SSC 4420638 G A 9 APOC1 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SSC 18 961 T C 20 HNF4A 18 961 T C 85 801-1. 11) 15 10 8 85 2356 5187 7543 
20 7 G A  P BPC4 rs12037222 G A 1.061 (1.002-1.123) 0.059 (0.029) 4.38E-02 9934-16956 26890 
4420065 T C  LEPR 420065 C T 0 987 0 9 9 038 -0.013 (0.026) 6 19 1
T1D rs4129267 T/C 1 IL6R rs4129267 C/T 0.953 (0.907-1.002) -0.048 (0.025) 5.95E-02 9934-16956 26890 
T1D rs2794520 T/C 1 CRP rs2794520 C/T 0.991 (0.941-1.044) -0.009 (0.026) 7.43E-01 9934-16956 26890 
T1D rs12239046 T/C 1 NLRP3 rs12239046 C/T 0.977 (0.93-1.027) -0.023 (0.025) 3.68E-01 9934-16956 26890 
T1D rs1260326 C/T 2 GCKR rs1260326 C/T 0.968 (0.921-1.017) -0.032 (0.025) 2.02E-01 9934-16956 26890 
T1D rs6734238 A/G 2 IL1F10 rs6734238 G/A 0.991 (0.943-1.041) -0.009 (0.025) 7.23E-01 9934-16956 26890 
T1D rs4705952 A/G 5 IRF1 rs4705952 G/A 0.949 (0.89-1.011) -0.053 (0.033) 1.08E-01 9934-16956 26890 
T1D rs6901250 G/A 6 GPRC6A rs6901250 G/A 0.966 (0.917-1.018) -0.034 (0.027) 1.97E-01 9934-16956 26890 
T1D rs13233571 T/C 7 BCL7B rs13233571 C/T 0.928 (0.86-1.002) -0.074 (0.039) 5.68E-02 9934-16956 26890 
T1D rs9987289 A/G 8 PPP R3B rs9 87289 G/A 0.961 (0.879-1.051) -0.04 (0.046) 3.80E-01 9934-16956 26890 
T1D rs10745954 G/A 12 ASCL1 rs1 745954 G/A 0.987 (0.941-1.037) -0.013 (0.025) 6.08E-01 9934-16956 26890 
T1D rs1183910 A/G 12 HNF1A rs1183910 G/A 1.033 (0.981-1.088) 0.033 (0.027) 2.18E-01 9934-16956 26890 
T1D rs340029 C/T 15 RORA rs3 0029 C/T 0.978 (0.93-1.029) -0.022 (0.026) 3.98E-01 9934-16956 26890 
T1D rs 0521222 T/C 16 SALL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
T1D rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs1800961 T/C 20 HNF4A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
UC rs12037222 G/A 1 PABPC4 rs12037222 G/A 0.995 (0.944-1.049) -0.005 (0.027) 8.48E-01 6687-19718 26405 
UC rs4420065 T/C 1 LEPR rs4420065 T/C 1.017 (0.974-1.061) 0.017 (0.022) 4.41E-01 6687-19718 26405 
UC rs4129267 T/C 1 IL6R rs4129267 T/C 1.006 (0.964-1.049) 0.006 (0.022) 7.82E-01 6687-19718 26405 
UC rs2794520 T/C 1 CRP rs2794520 T/C 1.013 (0.97-1.058) 0.013 (0.022) 5.57E-01 6687-19718 26405 
UC rs12239046 T/C 1 NLRP3 rs12239046 T/C 0.979 (0.939-1.022) -0.021 (0.022) 3.38E-01 6687-19718 26405 
UC rs1260326 C/T 2 GCKR rs1260326 T/C 1.062 (1.018-1.108) 0.06 (0.022) 5.30E-03 6687-19718 26405 
UC rs6734238 A/G 2 IL1F10 rs6734238 A/G 0.995 (0.954-1.037) -0.005 (0.021) 8.09E-01 6687-19718 26405 
UC rs4705952 A/G 5 IRF1 rs4705952 A/G 1.04 (0.989-1.094) 0.039 (0.026) 1.33E-01 6687-19718 26405 
UC rs6901250 G/A 6 GPRC6A rs6901250 A/G 1.022 (0.978-1.068) 0.022 (0.023) 3.35E-01 6687-19718 26405 
UC rs13233571 T/C 7 BCL7B rs13233571 T/C 0.972 (0.91-1.037) -0.029 (0.033) 3.84E-01 6687-19718 26405 
UC rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
UC rs10745954 G/A 12 ASCL1 rs1588886 A/G 1.011 (0.97-1.054) 0.011 (0.021) 6.11E-01 6687-19718 26405 
UC rs1183910 A/G 12 HNF1A rs1183910 G/A 0.946 (0.903-0.992) -0.055 (0.024) 2.18E-02 6687-19718 26405 
UC rs340029 C/T 15 RORA rs340029 T/C 0.979 (0.938-1.021) -0.021 (0.022) 3.25E-01 6687-19718 26405 
UC rs10521222 T/C 16 SALL1 rs10521222 T/C 0.974 (0.872-1.088) -0.026 (0.056) 6.42E-01 6687-19718 26405 
UC rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.057 (1.013-1.103) 0.055 (0.022) 1.12E-02 6687-19718 26405 
UC rs4420638 G/A 19 APOC1 rs4420638 A/G 0.968 (0.891-1.052) -0.032 (0.043) 4.49E-01 6687-19718 26405 
UC rs1800961 T/C 20 HNF4A rs1800961 T/C 0.87 (0.757-1) -0.139 (0.071) 5.04E-02 6687-19718 26405 
KOA rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.057 (0.028) 4.10E-02 5755-18505 24260 
KOA rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.025 (0.024) 2.92E-01 5755-18505 24260 
KOA rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.038 (0.024) 1.03E-01 5755-18505 24260 
















N Controls N Total 
T1D 4420638 G A 9 APOC1 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D 18 961 T C 20 HNF4A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
2037 G A  P BPC4 2037 G A 95 944 49 05 27 8 8
4420065 T C  LEPR 4420065 T C 1 0 974 061 17 4 41 1
1 9267 T C  IL6R 1 9267 T C 1 006 964 49 0.006 (0.022) 7 82
2794520 1 CRP 2794520 1 013 (0.9 .058) 0.013 (0.022) 57 1
UC 2 9046 T C NLRP3 2 9046 T C 0.979 (0.939-1.022) -0.021 (0.022) 3 38 1 6687 9718 6405
UC 126 326 C T 2 GCK 126 326 T C 1.062 (1.018-1.108) 6 (0.02 ) 5 30 3 6687 9718 6405
UC 6734 38 A G 2 1F10 6734 38 A G 0.995 (0.954-1.037) 05 1 8 9 6687 9718 6405
UC rs4705952 A/G 5 IRF1 rs4705952 A/G 1.04 (0.989-1.094) 0.039 (0.026) 1.33E-01 6687-19718 26405 
UC rs6901250 G/A 6 GPRC6A rs6901250 A/G 1.022 (0.978-1.068) 0.022 (0.023) 3.35E-01 6687-19718 26405 
UC rs13233571 T/C 7 BCL7B rs13233571 T/C 0.972 (0.91-1.037) -0.029 (0.033) 3.84E-01 6687-19718 26405 
UC rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
UC rs10745954 G/A 12 ASCL1 rs1588886 A/G 1.011 (0.97-1.054) 0.011 (0.021) 6.11E-01 6687-19718 26405 
UC rs1183910 A/G 12 HNF1A rs1183910 G/A 0.946 (0.903-0.992) -0.055 (0.024) 2.18E-02 6687-19718 26405 
UC rs340029 C/T 15 RORA rs340029 T/C 0.979 (0.938-1.021) -0.021 (0.022) 3.25E-01 6687-19718 26405 
UC rs10521222 T/C 16 SALL1 rs10521222 T/C 0.974 (0.872-1.088) -0.026 (0.056) 6.42E-01 6687-19718 26405 
UC rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.057 (1.013-1.103) 0.055 (0.022) 1.12E-02 6687-19718 26405 
UC rs4420638 G/A 19 APOC1 rs4420638 A/G 0.968 (0.891-1.052) -0.032 (0.043) 4.49E-01 6687-19718 26405 
UC rs1800961 T/C 20 HNF4A rs1800961 T/C 0.87 (0.757-1) -0.139 (0.071) 5.04E-02 6687-19718 26405 
KOA rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.057 (0.028) 4.10E-02 5755-18505 24260 
KOA rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.025 (0.024) 2.92E-01 5755-18505 24260 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
KOA rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) 0.02 (0.025) 4.18E-01 5755-18505 24260 
KOA rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.008 (0.024) 7.29E-01 5755-18505 24260 
KOA rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.014 (0.024) 5.59E-01 5755-18505 24260 
KOA rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) -0.008 (0.024) 7.46E-01 5755-18505 24260 
KOA rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) -0.04 (0.031) 1.92E-01 5755-18505 24260 
KOA rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) -0.012 (0.026) 6.49E-01 5755-18505 24260 
KOA rs13 33571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.061 (0.036) 9.36E-02 5755-18505 24260 
KOA rs9987289 A/G 8 PPP1R3B rs99 7289 G/A ─ (─-─) 0.029 (0.042) 4.94E-01 5755-18505 24260 
KOA rs1 745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.009 (0.023) 7.00E-01 5755-18505 24260 
KOA rs1183910 A/G 12 HNF1A rs1 3910 G/A ─ (─-─) -0.01 (0.025) 6.80E-01 5755-18505 24260 
KOA rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.046 (0.024) 5.62E-02 5755-18505 24260 
KOA rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.044 (0.058) 4.48E-01 5755-18505 24260 
KOA rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.013 (0.024) 5.92E-01 5755-18505 24260 
KOA rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.129 (0.042) 2.23E-03 5755-18505 24260 
KOA rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.049 (0.065) 4.50E-01 5755-18505 24260 
Cardiovascular 
CAD rs12037222 G/A 1 PABPC4 rs12037222 A/G 0.985 (0.954-1.018) -0.015 (0.017) 3.72E-01 22233-64762 86995 
CAD rs4420065 T/C 1 LEPR rs4420065 T/C 0.97 (0.942-0.998) -0.031 (0.015) 8.65E-02 22233-64762 86995 
CAD rs4129267 T/C 1 IL6R rs4129267 T/C 1.049 (1.02-1.079) 0.048 (0.014) 2.42E-03 22233-64762 86995 
CAD rs2794520 T/C 1 CRP rs2794520 T/C 1.024 (0.995-1.054) 0.024 (0.015) 1.11E-01 22233-64762 86995 
CAD rs12 39046 T/C 1 NLRP3 rs12239046 T/C 1.006 (0.974-1.038) 0.006 (0.016) 3.90E-01 22233-64762 86995 
CAD rs1260326 C/T 2 GCKR rs1260326 T/C 0.976 (0.949-1.005) -0.024 (0.015) 1.36E-01 22233-64762 86995 
CAD rs6734238 A/G 2 IL1F10 rs6734238 A/G 0.968 (0.942-0.995) -0.033 (0.014) 1.45E-02 22233-64762 86995 
















N Controls N Total 
27 4520 1 CRP 2794520 0.02 (0. 25) 18
KOA rs12 39046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.008 (0.024) 7.29E-01 5755-18505 24260 
KOA rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.014 (0.024) 5.59E-01 5755-18505 24260 
KOA rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) -0.008 (0.024) 7.46E-01 5755-18505 24260 
KOA rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) -0.04 (0.031) 1.92E-01 5755-18505 24260 
KOA rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) -0.012 (0.026) 6.49E-01 5755-18505 24260 
KOA rs13 33571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.061 (0.036) 9.36E-02 5755-18505 24260 
KOA rs9987289 A/G 8 PPP R3B rs99 7289 G/A ─ (─-─) 0.029 (0.042) 4.94E-01 5755-18505 24260 
KOA rs1 745954 G/A 12 ASCL1 rs1 745954 G/A ─ (─-─) 0.009 (0.023) 7.00E-01 5755-18505 24260 
KOA rs1183910 A/G 12 HNF1A rs1 3910 G/A ─ (─-─) -0.01 (0.025) 6.80E-01 5755-18505 24260 
KOA rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.046 (0.024) 5.62E-02 5755-18505 24260 
KOA rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.044 (0.058) 4.48E-01 5755-18505 24260 
KOA rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.013 (0.024) 5.92E-01 5755-18505 24260 
KOA rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.129 (0.042) 2.23E-03 5755-18505 24260 
KOA rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.049 (0.065) 4.50E-01 5755-18505 24260 
Cardiovascular 
CAD rs12037222 G/A 1 PABPC4 rs12037222 A/G 0.985 (0.954-1.018) -0.015 (0.017) 3.72E-01 22233-64762 86995 
CAD rs44 0065 T/C 1 LEPR rs4420065 T/C 0.97 (0.942-0.998) -0.031 (0.015) 8.65E-02 22233-64762 86995 
CAD rs4129267 T/C 1 IL6R rs4129267 T/C 1.049 (1.02-1.079) 0.048 (0.014) 2.42E-03 22233-64762 86995 
CAD rs2794520 T/C 1 CRP rs2794520 T/C 1.024 (0.995-1.054) 0.024 (0.015) 1.11E-01 22233-64762 86995 
CAD rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.006 (0.974-1.038) 0.006 (0.016) 3.90E-01 22233-64762 86995 
CAD rs1260326 C/T 2 GCKR rs1260326 T/C 0.976 (0.949-1.005) -0.024 (0.015) 1.36E-01 22233-64762 86995 
CAD rs6734238 A/G 2 IL1F10 rs6734238 A/G 0.968 (0.942-0.995) -0.033 (0.014) 1.45E-02 22233-64762 86995 
210204-L-bw-Vaez
















N Controls N Total 
T1D rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D rs1800961 T/C 20 HNF4A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
UC rs12037222 G/A 1 PABPC4 rs12037222 G/A 0.995 (0.944-1.049) -0.005 (0.027) 8.48E-01 6687-19718 26405 
UC rs4420065 T/C 1 LEPR rs4420065 T/C 1.017 (0.974-1.061) 0.017 (0.022) 4.41E-01 6687-19718 26405 
UC rs4129267 T/C 1 IL6R rs4129267 T/C 1.006 (0.964-1.049) 0.006 (0.022) 7.82E-01 6687-19718 26405 
UC rs2794520 T/C 1 CRP rs2794520 T/C 1.013 (0.97-1.058) 0.013 (0.022) 5.57E-01 6687-19718 26405 
UC rs12239046 T/C 1 NLRP3 rs12239046 T/C 0.979 (0.939-1.022) -0.021 (0.022) 3.38E-01 6687-19718 26405 
UC rs1260326 C/T 2 GCKR rs1260326 T/C 1.062 (1.018-1.108) 0.06 (0.022) 5.30E-03 6687-19718 26405 
UC rs6734238 A/G 2 IL1F10 rs6734238 A/G 0.995 (0.954-1.037) -0.005 (0.021) 8.09E-01 6687-19718 26405 
UC rs4705952 A/G 5 IRF1 rs4705952 A/G 1.04 (0.989-1.094) 0.039 (0.026) 1.33E-01 6687-19718 26405 
UC rs6901250 G/A 6 GPRC6A rs6901250 A/G 1.022 (0.978-1.068) 0.022 (0.023) 3.35E-01 6687-19718 26405 
UC rs13233571 T/C 7 BCL7B rs13233571 T/C 0.972 (0.91-1.037) -0.029 (0.033) 3.84E-01 6687-19718 26405 
UC rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
UC rs10745954 G/A 12 ASCL1 rs1588886 A/G 1.011 (0.97-1.054) 0.011 (0.021) 6.11E-01 6687-19718 26405 
UC rs1183910 A/G 12 HNF1A rs1183910 G/A 0.946 (0.903-0.992) -0.055 (0.024) 2.18E-02 6687-19718 26405 
UC rs340029 C/T 15 RORA rs340029 T/C 0.979 (0.938-1.021) -0.021 (0.022) 3.25E-01 6687-19718 26405 
UC rs10521222 T/C 16 SALL1 rs10521222 T/C 0.974 (0.872-1.088) -0.026 (0.056) 6.42E-01 6687-19718 26405 
UC rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.057 (1.013-1.103) 0.055 (0.022) 1.12E-02 6687-19718 26405 
UC rs4420638 G/A 19 APOC1 rs4420638 A/G 0.968 (0.891-1.052) -0.032 (0.043) 4.49E-01 6687-19718 26405 
UC rs1800961 T/C 20 HNF4A rs1800961 T/C 0.87 (0.757-1) -0.139 (0.071) 5.04E-02 6687-19718 26405 
KOA rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.057 (0.028) 4.10E-02 5755-18505 24260 
KOA rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.025 (0.024) 2.92E-01 5755-18505 24260 
KOA rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.038 (0.024) 1.03E-01 5755-18505 24260 
















N Controls N Total 
T1D 4420638 G A 9 APOC1 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
T1D 18 961 T C 20 HNF4A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
2037 G A  P BPC4 2037 G A 95 944 49 05 27 8 8
4420065 T C  LEPR 4420065 T C 1 0 974 061 17 4 41 1
1 9267 T C  IL6R 1 9267 T C 1 006 964 49 0.006 (0.022) 7 82
2794520 1 CRP 2794520 1 013 (0.9 .058) 0.013 (0.022) 57 1
UC 2 9046 T C NLRP3 2 9046 T C 0.979 (0.939-1.022) -0.021 (0.022) 3 38 1 6687 9718 6405
UC 126 326 C T 2 GCK 126 326 T C 1.062 (1.018-1.108) 6 (0.02 ) 5 30 3 6687 9718 6405
UC 6734 38 A G 2 1F10 6734 38 A G 0.995 (0.954-1.037) 05 1 8 9 6687 9718 6405
UC rs4705952 A/G 5 IRF1 rs4705952 A/G 1.04 (0.989-1.094) 0.039 (0.026) 1.33E-01 6687-19718 26405 
UC rs6901250 G/A 6 GPRC6A rs6901250 A/G 1.022 (0.978-1.068) 0.022 (0.023) 3.35E-01 6687-19718 26405 
UC rs13233571 T/C 7 BCL7B rs13233571 T/C 0.972 (0.91-1.037) -0.029 (0.033) 3.84E-01 6687-19718 26405 
UC rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
UC rs10745954 G/A 12 ASCL1 rs1588886 A/G 1.011 (0.97-1.054) 0.011 (0.021) 6.11E-01 6687-19718 26405 
UC rs1183910 A/G 12 HNF1A rs1183910 G/A 0.946 (0.903-0.992) -0.055 (0.024) 2.18E-02 6687-19718 26405 
UC rs340029 C/T 15 RORA rs340029 T/C 0.979 (0.938-1.021) -0.021 (0.022) 3.25E-01 6687-19718 26405 
UC rs10521222 T/C 16 SALL1 rs10521222 T/C 0.974 (0.872-1.088) -0.026 (0.056) 6.42E-01 6687-19718 26405 
UC rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.057 (1.013-1.103) 0.055 (0.022) 1.12E-02 6687-19718 26405 
UC rs4420638 G/A 19 APOC1 rs4420638 A/G 0.968 (0.891-1.052) -0.032 (0.043) 4.49E-01 6687-19718 26405 
UC rs1800961 T/C 20 HNF4A rs1800961 T/C 0.87 (0.757-1) -0.139 (0.071) 5.04E-02 6687-19718 26405 
KOA rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.057 (0.028) 4.10E-02 5755-18505 24260 
KOA rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.025 (0.024) 2.92E-01 5755-18505 24260 
KOA rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.038 (0.024) 1.03E-01 5755-18505 24260 
















N Controls N Total 
KOA rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) 0.02 (0.025) 4.18E-01 5755-18505 24260 
KOA rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.008 (0.024) 7.29E-01 5755-18505 24260 
KOA rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.014 (0.024) 5.59E-01 5755-18505 24260 
KOA rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) -0.008 (0.024) 7.46E-01 5755-18505 24260 
KOA rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) -0.04 (0.031) 1.92E-01 5755-18505 24260 
KOA rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) -0.012 (0.026) 6.49E-01 5755-18505 24260 
KOA rs13 33571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.061 (0.036) 9.36E-02 5755-18505 24260 
KOA rs9987289 A/G 8 PPP1R3B rs99 7289 G/A ─ (─-─) 0.029 (0.042) 4.94E-01 5755-18505 24260 
KOA rs1 745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.009 (0.023) 7.00E-01 5755-18505 24260 
KOA rs1183910 A/G 12 HNF1A rs1 3910 G/A ─ (─-─) -0.01 (0.025) 6.80E-01 5755-18505 24260 
KOA rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.046 (0.024) 5.62E-02 5755-18505 24260 
KOA rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.044 (0.058) 4.48E-01 5755-18505 24260 
KOA rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.013 (0.024) 5.92E-01 5755-18505 24260 
KOA rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.129 (0.042) 2.23E-03 5755-18505 24260 
KOA rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.049 (0.065) 4.50E-01 5755-18505 24260 
Cardiovascular 
CAD rs12037222 G/A 1 PABPC4 rs12037222 A/G 0.985 (0.954-1.018) -0.015 (0.017) 3.72E-01 22233-64762 86995 
CAD rs4420065 T/C 1 LEPR rs4420065 T/C 0.97 (0.942-0.998) -0.031 (0.015) 8.65E-02 22233-64762 86995 
CAD rs4129267 T/C 1 IL6R rs4129267 T/C 1.049 (1.02-1.079) 0.048 (0.014) 2.42E-03 22233-64762 86995 
CAD rs2794520 T/C 1 CRP rs2794520 T/C 1.024 (0.995-1.054) 0.024 (0.015) 1.11E-01 22233-64762 86995 
CAD rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.006 (0.974-1.038) 0.006 (0.016) 3.90E-01 22233-64762 86995 
CAD rs1260326 C/T 2 GCKR rs1260326 T/C 0.976 (0.949-1.005) -0.024 (0.015) 1.36E-01 22233-64762 86995 
CAD rs6734238 A/G 2 IL1F10 rs6734238 A/G 0.968 (0.942-0.995) -0.033 (0.014) 1.45E-02 22233-64762 86995 
















N Controls N Total 
27 4520 1 CRP 2794520 0.02 (0. 25) 18
KOA rs12 39046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.008 (0.024) 7.29E-01 5755-18505 24260 
KOA rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.014 (0.024) 5.59E-01 5755-18505 24260 
KOA rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) -0.008 (0.024) 7.46E-01 5755-18505 24260 
KOA rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) -0.04 (0.031) 1.92E-01 5755-18505 24260 
KOA rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) -0.012 (0.026) 6.49E-01 5755-18505 24260 
KOA rs13 33571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.061 (0.036) 9.36E-02 5755-18505 24260 
KOA rs9987289 A/G 8 PPP R3B rs99 7289 G/A ─ (─-─) 0.029 (0.042) 4.94E-01 5755-18505 24260 
KOA rs1 745954 G/A 12 ASCL1 rs1 745954 G/A ─ (─-─) 0.009 (0.023) 7.00E-01 5755-18505 24260 
KOA rs1183910 A/G 12 HNF1A rs1 3910 G/A ─ (─-─) -0.01 (0.025) 6.80E-01 5755-18505 24260 
KOA rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.046 (0.024) 5.62E-02 5755-18505 24260 
KOA rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.044 (0.058) 4.48E-01 5755-18505 24260 
KOA rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.013 (0.024) 5.92E-01 5755-18505 24260 
KOA rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.129 (0.042) 2.23E-03 5755-18505 24260 
KOA rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.049 (0.065) 4.50E-01 5755-18505 24260 
Cardiovascular 
CAD rs12037222 G/A 1 PABPC4 rs12037222 A/G 0.985 (0.954-1.018) -0.015 (0.017) 3.72E-01 22233-64762 86995 
CAD rs4420065 T/C 1 LEPR rs4420065 T/C 0.97 (0.942-0.998) -0.031 (0.015) 8.65E-02 22233-64762 86995 
CAD rs4129267 T/C 1 IL6R rs4129267 T/C 1.049 (1.02-1.079) 0.048 (0.014) 2.42E-03 22233-64762 86995 
CAD rs2794520 T/C 1 CRP rs2794520 T/C 1.024 (0.995-1.054) 0.024 (0.015) 1.11E-01 22233-64762 86995 
CAD rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.006 (0.974-1.038) 0.006 (0.016) 3.90E-01 22233-64762 86995 
CAD rs1260326 C/T 2 GCKR rs1260326 T/C 0.976 (0.949-1.005) -0.024 (0.015) 1.36E-01 22233-64762 86995 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
CAD rs4705952 A/G 5 IRF1 rs4705952 A/G 0.979 (0.943-1.016) -0.022 (0.019) 4.02E-01 22233-64762 86995 
CAD rs6901250 G/A 6 GPRC6A rs6901250 A/G 0.997 (0.968-1.027) -0.003 (0.015) 8.95E-01 22233-64762 86995 
CAD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.951 (0.911-0.993) -0.05 (0.022) 3.14E-02 22233-64762 86995 
CAD rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.022 (0.972-1.074) 0.021 (0.026) 8.95E-01 22233-64762 86995 
CAD rs10745954 G/A 12 ASCL1 rs10745954 A/G 1.04 (1.012-1.068) 0.039 (0.014) 1.95E-02 22233-64762 86995 
CAD rs1183910 A/G 12 HNF1A rs1183910 A/G 0.931 (0.904-0.959) -0.071 (0.015) 2.26E-06 22233-64762 86995 
CAD rs340029 C/T 15 RORA rs340029 T/C 1.008 (0.977-1.041) 0.008 (0.016) 6.00E-01 22233-64762 86995 
CAD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.025 (0.939-1.118) 0.025 (0.044) 5.80E-01 22233-64762 86995 
CAD rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.011 (0.983-1.04) 0.011 (0.014) 4.37E-01 22233-64762 86995 
CAD rs4420638 G/A 19 APOC1 rs4420638 A/G 1.119 (1.054-1.187) 0.112 (0.03) 3.34E-03 22233-64762 86995 
CAD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.97 (0.89-1.058) -0.03 (0.044) 4.91E-01 22233-64762 86995 
DBP rs12037222 G/A 1 PABPC4 rs12037222 A/G ─ (─-─) -0.22 (0.074) 3.09E-03 ─-─ 67880 
DBP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.041 (0.064) 5.25E-01 ─-─ 65966 
DBP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.047 (0.063) 4.51E-01 ─-─ 68976 
DBP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.162 (0.065) 1.26E-02 ─-─ 69196 
DBP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.097 (0.066) 1.40E-01 ─-─ 60600 
DBP rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.019 (0.063) 7.59E-01 ─-─ 68609 
DBP rs6734238 A/G 2 IL1F10 rs6734238 A/G ─ (─-─) -0.109 (0.063) 8.11E-02 ─-─ 69303 
DBP rs4705952 A/G 5 IRF1 rs4705952 A/G ─ (─-─) -0.011 (0.081) 8.91E-01 ─-─ 56514 
DBP rs6901250 G/A 6 GPRC6A rs6901250 A/G ─ (─-─) 0.107 (0.066) 1.05E-01 ─-─ 67518 
DBP rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.174 (0.096) 7.00E-02 ─-─ 68151 
DBP rs9987289 A/G 8 PPP1R3B rs9987289 A/G ─ (─-─) -0.047 (0.109) 6.63E-01 ─-─ 66541 
DBP rs10745954 G/A 12 ASCL1 rs10745954 A/G ─ (─-─) -0.034 (0.061) 5.82E-01 ─-─ 69372 
















N Controls N Total 
CAD 4 05952 A G 5 IRF1 4 05952 A G 0.979 (0.943-1.016) 02 19 4 02 1 22233-64762 869 5
CAD 6901250 G A 6 GP C6A 6901250 A G 0.997 (0.968-1.027) -0.003 (0.015) 8 95 22233-64762 86995
CAD 323 571 T C 7 B L7B 323 571 T C 0.951 (0.911-0.993) -0.05 (0. 22) 3 14 2 22233-64762 86995
CAD 9987 89 8 PPP1R3B 9987 89 1.022 (0.972-1.074) 0.021 (0.026) 95 1 22233-64762 86995
CAD 10745954 G A 12 ASCL1 10745954 1.04 (1.012-1.068) 0.039 (0.014) 1 5 2 22233-64762 8 995
CAD 118391 A G 12 HNF1A 118391 0.931 (0.904-0.959) -0.071 (0.015) 2 26 6 22233-64762 86995
CAD 340029 C T 15 RORA 340029 T C 1.008 (0.977-1.041) 0.008 (0.016) 6 1 22233-64762 86995
CAD 10521222 T C 16 SALL1 10521222 T C 1.025 (0.939-1.118) 0.025 (0.044) 5 80 22233-64762 8 995
CAD 2847281 8 PTPN2 2847281 1.011 (0.983-1.04) 0.011 (0.014) 4 37 22233-64762 86995
CAD rs4420638 G/A 19 APOC1 rs4420638 A/G 1.119 (1.054-1.187) 0.112 (0.03) 3.34E-03 22233-64762 86995 
CAD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.97 (0.89-1.058) -0.03 (0.044) 4.91E-01 22233-64762 86995 
DBP rs12037222 G/A 1 PABPC4 rs12037222 A/G ─ (─-─) -0.22 (0.074) 3.09E-03 ─-─ 67880 
DBP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.041 (0.064) 5.25E-01 ─-─ 65966 
DBP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.047 (0.063) 4.51E-01 ─-─ 68976 
DBP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.162 (0.065) 1.26E-02 ─-─ 69196 
DBP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.097 (0.066) 1.40E-01 ─-─ 60600 
DBP rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.019 (0.063) 7.59E-01 ─-─ 68609 
DBP rs6734238 A/G 2 IL1F10 rs6734238 A/G ─ (─-─) -0.109 (0.063) 8.11E-02 ─-─ 69303 
DBP rs4705952 A/G 5 IRF1 rs4705952 A/G ─ (─-─) -0.011 (0.081) 8.91E-01 ─-─ 56514 
DBP rs6901250 G/A 6 GPRC6A rs6901250 A/G ─ (─-─) 0.107 (0.066) 1.05E-01 ─-─ 67518 
DBP rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.174 (0.096) 7.00E-02 ─-─ 68151 
DBP rs9987289 A/G 8 PPP1R3B rs9987289 A/G ─ (─-─) -0.047 (0.109) 6.63E-01 ─-─ 66541 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
DBP rs1183910 A/G 12 HNF1A rs1183910 A/G ─ (─-─) -0.014 (0.066) 8.32E-01 ─-─ 67545 
DBP rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) -0.021 (0.065) 7.52E-01 ─-─ 65484 
DBP rs10521222 T/C 16 SALL1 rs105 1222 C/T ─ (─-─) 0.295 (0.202) 1.45E-01 ─-─ 35027 
DBP rs2847281 G/A 18 PTPN2 rs2847281 A/G ─ (─-─) -0.059 (0.063) 3.50E-01 ─-─ 68443 
DBP rs4420638 G/A 19 APOC1 rs 420638 A/G ─ (─-─) -0.221 (0.103) 3.20E-02 ─-─ 43118 
DBP rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) 0.225 (0.217) 3.01E-01 ─-─ 40909 
IS rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.018 (0.037) 6.27E-01 3548-5972 9520 
IS rs4420065 T/C 1 LEPR rs 420065 T/C ─ (─-─) -0.044 (0.032) 1.70E-01 3548-5972 9520 
IS rs4129267 T/C 1 IL6R rs 129267 T/C ─ (─-─) 0.044 (0.032) 1.67E-01 3548-5972 9520 
IS rs2794520 T/C 1 CRP rs2 94520 T/C ─ (─-─) 0.048 (0.033) 1.53E-01 3548-5972 9520 
IS rs12239046 T/C 1 NLRP3 rs12239046 T/C ─ (─-─) 0.048 (0.032) 1.28E-01 3548-5972 9520 
IS rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) -0.026 (0.031) 4.15E-01 3548-5972 9520 
IS rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.013 (0.032) 6.92E-01 3548-5972 9520 
IS rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0.015 (0.04) 7.06E-01 3548-5972 9520 
IS rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.008 (0.033) 8.19E-01 3548-5972 9520 
IS rs13 33571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) 0.002 (0.048) 9.67E-01 3548-5972 9520 
IS rs9 87289 A/G 8 PPP R3B rs9987289 G/A ─ (─-─) 0.101 (0.054) 6.15E-02 3548-5972 9520 
IS rs1 5954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.05 (0.031) 1.08E-01 3548-5972 9520 
IS rs11 3910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.03 (0.033) 3.68E-01 3548-5972 9520 
IS rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) 0 (0.032) 9.90E-01 3548-5972 9520 
IS rs1 521222 T/C 16 SALL1 rs105 1222 T/C ─ (─-─) -0.012 (0.093) 9.01E-01 3548-5972 9520 
IS rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.035 (0.032) 2.65E-01 3548-5972 9520 
IS rs4420638 G/A 19 APOC1 rs 420638 G/A ─ (─-─) 0.019 (0.05) 7.07E-01 3548-5972 9520 
















N Controls N Total 
DBP 118391 A G 12 HNF1A 118391 A G -0.014 (0.066) 32 ─-─ 67545 
DBP 340029 C T 15 RORA 340029 C T -0.021 (0.065) 7 52 ─-─ 6 484 
DBP 10521222 T C 16 SALL1 105 1222 C T 295 202 1 4 1 ─-─ 3 027 
DBP 2847281 8 PTPN2 2847281 A G -0.059 ( .063) 3 50 ─-─ 68443 
DBP 4420638 G A 9 APOC1 420638 A G -0.221 ( .103) 20 2 ─-─ 43118 
DBP 18 961 T C 20 HNF4A 18 961 C T .225 (0.217) 3 01 ─-─ 409 9 
2037 G A  P BPC4 2037 G A 0.018 (0.037) 6 27
4420065 T C  LEPR 420065 T C 44 1 70
1 9267 T C  IL6R 1 9267 T C 44 32) 1 6
IS rs2794520 T/C 1 CRP rs2 94520 T/C ─ (─-─) 0.048 (0.033) 1.53E-01 3548-5972 9520 
IS rs12239046 T/C 1 NLRP3 rs12239046 T/C ─ (─-─) 0.048 (0.032) 1.28E-01 3548-5972 9520 
IS rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) -0.026 (0.031) 4.15E-01 3548-5972 9520 
IS rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.013 (0.032) 6.92E-01 3548-5972 9520 
IS rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0.015 (0.04) 7.06E-01 3548-5972 9520 
IS rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.008 (0.033) 8.19E-01 3548-5972 9520 
IS rs13233571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) 0.002 (0.048) 9.67E-01 3548-5972 9520 
IS rs9987289 A/G 8 PPP R3B rs9987289 G/A ─ (─-─) 0.101 (0.054) 6.15E-02 3548-5972 9520 
IS rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.05 (0.031) 1.08E-01 3548-5972 9520 
IS rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.03 (0.033) 3.68E-01 3548-5972 9520 
IS rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) 0 (0.032) 9.90E-01 3548-5972 9520 
IS rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) -0.012 (0.093) 9.01E-01 3548-5972 9520 
IS rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.035 (0.032) 2.65E-01 3548-5972 9520 
IS rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.019 (0.05) 7.07E-01 3548-5972 9520 
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N Controls N Total 
CAD rs4705952 A/G 5 IRF1 rs4705952 A/G 0.979 (0.943-1.016) -0.022 (0.019) 4.02E-01 22233-64762 86995 
CAD rs6901250 G/A 6 GPRC6A rs6901250 A/G 0.997 (0.968-1.027) -0.003 (0.015) 8.95E-01 22233-64762 86995 
CAD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.951 (0.911-0.993) -0.05 (0.022) 3.14E-02 22233-64762 86995 
CAD rs9987289 A/G 8 PPP1R3B rs9987289 A/G 1.022 (0.972-1.074) 0.021 (0.026) 8.95E-01 22233-64762 86995 
CAD rs10745954 G/A 12 ASCL1 rs10745954 A/G 1.04 (1.012-1.068) 0.039 (0.014) 1.95E-02 22233-64762 86995 
CAD rs1183910 A/G 12 HNF1A rs1183910 A/G 0.931 (0.904-0.959) -0.071 (0.015) 2.26E-06 22233-64762 86995 
CAD rs340029 C/T 15 RORA rs340029 T/C 1.008 (0.977-1.041) 0.008 (0.016) 6.00E-01 22233-64762 86995 
CAD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.025 (0.939-1.118) 0.025 (0.044) 5.80E-01 22233-64762 86995 
CAD rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.011 (0.983-1.04) 0.011 (0.014) 4.37E-01 22233-64762 86995 
CAD rs4420638 G/A 19 APOC1 rs4420638 A/G 1.119 (1.054-1.187) 0.112 (0.03) 3.34E-03 22233-64762 86995 
CAD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.97 (0.89-1.058) -0.03 (0.044) 4.91E-01 22233-64762 86995 
DBP rs12037222 G/A 1 PABPC4 rs12037222 A/G ─ (─-─) -0.22 (0.074) 3.09E-03 ─-─ 67880 
DBP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.041 (0.064) 5.25E-01 ─-─ 65966 
DBP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.047 (0.063) 4.51E-01 ─-─ 68976 
DBP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.162 (0.065) 1.26E-02 ─-─ 69196 
DBP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.097 (0.066) 1.40E-01 ─-─ 60600 
DBP rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.019 (0.063) 7.59E-01 ─-─ 68609 
DBP rs6734238 A/G 2 IL1F10 rs6734238 A/G ─ (─-─) -0.109 (0.063) 8.11E-02 ─-─ 69303 
DBP rs4705952 A/G 5 IRF1 rs4705952 A/G ─ (─-─) -0.011 (0.081) 8.91E-01 ─-─ 56514 
DBP rs6901250 G/A 6 GPRC6A rs6901250 A/G ─ (─-─) 0.107 (0.066) 1.05E-01 ─-─ 67518 
DBP rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.174 (0.096) 7.00E-02 ─-─ 68151 
DBP rs9987289 A/G 8 PPP1R3B rs9987289 A/G ─ (─-─) -0.047 (0.109) 6.63E-01 ─-─ 66541 
DBP rs10745954 G/A 12 ASCL1 rs10745954 A/G ─ (─-─) -0.034 (0.061) 5.82E-01 ─-─ 69372 
















N Controls N Total 
CAD 4 05952 A G 5 IRF1 4 05952 A G 0.979 (0.943-1.016) 02 19 4 02 1 22233-64762 869 5
CAD 6901250 G A 6 GP C6A 6901250 A G 0.997 (0.968-1.027) -0.003 (0.015) 8 95 22233-64762 86995
CAD 323 571 T C 7 B L7B 323 571 T C 0.951 (0.911-0.993) -0.05 (0. 22) 3 14 2 22233-64762 86995
CAD 9987 89 8 PPP1R3B 9987 89 1.022 (0.972-1.074) 0.021 (0.026) 95 1 22233-64762 86995
CAD 10745954 G A 12 ASCL1 10745954 1.04 (1.012-1.068) 0.039 (0.014) 1 5 2 22233-64762 8 995
CAD 118391 A G 12 HNF1A 118391 0.931 (0.904-0.959) -0.071 (0.015) 2 26 6 22233-64762 86995
CAD 340029 C T 15 RORA 340029 T C 1.008 (0.977-1.041) 0.008 (0.016) 6 1 22233-64762 86995
CAD 10521222 T C 16 SALL1 10521222 T C 1.025 (0.939-1.118) 0.025 (0.044) 5 80 22233-64762 8 995
CAD 2847281 8 PTPN2 2847281 1.011 (0.983-1.04) 0.011 (0.014) 4 37 22233-64762 86995
CAD rs4420638 G/A 19 APOC1 rs4420638 A/G 1.119 (1.054-1.187) 0.112 (0.03) 3.34E-03 22233-64762 86995 
CAD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.97 (0.89-1.058) -0.03 (0.044) 4.91E-01 22233-64762 86995 
DBP rs12037222 G/A 1 PABPC4 rs12037222 A/G ─ (─-─) -0.22 (0.074) 3.09E-03 ─-─ 67880 
DBP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.041 (0.064) 5.25E-01 ─-─ 65966 
DBP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.047 (0.063) 4.51E-01 ─-─ 68976 
DBP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.162 (0.065) 1.26E-02 ─-─ 69196 
DBP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.097 (0.066) 1.40E-01 ─-─ 60600 
DBP rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.019 (0.063) 7.59E-01 ─-─ 68609 
DBP rs6734238 A/G 2 IL1F10 rs6734238 A/G ─ (─-─) -0.109 (0.063) 8.11E-02 ─-─ 69303 
DBP rs4705952 A/G 5 IRF1 rs4705952 A/G ─ (─-─) -0.011 (0.081) 8.91E-01 ─-─ 56514 
DBP rs6901250 G/A 6 GPRC6A rs6901250 A/G ─ (─-─) 0.107 (0.066) 1.05E-01 ─-─ 67518 
DBP rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.174 (0.096) 7.00E-02 ─-─ 68151 
DBP rs9987289 A/G 8 PPP1R3B rs9987289 A/G ─ (─-─) -0.047 (0.109) 6.63E-01 ─-─ 66541 
DBP rs10745954 G/A 12 ASCL1 rs10745954 A/G ─ (─-─) -0.034 (0.061) 5.82E-01 ─-─ 69372 
















N Controls N Total 
DBP rs1183910 A/G 12 HNF1A rs1183910 A/G ─ (─-─) -0.014 (0.066) 8.32E-01 ─-─ 67545 
DBP rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) -0.021 (0.065) 7.52E-01 ─-─ 65484 
DBP rs10521222 T/C 16 SALL1 rs105 1222 C/T ─ (─-─) 0.295 (0.202) 1.45E-01 ─-─ 35027 
DBP rs2847281 G/A 18 PTPN2 rs2847281 A/G ─ (─-─) -0.059 (0.063) 3.50E-01 ─-─ 68443 
DBP rs4420638 G/A 19 APOC1 rs 420638 A/G ─ (─-─) -0.221 (0.103) 3.20E-02 ─-─ 43118 
DBP rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) 0.225 (0.217) 3.01E-01 ─-─ 40909 
IS rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.018 (0.037) 6.27E-01 3548-5972 9520 
IS rs4420065 T/C 1 LEPR rs 420065 T/C ─ (─-─) -0.044 (0.032) 1.70E-01 3548-5972 9520 
IS rs4129267 T/C 1 IL6R rs 129267 T/C ─ (─-─) 0.044 (0.032) 1.67E-01 3548-5972 9520 
IS rs2794520 T/C 1 CRP rs2 94520 T/C ─ (─-─) 0.048 (0.033) 1.53E-01 3548-5972 9520 
IS rs12239046 T/C 1 NLRP3 rs12239046 T/C ─ (─-─) 0.048 (0.032) 1.28E-01 3548-5972 9520 
IS rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) -0.026 (0.031) 4.15E-01 3548-5972 9520 
IS rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.013 (0.032) 6.92E-01 3548-5972 9520 
IS rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0.015 (0.04) 7.06E-01 3548-5972 9520 
IS rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.008 (0.033) 8.19E-01 3548-5972 9520 
IS rs13 33571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) 0.002 (0.048) 9.67E-01 3548-5972 9520 
IS rs9 87289 A/G 8 PPP R3B rs9987289 G/A ─ (─-─) 0.101 (0.054) 6.15E-02 3548-5972 9520 
IS rs1 5954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.05 (0.031) 1.08E-01 3548-5972 9520 
IS rs11 3910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.03 (0.033) 3.68E-01 3548-5972 9520 
IS rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) 0 (0.032) 9.90E-01 3548-5972 9520 
IS rs1 521222 T/C 16 SALL1 rs105 1222 T/C ─ (─-─) -0.012 (0.093) 9.01E-01 3548-5972 9520 
IS rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.035 (0.032) 2.65E-01 3548-5972 9520 
IS rs4420638 G/A 19 APOC1 rs 420638 G/A ─ (─-─) 0.019 (0.05) 7.07E-01 3548-5972 9520 
















N Controls N Total 
DBP 118391 A G 12 HNF1A 118391 A G -0.014 (0.066) 32 ─-─ 67545 
DBP 340029 C T 15 RORA 340029 C T -0.021 (0.065) 7 52 ─-─ 6 484 
DBP 10521222 T C 16 SALL1 105 1222 C T 295 202 1 4 1 ─-─ 3 027 
DBP 2847281 8 PTPN2 2847281 A G -0.059 ( .063) 3 50 ─-─ 68443 
DBP 4420638 G A 9 APOC1 420638 A G -0.221 ( .103) 20 2 ─-─ 43118 
DBP 18 961 T C 20 HNF4A 18 961 C T .225 (0.217) 3 01 ─-─ 409 9 
2037 G A  P BPC4 2037 G A 0.018 (0.037) 6 27
4420065 T C  LEPR 420065 T C 44 1 70
1 9267 T C  IL6R 1 9267 T C 44 32) 1 6
IS rs2794520 T/C 1 CRP rs2 94520 T/C ─ (─-─) 0.048 (0.033) 1.53E-01 3548-5972 9520 
IS rs12239046 T/C 1 NLRP3 rs12239046 T/C ─ (─-─) 0.048 (0.032) 1.28E-01 3548-5972 9520 
IS rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) -0.026 (0.031) 4.15E-01 3548-5972 9520 
IS rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.013 (0.032) 6.92E-01 3548-5972 9520 
IS rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0.015 (0.04) 7.06E-01 3548-5972 9520 
IS rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.008 (0.033) 8.19E-01 3548-5972 9520 
IS rs13233571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) 0.002 (0.048) 9.67E-01 3548-5972 9520 
IS rs9987289 A/G 8 PPP R3B rs9987289 G/A ─ (─-─) 0.101 (0.054) 6.15E-02 3548-5972 9520 
IS rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.05 (0.031) 1.08E-01 3548-5972 9520 
IS rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.03 (0.033) 3.68E-01 3548-5972 9520 
IS rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) 0 (0.032) 9.90E-01 3548-5972 9520 
IS rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) -0.012 (0.093) 9.01E-01 3548-5972 9520 
IS rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.035 (0.032) 2.65E-01 3548-5972 9520 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
IS rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) -0.098 (0.106) 3.54E-01 3548-5972 9520 
IS (CS) rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.102 (0.065) 1.14E-01 790-5972 6762 
IS (CS) rs4420065 T/C 1 LEPR rs4420065 T/C ─ (─-─) -0.036 (0.057) 5.28E-01 790-5972 6762 
IS (CS) rs4129267 T/C 1 IL6R rs4129267 T/C ─ (─-─) 0.02 (0.057) 7.19E-01 790-5972 6762 
IS (CS) rs2794520 T/C 1 CRP rs2794520 T/C ─ (─-─) 0.012 (0.059) 8.36E-01 790-5972 6762 
IS (CS) rs12239046 T/C 1 NLRP3 rs12239046 T/C ─ (─-─) 0.004 (0.057) 9.45E-01 790-5972 6762 
IS (CS) rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) -0.009 (0.056) 8.70E-01 790-5972 6762 
IS (CS) rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.066 (0.056) 2.43E-01 790-5972 6762 
IS (CS) rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.066 (0.069) 3.38E-01 790-5972 6762 
IS (CS) rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.027 (0.059) 6.50E-01 790-5972 6762 
IS (CS) rs13233571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) -0.064 (0.085) 4.52E-01 790-5972 6762 
IS (CS) rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) 0.195 (0.094) 3.76E-02 790-5972 6762 
IS (CS) rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.065 (0.055) 2.39E-01 790-5972 6762 
IS (CS) rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.068 (0.059) 2.50E-01 790-5972 6762 
IS (CS) rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) 0.028 (0.056) 6.17E-01 790-5972 6762 
IS (CS) rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) 0.142 (0.173) 4.12E-01 790-5972 6762 
IS (CS) rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.098 (0.057) 8.50E-02 790-5972 6762 
IS (CS) rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.114 (0.093) 2.20E-01 790-5972 6762 
IS (CS) rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) -0.057 (0.195) 7.70E-01 790-5972 6762 
IS (LVS) rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.014 (0.065) 8.28E-01 844-5972 6816 
IS (LVS) rs4420065 T/C 1 LEPR rs4420065 T/C ─ (─-─) 0.058 (0.056) 2.99E-01 844-5972 6816 
IS (LVS) rs4129267 T/C 1 IL6R rs4129267 T/C ─ (─-─) -0.042 (0.055) 4.45E-01 844-5972 6816 
IS (LVS) rs2794520 T/C 1 CRP rs2794520 T/C ─ (─-─) 0.089 (0.058) 1.25E-01 844-5972 6816 
















N Controls N Total 
18 961 T C 20 HNF4A 18 961 -0.098 (0.106) 3 54 3548-5972 9520
2037 G A  P BPC4 2037 G A 0 065 1 4
4420065 T C  LEPR 4420065 T C 36 5 28 1
1 9267 T C  IL6R 1 9267 T C 02 (0.057) 7 19
2794520 1 CRP 2794520 0.012 (0.059) 8 36
CS) 2 9046 T C NLRP3 2 9046 T C 0.004 (0.057) 9 45 790 762
CS) 126 326 C T 2 GCK 126 326 -0.009 (0.056) 8 70 790 762
CS) 6734 38 A G 2 1F10 6734 38 G A 0.066 (0.056) 2 3 790 762
CS) 4 05952 A G 5 IRF1 4 05952 G A -0.066 (0.069) 3 38 790 762
IS (CS) rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.027 (0.059) 6.50E-01 790-5972 6762 
IS (CS) rs13233571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) -0.064 (0.085) 4.52E-01 790-5972 6762 
IS (CS) rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) 0.195 (0.094) 3.76E-02 790-5972 6762 
IS (CS) rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.065 (0.055) 2.39E-01 790-5972 6762 
IS (CS) rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.068 (0.059) 2.50E-01 790-5972 6762 
IS (CS) rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) 0.028 (0.056) 6.17E-01 790-5972 6762 
IS (CS) rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) 0.142 (0.173) 4.12E-01 790-5972 6762 
IS (CS) rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.098 (0.057) 8.50E-02 790-5972 6762 
IS (CS) rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.114 (0.093) 2.20E-01 790-5972 6762 
IS (CS) rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) -0.057 (0.195) 7.70E-01 790-5972 6762 
IS (LVS) rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.014 (0.065) 8.28E-01 844-5972 6816 
IS (LVS) rs4420065 T/C 1 LEPR rs4420065 T/C ─ (─-─) 0.058 (0.056) 2.99E-01 844-5972 6816 
IS (LVS) rs4129267 T/C 1 IL6R rs4129267 T/C ─ (─-─) -0.042 (0.055) 4.45E-01 844-5972 6816 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
IS (LVS) rs12239046 T/C 1 NLRP3 rs1 239046 T/C ─ (─-─) 0.063 (0.056) 2.60E-01 844-5972 6816 
IS (LVS) rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) 0.014 (0.054) 8.02E-01 844-5972 6816 
IS (LVS) rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.001 (0.054) 9.81E-01 844-5972 6816 
IS (LVS) rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) -0.032 (0.068) 6.39E-01 844-5972 6816 
IS (LVS) rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.046 (0.057) 4.24E-01 844-5972 6816 
IS (LVS) rs13233571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) 0.041 (0.085) 6.33E-01 844-5972 6816 
IS (LVS) rs9987289 A/G 8 PPP R3B rs9987289 G/A ─ (─-─) -0.001 (0.097) 9.89E-01 844-5972 6816 
IS (LVS) rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.015 (0.053) 7.85E-01 844-5972 6816 
IS (LVS) rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.038 (0.059) 5.15E-01 844-5972 6816 
IS (LVS) rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) -0.082 (0.055) 1.37E-01 844-5972 6816 
IS (LVS) rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) -0.074 (0.159) 6.43E-01 844-5972 6816 
IS (LVS) rs2847281 G/A 18 PTPN2 rs 847281 G/A ─ (─-─) -0.011 (0.055) 8.35E-01 844-5972 6816 
IS (LVS) rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) -0.011 (0.088) 9.05E-01 844-5972 6816 
IS (LVS) rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) 0.134 (0.2) 5.04E-01 844-5972 6816 
IS (SVD) rs12037222 G/A 1 PABPC4 rs1 037222 G/A ─ (─-─) 0.012 (0.074) 8.72E-01 580-5972 6552 
IS (SVD) rs4420065 T/C 1 LEPR rs4420065 T/C ─ (─-─) -0.064 (0.064) 3.20E-01 580-5972 6552 
IS (SVD) rs4129267 T/C 1 IL6R rs4129267 T/C ─ (─-─) 0.051 (0.063) 4.17E-01 580-5972 6552 
IS (SVD) rs2794520 T/C 1 CRP rs 794520 T/C ─ (─-─) 0.035 (0.066) 5.94E-01 580-5972 6552 
IS (SVD) rs12239046 T/C 1 NLRP3 rs12239046 T/C ─ (─-─) 0.028 (0.064) 6.61E-01 580-5972 6552 
IS (SVD) rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) -0.074 (0.062) 2.31E-01 580-5972 6552 
IS (SVD) rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.001 (0.063) 9.91E-01 580-5972 6552 
IS (SVD) rs47 5952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0.192 (0.085) 2.42E-02 580-5972 6552 
IS (SVD) rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.017 (0.067) 8.00E-01 580-5972 6552 
















N Controls N Total 
L S) 2 9046 T C NLRP3 2 9046 T C 63 56 2 60 844 816
L S) 126 326 C T 2 GCK 126 326 0.014 (0.054) 8 02 844 816
L S) 6734 38 A G 2 1F10 6734 38 G A 0 54 9 81 844 816
L S) 4 05952 A G 5 IRF  4 05952 G A -0.032 (0.068) 6 39 844 816
L S) 6901250 G A 6 GP C6A 6901250 G A 46 57 4 24 844 816
L S) 323 571 T C 7 B L7B 323 571 0.041 (0.085) 6 3 844 816
L S) 9987 89 8 PPP R3B 9987 89 -0.001 (0.097) 89 844 816
L S) 10745954 G A 12 ASCL1 10745954 015 53 7 85 1 844 816
L S) 118391 A G 12 HNF1A 118391 -0.038 (0.059) 5 15 844 816
IS (LVS) rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) -0.082 (0.055) 1.37E-01 844-5972 6816 
IS (LVS) rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) -0.074 (0.159) 6.43E-01 844-5972 6816 
IS (LVS) rs2847281 G/A 18 PTPN2 rs 847281 G/A ─ (─-─) -0.011 (0.055) 8.35E-01 844-5972 6816 
IS (LVS) rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) -0.011 (0.088) 9.05E-01 844-5972 6816 
IS (LVS) rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) 0.134 (0.2) 5.04E-01 844-5972 6816 
IS (SVD) rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.012 (0.074) 8.72E-01 580-5972 6552 
IS (SVD) rs4420065 T/C 1 LEPR rs4420065 T/C ─ (─-─) -0.064 (0.064) 3.20E-01 580-5972 6552 
IS (SVD) rs4129267 T/C 1 IL6R rs4129267 T/C ─ (─-─) 0.051 (0.063) 4.17E-01 580-5972 6552 
IS (SVD) rs2794520 T/C 1 CRP rs 794520 T/C ─ (─-─) 0.035 (0.066) 5.94E-01 580-5972 6552 
IS (SVD) rs12239046 T/C 1 NLRP3 rs12239046 T/C ─ (─-─) 0.028 (0.064) 6.61E-01 580-5972 6552 
IS (SVD) rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) -0.074 (0.062) 2.31E-01 580-5972 6552 
IS (SVD) rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.001 (0.063) 9.91E-01 580-5972 6552 
IS (SVD) rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0.192 (0.085) 2.42E-02 580-5972 6552 
IS (SVD) rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.017 (0.067) 8.00E-01 580-5972 6552 
210204-L-bw-Vaez
















N Controls N Total 
IS rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) -0.098 (0.106) 3.54E-01 3548-5972 9520 
IS (CS) rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.102 (0.065) 1.14E-01 790-5972 6762 
IS (CS) rs4420065 T/C 1 LEPR rs4420065 T/C ─ (─-─) -0.036 (0.057) 5.28E-01 790-5972 6762 
IS (CS) rs4129267 T/C 1 IL6R rs4129267 T/C ─ (─-─) 0.02 (0.057) 7.19E-01 790-5972 6762 
IS (CS) rs2794520 T/C 1 CRP rs2794520 T/C ─ (─-─) 0.012 (0.059) 8.36E-01 790-5972 6762 
IS (CS) rs12239046 T/C 1 NLRP3 rs12239046 T/C ─ (─-─) 0.004 (0.057) 9.45E-01 790-5972 6762 
IS (CS) rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) -0.009 (0.056) 8.70E-01 790-5972 6762 
IS (CS) rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.066 (0.056) 2.43E-01 790-5972 6762 
IS (CS) rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.066 (0.069) 3.38E-01 790-5972 6762 
IS (CS) rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.027 (0.059) 6.50E-01 790-5972 6762 
IS (CS) rs13233571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) -0.064 (0.085) 4.52E-01 790-5972 6762 
IS (CS) rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) 0.195 (0.094) 3.76E-02 790-5972 6762 
IS (CS) rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.065 (0.055) 2.39E-01 790-5972 6762 
IS (CS) rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.068 (0.059) 2.50E-01 790-5972 6762 
IS (CS) rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) 0.028 (0.056) 6.17E-01 790-5972 6762 
IS (CS) rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) 0.142 (0.173) 4.12E-01 790-5972 6762 
IS (CS) rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.098 (0.057) 8.50E-02 790-5972 6762 
IS (CS) rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.114 (0.093) 2.20E-01 790-5972 6762 
IS (CS) rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) -0.057 (0.195) 7.70E-01 790-5972 6762 
IS (LVS) rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.014 (0.065) 8.28E-01 844-5972 6816 
IS (LVS) rs4420065 T/C 1 LEPR rs4420065 T/C ─ (─-─) 0.058 (0.056) 2.99E-01 844-5972 6816 
IS (LVS) rs4129267 T/C 1 IL6R rs4129267 T/C ─ (─-─) -0.042 (0.055) 4.45E-01 844-5972 6816 
IS (LVS) rs2794520 T/C 1 CRP rs2794520 T/C ─ (─-─) 0.089 (0.058) 1.25E-01 844-5972 6816 
















N Controls N Total 
18 961 T C 20 HNF4A 18 961 -0.098 (0.106) 3 54 3548-5972 9520
2037 G A  P BPC4 2037 G A 0 065 1 4
4420065 T C  LEPR 4420065 T C 36 5 28 1
1 9267 T C  IL6R 1 9267 T C 02 (0.057) 7 19
2794520 1 CRP 2794520 0.012 (0.059) 8 36
CS) 2 9046 T C NLRP3 2 9046 T C 0.004 (0.057) 9 45 790 762
CS) 126 326 C T 2 GCK 126 326 -0.009 (0.056) 8 70 790 762
CS) 6734 38 A G 2 1F10 6734 38 G A 0.066 (0.056) 2 3 790 762
CS) 4 05952 A G 5 IRF1 4 05952 G A -0.066 (0.069) 3 38 790 762
IS (CS) rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.027 (0.059) 6.50E-01 790-5972 6762 
IS (CS) rs13233571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) -0.064 (0.085) 4.52E-01 790-5972 6762 
IS (CS) rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) 0.195 (0.094) 3.76E-02 790-5972 6762 
IS (CS) rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.065 (0.055) 2.39E-01 790-5972 6762 
IS (CS) rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.068 (0.059) 2.50E-01 790-5972 6762 
IS (CS) rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) 0.028 (0.056) 6.17E-01 790-5972 6762 
IS (CS) rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) 0.142 (0.173) 4.12E-01 790-5972 6762 
IS (CS) rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.098 (0.057) 8.50E-02 790-5972 6762 
IS (CS) rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.114 (0.093) 2.20E-01 790-5972 6762 
IS (CS) rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) -0.057 (0.195) 7.70E-01 790-5972 6762 
IS (LVS) rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.014 (0.065) 8.28E-01 844-5972 6816 
IS (LVS) rs4420065 T/C 1 LEPR rs4420065 T/C ─ (─-─) 0.058 (0.056) 2.99E-01 844-5972 6816 
IS (LVS) rs4129267 T/C 1 IL6R rs4129267 T/C ─ (─-─) -0.042 (0.055) 4.45E-01 844-5972 6816 
IS (LVS) rs2794520 T/C 1 CRP rs2794520 T/C ─ (─-─) 0.089 (0.058) 1.25E-01 844-5972 6816 
















N Controls N Total 
IS (LVS) rs12239046 T/C 1 NLRP3 rs1 239046 T/C ─ (─-─) 0.063 (0.056) 2.60E-01 844-5972 6816 
IS (LVS) rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) 0.014 (0.054) 8.02E-01 844-5972 6816 
IS (LVS) rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.001 (0.054) 9.81E-01 844-5972 6816 
IS (LVS) rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) -0.032 (0.068) 6.39E-01 844-5972 6816 
IS (LVS) rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.046 (0.057) 4.24E-01 844-5972 6816 
IS (LVS) rs13233571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) 0.041 (0.085) 6.33E-01 844-5972 6816 
IS (LVS) rs9987289 A/G 8 PPP R3B rs9987289 G/A ─ (─-─) -0.001 (0.097) 9.89E-01 844-5972 6816 
IS (LVS) rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.015 (0.053) 7.85E-01 844-5972 6816 
IS (LVS) rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.038 (0.059) 5.15E-01 844-5972 6816 
IS (LVS) rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) -0.082 (0.055) 1.37E-01 844-5972 6816 
IS (LVS) rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) -0.074 (0.159) 6.43E-01 844-5972 6816 
IS (LVS) rs2847281 G/A 18 PTPN2 rs 847281 G/A ─ (─-─) -0.011 (0.055) 8.35E-01 844-5972 6816 
IS (LVS) rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) -0.011 (0.088) 9.05E-01 844-5972 6816 
IS (LVS) rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) 0.134 (0.2) 5.04E-01 844-5972 6816 
IS (SVD) rs12037222 G/A 1 PABPC4 rs1 037222 G/A ─ (─-─) 0.012 (0.074) 8.72E-01 580-5972 6552 
IS (SVD) rs4420065 T/C 1 LEPR rs4420065 T/C ─ (─-─) -0.064 (0.064) 3.20E-01 580-5972 6552 
IS (SVD) rs4129267 T/C 1 IL6R rs4129267 T/C ─ (─-─) 0.051 (0.063) 4.17E-01 580-5972 6552 
IS (SVD) rs2794520 T/C 1 CRP rs 794520 T/C ─ (─-─) 0.035 (0.066) 5.94E-01 580-5972 6552 
IS (SVD) rs12239046 T/C 1 NLRP3 rs12239046 T/C ─ (─-─) 0.028 (0.064) 6.61E-01 580-5972 6552 
IS (SVD) rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) -0.074 (0.062) 2.31E-01 580-5972 6552 
IS (SVD) rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.001 (0.063) 9.91E-01 580-5972 6552 
IS (SVD) rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0.192 (0.085) 2.42E-02 580-5972 6552 
IS (SVD) rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.017 (0.067) 8.00E-01 580-5972 6552 
















N Controls N Total 
L S) 2 9046 T C NLRP3 2 9046 T C 63 56 2 60 844 816
L S) 126 326 C T 2 GCK 126 326 0.014 (0.054) 8 02 844 816
L S) 6734 38 A G 2 1F10 6734 38 G A 0 54 9 81 844 816
L S) 4 05952 A G 5 IRF  4 05952 G A -0.032 (0.068) 6 39 844 816
L S) 6901250 G A 6 GP C6A 6901250 G A 46 57 4 24 844 816
L S) 323 571 T C 7 B L7B 323 571 0.041 (0.085) 6 3 844 816
L S) 9987 89 8 PPP R3B 9987 89 -0.001 (0.097) 89 844 816
L S) 10745954 G A 12 ASCL1 10745954 015 53 7 85 1 844 816
L S) 118391 A G 12 HNF1A 118391 -0.038 (0.059) 5 15 844 816
IS (LVS) rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) -0.082 (0.055) 1.37E-01 844-5972 6816 
IS (LVS) rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) -0.074 (0.159) 6.43E-01 844-5972 6816 
IS (LVS) rs2847281 G/A 18 PTPN2 rs 847281 G/A ─ (─-─) -0.011 (0.055) 8.35E-01 844-5972 6816 
IS (LVS) rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) -0.011 (0.088) 9.05E-01 844-5972 6816 
IS (LVS) rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) 0.134 (0.2) 5.04E-01 844-5972 6816 
IS (SVD) rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.012 (0.074) 8.72E-01 580-5972 6552 
IS (SVD) rs4420065 T/C 1 LEPR rs4420065 T/C ─ (─-─) -0.064 (0.064) 3.20E-01 580-5972 6552 
IS (SVD) rs4129267 T/C 1 IL6R rs4129267 T/C ─ (─-─) 0.051 (0.063) 4.17E-01 580-5972 6552 
IS (SVD) rs2794520 T/C 1 CRP rs 794520 T/C ─ (─-─) 0.035 (0.066) 5.94E-01 580-5972 6552 
IS (SVD) rs12239046 T/C 1 NLRP3 rs12239046 T/C ─ (─-─) 0.028 (0.064) 6.61E-01 580-5972 6552 
IS (SVD) rs1260326 C/T 2 GCKR rs1260326 T/C ─ (─-─) -0.074 (0.062) 2.31E-01 580-5972 6552 
IS (SVD) rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.001 (0.063) 9.91E-01 580-5972 6552 
IS (SVD) rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0.192 (0.085) 2.42E-02 580-5972 6552 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
IS (SVD) rs13233571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) -0.078 (0.094) 4.08E-01 580-5972 6552 
IS (SVD) rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) 0.063 (0.108) 5.56E-01 580-5972 6552 
IS (SVD) rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.005 (0.062) 9.39E-01 580-5972 6552 
IS (SVD) rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.055 (0.066) 4.12E-01 580-5972 6552 
IS (SVD) rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) 0.077 (0.063) 2.21E-01 580-5972 6552 
IS (SVD) rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) -0.102 (0.182) 5.74E-01 580-5972 6552 
IS (SVD) rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.007 (0.063) 9.15E-01 580-5972 6552 
IS (SVD) rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) -0.083 (0.096) 3.90E-01 580-5972 6552 
IS (SVD) rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) -0.099 (0.208) 6.35E-01 580-5972 6552 
SBP rs12037222 G/A 1 PABPC4 rs12037222 A/G ─ (─-─) -0.342 (0.118) 3.71E-03 ─-─ 67888 
SBP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.086 (0.101) 3.94E-01 ─-─ 65988 
SBP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.068 (0.1) 4.95E-01 ─-─ 68977 
SBP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.294 (0.102) 4.04E-03 ─-─ 69186 
SBP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.063 (0.104) 5.45E-01 ─-─ 60617 
SBP rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.102 (0.099) 3.03E-01 ─-─ 68614 
SBP rs6734238 A/G 2 IL1F10 rs6734238 A/G ─ (─-─) -0.029 (0.099) 7.73E-01 ─-─ 69311 
SBP rs4705952 A/G 5 IRF1 rs4705952 A/G ─ (─-─) -0.222 (0.128) 8.37E-02 ─-─ 56592 
SBP rs6901250 G/A 6 GPRC6A rs6901250 A/G ─ (─-─) 0.076 (0.104) 4.66E-01 ─-─ 67543 
SBP rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.105 (0.151) 4.85E-01 ─-─ 68175 
SBP rs9987289 A/G 8 PPP1R3B rs9987289 A/G ─ (─-─) -0.095 (0.169) 5.75E-01 ─-─ 66543 
SBP rs10745954 G/A 12 ASCL1 rs10745954 A/G ─ (─-─) -0.024 (0.097) 8.08E-01 ─-─ 69368 
SBP rs1183910 A/G 12 HNF1A rs1183910 A/G ─ (─-─) -0.077 (0.104) 4.59E-01 ─-─ 67585 
SBP rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.02 (0.103) 8.45E-01 ─-─ 65502 
















N Controls N Total 
IS (SVD) 323 571 T C 7 B L7B 323 571 T C -0.078 (0.094) 4 8 580-5972 552 
IS (SVD) 9987 89 8 PPP1R3B 9987 89 G A 0.063 (0.108) 5 56 580-5972 552 
IS (SVD) 10745954 G A 12 ASCL1 10745954 G A 0.005 (0.062) 9 9 1 580-5972 65 2 
IS (SVD) 118391 A G 12 HNF1A 118391 G A 55 066 12 580-5972 5 2 
IS (SVD) 340029 C T 15 RORA 340029 T C 0.077 (0.063) 2 21 580-5972 552 
IS (SVD) 10521222 T C 16 SALL1 10521222 T C 102 82 4 580-5972 5 2 
IS (SVD) 2847281 8 PTPN2 2847281 G A 0.007 (0.063) 9 15 580-5972 552 
IS (SVD) 4420638 G A 9 APOC1 4420638 G A 83 096 3 90 580-5972 5 2 
IS (SVD) 18 961 T C 20 HNF4A 18 961 T C -0.099 (0.208) 6 3 580-5972 2 
SBP rs12037222 G/A 1 PABPC4 rs12037222 A/G ─ (─-─) -0.342 (0.118) 3.71E-03 ─-─ 67888 
SBP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.086 (0.101) 3.94E-01 ─-─ 65988 
SBP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.068 (0.1) 4.95E-01 ─-─ 68977 
SBP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.294 (0.102) 4.04E-03 ─-─ 69186 
SBP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.063 (0.104) 5.45E-01 ─-─ 60617 
SBP rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.102 (0.099) 3.03E-01 ─-─ 68614 
SBP rs6734238 A/G 2 IL1F10 rs6734238 A/G ─ (─-─) -0.029 (0.099) 7.73E-01 ─-─ 69311 
SBP rs4705952 A/G 5 IRF1 rs4705952 A/G ─ (─-─) -0.222 (0.128) 8.37E-02 ─-─ 56592 
SBP rs6901250 G/A 6 GPRC6A rs6901250 A/G ─ (─-─) 0.076 (0.104) 4.66E-01 ─-─ 67543 
SBP rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.105 (0.151) 4.85E-01 ─-─ 68175 
SBP rs9987289 A/G 8 PPP1R3B rs9987289 A/G ─ (─-─) -0.095 (0.169) 5.75E-01 ─-─ 66543 
SBP rs10745954 G/A 12 ASCL1 rs10745954 A/G ─ (─-─) -0.024 (0.097) 8.08E-01 ─-─ 69368 
SBP rs1183910 A/G 12 HNF1A rs1183910 A/G ─ (─-─) -0.077 (0.104) 4.59E-01 ─-─ 67585 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
SBP rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.295 (0.323) 3.61E-01 ─-─ 35551 
SBP rs2847281 G/A 18 PTPN2 rs 847281 A/G ─ (─-─) -0.14 (0.099) 1.58E-01 ─-─ 68473 
SBP rs4420638 G/A 19 APOC1 rs4420638 A/G ─ (─-─) -0.171 (0.164) 2.97E-01 ─-─ 43081 
SBP rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.215 (0.347) 5.36E-01 ─-─ 40946 
Metabolic 
BMI rs12 37222 G/A 1 PABPC4 rs2293476 G/C ─ (─-─) 0.007 (0.006) 2.04E-01 ─-─ 123847 
BMI rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.005 (0.005) 3.62E-01 ─-─ 123855 
BMI rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) 0.002 (0.005) 6.23E-01 ─-─ 123848 
BMI rs27 4520 T/C 1 CRP rs2794520 C/T ─ (─-─) 0.003 (0.005) 5.32E-01 ─-─ 123792 
BMI rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.001 (0.005) 9.16E-01 ─-─ 118921 
BMI rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) -0.007 (0.005) 1.29E-01 ─-─ 123755 
BMI rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.002 (0.005) 7.38E-01 ─-─ 123839 
BMI rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.006 (0.006) 3.74E-01 ─-─ 123743 
BMI rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.002 (0.005) 6.64E-01 ─-─ 123860 
BMI rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.003 (0.007) 6.55E-01 ─-─ 123866 
BMI rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) 0.007 (0.008) 3.88E-01 ─-─ 123831 
BMI rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.003 (0.005) 4.78E-01 ─-─ 123862 
BMI rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.005) 8.64E-01 ─-─ 123862 
BMI rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.012 (0.005) 1.47E-02 ─-─ 123762 
BMI rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) -0.005 (0.014) 7.21E-01 ─-─ 87391 
BMI rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.014 (0.005) 2.73E-03 ─-─ 123848 
BMI rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.009 (0.008) 2.45E-01 ─-─ 109510 
BMI rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) 0.002 (0.015) 9.05E-01 ─-─ 82069 
















N Controls N Total 
SBP rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.295 (0.323) 3.61E-01 ─-─ 35551 
SBP rs2847281 G/A 18 PTPN2 rs 847281 A/G ─ (─-─) -0.14 (0.099) 1.58E-01 ─-─ 68473 
SBP rs4420638 G/A 19 APOC1 rs4420638 A/G ─ (─-─) -0.171 (0.164) 2.97E-01 ─-─ 43081 
SBP rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.215 (0.347) 5.36E-01 ─-─ 40946 
Metabolic 
2037 G A  P BPC4 2293476 G C 0.007 (0.006) 2 04 12 847 
4420065 T C  LEPR 4420065 C T 0.005 (0.005) 3 62 1 55
1 9267 T C  IL6R 1 9267 C T 2 5 6 23 23848
2794520 1 CRP 2794520 3 0 5 32 1 37 2 
BMI rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.001 (0.005) 9.16E-01 ─-─ 118921 
BMI rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) -0.007 (0.005) 1.29E-01 ─-─ 123755 
BMI rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.002 (0.005) 7.38E-01 ─-─ 123839 
BMI rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.006 (0.006) 3.74E-01 ─-─ 123743 
BMI rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.002 (0.005) 6.64E-01 ─-─ 123860 
BMI rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.003 (0.007) 6.55E-01 ─-─ 123866 
BMI rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) 0.007 (0.008) 3.88E-01 ─-─ 123831 
BMI rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.003 (0.005) 4.78E-01 ─-─ 123862 
BMI rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.005) 8.64E-01 ─-─ 123862 
BMI rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.012 (0.005) 1.47E-02 ─-─ 123762 
BMI rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) -0.005 (0.014) 7.21E-01 ─-─ 87391 
BMI rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.014 (0.005) 2.73E-03 ─-─ 123848 
BMI rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.009 (0.008) 2.45E-01 ─-─ 109510 
BMI rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) 0.002 (0.015) 9.05E-01 ─-─ 82069 
210204-L-bw-Vaez
















N Controls N Total 
IS (SVD) rs13233571 T/C 7 BCL7B rs13233571 T/C ─ (─-─) -0.078 (0.094) 4.08E-01 580-5972 6552 
IS (SVD) rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) 0.063 (0.108) 5.56E-01 580-5972 6552 
IS (SVD) rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.005 (0.062) 9.39E-01 580-5972 6552 
IS (SVD) rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.055 (0.066) 4.12E-01 580-5972 6552 
IS (SVD) rs340029 C/T 15 RORA rs340029 T/C ─ (─-─) 0.077 (0.063) 2.21E-01 580-5972 6552 
IS (SVD) rs10521222 T/C 16 SALL1 rs10521222 T/C ─ (─-─) -0.102 (0.182) 5.74E-01 580-5972 6552 
IS (SVD) rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.007 (0.063) 9.15E-01 580-5972 6552 
IS (SVD) rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) -0.083 (0.096) 3.90E-01 580-5972 6552 
IS (SVD) rs1800961 T/C 20 HNF4A rs1800961 T/C ─ (─-─) -0.099 (0.208) 6.35E-01 580-5972 6552 
SBP rs12037222 G/A 1 PABPC4 rs12037222 A/G ─ (─-─) -0.342 (0.118) 3.71E-03 ─-─ 67888 
SBP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.086 (0.101) 3.94E-01 ─-─ 65988 
SBP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.068 (0.1) 4.95E-01 ─-─ 68977 
SBP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.294 (0.102) 4.04E-03 ─-─ 69186 
SBP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.063 (0.104) 5.45E-01 ─-─ 60617 
SBP rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.102 (0.099) 3.03E-01 ─-─ 68614 
SBP rs6734238 A/G 2 IL1F10 rs6734238 A/G ─ (─-─) -0.029 (0.099) 7.73E-01 ─-─ 69311 
SBP rs4705952 A/G 5 IRF1 rs4705952 A/G ─ (─-─) -0.222 (0.128) 8.37E-02 ─-─ 56592 
SBP rs6901250 G/A 6 GPRC6A rs6901250 A/G ─ (─-─) 0.076 (0.104) 4.66E-01 ─-─ 67543 
SBP rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.105 (0.151) 4.85E-01 ─-─ 68175 
SBP rs9987289 A/G 8 PPP1R3B rs9987289 A/G ─ (─-─) -0.095 (0.169) 5.75E-01 ─-─ 66543 
SBP rs10745954 G/A 12 ASCL1 rs10745954 A/G ─ (─-─) -0.024 (0.097) 8.08E-01 ─-─ 69368 
SBP rs1183910 A/G 12 HNF1A rs1183910 A/G ─ (─-─) -0.077 (0.104) 4.59E-01 ─-─ 67585 
SBP rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.02 (0.103) 8.45E-01 ─-─ 65502 
















N Controls N Total 
IS (SVD) 323 571 T C 7 B L7B 323 571 T C -0.078 (0.094) 4 8 580-5972 552 
IS (SVD) 9987 89 8 PPP1R3B 9987 89 G A 0.063 (0.108) 5 56 580-5972 552 
IS (SVD) 10745954 G A 12 ASCL1 10745954 G A 0.005 (0.062) 9 9 1 580-5972 65 2 
IS (SVD) 118391 A G 12 HNF1A 118391 G A 55 066 12 580-5972 5 2 
IS (SVD) 340029 C T 15 RORA 340029 T C 0.077 (0.063) 2 21 580-5972 552 
IS (SVD) 10521222 T C 16 SALL1 10521222 T C 102 82 4 580-5972 5 2 
IS (SVD) 2847281 8 PTPN2 2847281 G A 0.007 (0.063) 9 15 580-5972 552 
IS (SVD) 4420638 G A 9 APOC1 4420638 G A 83 096 3 90 580-5972 5 2 
IS (SVD) 18 961 T C 20 HNF4A 18 961 T C -0.099 (0.208) 6 3 580-5972 2 
SBP rs12037222 G/A 1 PABPC4 rs12037222 A/G ─ (─-─) -0.342 (0.118) 3.71E-03 ─-─ 67888 
SBP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.086 (0.101) 3.94E-01 ─-─ 65988 
SBP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.068 (0.1) 4.95E-01 ─-─ 68977 
SBP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.294 (0.102) 4.04E-03 ─-─ 69186 
SBP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.063 (0.104) 5.45E-01 ─-─ 60617 
SBP rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.102 (0.099) 3.03E-01 ─-─ 68614 
SBP rs6734238 A/G 2 IL1F10 rs6734238 A/G ─ (─-─) -0.029 (0.099) 7.73E-01 ─-─ 69311 
SBP rs4705952 A/G 5 IRF1 rs4705952 A/G ─ (─-─) -0.222 (0.128) 8.37E-02 ─-─ 56592 
SBP rs6901250 G/A 6 GPRC6A rs6901250 A/G ─ (─-─) 0.076 (0.104) 4.66E-01 ─-─ 67543 
SBP rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.105 (0.151) 4.85E-01 ─-─ 68175 
SBP rs9987289 A/G 8 PPP1R3B rs9987289 A/G ─ (─-─) -0.095 (0.169) 5.75E-01 ─-─ 66543 
SBP rs10745954 G/A 12 ASCL1 rs10745954 A/G ─ (─-─) -0.024 (0.097) 8.08E-01 ─-─ 69368 
SBP rs1183910 A/G 12 HNF1A rs1183910 A/G ─ (─-─) -0.077 (0.104) 4.59E-01 ─-─ 67585 
SBP rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.02 (0.103) 8.45E-01 ─-─ 65502 
















N Controls N Total 
SBP rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.295 (0.323) 3.61E-01 ─-─ 35551 
SBP rs2847281 G/A 18 PTPN2 rs 847281 A/G ─ (─-─) -0.14 (0.099) 1.58E-01 ─-─ 68473 
SBP rs4420638 G/A 19 APOC1 rs4420638 A/G ─ (─-─) -0.171 (0.164) 2.97E-01 ─-─ 43081 
SBP rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.215 (0.347) 5.36E-01 ─-─ 40946 
Metabolic 
BMI rs12037222 G/A 1 PABPC4 rs2293476 G/C ─ (─-─) 0.007 (0.006) 2.04E-01 ─-─ 123847 
BMI rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.005 (0.005) 3.62E-01 ─-─ 123855 
BMI rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) 0.002 (0.005) 6.23E-01 ─-─ 123848 
BMI rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) 0.003 (0.005) 5.32E-01 ─-─ 123792 
BMI rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.001 (0.005) 9.16E-01 ─-─ 118921 
BMI rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) -0.007 (0.005) 1.29E-01 ─-─ 123755 
BMI rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.002 (0.005) 7.38E-01 ─-─ 123839 
BMI rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.006 (0.006) 3.74E-01 ─-─ 123743 
BMI rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.002 (0.005) 6.64E-01 ─-─ 123860 
BMI rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.003 (0.007) 6.55E-01 ─-─ 123866 
BMI rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) 0.007 (0.008) 3.88E-01 ─-─ 123831 
BMI rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.003 (0.005) 4.78E-01 ─-─ 123862 
BMI rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.005) 8.64E-01 ─-─ 123862 
BMI rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.012 (0.005) 1.47E-02 ─-─ 123762 
BMI rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) -0.005 (0.014) 7.21E-01 ─-─ 87391 
BMI rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.014 (0.005) 2.73E-03 ─-─ 123848 
BMI rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.009 (0.008) 2.45E-01 ─-─ 109510 
BMI rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) 0.002 (0.015) 9.05E-01 ─-─ 82069 
















N Controls N Total 
SBP rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.295 (0.323) 3.61E-01 ─-─ 35551 
SBP rs2847281 G/A 18 PTPN2 rs 847281 A/G ─ (─-─) -0.14 (0.099) 1.58E-01 ─-─ 68473 
SBP rs4420638 G/A 19 APOC1 rs4420638 A/G ─ (─-─) -0.171 (0.164) 2.97E-01 ─-─ 43081 
SBP rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.215 (0.347) 5.36E-01 ─-─ 40946 
Metabolic 
2037 G A  P BPC4 2293476 G C 0.007 (0.006) 2 04 12 847 
4420065 T C  LEPR 4420065 C T 0.005 (0.005) 3 62 1 55
1 9267 T C  IL6R 1 9267 C T 2 5 6 23 23848
2794520 1 CRP 2794520 3 0 5 32 1 37 2 
BMI rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.001 (0.005) 9.16E-01 ─-─ 118921 
BMI rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) -0.007 (0.005) 1.29E-01 ─-─ 123755 
BMI rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.002 (0.005) 7.38E-01 ─-─ 123839 
BMI rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.006 (0.006) 3.74E-01 ─-─ 123743 
BMI rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.002 (0.005) 6.64E-01 ─-─ 123860 
BMI rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.003 (0.007) 6.55E-01 ─-─ 123866 
BMI rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) 0.007 (0.008) 3.88E-01 ─-─ 123831 
BMI rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.003 (0.005) 4.78E-01 ─-─ 123862 
BMI rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.005) 8.64E-01 ─-─ 123862 
BMI rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.012 (0.005) 1.47E-02 ─-─ 123762 
BMI rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) -0.005 (0.014) 7.21E-01 ─-─ 87391 
BMI rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) -0.014 (0.005) 2.73E-03 ─-─ 123848 
BMI rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.009 (0.008) 2.45E-01 ─-─ 109510 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
SA rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.003 (0.002) 1.79E-01 ─-─ 53189 
SA rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.004 (0.002) 2.44E-02 ─-─ 53189 
SA rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) 0.004 (0.002) 1.98E-02 ─-─ 53164 
SA rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) 0.001 (0.002) 6.86E-01 ─-─ 53179 
SA rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.003 (0.002) 1.27E-01 ─-─ 53138 
SA rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.012 (0.002) 2.89E-14 ─-─ 53189 
SA rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.003 (0.002) 7.54E-02 ─-─ 53188 
SA rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.004 (0.002) 5.54E-02 ─-─ 53174 
SA rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.002 (0.002) 3.83E-01 ─-─ 53189 
SA rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.007 (0.003) 6.77E-03 ─-─ 53189 
SA rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) -0.014 (0.003) 5.48E-06 ─-─ 53189 
SA rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.001 (0.002) 7.59E-01 ─-─ 53189 
SA rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.002) 7.85E-01 ─-─ 53189 
SA rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) -0.001 (0.002) 4.89E-01 ─-─ 53170 
SA rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.012 (0.005) 2.70E-02 ─-─ 45071 
SA rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.004 (0.002) 3.19E-02 ─-─ 53175 
SA rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.007 (0.003) 1.03E-02 ─-─ 49729 
SA rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.005 (0.006) 3.87E-01 ─-─ 40022 
SP rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.006 (0.004) 2.16E-01 ─-─ 25537 
SP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.004 (0.004) 3.75E-01 ─-─ 25537 
SP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.007 (0.004) 6.91E-02 ─-─ 25513 
SP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) 0.002 (0.004) 6.85E-01 ─-─ 25527 
SP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) -0.003 (0.004) 4.32E-01 ─-─ 25485 
















N Controls N Total 
2037 G A  P BPC4 2037 G A -0.003 (0.002) 1 9 1 53189
4420065 T C  LEPR 4420065 C T 2 44 89
1 9267 T C  IL6R 1 9267 C T 4 2 98 53164
2794520 1 CRP 2794520 0.001 (0.002) 6 6 53179
A 2 9046 T C NLRP3 2 9046 C T 0.003 (0.002) 1 27 531 8
A 126 326 C T 2 GCK 126 326 0.012 (0.002) 2 89 14 53189
A 6734 38 A G 2 1F10 6734 38 G A 0.003 (0.002) 7 54 53188
A 4 05952 A G 5 IRF1 4 05952 G A -0.004 (0.002) 5 54 2 53174
A 6901250 G A 6 GP C6A 6901250 G A 0.002 (0.002) 3 83 531 9
SA rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.007 (0.003) 6.77E-03 ─-─ 53189 
SA rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) -0.014 (0.003) 5.48E-06 ─-─ 53189 
SA rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.001 (0.002) 7.59E-01 ─-─ 53189 
SA rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.002) 7.85E-01 ─-─ 53189 
SA rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) -0.001 (0.002) 4.89E-01 ─-─ 53170 
SA rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.012 (0.005) 2.70E-02 ─-─ 45071 
SA rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.004 (0.002) 3.19E-02 ─-─ 53175 
SA rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.007 (0.003) 1.03E-02 ─-─ 49729 
SA rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.005 (0.006) 3.87E-01 ─-─ 40022 
SP rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.006 (0.004) 2.16E-01 ─-─ 25537 
SP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.004 (0.004) 3.75E-01 ─-─ 25537 
SP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.007 (0.004) 6.91E-02 ─-─ 25513 
SP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) 0.002 (0.004) 6.85E-01 ─-─ 25527 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
SP rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.015 (0.004) 1.06E-04 ─-─ 25537 
SP rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) -0.001 (0.004) 8.94E-01 ─-─ 25536 
SP rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.009 (0.005) 7.03E-02 ─-─ 25522 
SP rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.004 (0.004) 3.75E-01 ─-─ 25537 
SP rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.007 (0.006) 2.59E-01 ─-─ 25537 
SP rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) -0.009 (0.007) 1.79E-01 ─-─ 25537 
SP rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.007 (0.004) 7.41E-02 ─-─ 25537 
SP rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.004) 8.59E-01 ─-─ 25537 
SP rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.004 (0.004) 3.62E-01 ─-─ 25518 
SP rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.003 (0.013) 8.18E-01 ─-─ 20154 
SP rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.003 (0.004) 5.04E-01 ─-─ 25523 
SP rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.007 (0.006) 1.97E-01 ─-─ 22078 
SP rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.017 (0.014) 2.31E-01 ─-─ 16694 
T2D rs12037222 G/A 1 PABPC4 rs12037222 G/A 1.032 (0.983-1.082) 0.031 (0.024) 2.03E-01 ─-─ 22570 
T2D rs4420065 T/C 1 LEPR rs4420065 C/T 1 (0.959-1.043) 0 (0.021) 9.87E-01 ─-─ 22570 
T2D rs4129267 T/C 1 IL6R rs4129267 T/C 1.037 (0.995-1.08) 0.036 (0.021) 8.22E-02 ─-─ 22570 
T2D rs2794520 T/C 1 CRP rs2794520 T/C 1.019 (0.977-1.063) 0.019 (0.022) 3.86E-01 ─-─ 22570 
T2D rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.005 (0.963-1.049) 0.005 (0.022) 8.19E-01 ─-─ 22570 
T2D rs1260326 C/T 2 GCKR rs1260326 T/C 1.016 (0.975-1.058) 0.015 (0.021) 4.61E-01 ─-─ 22570 
T2D rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.024 (0.983-1.066) 0.023 (0.021) 2.55E-01 ─-─ 22570 
T2D rs4705952 A/G 5 IRF1 rs4705952 A/G 1.007 (0.953-1.063) 0.007 (0.028) 8.12E-01 ─-─ 22570 
T2D rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.001 (0.958-1.045) 0.001 (0.022) 9.77E-01 ─-─ 22570 
T2D rs13233571 T/C 7 BCL7B rs13233571 C/T 1.043 (0.981-1.11) 0.042 (0.031) 1.79E-01 ─-─ 22570 
















N Controls N Total 
SP 126 326 C T 2 GCK 126 326 ─ (─-─) .015 (0.004) 1 06 4 5 37
SP 6734 38 A G 2 1F10 6734 38 G A ─ (─-─) -0.001 (0.004) 94 1 5 36
SP 4 05952 A G 5 IRF1 4 05952 G A ─ (─-─) -0.009 (0.005) 7 03 2 5 22
SP 6901250 G A 6 GP C6A 6901250 G A ─ (─-─) 4 04 3 75 5 37
SP 323 571 T C 7 B L7B 323 571 C T ─ (─-─) -0.007 (0.006) 2 59 5 37
SP 9987 89 8 PPP R3B 9987 89 G A ─ (─-─) -0.009 (0.007) 1 79 5 37
SP 10745954 G A 12 ASCL1 10745954 G A ─ (─-─) -0.007 (0.004) 7 41 2 5 37
SP 118391 A G 12 HNF1A 118391 ─ (─-─) -0.001 (0.004) 8 59 5 37
SP 340029 C T 15 RORA 340029 ─ (─-─) 04 04 3 62 5 18
SP rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.003 (0.013) 8.18E-01 ─-─ 20154 
SP rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.003 (0.004) 5.04E-01 ─-─ 25523 
SP rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.007 (0.006) 1.97E-01 ─-─ 22078 
SP rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.017 (0.014) 2.31E-01 ─-─ 16694 
T2D rs12037222 G/A 1 PABPC4 rs12037222 G/A 1.032 (0.983-1.082) 0.031 (0.024) 2.03E-01 ─-─ 22570 
T2D rs4420065 T/C 1 LEPR rs4420065 C/T 1 (0.959-1.043) 0 (0.021) 9.87E-01 ─-─ 22570 
T2D rs4129267 T/C 1 IL6R rs4129267 T/C 1.037 (0.995-1.08) 0.036 (0.021) 8.22E-02 ─-─ 22570 
T2D rs2794520 T/C 1 CRP rs2794520 T/C 1.019 (0.977-1.063) 0.019 (0.022) 3.86E-01 ─-─ 22570 
T2D rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.005 (0.963-1.049) 0.005 (0.022) 8.19E-01 ─-─ 22570 
T2D rs1260326 C/T 2 GCKR rs1260326 T/C 1.016 (0.975-1.058) 0.015 (0.021) 4.61E-01 ─-─ 22570 
T2D rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.024 (0.983-1.066) 0.023 (0.021) 2.55E-01 ─-─ 22570 
T2D rs4705952 A/G 5 IRF1 rs4705952 A/G 1.007 (0.953-1.063) 0.007 (0.028) 8.12E-01 ─-─ 22570 
T2D rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.001 (0.958-1.045) 0.001 (0.022) 9.77E-01 ─-─ 22570 
T2D rs13233571 T/C 7 BCL7B rs13233571 C/T 1.043 (0.981-1.11) 0.042 (0.031) 1.79E-01 ─-─ 22570 
210204-L-bw-Vaez
















N Controls N Total 
SA rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.003 (0.002) 1.79E-01 ─-─ 53189 
SA rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.004 (0.002) 2.44E-02 ─-─ 53189 
SA rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) 0.004 (0.002) 1.98E-02 ─-─ 53164 
SA rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) 0.001 (0.002) 6.86E-01 ─-─ 53179 
SA rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0.003 (0.002) 1.27E-01 ─-─ 53138 
SA rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.012 (0.002) 2.89E-14 ─-─ 53189 
SA rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.003 (0.002) 7.54E-02 ─-─ 53188 
SA rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.004 (0.002) 5.54E-02 ─-─ 53174 
SA rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.002 (0.002) 3.83E-01 ─-─ 53189 
SA rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.007 (0.003) 6.77E-03 ─-─ 53189 
SA rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) -0.014 (0.003) 5.48E-06 ─-─ 53189 
SA rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.001 (0.002) 7.59E-01 ─-─ 53189 
SA rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.002) 7.85E-01 ─-─ 53189 
SA rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) -0.001 (0.002) 4.89E-01 ─-─ 53170 
SA rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.012 (0.005) 2.70E-02 ─-─ 45071 
SA rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.004 (0.002) 3.19E-02 ─-─ 53175 
SA rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.007 (0.003) 1.03E-02 ─-─ 49729 
SA rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.005 (0.006) 3.87E-01 ─-─ 40022 
SP rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.006 (0.004) 2.16E-01 ─-─ 25537 
SP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.004 (0.004) 3.75E-01 ─-─ 25537 
SP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.007 (0.004) 6.91E-02 ─-─ 25513 
SP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) 0.002 (0.004) 6.85E-01 ─-─ 25527 
SP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) -0.003 (0.004) 4.32E-01 ─-─ 25485 
















N Controls N Total 
2037 G A  P BPC4 2037 G A -0.003 (0.002) 1 9 1 53189
4420065 T C  LEPR 4420065 C T 2 44 89
1 9267 T C  IL6R 1 9267 C T 4 2 98 53164
2794520 1 CRP 2794520 0.001 (0.002) 6 6 53179
A 2 9046 T C NLRP3 2 9046 C T 0.003 (0.002) 1 27 531 8
A 126 326 C T 2 GCK 126 326 0.012 (0.002) 2 89 14 53189
A 6734 38 A G 2 1F10 6734 38 G A 0.003 (0.002) 7 54 53188
A 4 05952 A G 5 IRF1 4 05952 G A -0.004 (0.002) 5 54 2 53174
A 6901250 G A 6 GP C6A 6901250 G A 0.002 (0.002) 3 83 531 9
SA rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.007 (0.003) 6.77E-03 ─-─ 53189 
SA rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) -0.014 (0.003) 5.48E-06 ─-─ 53189 
SA rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.001 (0.002) 7.59E-01 ─-─ 53189 
SA rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.002) 7.85E-01 ─-─ 53189 
SA rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) -0.001 (0.002) 4.89E-01 ─-─ 53170 
SA rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.012 (0.005) 2.70E-02 ─-─ 45071 
SA rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.004 (0.002) 3.19E-02 ─-─ 53175 
SA rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.007 (0.003) 1.03E-02 ─-─ 49729 
SA rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.005 (0.006) 3.87E-01 ─-─ 40022 
SP rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.006 (0.004) 2.16E-01 ─-─ 25537 
SP rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.004 (0.004) 3.75E-01 ─-─ 25537 
SP rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.007 (0.004) 6.91E-02 ─-─ 25513 
SP rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) 0.002 (0.004) 6.85E-01 ─-─ 25527 
SP rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) -0.003 (0.004) 4.32E-01 ─-─ 25485 
















N Controls N Total 
SP rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.015 (0.004) 1.06E-04 ─-─ 25537 
SP rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) -0.001 (0.004) 8.94E-01 ─-─ 25536 
SP rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.009 (0.005) 7.03E-02 ─-─ 25522 
SP rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.004 (0.004) 3.75E-01 ─-─ 25537 
SP rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.007 (0.006) 2.59E-01 ─-─ 25537 
SP rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) -0.009 (0.007) 1.79E-01 ─-─ 25537 
SP rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.007 (0.004) 7.41E-02 ─-─ 25537 
SP rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.004) 8.59E-01 ─-─ 25537 
SP rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.004 (0.004) 3.62E-01 ─-─ 25518 
SP rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.003 (0.013) 8.18E-01 ─-─ 20154 
SP rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.003 (0.004) 5.04E-01 ─-─ 25523 
SP rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.007 (0.006) 1.97E-01 ─-─ 22078 
SP rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.017 (0.014) 2.31E-01 ─-─ 16694 
T2D rs12037222 G/A 1 PABPC4 rs12037222 G/A 1.032 (0.983-1.082) 0.031 (0.024) 2.03E-01 ─-─ 22570 
T2D rs4420065 T/C 1 LEPR rs4420065 C/T 1 (0.959-1.043) 0 (0.021) 9.87E-01 ─-─ 22570 
T2D rs4129267 T/C 1 IL6R rs4129267 T/C 1.037 (0.995-1.08) 0.036 (0.021) 8.22E-02 ─-─ 22570 
T2D rs2794520 T/C 1 CRP rs2794520 T/C 1.019 (0.977-1.063) 0.019 (0.022) 3.86E-01 ─-─ 22570 
T2D rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.005 (0.963-1.049) 0.005 (0.022) 8.19E-01 ─-─ 22570 
T2D rs1260326 C/T 2 GCKR rs1260326 T/C 1.016 (0.975-1.058) 0.015 (0.021) 4.61E-01 ─-─ 22570 
T2D rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.024 (0.983-1.066) 0.023 (0.021) 2.55E-01 ─-─ 22570 
T2D rs4705952 A/G 5 IRF1 rs4705952 A/G 1.007 (0.953-1.063) 0.007 (0.028) 8.12E-01 ─-─ 22570 
T2D rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.001 (0.958-1.045) 0.001 (0.022) 9.77E-01 ─-─ 22570 
T2D rs13233571 T/C 7 BCL7B rs13233571 C/T 1.043 (0.981-1.11) 0.042 (0.031) 1.79E-01 ─-─ 22570 
















N Controls N Total 
SP 126 326 C T 2 GCK 126 326 ─ (─-─) .015 (0.004) 1 06 4 5 37
SP 6734 38 A G 2 1F10 6734 38 G A ─ (─-─) -0.001 (0.004) 94 1 5 36
SP 4 05952 A G 5 IRF1 4 05952 G A ─ (─-─) -0.009 (0.005) 7 03 2 5 22
SP 6901250 G A 6 GP C6A 6901250 G A ─ (─-─) 4 04 3 75 5 37
SP 323 571 T C 7 B L7B 323 571 C T ─ (─-─) -0.007 (0.006) 2 59 5 37
SP 9987 89 8 PPP R3B 9987 89 G A ─ (─-─) -0.009 (0.007) 1 79 5 37
SP 10745954 G A 12 ASCL1 10745954 G A ─ (─-─) -0.007 (0.004) 7 41 2 5 37
SP 118391 A G 12 HNF1A 118391 ─ (─-─) -0.001 (0.004) 8 59 5 37
SP 340029 C T 15 RORA 340029 ─ (─-─) 04 04 3 62 5 18
SP rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.003 (0.013) 8.18E-01 ─-─ 20154 
SP rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.003 (0.004) 5.04E-01 ─-─ 25523 
SP rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.007 (0.006) 1.97E-01 ─-─ 22078 
SP rs1800961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.017 (0.014) 2.31E-01 ─-─ 16694 
T2D rs12037222 G/A 1 PABPC4 rs12037222 G/A 1.032 (0.983-1.082) 0.031 (0.024) 2.03E-01 ─-─ 22570 
T2D rs4420065 T/C 1 LEPR rs4420065 C/T 1 (0.959-1.043) 0 (0.021) 9.87E-01 ─-─ 22570 
T2D rs4129267 T/C 1 IL6R rs4129267 T/C 1.037 (0.995-1.08) 0.036 (0.021) 8.22E-02 ─-─ 22570 
T2D rs2794520 T/C 1 CRP rs2794520 T/C 1.019 (0.977-1.063) 0.019 (0.022) 3.86E-01 ─-─ 22570 
T2D rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.005 (0.963-1.049) 0.005 (0.022) 8.19E-01 ─-─ 22570 
T2D rs1260326 C/T 2 GCKR rs1260326 T/C 1.016 (0.975-1.058) 0.015 (0.021) 4.61E-01 ─-─ 22570 
T2D rs6734238 A/G 2 IL1F10 rs6734238 A/G 1.024 (0.983-1.066) 0.023 (0.021) 2.55E-01 ─-─ 22570 
T2D rs4705952 A/G 5 IRF1 rs4705952 A/G 1.007 (0.953-1.063) 0.007 (0.028) 8.12E-01 ─-─ 22570 
T2D rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.001 (0.958-1.045) 0.001 (0.022) 9.77E-01 ─-─ 22570 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
T2D rs9987289 A/G 8 PPP1R3B rs9987289 G/A 1.042 (0.974-1.115) 0.041 (0.035) 2.33E-01 ─-─ 22570 
T2D rs10745954 G/A 12 ASCL1 rs10745954 A/G 1.014 (0.975-1.055) 0.014 (0.02) 4.89E-01 ─-─ 22570 
T2D rs1183910 A/G 12 HNF1A rs1183910 G/A 1.062 (1.017-1.109) 0.06 (0.022) 6.09E-03 ─-─ 22570 
T2D rs340029 C/T 15 RORA rs340029 C/T 1.029 (0.985-1.074) 0.028 (0.022) 2.03E-01 ─-─ 22570 
T2D rs10521222 T/C 16 SALL1 rs10521222 T/C 1.011 (0.896-1.141) 0.011 (0.062) 8.56E-01 ─-─ 13971 
T2D rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.001 (0.961-1.042) 0.001 (0.021) 9.77E-01 ─-─ 22570 
T2D rs4420638 G/A 19 APOC1 rs4420638 G/A 1.147 (1.073-1.226) 0.137 (0.034) 5.41E-05 ─-─ 18352 
T2D rs1800961 T/C 20 HNF4A rs1800961 C/T 1.141 (1.002-1.3) 0.132 (0.066) 4.71E-02 ─-─ 13971 
CKD rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.008 (0.024) 7.51E-01 6271-68083 74354 
CKD rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.068 (0.021) 1.12E-03 6271-68083 74354 
CKD rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.012 (0.021) 5.79E-01 6271-68083 74354 
CKD rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.014 (0.022) 5.15E-01 6271-68083 74354 
CKD rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) -0.031 (0.021) 1.44E-01 6271-68083 74354 
CKD rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) -0.034 (0.021) 1.08E-01 6271-68083 74354 
CKD rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.006 (0.021) 7.65E-01 6271-68083 74354 
CKD rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.02 (0.026) 4.42E-01 6271-68083 74354 
CKD rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.039 (0.022) 8.02E-02 6271-68083 74354 
CKD rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.03 (0.032) 3.55E-01 6271-68083 74354 
CKD rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) -0.016 (0.037) 6.71E-01 6271-68083 74354 
CKD rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.031 (0.02) 1.29E-01 6271-68083 74354 
CKD rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.027 (0.022) 2.18E-01 6271-68083 74354 
CKD rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.009 (0.021) 6.78E-01 6271-68083 74354 
CKD rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) -0.018 (0.055) 7.36E-01 6271-68083 74354 
















N Controls N Total 
T2D 9987 89 8 PPP1R3B 9987 89 1.042 (0.974-1.115) 41 35 2 33 ─-─ 22570
T2D 10745954 G A 12 ASCL1 10745954 A G 1.014 (0.975-1.055) 0.014 (0. 2) 89 ─-─ 22570
T2D 118391 A G 12 HNF1A 118391 1.062 (1.017-1.109) 6 (0.02 ) 6 9 3 ─-─ 22570
T2D 340029 C T 15 RORA 340029 1.029 (0.985-1.074) 0.028 (0. 22) 2 03 ─-─ 22570
T2D 10521222 T C 16 SALL1 10521222 T C 1.011 (0.896-1.141) 0.011 (0.062) 8 56 ─-─ 13971
T2D 2847281 8 PTPN2 2847281 A G 1.001 (0.961-1.042) 0.001 (0.021) 9 77 ─-─ 22570
T2D 4420638 G A 9 APOC1 4420638 1.147 (1.073-1.226) 13 34 5 41 5 ─-─ 18 2
T2D 18 961 T C 20 HNF4A 18 961 1.141 (1.002-1.3) 132 66 4 1 2 ─-─ 13971
2037 G A  P BPC4 2037 G A 0.008 (0.024) 51
CKD rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.068 (0.021) 1.12E-03 6271-68083 74354 
CKD rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.012 (0.021) 5.79E-01 6271-68083 74354 
CKD rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.014 (0.022) 5.15E-01 6271-68083 74354 
CKD rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) -0.031 (0.021) 1.44E-01 6271-68083 74354 
CKD rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) -0.034 (0.021) 1.08E-01 6271-68083 74354 
CKD rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.006 (0.021) 7.65E-01 6271-68083 74354 
CKD rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.02 (0.026) 4.42E-01 6271-68083 74354 
CKD rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.039 (0.022) 8.02E-02 6271-68083 74354 
CKD rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.03 (0.032) 3.55E-01 6271-68083 74354 
CKD rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) -0.016 (0.037) 6.71E-01 6271-68083 74354 
CKD rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.031 (0.02) 1.29E-01 6271-68083 74354 
CKD rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.027 (0.022) 2.18E-01 6271-68083 74354 
CKD rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.009 (0.021) 6.78E-01 6271-68083 74354 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
CKD rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.026 (0.021) 2.15E-01 6271-68083 74354 
CKD rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.005 (0.035) 8.79E-01 6271-68083 74354 
CKD rs18 0961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.005 (0.061) 9.30E-01 6271-68083 74354 
eGFR rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.001 (0.001) 4.20E-01 ─-─ 74354 
eGFR rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.004 (0.001) 4.87E-03 ─-─ 74354 
eGFR rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) 0 (0.001) 8.16E-01 ─-─ 74354 
eGFR rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.001 (0.001) 6.34E-01 ─-─ 74354 
eGFR rs12 39046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0 (0.001) 9.05E-01 ─-─ 74354 
eGFR rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.009 (0.001) 4.48E-12 ─-─ 74354 
eGFR rs6734238 A/G 2 IL1F10 rs67 4238 G/A ─ (─-─) -0.001 (0.001) 5.56E-01 ─-─ 74354 
eGFR rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0 (0.002) 9.19E-01 ─-─ 74354 
eGFR rs69 1250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) -0.002 (0.001) 1.94E-01 ─-─ 74354 
eGFR rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.003 (0.002) 9.79E-02 ─-─ 74354 
eGFR rs9987289 A/G 8 PPP R3B rs9987289 G/A ─ (─-─) -0.002 (0.002) 4.31E-01 ─-─ 74354 
eGFR rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.002 (0.001) 6.39E-02 ─-─ 74354 
eGFR rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.001) 4.46E-01 ─-─ 74354 
eGFR rs34 029 C/T 15 RORA rs340029 C/T ─ (─-─) 0 (0.001) 7.49E-01 ─-─ 74354 
eGFR rs1 521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.006 (0.003) 7.95E-02 ─-─ 74354 
eGFR rs28 7281 G/A 18 PTPN2 rs2 47281 G/A ─ (─-─) -0.003 (0.001) 2.44E-02 ─-─ 74354 
eGFR rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0 (0.002) 9.56E-01 ─-─ 74354 
eGFR rs1800961 T/C 20 HNF4A rs1 00961 C/T ─ (─-─) 0.007 (0.004) 6.44E-02 ─-─ 74354 
Neurodegenerative 
ALS rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.056 (0.991-1.125) 0.054 (0.032) 9.16E-02 ─-─ 12263 
















N Controls N Total 
CKD 2847281 8 PTPN2 2 47281 26 2 2 15 1 6271-68083 
CKD 4420638 G A 9 APOC1 4420638 0.005 (0.035) 8 79 6271-68083 
CKD 18 961 T C 20 HNF4A 1 961 -0. 05 (0.061) 9 30 6271-68083 
2037 G A  P BPC4 2037 G A -0.001 (0.001) 4 20 1
4420065 T C  LEPR 4420065 C T 4 4 87 3
1 9267 T C  IL6R 1 9267 C T 1 8 1
2794520 1 CRP 2794520 -0.001 (0.001) 3 1
eGFR rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0 (0.001) 9.05E-01 ─-─ 74354 
eGFR rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.009 (0.001) 4.48E-12 ─-─ 74354 
eGFR rs6734238 A/G 2 IL1F10 rs67 4238 G/A ─ (─-─) -0.001 (0.001) 5.56E-01 ─-─ 74354 
eGFR rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0 (0.002) 9.19E-01 ─-─ 74354 
eGFR rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) -0.002 (0.001) 1.94E-01 ─-─ 74354 
eGFR rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.003 (0.002) 9.79E-02 ─-─ 74354 
eGFR rs9987289 A/G 8 PPP R3B rs9987289 G/A ─ (─-─) -0.002 (0.002) 4.31E-01 ─-─ 74354 
eGFR rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.002 (0.001) 6.39E-02 ─-─ 74354 
eGFR rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.001) 4.46E-01 ─-─ 74354 
eGFR rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0 (0.001) 7.49E-01 ─-─ 74354 
eGFR rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.006 (0.003) 7.95E-02 ─-─ 74354 
eGFR rs2847281 G/A 18 PTPN2 rs2 47281 G/A ─ (─-─) -0.003 (0.001) 2.44E-02 ─-─ 74354 
eGFR rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0 (0.002) 9.56E-01 ─-─ 74354 
eGFR rs1800961 T/C 20 HNF4A rs1 00961 C/T ─ (─-─) 0.007 (0.004) 6.44E-02 ─-─ 74354 
Neurodegenerative 
ALS rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.056 (0.991-1.125) 0.054 (0.032) 9.16E-02 ─-─ 12263 
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N Controls N Total 
T2D rs9987289 A/G 8 PPP1R3B rs9987289 G/A 1.042 (0.974-1.115) 0.041 (0.035) 2.33E-01 ─-─ 22570 
T2D rs10745954 G/A 12 ASCL1 rs10745954 A/G 1.014 (0.975-1.055) 0.014 (0.02) 4.89E-01 ─-─ 22570 
T2D rs1183910 A/G 12 HNF1A rs1183910 G/A 1.062 (1.017-1.109) 0.06 (0.022) 6.09E-03 ─-─ 22570 
T2D rs340029 C/T 15 RORA rs340029 C/T 1.029 (0.985-1.074) 0.028 (0.022) 2.03E-01 ─-─ 22570 
T2D rs10521222 T/C 16 SALL1 rs10521222 T/C 1.011 (0.896-1.141) 0.011 (0.062) 8.56E-01 ─-─ 13971 
T2D rs2847281 G/A 18 PTPN2 rs2847281 A/G 1.001 (0.961-1.042) 0.001 (0.021) 9.77E-01 ─-─ 22570 
T2D rs4420638 G/A 19 APOC1 rs4420638 G/A 1.147 (1.073-1.226) 0.137 (0.034) 5.41E-05 ─-─ 18352 
T2D rs1800961 T/C 20 HNF4A rs1800961 C/T 1.141 (1.002-1.3) 0.132 (0.066) 4.71E-02 ─-─ 13971 
CKD rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) 0.008 (0.024) 7.51E-01 6271-68083 74354 
CKD rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.068 (0.021) 1.12E-03 6271-68083 74354 
CKD rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.012 (0.021) 5.79E-01 6271-68083 74354 
CKD rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.014 (0.022) 5.15E-01 6271-68083 74354 
CKD rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) -0.031 (0.021) 1.44E-01 6271-68083 74354 
CKD rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) -0.034 (0.021) 1.08E-01 6271-68083 74354 
CKD rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.006 (0.021) 7.65E-01 6271-68083 74354 
CKD rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.02 (0.026) 4.42E-01 6271-68083 74354 
CKD rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.039 (0.022) 8.02E-02 6271-68083 74354 
CKD rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.03 (0.032) 3.55E-01 6271-68083 74354 
CKD rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) -0.016 (0.037) 6.71E-01 6271-68083 74354 
CKD rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.031 (0.02) 1.29E-01 6271-68083 74354 
CKD rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.027 (0.022) 2.18E-01 6271-68083 74354 
CKD rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.009 (0.021) 6.78E-01 6271-68083 74354 
CKD rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) -0.018 (0.055) 7.36E-01 6271-68083 74354 
















N Controls N Total 
T2D 9987 89 8 PPP1R3B 9987 89 1.042 (0.974-1.115) 41 35 2 33 ─-─ 22570
T2D 10745954 G A 12 ASCL1 10745954 A G 1.014 (0.975-1.055) 0.014 (0. 2) 89 ─-─ 22570
T2D 118391 A G 12 HNF1A 118391 1.062 (1.017-1.109) 6 (0.02 ) 6 9 3 ─-─ 22570
T2D 340029 C T 15 RORA 340029 1.029 (0.985-1.074) 0.028 (0. 22) 2 03 ─-─ 22570
T2D 10521222 T C 16 SALL1 10521222 T C 1.011 (0.896-1.141) 0.011 (0.062) 8 56 ─-─ 13971
T2D 2847281 8 PTPN2 2847281 A G 1.001 (0.961-1.042) 0.001 (0.021) 9 77 ─-─ 22570
T2D 4420638 G A 9 APOC1 4420638 1.147 (1.073-1.226) 13 34 5 41 5 ─-─ 18 2
T2D 18 961 T C 20 HNF4A 18 961 1.141 (1.002-1.3) 132 66 4 1 2 ─-─ 13971
2037 G A  P BPC4 2037 G A 0.008 (0.024) 51
CKD rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) 0.068 (0.021) 1.12E-03 6271-68083 74354 
CKD rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) -0.012 (0.021) 5.79E-01 6271-68083 74354 
CKD rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.014 (0.022) 5.15E-01 6271-68083 74354 
CKD rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) -0.031 (0.021) 1.44E-01 6271-68083 74354 
CKD rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) -0.034 (0.021) 1.08E-01 6271-68083 74354 
CKD rs6734238 A/G 2 IL1F10 rs6734238 G/A ─ (─-─) 0.006 (0.021) 7.65E-01 6271-68083 74354 
CKD rs4705952 A/G 5 IRF1 rs4705952 G/A ─ (─-─) -0.02 (0.026) 4.42E-01 6271-68083 74354 
CKD rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) 0.039 (0.022) 8.02E-02 6271-68083 74354 
CKD rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.03 (0.032) 3.55E-01 6271-68083 74354 
CKD rs9987289 A/G 8 PPP1R3B rs9987289 G/A ─ (─-─) -0.016 (0.037) 6.71E-01 6271-68083 74354 
CKD rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) -0.031 (0.02) 1.29E-01 6271-68083 74354 
CKD rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) 0.027 (0.022) 2.18E-01 6271-68083 74354 
CKD rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0.009 (0.021) 6.78E-01 6271-68083 74354 
CKD rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) -0.018 (0.055) 7.36E-01 6271-68083 74354 
















N Controls N Total 
CKD rs2847281 G/A 18 PTPN2 rs2847281 G/A ─ (─-─) 0.026 (0.021) 2.15E-01 6271-68083 74354 
CKD rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0.005 (0.035) 8.79E-01 6271-68083 74354 
CKD rs18 0961 T/C 20 HNF4A rs1800961 C/T ─ (─-─) -0.005 (0.061) 9.30E-01 6271-68083 74354 
eGFR rs12037222 G/A 1 PABPC4 rs12037222 G/A ─ (─-─) -0.001 (0.001) 4.20E-01 ─-─ 74354 
eGFR rs4420065 T/C 1 LEPR rs4420065 C/T ─ (─-─) -0.004 (0.001) 4.87E-03 ─-─ 74354 
eGFR rs4129267 T/C 1 IL6R rs4129267 C/T ─ (─-─) 0 (0.001) 8.16E-01 ─-─ 74354 
eGFR rs2794520 T/C 1 CRP rs2794520 C/T ─ (─-─) -0.001 (0.001) 6.34E-01 ─-─ 74354 
eGFR rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0 (0.001) 9.05E-01 ─-─ 74354 
eGFR rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.009 (0.001) 4.48E-12 ─-─ 74354 
eGFR rs6734238 A/G 2 IL1F10 rs67 4238 G/A ─ (─-─) -0.001 (0.001) 5.56E-01 ─-─ 74354 
eGFR rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0 (0.002) 9.19E-01 ─-─ 74354 
eGFR rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) -0.002 (0.001) 1.94E-01 ─-─ 74354 
eGFR rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.003 (0.002) 9.79E-02 ─-─ 74354 
eGFR rs9987289 A/G 8 PPP R3B rs9987289 G/A ─ (─-─) -0.002 (0.002) 4.31E-01 ─-─ 74354 
eGFR rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.002 (0.001) 6.39E-02 ─-─ 74354 
eGFR rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.001) 4.46E-01 ─-─ 74354 
eGFR rs34 029 C/T 15 RORA rs340029 C/T ─ (─-─) 0 (0.001) 7.49E-01 ─-─ 74354 
eGFR rs1 521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.006 (0.003) 7.95E-02 ─-─ 74354 
eGFR rs28 7281 G/A 18 PTPN2 rs2 47281 G/A ─ (─-─) -0.003 (0.001) 2.44E-02 ─-─ 74354 
eGFR rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0 (0.002) 9.56E-01 ─-─ 74354 
eGFR rs1800961 T/C 20 HNF4A rs1 00961 C/T ─ (─-─) 0.007 (0.004) 6.44E-02 ─-─ 74354 
Neurodegenerative 
ALS rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.056 (0.991-1.125) 0.054 (0.032) 9.16E-02 ─-─ 12263 
















N Controls N Total 
CKD 2847281 8 PTPN2 2 47281 26 2 2 15 1 6271-68083 
CKD 4420638 G A 9 APOC1 4420638 0.005 (0.035) 8 79 6271-68083 
CKD 18 961 T C 20 HNF4A 1 961 -0. 05 (0.061) 9 30 6271-68083 
2037 G A  P BPC4 2037 G A -0.001 (0.001) 4 20 1
4420065 T C  LEPR 4420065 C T 4 4 87 3
1 9267 T C  IL6R 1 9267 C T 1 8 1
2794520 1 CRP 2794520 -0.001 (0.001) 3 1
eGFR rs12239046 T/C 1 NLRP3 rs12239046 C/T ─ (─-─) 0 (0.001) 9.05E-01 ─-─ 74354 
eGFR rs1260326 C/T 2 GCKR rs1260326 C/T ─ (─-─) 0.009 (0.001) 4.48E-12 ─-─ 74354 
eGFR rs6734238 A/G 2 IL1F10 rs67 4238 G/A ─ (─-─) -0.001 (0.001) 5.56E-01 ─-─ 74354 
eGFR rs4705952 A/G 5 IRF  rs4705952 G/A ─ (─-─) 0 (0.002) 9.19E-01 ─-─ 74354 
eGFR rs6901250 G/A 6 GPRC6A rs6901250 G/A ─ (─-─) -0.002 (0.001) 1.94E-01 ─-─ 74354 
eGFR rs13233571 T/C 7 BCL7B rs13233571 C/T ─ (─-─) -0.003 (0.002) 9.79E-02 ─-─ 74354 
eGFR rs9987289 A/G 8 PPP R3B rs9987289 G/A ─ (─-─) -0.002 (0.002) 4.31E-01 ─-─ 74354 
eGFR rs10745954 G/A 12 ASCL1 rs10745954 G/A ─ (─-─) 0.002 (0.001) 6.39E-02 ─-─ 74354 
eGFR rs1183910 A/G 12 HNF1A rs1183910 G/A ─ (─-─) -0.001 (0.001) 4.46E-01 ─-─ 74354 
eGFR rs340029 C/T 15 RORA rs340029 C/T ─ (─-─) 0 (0.001) 7.49E-01 ─-─ 74354 
eGFR rs10521222 T/C 16 SALL1 rs10521222 C/T ─ (─-─) 0.006 (0.003) 7.95E-02 ─-─ 74354 
eGFR rs2847281 G/A 18 PTPN2 rs2 47281 G/A ─ (─-─) -0.003 (0.001) 2.44E-02 ─-─ 74354 
eGFR rs4420638 G/A 19 APOC1 rs4420638 G/A ─ (─-─) 0 (0.002) 9.56E-01 ─-─ 74354 
eGFR rs1800961 T/C 20 HNF4A rs1 00961 C/T ─ (─-─) 0.007 (0.004) 6.44E-02 ─-─ 74354 
Neurodegenerative 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
ALS rs4420065 T/C 1 LEPR rs2211651 G/T 0.996 (0.942-1.054) -0.004 (0.029) 8.96E-01 ─-─ 12245 
ALS rs4129267 T/C 1 IL6R rs4129267 C/T 1.018 (0.963-1.076) 0.018 (0.028) 5.38E-01 ─-─ 12260 
ALS rs2794520 T/C 1 CRP rs2794520 C/T 1.019 (0.961-1.08) 0.019 (0.03) 5.29E-01 ─-─ 12260 
ALS rs12239046 T/C 1 NLRP3 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1260326 C/T 2 GCKR rs1260326 C/T 1.015 (0.961-1.072) 0.015 (0.028) 6.03E-01 ─-─ 12181 
ALS rs6734238 A/G 2 IL1F10 rs1446510 C/T 1 (0.946-1.057) 0 (0.028) 9.97E-01 ─-─ 12262 
ALS rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs6901250 G/A 6 GPRC6A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs13233571 T/C 7 BCL7B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs10745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs340029 C/T 15 RORA rs340029 T/C 0.962 (0.91-1.017) -0.039 (0.028) 1.72E-01 ─-─ 12246 
ALS rs10521222 T/C 16 SALL1 rs10521222 C/T 1.002 (0.88-1.141) 0.002 (0.066) 9.70E-01 ─-─ 12258 
ALS rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1800961 T/C 20 HNF4A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.03 (0.968-1.095) 0.03 (0.031) 3.49E-01 4663-8357 13020 
ALZ rs4420065 T/C 1 LEPR rs4420065 T/C 0.954 (0.866-1.051) -0.047 (0.045) 3.37E-01 4663-8357 13020 
ALZ rs4129267 T/C 1 IL6R rs4129267 T/C 1.047 (0.994-1.104) 0.046 (0.027) 8.52E-02 4663-8357 13020 
ALZ rs2794520 T/C 1 CRP rs2794520 T/C 1.034 (0.979-1.093) 0.034 (0.028) 2.31E-01 4663-8357 13020 
ALZ rs12239046 T/C 1 NLRP3 rs10157379 T/C 1.036 (0.98-1.096) 0.036 (0.029) 2.07E-01 4663-8357 13020 
ALZ rs1260326 C/T 2 GCKR rs1260326 T/C 0.991 (0.938-1.047) -0.009 (0.027) 7.47E-01 4663-8357 13020 
















N Controls N Total 
4420065 T C  LEPR rs2211651 G T 0.996 (0.942-1.054) -0.004 (0.029) 8.96E-01 12245 
1 9267 T C  IL6R rs4129267 C T 1.018 (0.963-1.076) 0.018 (0.028) 5.38E-01 12260 
2794520 1 CRP rs2794520 C T 1.019 (0.961-1.08) 0.019 (0.03) 5.29E-01 12260 
S 2 9046 T C NLRP3 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
S 126 326 C T 2 GCK 126 326 C T 1 015 9 1 72 0.015 (0.028) 6 03 ─-─ 2181
S 6734 38 A G 2 1F10 1446510 C T  (0.946-1.057)  (0.028) 9 97 1 ─-─ 2262
S 4 05952 A G 5 IRF1 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
S 6901250 G A 6 GP C6A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
S 323 571 T C 7 B L7B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs10745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs340029 C/T 15 RORA rs340029 T/C 0.962 (0.91-1.017) -0.039 (0.028) 1.72E-01 ─-─ 12246 
ALS rs10521222 T/C 16 SALL1 rs10521222 C/T 1.002 (0.88-1.141) 0.002 (0.066) 9.70E-01 ─-─ 12258 
ALS rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1800961 T/C 20 HNF4A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.03 (0.968-1.095) 0.03 (0.031) 3.49E-01 4663-8357 13020 
ALZ rs4420065 T/C 1 LEPR rs4420065 T/C 0.954 (0.866-1.051) -0.047 (0.045) 3.37E-01 4663-8357 13020 
ALZ rs4129267 T/C 1 IL6R rs4129267 T/C 1.047 (0.994-1.104) 0.046 (0.027) 8.52E-02 4663-8357 13020 
ALZ rs2794520 T/C 1 CRP rs2794520 T/C 1.034 (0.979-1.093) 0.034 (0.028) 2.31E-01 4663-8357 13020 
ALZ rs12239046 T/C 1 NLRP3 rs10157379 T/C 1.036 (0.98-1.096) 0.036 (0.029) 2.07E-01 4663-8357 13020 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
ALZ rs673 238 A/G 2 IL1F10 rs4496335 C/T 0.996 (0.938-1.058) -0.004 (0.03) 9.00E-01 4663-8357 13020 
ALZ rs4705952 A/G 5 IRF  ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs69012 0 G/A 6 GPRC6A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs13233571 T/C 7 BCL7B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs9987289 A/G 8 PPP R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs10745954 G/A 12 ASCL1 rs10778212 G/A 1.078 (1.021-1.138) 0.075 (0.029) 6.33E-03 4663-8357 13020 
ALZ rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs340029 C/T 15 RORA rs340029 T/C 0.968 (0.914-1.027) -0.032 (0.028) 2.82E-01 4663-8357 13020 
ALZ rs10521222 T/C 16 SALL1 rs10521222 C/T 0.961 (0.833-1.109) -0.04 (0.065) 5.88E-01 4663-8357 13020 
ALZ rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs18 0961 T/C 20 HNF4A rs1800961 C/T 0.991 (0.777-1.266) -0.009 (0.11) 9.45E-01 4663-8357 13020 
PKD rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.022 (0.98-1.066) 0.022 (0.021) 3.02E-01 5333-12019 17352 
PKD rs4 20065 T/C 1 LEPR ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs4129267 T/C 1 IL6R rs4129267 A/G 1.012 (0.976-1.05) 0.012 (0.019) 5.12E-01 5333-12019 17352 
PKD rs2794520 T/C 1 CRP rs2794520 A/G 1 (0.963-1.038) 0 (0.019) 9.92E-01 5333-12019 17352 
PKD rs12239046 T/C 1 NLRP3 rs10157379 A/G 0.967 (0.933-1.002) -0.034 (0.018) 6.64E-02 5333-12019 17352 
PKD rs1260326 C/T 2 GCKR rs1260326 A/G 1.012 (0.975-1.051) 0.012 (0.019) 5.31E-01 5333-12019 17352 
PKD rs6734238 A/G 2 IL1F10 rs4496335 A/G 0.991 (0.955-1.028) -0.009 (0.019) 6.29E-01 5333-12019 17352 
PKD rs47 5952 A/G 5 IRF  ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs6901250 G/A 6 GPRC6A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs13233571 T/C 7 BCL7B rs714052 A/G 1.036 (0.982-1.093) 0.035 (0.027) 2.01E-01 5333-12019 17352 
PKD rs998 289 A/G 8 PPP R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
















N Controls N Total 
ALZ 673 38 A G 2 1F10 496335 C T 0 996 38 8) -0.004 (0.03) 9 00 466 8357 3020
ALZ 4 5952 A G 5 IRF  ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ 6901250 G A 6 GP C6A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ 323 571 T C 7 B L7B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ 9987 89 8 PPP R3B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ 107 5954 G A 12 ASCL1 rs10778212 G A 1.078 (1.021-1.138) 0.075 (0.029) 6.33E-03 4663-8357 13020 
ALZ 118 91 A G 12 HNF1A 
ALZ 340029 C T 15 RORA 340 29 T C 0 968 14 27 -0.032 (0.028) 82 466 8357 3020
ALZ 1 521222 T C 16 SALL1 rs10521222 C T 0.961 (0.833-1.109) -0.04 (0.065) 5.88E-01 4663-8357 13020 
ALZ rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs1800961 T/C 20 HNF4A rs1800961 C/T 0.991 (0.777-1.266) -0.009 (0.11) 9.45E-01 4663-8357 13020 
PKD rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.022 (0.98-1.066) 0.022 (0.021) 3.02E-01 5333-12019 17352 
PKD rs4 20065 T/C 1 LEPR ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs4129267 T/C 1 IL6R rs4129267 A/G 1.012 (0.976-1.05) 0.012 (0.019) 5.12E-01 5333-12019 17352 
PKD rs2794520 T/C 1 CRP rs2794520 A/G 1 (0.963-1.038) 0 (0.019) 9.92E-01 5333-12019 17352 
PKD rs12239046 T/C 1 NLRP3 rs10157379 A/G 0.967 (0.933-1.002) -0.034 (0.018) 6.64E-02 5333-12019 17352 
PKD rs1260326 C/T 2 GCKR rs1260326 A/G 1.012 (0.975-1.051) 0.012 (0.019) 5.31E-01 5333-12019 17352 
PKD rs6734238 A/G 2 IL1F10 rs4496335 A/G 0.991 (0.955-1.028) -0.009 (0.019) 6.29E-01 5333-12019 17352 
PKD rs47 5952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs6901250 G/A 6 GPRC6A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs13233571 T/C 7 BCL7B rs714052 A/G 1.036 (0.982-1.093) 0.035 (0.027) 2.01E-01 5333-12019 17352 
PKD rs998 289 A/G 8 PPP R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
210204-L-bw-Vaez
















N Controls N Total 
ALS rs4420065 T/C 1 LEPR rs2211651 G/T 0.996 (0.942-1.054) -0.004 (0.029) 8.96E-01 ─-─ 12245 
ALS rs4129267 T/C 1 IL6R rs4129267 C/T 1.018 (0.963-1.076) 0.018 (0.028) 5.38E-01 ─-─ 12260 
ALS rs2794520 T/C 1 CRP rs2794520 C/T 1.019 (0.961-1.08) 0.019 (0.03) 5.29E-01 ─-─ 12260 
ALS rs12239046 T/C 1 NLRP3 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1260326 C/T 2 GCKR rs1260326 C/T 1.015 (0.961-1.072) 0.015 (0.028) 6.03E-01 ─-─ 12181 
ALS rs6734238 A/G 2 IL1F10 rs1446510 C/T 1 (0.946-1.057) 0 (0.028) 9.97E-01 ─-─ 12262 
ALS rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs6901250 G/A 6 GPRC6A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs13233571 T/C 7 BCL7B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs10745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs340029 C/T 15 RORA rs340029 T/C 0.962 (0.91-1.017) -0.039 (0.028) 1.72E-01 ─-─ 12246 
ALS rs10521222 T/C 16 SALL1 rs10521222 C/T 1.002 (0.88-1.141) 0.002 (0.066) 9.70E-01 ─-─ 12258 
ALS rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1800961 T/C 20 HNF4A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.03 (0.968-1.095) 0.03 (0.031) 3.49E-01 4663-8357 13020 
ALZ rs4420065 T/C 1 LEPR rs4420065 T/C 0.954 (0.866-1.051) -0.047 (0.045) 3.37E-01 4663-8357 13020 
ALZ rs4129267 T/C 1 IL6R rs4129267 T/C 1.047 (0.994-1.104) 0.046 (0.027) 8.52E-02 4663-8357 13020 
ALZ rs2794520 T/C 1 CRP rs2794520 T/C 1.034 (0.979-1.093) 0.034 (0.028) 2.31E-01 4663-8357 13020 
ALZ rs12239046 T/C 1 NLRP3 rs10157379 T/C 1.036 (0.98-1.096) 0.036 (0.029) 2.07E-01 4663-8357 13020 
ALZ rs1260326 C/T 2 GCKR rs1260326 T/C 0.991 (0.938-1.047) -0.009 (0.027) 7.47E-01 4663-8357 13020 
















N Controls N Total 
4420065 T C  LEPR rs2211651 G T 0.996 (0.942-1.054) -0.004 (0.029) 8.96E-01 12245 
1 9267 T C  IL6R rs4129267 C T 1.018 (0.963-1.076) 0.018 (0.028) 5.38E-01 12260 
2794520 1 CRP rs2794520 C T 1.019 (0.961-1.08) 0.019 (0.03) 5.29E-01 12260 
S 2 9046 T C NLRP3 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
S 126 326 C T 2 GCK 126 326 C T 1 015 9 1 72 0.015 (0.028) 6 03 ─-─ 2181
S 6734 38 A G 2 1F10 1446510 C T  (0.946-1.057)  (0.028) 9 97 1 ─-─ 2262
S 4 05952 A G 5 IRF1 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
S 6901250 G A 6 GP C6A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
S 323 571 T C 7 B L7B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs10745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs340029 C/T 15 RORA rs340029 T/C 0.962 (0.91-1.017) -0.039 (0.028) 1.72E-01 ─-─ 12246 
ALS rs10521222 T/C 16 SALL1 rs10521222 C/T 1.002 (0.88-1.141) 0.002 (0.066) 9.70E-01 ─-─ 12258 
ALS rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALS rs1800961 T/C 20 HNF4A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.03 (0.968-1.095) 0.03 (0.031) 3.49E-01 4663-8357 13020 
ALZ rs4420065 T/C 1 LEPR rs4420065 T/C 0.954 (0.866-1.051) -0.047 (0.045) 3.37E-01 4663-8357 13020 
ALZ rs4129267 T/C 1 IL6R rs4129267 T/C 1.047 (0.994-1.104) 0.046 (0.027) 8.52E-02 4663-8357 13020 
ALZ rs2794520 T/C 1 CRP rs2794520 T/C 1.034 (0.979-1.093) 0.034 (0.028) 2.31E-01 4663-8357 13020 
ALZ rs12239046 T/C 1 NLRP3 rs10157379 T/C 1.036 (0.98-1.096) 0.036 (0.029) 2.07E-01 4663-8357 13020 
ALZ rs1260326 C/T 2 GCKR rs1260326 T/C 0.991 (0.938-1.047) -0.009 (0.027) 7.47E-01 4663-8357 13020 
















N Controls N Total 
ALZ rs673 238 A/G 2 IL1F10 rs4496335 C/T 0.996 (0.938-1.058) -0.004 (0.03) 9.00E-01 4663-8357 13020 
ALZ rs4705952 A/G 5 IRF  ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs6901250 G/A 6 GPRC6A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs13233571 T/C 7 BCL7B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs9987289 A/G 8 PPP R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs10745954 G/A 12 ASCL1 rs10778212 G/A 1.078 (1.021-1.138) 0.075 (0.029) 6.33E-03 4663-8357 13020 
ALZ rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs340029 C/T 15 RORA rs340029 T/C 0.968 (0.914-1.027) -0.032 (0.028) 2.82E-01 4663-8357 13020 
ALZ rs10521222 T/C 16 SALL1 rs10521222 C/T 0.961 (0.833-1.109) -0.04 (0.065) 5.88E-01 4663-8357 13020 
ALZ rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs1800961 T/C 20 HNF4A rs1800961 C/T 0.991 (0.777-1.266) -0.009 (0.11) 9.45E-01 4663-8357 13020 
PKD rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.022 (0.98-1.066) 0.022 (0.021) 3.02E-01 5333-12019 17352 
PKD rs4 20065 T/C 1 LEPR ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs4129267 T/C 1 IL6R rs4129267 A/G 1.012 (0.976-1.05) 0.012 (0.019) 5.12E-01 5333-12019 17352 
PKD rs2794520 T/C 1 CRP rs2794520 A/G 1 (0.963-1.038) 0 (0.019) 9.92E-01 5333-12019 17352 
PKD rs12239046 T/C 1 NLRP3 rs10157379 A/G 0.967 (0.933-1.002) -0.034 (0.018) 6.64E-02 5333-12019 17352 
PKD rs1260326 C/T 2 GCKR rs1260326 A/G 1.012 (0.975-1.051) 0.012 (0.019) 5.31E-01 5333-12019 17352 
PKD rs6734238 A/G 2 IL1F10 rs4496335 A/G 0.991 (0.955-1.028) -0.009 (0.019) 6.29E-01 5333-12019 17352 
PKD rs47 5952 A/G 5 IRF  ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs6901250 G/A 6 GPRC6A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs13233571 T/C 7 BCL7B rs714052 A/G 1.036 (0.982-1.093) 0.035 (0.027) 2.01E-01 5333-12019 17352 
PKD rs998 289 A/G 8 PPP R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
















N Controls N Total 
ALZ 673 38 A G 2 1F10 496335 C T 0 996 38 8) -0.004 (0.03) 9 00 466 8357 3020
ALZ 4 05952 A G 5 IRF  ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ 6901250 G A 6 GP C6A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ 323 571 T C 7 B L7B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ 9987 89 8 PPP R3B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ 107 5954 G A 12 ASCL1 rs10778212 G A 1.078 (1.021-1.138) 0.075 (0.029) 6.33E-03 4663-8357 13020 
ALZ 118 91 A G 12 HNF1A 
ALZ 340029 C T 15 RORA 340 29 T C 0 968 14 27 -0.032 (0.028) 82 466 8357 3020
ALZ 1 521222 T C 16 SALL1 rs10521222 C T 0.961 (0.833-1.109) -0.04 (0.065) 5.88E-01 4663-8357 13020 
ALZ rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
ALZ rs1800961 T/C 20 HNF4A rs1800961 C/T 0.991 (0.777-1.266) -0.009 (0.11) 9.45E-01 4663-8357 13020 
PKD rs12037222 G/A 1 PABPC4 rs4660293 A/G 1.022 (0.98-1.066) 0.022 (0.021) 3.02E-01 5333-12019 17352 
PKD rs4 20065 T/C 1 LEPR ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs4129267 T/C 1 IL6R rs4129267 A/G 1.012 (0.976-1.05) 0.012 (0.019) 5.12E-01 5333-12019 17352 
PKD rs2794520 T/C 1 CRP rs2794520 A/G 1 (0.963-1.038) 0 (0.019) 9.92E-01 5333-12019 17352 
PKD rs12239046 T/C 1 NLRP3 rs10157379 A/G 0.967 (0.933-1.002) -0.034 (0.018) 6.64E-02 5333-12019 17352 
PKD rs1260326 C/T 2 GCKR rs1260326 A/G 1.012 (0.975-1.051) 0.012 (0.019) 5.31E-01 5333-12019 17352 
PKD rs6734238 A/G 2 IL1F10 rs4496335 A/G 0.991 (0.955-1.028) -0.009 (0.019) 6.29E-01 5333-12019 17352 
PKD rs47 5952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs6901250 G/A 6 GPRC6A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs13233571 T/C 7 BCL7B rs714052 A/G 1.036 (0.982-1.093) 0.035 (0.027) 2.01E-01 5333-12019 17352 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
PKD rs10745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs340029 C/T 15 RORA rs340029 A/G 0.992 (0.956-1.03) -0.008 (0.019) 6.71E-01 5333-12019 17352 
PKD rs10521222 T/C 16 SALL1 rs10521222 A/G 0.983 (0.908-1.064) -0.017 (0.041) 6.70E-01 5333-12019 17352 
PKD rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs1800961 T/C 20 HNF4A rs1800961 A/G 1.056 (0.961-1.16) 0.054 (0.048) 2.60E-01 5333-12019 17352 
Psychiatric 
AUT rs12037222 G/A 1 PABPC4 rs2293476 G/C 0.974 (─-─) -0.027 (0.04) 6.77E-01 90-1476 1566 
AUT rs4420065 T/C 1 LEPR ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs4129267 T/C 1 IL6R rs4537545 C/T 1.071 (─-─) 0.069 (0.368) 1.87E-01 90-1476 1566 
AUT rs2794520 T/C 1 CRP rs7553007 C/T 1.03 (─-─) 0.03 (0.05) 5.87E-01 90-1476 1566 
AUT rs12239046 T/C 1 NLRP3 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs1260326 C/T 2 GCKR rs780094 C/T 0.911 (─-─) -0.094 (1.154) 8.12E-02 90-1476 1566 
AUT rs6734238 A/G 2 IL1F10 rs10176274 G/C 1.05 (─-─) 0.049 (0.134) 3.64E-01 90-1476 1566 
AUT rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs6901250 G/A 6 GPRC6A rs6924002 A/T 0.985 (─-─) -0.015 (0.019) 7.86E-01 90-1476 1566 
AUT rs13233571 T/C 7 BCL7B rs17145738 C/T 0.951 (─-─) -0.05 (0.095) 5.27E-01 90-1476 1566 
AUT rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs10745954 G/A 12 ASCL1 rs7972145 G/A 0.995 (─-─) -0.005 (0.005) 9.20E-01 90-1476 1566 
AUT rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs340029 C/T 15 RORA ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs10521222 T/C 16 SALL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
















N Controls N Total 
PKD rs10745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs340029 C/T 15 RORA rs340029 A/G 0.992 (0.956-1.03) -0.008 (0.019) 6.71E-01 5333-12019 17352 
PKD rs10521222 T/C 16 SALL1 rs10521222 A/G 0.983 (0.908-1.064) -0.017 (0.041) 6.70E-01 5333-12019 17352 
PKD rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs1800961 T/C 20 HNF4A rs1800961 A/G 1.056 (0.961-1.16) 0.054 (0.048) 2.60E-01 5333-12019 17352 
Psychiatric 
2037 G A  P BPC4 rs2293476 G C 0.974 (─-─) -0.027 (0.04) 6.77E-01 90-1476 1566 
AUT rs4420065 T/C 1 LEPR ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs4129267 T/C 1 IL6R rs4537545 C/T 1.071 (─-─) 0.069 (0.368) 1.87E-01 90-1476 1566 
AUT rs2794520 T/C 1 CRP rs7553007 C/T 1.03 (─-─) 0.03 (0.05) 5.87E-01 90-1476 1566 
AUT rs12239046 T/C 1 NLRP3 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs1260326 C/T 2 GCKR rs780094 C/T 0.911 (─-─) -0.094 (1.154) 8.12E-02 90-1476 1566 
AUT rs6734238 A/G 2 IL1F10 rs10176274 G/C 1.05 (─-─) 0.049 (0.134) 3.64E-01 90-1476 1566 
AUT rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs6901250 G/A 6 GPRC6A rs6924002 A/T 0.985 (─-─) -0.015 (0.019) 7.86E-01 90-1476 1566 
AUT rs13233571 T/C 7 BCL7B rs17145738 C/T 0.951 (─-─) -0.05 (0.095) 5.27E-01 90-1476 1566 
AUT rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs10745954 G/A 12 ASCL1 rs7972145 G/A 0.995 (─-─) -0.005 (0.005) 9.20E-01 90-1476 1566 
AUT rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs340029 C/T 15 RORA ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
AUT rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs4420638 G/A 19 APOC1 rs4420638 T/C 0.87 (─-─) -0.14 (4.028) 3.47E-02 90-1476 1566 
AUT rs1800961 T/C 20 HNF4A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
BPD rs12037222 G/A 1 PABPC4 rs12037222 G/A 1.038 (0.983-1.097) 0.037 (0.028) 1.81E-01 7481-9250 16731 
BPD rs4420065 T/C 1 LEPR rs4420065 T/C 0.98 (0.935-1.028) -0.02 (0.024) 4.13E-01 7481-9250 16731 
BPD rs4129267 T/C 1 IL6R rs4129267 T/C 1.041 (0.993-1.091) 0.04 (0.024) 9.16E-02 7481-9250 16731 
BPD rs2794520 T/C 1 CRP rs27 4520 T/C 1.054 (1.004-1.106) 0.052 (0.025) 3.25E-02 7481-9250 16731 
BPD rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.042 (0.988-1.099) 0.041 (0.027) 1.30E-01 7481-9250 16731 
BPD rs1260326 C/T 2 GCKR rs1260326 T/C 0.93 (0.887-0.974) -0.073 (0.024) 2.31E-03 7481-9250 16731 
BPD rs6734238 A/G 2 IL1F10 rs6734238 G/A 0.993 (0.948-1.04) -0.007 (0.024) 7.65E-01 7481-9250 16731 
BPD rs4705952 A/G 5 IRF1 rs4705952 G/A 0.985 (0.927-1.046) -0.015 (0.031) 6.22E-01 7481-9250 16731 
BPD rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.001 (0.953-1.051) 0.001 (0.025) 9.73E-01 7481-9250 16731 
BPD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.963 (0.898-1.032) -0.038 (0.035) 2.85E-01 7481-9250 16731 
BPD rs9987289 A/G 8 PPP1R3B rs9987289 G/A 1.011 (0.933-1.097) 0.011 (0.041) 7.84E-01 7481-9250 16731 
BPD rs10745954 G/A 12 ASCL1 rs10745954 G/A 0.981 (0.937-1.027) -0.019 (0.023) 4.08E-01 7481-9250 16731 
BPD rs1183910 A/G 12 HNF1A rs1183910 G/A 1.019 (0.97-1.07) 0.018 (0.025) 4.62E-01 7481-9250 16731 
BPD rs340029 C/T 15 RORA rs340029 T/C 1.01 (0.961-1.06) 0.009 (0.025) 7.07E-01 7481-9250 16731 
BPD rs1 521222 T/C 16 SALL1 rs10521222 T/C 1.017 (0.872-1.185) 0.016 (0.078) 8.34E-01 7481-9250 16731 
BPD rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.981 (0.936-1.028) -0.019 (0.024) 4.24E-01 7481-9250 16731 
BPD rs4420638 G/A 19 APOC1 rs4420638 G/A 1.07 (1.005-1.14) 0.068 (0.032) 3.53E-02 7481-9250 16731 
BPD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.935 (0.788-1.109) -0.067 (0.087) 4.39E-01 7481-9250 16731 
MDD rs12037222 G/A 1 PABPC4 rs2293476 G/C 1.017 (0.969-1.068) 0.017 (0.025) 4.88E-01 9240-9519 18759 
MDD rs4420065 T/C 1 LEPR rs4420065 C/T 0.962 (0.921-1.004) -0.039 (0.022) 7.48E-02 9240-9519 18759 
















N Controls N Total 
AUT 2847281 8 PTPN2 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT 4420638 G A 9 APOC1 4420638 T C 0 87 (─-─) -0.14 (4. 28) 3 47 2 90-1476 566 
AUT 18 961 T C 20 HNF4A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
2037 G A  P BPC4 2037 G A 38 983 097 37 2 1 81
4420065 T C  LEPR 4420065 T C  (0.935-1.028) 2 (0.024) 13
1 9267 T C  IL6R 1 9267 T C 41 (0.993-1.091) 4 (0.024) 9 16
2794520 1 CRP 27 4520 1 054 1 004 6 0.052 (0.025) 3 25 2
BPD 2 9046 T C NLRP3 1 2 9046 T  42 88 99 41 7 1 30 7481 250 6 31
BPD 126 326 C T 2 GCK 126 326 T C 3 (0.887-0.974) 73 4 2 31 3 7481 250 6 31
BPD rs6734238 A/G 2 IL1F10 rs6734238 G/A 0.993 (0.948-1.04) -0.007 (0.024) 7.65E-01 7481-9250 16731 
BPD rs4705952 A/G 5 IRF1 rs4705952 G/A 0.985 (0.927-1.046) -0.015 (0.031) 6.22E-01 7481-9250 16731 
BPD rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.001 (0.953-1.051) 0.001 (0.025) 9.73E-01 7481-9250 16731 
BPD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.963 (0.898-1.032) -0.038 (0.035) 2.85E-01 7481-9250 16731 
BPD rs9987289 A/G 8 PPP1R3B rs9987289 G/A 1.011 (0.933-1.097) 0.011 (0.041) 7.84E-01 7481-9250 16731 
BPD rs10745954 G/A 12 ASCL1 rs10745954 G/A 0.981 (0.937-1.027) -0.019 (0.023) 4.08E-01 7481-9250 16731 
BPD rs1183910 A/G 12 HNF1A rs1183910 G/A 1.019 (0.97-1.07) 0.018 (0.025) 4.62E-01 7481-9250 16731 
BPD rs340029 C/T 15 RORA rs340029 T/C 1.01 (0.961-1.06) 0.009 (0.025) 7.07E-01 7481-9250 16731 
BPD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.017 (0.872-1.185) 0.016 (0.078) 8.34E-01 7481-9250 16731 
BPD rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.981 (0.936-1.028) -0.019 (0.024) 4.24E-01 7481-9250 16731 
BPD rs4420638 G/A 19 APOC1 rs4420638 G/A 1.07 (1.005-1.14) 0.068 (0.032) 3.53E-02 7481-9250 16731 
BPD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.935 (0.788-1.109) -0.067 (0.087) 4.39E-01 7481-9250 16731 
MDD rs12037222 G/A 1 PABPC4 rs2293476 G/C 1.017 (0.969-1.068) 0.017 (0.025) 4.88E-01 9240-9519 18759 
MDD rs4420065 T/C 1 LEPR rs4420065 C/T 0.962 (0.921-1.004) -0.039 (0.022) 7.48E-02 9240-9519 18759 
210204-L-bw-Vaez
















N Controls N Total 
PKD rs10745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs340029 C/T 15 RORA rs340029 A/G 0.992 (0.956-1.03) -0.008 (0.019) 6.71E-01 5333-12019 17352 
PKD rs10521222 T/C 16 SALL1 rs10521222 A/G 0.983 (0.908-1.064) -0.017 (0.041) 6.70E-01 5333-12019 17352 
PKD rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs1800961 T/C 20 HNF4A rs1800961 A/G 1.056 (0.961-1.16) 0.054 (0.048) 2.60E-01 5333-12019 17352 
Psychiatric 
AUT rs12037222 G/A 1 PABPC4 rs2293476 G/C 0.974 (─-─) -0.027 (0.04) 6.77E-01 90-1476 1566 
AUT rs4420065 T/C 1 LEPR ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs4129267 T/C 1 IL6R rs4537545 C/T 1.071 (─-─) 0.069 (0.368) 1.87E-01 90-1476 1566 
AUT rs2794520 T/C 1 CRP rs7553007 C/T 1.03 (─-─) 0.03 (0.05) 5.87E-01 90-1476 1566 
AUT rs12239046 T/C 1 NLRP3 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs1260326 C/T 2 GCKR rs780094 C/T 0.911 (─-─) -0.094 (1.154) 8.12E-02 90-1476 1566 
AUT rs6734238 A/G 2 IL1F10 rs10176274 G/C 1.05 (─-─) 0.049 (0.134) 3.64E-01 90-1476 1566 
AUT rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs6901250 G/A 6 GPRC6A rs6924002 A/T 0.985 (─-─) -0.015 (0.019) 7.86E-01 90-1476 1566 
AUT rs13233571 T/C 7 BCL7B rs17145738 C/T 0.951 (─-─) -0.05 (0.095) 5.27E-01 90-1476 1566 
AUT rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs10745954 G/A 12 ASCL1 rs7972145 G/A 0.995 (─-─) -0.005 (0.005) 9.20E-01 90-1476 1566 
AUT rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs340029 C/T 15 RORA ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs10521222 T/C 16 SALL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
















N Controls N Total 
PKD rs10745954 G/A 12 ASCL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs340029 C/T 15 RORA rs340029 A/G 0.992 (0.956-1.03) -0.008 (0.019) 6.71E-01 5333-12019 17352 
PKD rs10521222 T/C 16 SALL1 rs10521222 A/G 0.983 (0.908-1.064) -0.017 (0.041) 6.70E-01 5333-12019 17352 
PKD rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
PKD rs1800961 T/C 20 HNF4A rs1800961 A/G 1.056 (0.961-1.16) 0.054 (0.048) 2.60E-01 5333-12019 17352 
Psychiatric 
2037 G A  P BPC4 rs2293476 G C 0.974 (─-─) -0.027 (0.04) 6.77E-01 90-1476 1566 
AUT rs4420065 T/C 1 LEPR ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs4129267 T/C 1 IL6R rs4537545 C/T 1.071 (─-─) 0.069 (0.368) 1.87E-01 90-1476 1566 
AUT rs2794520 T/C 1 CRP rs7553007 C/T 1.03 (─-─) 0.03 (0.05) 5.87E-01 90-1476 1566 
AUT rs12239046 T/C 1 NLRP3 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs1260326 C/T 2 GCKR rs780094 C/T 0.911 (─-─) -0.094 (1.154) 8.12E-02 90-1476 1566 
AUT rs6734238 A/G 2 IL1F10 rs10176274 G/C 1.05 (─-─) 0.049 (0.134) 3.64E-01 90-1476 1566 
AUT rs4705952 A/G 5 IRF1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs6901250 G/A 6 GPRC6A rs6924002 A/T 0.985 (─-─) -0.015 (0.019) 7.86E-01 90-1476 1566 
AUT rs13233571 T/C 7 BCL7B rs17145738 C/T 0.951 (─-─) -0.05 (0.095) 5.27E-01 90-1476 1566 
AUT rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs10745954 G/A 12 ASCL1 rs7972145 G/A 0.995 (─-─) -0.005 (0.005) 9.20E-01 90-1476 1566 
AUT rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs340029 C/T 15 RORA ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs10521222 T/C 16 SALL1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
















N Controls N Total 
AUT rs2847281 G/A 18 PTPN2 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT rs4420638 G/A 19 APOC1 rs4420638 T/C 0.87 (─-─) -0.14 (4.028) 3.47E-02 90-1476 1566 
AUT rs1800961 T/C 20 HNF4A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
BPD rs12037222 G/A 1 PABPC4 rs12037222 G/A 1.038 (0.983-1.097) 0.037 (0.028) 1.81E-01 7481-9250 16731 
BPD rs4420065 T/C 1 LEPR rs4420065 T/C 0.98 (0.935-1.028) -0.02 (0.024) 4.13E-01 7481-9250 16731 
BPD rs4129267 T/C 1 IL6R rs4129267 T/C 1.041 (0.993-1.091) 0.04 (0.024) 9.16E-02 7481-9250 16731 
BPD rs2794520 T/C 1 CRP rs27 4520 T/C 1.054 (1.004-1.106) 0.052 (0.025) 3.25E-02 7481-9250 16731 
BPD rs12239046 T/C 1 NLRP3 rs12239046 T/C 1.042 (0.988-1.099) 0.041 (0.027) 1.30E-01 7481-9250 16731 
BPD rs1260326 C/T 2 GCKR rs1260326 T/C 0.93 (0.887-0.974) -0.073 (0.024) 2.31E-03 7481-9250 16731 
BPD rs6734238 A/G 2 IL1F10 rs6734238 G/A 0.993 (0.948-1.04) -0.007 (0.024) 7.65E-01 7481-9250 16731 
BPD rs4705952 A/G 5 IRF1 rs4705952 G/A 0.985 (0.927-1.046) -0.015 (0.031) 6.22E-01 7481-9250 16731 
BPD rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.001 (0.953-1.051) 0.001 (0.025) 9.73E-01 7481-9250 16731 
BPD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.963 (0.898-1.032) -0.038 (0.035) 2.85E-01 7481-9250 16731 
BPD rs9987289 A/G 8 PPP1R3B rs9987289 G/A 1.011 (0.933-1.097) 0.011 (0.041) 7.84E-01 7481-9250 16731 
BPD rs10745954 G/A 12 ASCL1 rs10745954 G/A 0.981 (0.937-1.027) -0.019 (0.023) 4.08E-01 7481-9250 16731 
BPD rs1183910 A/G 12 HNF1A rs1183910 G/A 1.019 (0.97-1.07) 0.018 (0.025) 4.62E-01 7481-9250 16731 
BPD rs340029 C/T 15 RORA rs340029 T/C 1.01 (0.961-1.06) 0.009 (0.025) 7.07E-01 7481-9250 16731 
BPD rs1 521222 T/C 16 SALL1 rs10521222 T/C 1.017 (0.872-1.185) 0.016 (0.078) 8.34E-01 7481-9250 16731 
BPD rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.981 (0.936-1.028) -0.019 (0.024) 4.24E-01 7481-9250 16731 
BPD rs4420638 G/A 19 APOC1 rs4420638 G/A 1.07 (1.005-1.14) 0.068 (0.032) 3.53E-02 7481-9250 16731 
BPD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.935 (0.788-1.109) -0.067 (0.087) 4.39E-01 7481-9250 16731 
MDD rs12037222 G/A 1 PABPC4 rs2293476 G/C 1.017 (0.969-1.068) 0.017 (0.025) 4.88E-01 9240-9519 18759 
MDD rs4420065 T/C 1 LEPR rs4420065 C/T 0.962 (0.921-1.004) -0.039 (0.022) 7.48E-02 9240-9519 18759 
















N Controls N Total 
AUT 2847281 8 PTPN2 ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
AUT 4420638 G A 9 APOC1 4420638 T C 0 87 (─-─) -0.14 (4. 28) 3 47 2 90-1476 566 
AUT 18 961 T C 20 HNF4A ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
2037 G A  P BPC4 2037 G A 38 983 097 37 2 1 81
4420065 T C  LEPR 4420065 T C  (0.935-1.028) 2 (0.024) 13
1 9267 T C  IL6R 1 9267 T C 41 (0.993-1.091) 4 (0.024) 9 16
2794520 1 CRP 27 4520 1 054 1 004 6 0.052 (0.025) 3 25 2
BPD 2 9046 T C NLRP3 1 2 9046 T  42 88 99 41 7 1 30 7481 250 6 31
BPD 126 326 C T 2 GCK 126 326 T C 3 (0.887-0.974) 73 4 2 31 3 7481 250 6 31
BPD rs6734238 A/G 2 IL1F10 rs6734238 G/A 0.993 (0.948-1.04) -0.007 (0.024) 7.65E-01 7481-9250 16731 
BPD rs4705952 A/G 5 IRF1 rs4705952 G/A 0.985 (0.927-1.046) -0.015 (0.031) 6.22E-01 7481-9250 16731 
BPD rs6901250 G/A 6 GPRC6A rs6901250 G/A 1.001 (0.953-1.051) 0.001 (0.025) 9.73E-01 7481-9250 16731 
BPD rs13233571 T/C 7 BCL7B rs13233571 T/C 0.963 (0.898-1.032) -0.038 (0.035) 2.85E-01 7481-9250 16731 
BPD rs9987289 A/G 8 PPP1R3B rs9987289 G/A 1.011 (0.933-1.097) 0.011 (0.041) 7.84E-01 7481-9250 16731 
BPD rs10745954 G/A 12 ASCL1 rs10745954 G/A 0.981 (0.937-1.027) -0.019 (0.023) 4.08E-01 7481-9250 16731 
BPD rs1183910 A/G 12 HNF1A rs1183910 G/A 1.019 (0.97-1.07) 0.018 (0.025) 4.62E-01 7481-9250 16731 
BPD rs340029 C/T 15 RORA rs340029 T/C 1.01 (0.961-1.06) 0.009 (0.025) 7.07E-01 7481-9250 16731 
BPD rs10521222 T/C 16 SALL1 rs10521222 T/C 1.017 (0.872-1.185) 0.016 (0.078) 8.34E-01 7481-9250 16731 
BPD rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.981 (0.936-1.028) -0.019 (0.024) 4.24E-01 7481-9250 16731 
BPD rs4420638 G/A 19 APOC1 rs4420638 G/A 1.07 (1.005-1.14) 0.068 (0.032) 3.53E-02 7481-9250 16731 
BPD rs1800961 T/C 20 HNF4A rs1800961 T/C 0.935 (0.788-1.109) -0.067 (0.087) 4.39E-01 7481-9250 16731 
MDD rs12037222 G/A 1 PABPC4 rs2293476 G/C 1.017 (0.969-1.068) 0.017 (0.025) 4.88E-01 9240-9519 18759 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
MDD rs4129267 T/C 1 IL6R rs4129267 C/T 1.002 (0.96-1.046) 0.002 (0.022) 9.22E-01 9240-9519 18759 
MDD rs2794520 T/C 1 CRP rs2794520 C/T 0.995 (0.952-1.039) -0.006 (0.023) 8.08E-01 9240-9519 18759 
MDD rs12239046 T/C 1 NLRP3 rs12239046 C/T 0.971 (0.929-1.014) -0.03 (0.022) 1.86E-01 9240-9519 18759 
MDD rs1260326 C/T 2 GCKR rs1260326 C/T 0.998 (0.956-1.042) -0.002 (0.022) 9.38E-01 9240-9519 18759 
MDD rs6734238 A/G 2 IL1F10 rs6734238 G/A 0.997 (0.955-1.039) -0.003 (0.022) 8.73E-01 9240-9519 18759 
MDD rs4705952 A/G 5 IRF1 rs4705952 G/A 0.98 (0.931-1.032) -0.02 (0.026) 4.42E-01 9240-9519 18759 
MDD rs6901250 G/A 6 GPRC6A rs6901250 G/A 0.988 (0.943-1.035) -0.012 (0.024) 6.06E-01 9240-9519 18759 
MDD rs13233571 T/C 7 BCL7B rs13233571 C/T 1.006 (0.942-1.074) 0.006 (0.034) 8.58E-01 9240-9519 18759 
MDD rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs10745954 G/A 12 ASCL1 rs7972145 C/T 1.023 (0.981-1.066) 0.023 (0.021) 2.79E-01 9240-9519 18759 
MDD rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs340029 C/T 15 RORA rs340029 C/T 1.041 (0.997-1.087) 0.04 (0.022) 6.75E-02 9240-9519 18759 
MDD rs10521222 T/C 16 SALL1 rs10521222 C/T 1.006 (0.904-1.119) 0.006 (0.054) 9.19E-01 9240-9519 18759 
MDD rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.993 (0.951-1.036) -0.007 (0.022) 7.37E-01 9240-9519 18759 
MDD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs1800961 T/C 20 HNF4A rs1800961 C/T 1.021 (0.887-1.176) 0.021 (0.072) 7.77E-01 9240-9519 18759 
SCZ rs12037222 G/A 1 PABPC4 rs2293476 G/C 0.99 (0.966-1.015) -0.01 (0.013) 4.81E-02 34241-45604 79845 
SCZ rs4420065 T/C 1 LEPR rs4420065 C/T 1.023 (1.001-1.045) 0.022 (0.011) 9.39E-02 34241-45604 79845 
SCZ rs4129267 T/C 1 IL6R rs4129267 C/T 1.026 (1.005-1.048) 0.026 (0.011) 1.95E-01 34241-45604 79845 
SCZ rs2794520 T/C 1 CRP rs2794520 C/T 1.022 (1-1.045) 0.022 (0.011) 3.18E-01 34241-45604 79845 
SCZ rs12239046 T/C 1 NLRP3 rs12239046 C/T 1.003 (0.982-1.025) 0.003 (0.011) 9.14E-01 34241-45604 79845 
SCZ rs1260326 C/T 2 GCKR rs1260326 C/T 0.994 (0.973-1.015) -0.006 (0.011) 2.12E-02 34241-45604 79845 
SCZ rs6734238 A/G 2 IL1F10 rs6734238 G/A 1.003 (0.981-1.025) 0.003 (0.011) 9.44E-01 34241-45604 79845 
















N Controls N Total 
1 9267 T C  IL6R rs4129267 C T 1.002 (0.96-1.046) 0.002 (0.022) 9.22E-01 9240-9519 18759 
2794520 1 CRP 2794520 0 995 952 039 -0.006 (0.023) 8 08
MDD 2 9046 T C NLRP3 1 2 9046 C T 71 (0.929-1.014) 3 22 1 6 1 9240-9519 18759
MDD 126 326 C T 2 GCK 126 326 0 998 0 956 2 -0.002 (0.022) 8 1 9240-9519 18759
MDD 6734 38 A G 2 1F10 6734 38 G A 0 997 0 95 39 -0.003 (0.022) 8 73 9240-9519 18759
MDD 4 05952 A G 5 IRF1 4 05952 G A 0 98 (0.931-1.032) -0.02 (0. 26) 4 42 9240-9519 18759
MDD 6901250 G A 6 GP C6A 6901250 G A 0 988 43 3 -0.012 (0.024) 6 06 9240-9519 18759
MDD 323 571 T C 7 B L7B 323 571 1 006 42 74 0.006 (0.034) 8 58 1 9240-9519 18759
MDD 9987 89 8 PPP1R3B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs10745954 G/A 12 ASCL1 rs7972145 C/T 1.023 (0.981-1.066) 0.023 (0.021) 2.79E-01 9240-9519 18759 
MDD rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs340029 C/T 15 RORA rs340029 C/T 1.041 (0.997-1.087) 0.04 (0.022) 6.75E-02 9240-9519 18759 
MDD rs10521222 T/C 16 SALL1 rs10521222 C/T 1.006 (0.904-1.119) 0.006 (0.054) 9.19E-01 9240-9519 18759 
MDD rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.993 (0.951-1.036) -0.007 (0.022) 7.37E-01 9240-9519 18759 
MDD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs1800961 T/C 20 HNF4A rs1800961 C/T 1.021 (0.887-1.176) 0.021 (0.072) 7.77E-01 9240-9519 18759 
SCZ rs12037222 G/A 1 PABPC4 rs2293476 G/C 0.99 (0.966-1.015) -0.01 (0.013) 4.81E-02 34241-45604 79845 
SCZ rs4420065 T/C 1 LEPR rs4420065 C/T 1.023 (1.001-1.045) 0.022 (0.011) 9.39E-02 34241-45604 79845 
SCZ rs4129267 T/C 1 IL6R rs4129267 C/T 1.026 (1.005-1.048) 0.026 (0.011) 1.95E-01 34241-45604 79845 
SCZ rs2794520 T/C 1 CRP rs2794520 C/T 1.022 (1-1.045) 0.022 (0.011) 3.18E-01 34241-45604 79845 
SCZ rs12239046 T/C 1 NLRP3 rs12239046 C/T 1.003 (0.982-1.025) 0.003 (0.011) 9.14E-01 34241-45604 79845 
SCZ rs1260326 C/T 2 GCKR rs1260326 C/T 0.994 (0.973-1.015) -0.006 (0.011) 2.12E-02 34241-45604 79845 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































N Controls N Total 
SCZ rs4705952 A/G 5 IRF  rs4705952 G/A 1.003 (0.98-1.027) 0.003 (0.012) 4.56E-01 34241-45604 79845 
SCZ rs6901250 G/A 6 GPRC6A rs6 01250 G/A 0.987 (0.965-1.009) -0.013 (0.011) 5.31E-01 34241-45604 79845 
SCZ rs13233571 T/C 7 BCL7B rs 3233571 C/T 0.987 (0.955-1.02) -0.013 (0.017) 3.26E-01 34241-45604 79845 
SCZ rs9987289 A/G 8 PPP R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs1 745954 G/A 12 ASCL1 rs7 72145 C/T 0.982 (0.962-1.003) -0.018 (0.011) 7.44E-03 34241-45604 79845 
SCZ rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs340029 C/T 15 RORA rs340029 C/T 1.004 (0.983-1.027) 0.004 (0.011) 9.05E-01 34241-45604 79845 
SCZ rs1 521222 T/C 16 SALL1 rs 0521222 C/T 1.009 (0.947-1.076) 0.009 (0.033) 2.89E-01 34241-45604 79845 
SCZ rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.011 (0.99-1.033) 0.011 (0.011) 2.81E-01 34241-45604 79845 
SCZ rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs1800961 T/C 20 HNF4A rs1800961 C/T 0.97 (0.914-1.029) -0.031 (0.03) 8.78E-01 34241-45604 79845 
 
SNP indicates single nucleotide polymorphism; Requested SNP Alleles, lowering allele/increasing allele respectively; Chr, 
chromosome; Lookup SNP Alleles, non-coded allele/coded allele respectively; Odds Ratio, Odds Ratio (95% Confidence 
Interval) for  coded allele; and Beta (SE), effect size (standard error) for  coded allele. 
Disease/trait abbreviations: CED indicates Celiac Disease; IBD, Inflammatory Bowel Disease (all types); CD, Crohn's Disease; 
UC, Ulcerative Colitis; PSV, Psoriasis Vulgaris; PSA, Psoriatic Arthritis; PSC, Psoriasis Cutaneous; RA, Rheumatoid Arthritis; 
SLE, Systemic Lupus Erythematosus; SSC, Systemic Sclerosis; T1D, Type 1 Diabetes; KOA, Knee Osteoarthritis; CAD, Coronary 
Artery Disease; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; IS, Ischemic Stroke (all types); IS (CS), Ischemic 
Stroke (Cardioembloic); IS (LVS), Ischemic Stroke (Large Vessel); IS (SVD), Ischemic Stroke (Small Vessel); BMI, Body Mass 
Index; T2D, Type 2 Diabetes; CKD, Chronic Kidney Disease; eGFR, eGFR for creatinine; SA, Serum Albumin Levels; SP, Serum 
Protein Levels; ALS, Amyotrophic Lateral Sclerosis; ALZ, Alzheimer's Disease; PKD, Parkinsons's Disease; AUT, Autism; BPD, 
Bipolar Disorder; MDD, Major Depressive Disorder; and SCZ, Schizophrenia.  
















N Controls N Total 
SCZ rs4705952 A/G 5 IRF  rs4705952 G/A 1.003 (0.98-1.027) 0.003 (0.012) 4.56E-01 34241-45604 79845 
SCZ rs6901250 G/A 6 GPRC6A rs6 01250 G/A 0.987 (0.965-1.009) -0.013 (0.011) 5.31E-01 34241-45604 79845 
SCZ rs13233571 T/C 7 BCL7B rs 3233571 C/T 0.987 (0.955-1.02) -0.013 (0.017) 3.26E-01 34241-45604 79845 
SCZ rs9987289 A/G 8 PPP R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs1 745954 G/A 12 ASCL1 rs7 72145 C/T 0.982 (0.962-1.003) -0.018 (0.011) 7.44E-03 34241-45604 79845 
SCZ rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs340029 C/T 15 RORA rs34 029 C/T 1.004 (0.983-1.027) 0.004 (0.011) 9.05E-01 34241-45604 79845 
SCZ rs1 521222 T/C 16 SALL1 rs 0521222 /T 1.009 (0.947-1.076) 0.009 (0.033) 2.89E-01 34241-45604 79845 
SCZ rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.011 (0.99-1.033) 0.011 (0.011) 2.81E-01 34241-45604 79845 
SCZ rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs1800961 T/C 20 HNF4A rs1800961 C/T 0.97 (0.914-1.029) -0.031 (0.03) 8.78E-01 34241-45604 79845 
 
SNP indicates single nucleotide polymorphism; Requested SNP Alleles, lowering allele/increasing allele respectively; Chr, 
chromosome; Lookup SNP Alleles, non-coded allele/coded allele respectively; Odds Ratio, Odds Ratio (95% Confidence 
Interval) for  coded allele; and Beta (SE), effect size (standard error) for  coded allele. 
Disease/trait abbreviations: CED indicates Celiac Disease; IBD, Inflammatory Bowel Disease (all types); CD, Crohn's Disease; 
UC, Ulcerative olitis; PSV, Psoriasis Vulgaris; PSA, Psoriatic Arthritis; PSC, Psoriasis Cutaneous; RA, Rheumatoid Arthritis; 
SLE, Systemic Lupus Erythematosus; SSC, Systemic Sclerosis; T1D, Type 1 Diabetes; KOA, Knee Osteoarthritis; CAD, Coronary 
Artery Disease; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; IS, Ischemic Stroke (all types); IS (CS), Ischemic 
Stroke (Cardioembloic); IS (LVS), Ischemic Stroke (Large Vessel); IS (SVD), Ischemic Stroke (Small Vessel); BMI, Body Mass 
Index; T2D, Type 2 Diabetes; CKD, Chronic Kidney Disease; eGFR, eGFR for creatinine; SA, Serum Albumin Levels; SP, Serum 
Protein Levels; ALS, Amyotrophic Lateral Sclerosis; ALZ, Alzheimer's Disease; PKD, Parkinsons's Disease; AUT, Autism; BPD, 
Bipolar Disorder; MDD, Major Depressive Disorder; and SCZ, Schizophrenia.  
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N Controls N Total 
MDD rs4129267 T/C 1 IL6R rs4129267 C/T 1.002 (0.96-1.046) 0.002 (0.022) 9.22E-01 9240-9519 18759 
MDD rs2794520 T/C 1 CRP rs2794520 C/T 0.995 (0.952-1.039) -0.006 (0.023) 8.08E-01 9240-9519 18759 
MDD rs12239046 T/C 1 NLRP3 rs12239046 C/T 0.971 (0.929-1.014) -0.03 (0.022) 1.86E-01 9240-9519 18759 
MDD rs1260326 C/T 2 GCKR rs1260326 C/T 0.998 (0.956-1.042) -0.002 (0.022) 9.38E-01 9240-9519 18759 
MDD rs6734238 A/G 2 IL1F10 rs6734238 G/A 0.997 (0.955-1.039) -0.003 (0.022) 8.73E-01 9240-9519 18759 
MDD rs4705952 A/G 5 IRF1 rs4705952 G/A 0.98 (0.931-1.032) -0.02 (0.026) 4.42E-01 9240-9519 18759 
MDD rs6901250 G/A 6 GPRC6A rs6901250 G/A 0.988 (0.943-1.035) -0.012 (0.024) 6.06E-01 9240-9519 18759 
MDD rs13233571 T/C 7 BCL7B rs13233571 C/T 1.006 (0.942-1.074) 0.006 (0.034) 8.58E-01 9240-9519 18759 
MDD rs9987289 A/G 8 PPP1R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs10745954 G/A 12 ASCL1 rs7972145 C/T 1.023 (0.981-1.066) 0.023 (0.021) 2.79E-01 9240-9519 18759 
MDD rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs340029 C/T 15 RORA rs340029 C/T 1.041 (0.997-1.087) 0.04 (0.022) 6.75E-02 9240-9519 18759 
MDD rs10521222 T/C 16 SALL1 rs10521222 C/T 1.006 (0.904-1.119) 0.006 (0.054) 9.19E-01 9240-9519 18759 
MDD rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.993 (0.951-1.036) -0.007 (0.022) 7.37E-01 9240-9519 18759 
MDD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs1800961 T/C 20 HNF4A rs1800961 C/T 1.021 (0.887-1.176) 0.021 (0.072) 7.77E-01 9240-9519 18759 
SCZ rs12037222 G/A 1 PABPC4 rs2293476 G/C 0.99 (0.966-1.015) -0.01 (0.013) 4.81E-02 34241-45604 79845 
SCZ rs4420065 T/C 1 LEPR rs4420065 C/T 1.023 (1.001-1.045) 0.022 (0.011) 9.39E-02 34241-45604 79845 
SCZ rs4129267 T/C 1 IL6R rs4129267 C/T 1.026 (1.005-1.048) 0.026 (0.011) 1.95E-01 34241-45604 79845 
SCZ rs2794520 T/C 1 CRP rs2794520 C/T 1.022 (1-1.045) 0.022 (0.011) 3.18E-01 34241-45604 79845 
SCZ rs12239046 T/C 1 NLRP3 rs12239046 C/T 1.003 (0.982-1.025) 0.003 (0.011) 9.14E-01 34241-45604 79845 
SCZ rs1260326 C/T 2 GCKR rs1260326 C/T 0.994 (0.973-1.015) -0.006 (0.011) 2.12E-02 34241-45604 79845 
SCZ rs6734238 A/G 2 IL1F10 rs6734238 G/A 1.003 (0.981-1.025) 0.003 (0.011) 9.44E-01 34241-45604 79845 
















N Controls N Total 
1 9267 T C  IL6R rs4129267 C T 1.002 (0.96-1.046) 0.002 (0.022) 9.22E-01 9240-9519 18759 
2794520 1 CRP 2794520 0 995 952 039 -0.006 (0.023) 8 08
MDD 2 9046 T C NLRP3 1 2 9046 C T 71 (0.929-1.014) 3 22 1 6 1 9240-9519 18759
MDD 126 326 C T 2 GCK 126 326 0 998 0 956 2 -0.002 (0.022) 8 1 9240-9519 18759
MDD 6734 38 A G 2 1F10 6734 38 G A 0 997 0 95 39 -0.003 (0.022) 8 73 9240-9519 18759
MDD 4 05952 A G 5 IRF1 4 05952 G A 0 98 (0.931-1.032) -0.02 (0. 26) 4 42 9240-9519 18759
MDD 6901250 G A 6 GP C6A 6901250 G A 0 988 43 3 -0.012 (0.024) 6 06 9240-9519 18759
MDD 323 571 T C 7 B L7B 323 571 1 006 42 74 0.006 (0.034) 8 58 1 9240-9519 18759
MDD 9987 89 8 PPP1R3B ─ ─ ─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs10745954 G/A 12 ASCL1 rs7972145 C/T 1.023 (0.981-1.066) 0.023 (0.021) 2.79E-01 9240-9519 18759 
MDD rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs340029 C/T 15 RORA rs340029 C/T 1.041 (0.997-1.087) 0.04 (0.022) 6.75E-02 9240-9519 18759 
MDD rs10521222 T/C 16 SALL1 rs10521222 C/T 1.006 (0.904-1.119) 0.006 (0.054) 9.19E-01 9240-9519 18759 
MDD rs2847281 G/A 18 PTPN2 rs2847281 G/A 0.993 (0.951-1.036) -0.007 (0.022) 7.37E-01 9240-9519 18759 
MDD rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
MDD rs1800961 T/C 20 HNF4A rs1800961 C/T 1.021 (0.887-1.176) 0.021 (0.072) 7.77E-01 9240-9519 18759 
SCZ rs12037222 G/A 1 PABPC4 rs2293476 G/C 0.99 (0.966-1.015) -0.01 (0.013) 4.81E-02 34241-45604 79845 
SCZ rs4420065 T/C 1 LEPR rs4420065 C/T 1.023 (1.001-1.045) 0.022 (0.011) 9.39E-02 34241-45604 79845 
SCZ rs4129267 T/C 1 IL6R rs4129267 C/T 1.026 (1.005-1.048) 0.026 (0.011) 1.95E-01 34241-45604 79845 
SCZ rs2794520 T/C 1 CRP rs2794520 C/T 1.022 (1-1.045) 0.022 (0.011) 3.18E-01 34241-45604 79845 
SCZ rs12239046 T/C 1 NLRP3 rs12239046 C/T 1.003 (0.982-1.025) 0.003 (0.011) 9.14E-01 34241-45604 79845 
SCZ rs1260326 C/T 2 GCKR rs1260326 C/T 0.994 (0.973-1.015) -0.006 (0.011) 2.12E-02 34241-45604 79845 
SCZ rs6734238 A/G 2 IL1F10 rs6734238 G/A 1.003 (0.981-1.025) 0.003 (0.011) 9.44E-01 34241-45604 79845 
















N Controls N Total 
SCZ rs4705952 A/G 5 IRF  rs4705952 G/A 1.003 (0.98-1.027) 0.003 (0.012) 4.56E-01 34241-45604 79845 
SCZ rs6901250 G/A 6 GPRC6A rs6 01250 G/A 0.987 (0.965-1.009) -0.013 (0.011) 5.31E-01 34241-45604 79845 
SCZ rs13233571 T/C 7 BCL7B rs 3233571 C/T 0.987 (0.955-1.02) -0.013 (0.017) 3.26E-01 34241-45604 79845 
SCZ rs9987289 A/G 8 PPP R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs1 745954 G/A 12 ASCL1 rs7 72145 C/T 0.982 (0.962-1.003) -0.018 (0.011) 7.44E-03 34241-45604 79845 
SCZ rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs340029 C/T 15 RORA rs340029 C/T 1.004 (0.983-1.027) 0.004 (0.011) 9.05E-01 34241-45604 79845 
SCZ rs1 521222 T/C 16 SALL1 rs 0521222 C/T 1.009 (0.947-1.076) 0.009 (0.033) 2.89E-01 34241-45604 79845 
SCZ rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.011 (0.99-1.033) 0.011 (0.011) 2.81E-01 34241-45604 79845 
SCZ rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs1800961 T/C 20 HNF4A rs1800961 C/T 0.97 (0.914-1.029) -0.031 (0.03) 8.78E-01 34241-45604 79845 
 
SNP indicates single nucleotide polymorphism; Requested SNP Alleles, lowering allele/increasing allele respectively; Chr, 
chromosome; Lookup SNP Alleles, non-coded allele/coded allele respectively; Odds Ratio, Odds Ratio (95% Confidence 
Interval) for  coded allele; and Beta (SE), effect size (standard error) for  coded allele. 
Disease/trait abbreviations: CED indicates Celiac Disease; IBD, Inflammatory Bowel Disease (all types); CD, Crohn's Disease; 
UC, Ulcerative Colitis; PSV, Psoriasis Vulgaris; PSA, Psoriatic Arthritis; PSC, Psoriasis Cutaneous; RA, Rheumatoid Arthritis; 
SLE, Systemic Lupus Erythematosus; SSC, Systemic Sclerosis; T1D, Type 1 Diabetes; KOA, Knee Osteoarthritis; CAD, Coronary 
Artery Disease; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; IS, Ischemic Stroke (all types); IS (CS), Ischemic 
Stroke (Cardioembloic); IS (LVS), Ischemic Stroke (Large Vessel); IS (SVD), Ischemic Stroke (Small Vessel); BMI, Body Mass 
Index; T2D, Type 2 Diabetes; CKD, Chronic Kidney Disease; eGFR, eGFR for creatinine; SA, Serum Albumin Levels; SP, Serum 
Protein Levels; ALS, Amyotrophic Lateral Sclerosis; ALZ, Alzheimer's Disease; PKD, Parkinsons's Disease; AUT, Autism; BPD, 
Bipolar Disorder; MDD, Major Depressive Disorder; and SCZ, Schizophrenia.  
















N Controls N Total 
SCZ rs4705952 A/G 5 IRF  rs4705952 G/A 1.003 (0.98-1.027) 0.003 (0.012) 4.56E-01 34241-45604 79845 
SCZ rs6901250 G/A 6 GPRC6A rs6 01250 G/A 0.987 (0.965-1.009) -0.013 (0.011) 5.31E-01 34241-45604 79845 
SCZ rs13233571 T/C 7 BCL7B rs 3233571 C/T 0.987 (0.955-1.02) -0.013 (0.017) 3.26E-01 34241-45604 79845 
SCZ rs9987289 A/G 8 PPP R3B ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs1 745954 G/A 12 ASCL1 rs7 72145 C/T 0.982 (0.962-1.003) -0.018 (0.011) 7.44E-03 34241-45604 79845 
SCZ rs1183910 A/G 12 HNF1A ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs340029 C/T 15 RORA rs34 029 C/T 1.004 (0.983-1.027) 0.004 (0.011) 9.05E-01 34241-45604 79845 
SCZ rs1 521222 T/C 16 SALL1 rs 0521222 /T 1.009 (0.947-1.076) 0.009 (0.033) 2.89E-01 34241-45604 79845 
SCZ rs2847281 G/A 18 PTPN2 rs2847281 G/A 1.011 (0.99-1.033) 0.011 (0.011) 2.81E-01 34241-45604 79845 
SCZ rs4420638 G/A 19 APOC1 ─ ─/─ ─ (─-─) ─ (─) ─ ─-─ ─ 
SCZ rs1800961 T/C 20 HNF4A rs1800961 C/T 0.97 (0.914-1.029) -0.031 (0.03) 8.78E-01 34241-45604 79845 
 
SNP indicates single nucleotide polymorphism; Requested SNP Alleles, lowering allele/increasing allele respectively; Chr, 
chromosome; Lookup SNP Alleles, non-coded allele/coded allele respectively; Odds Ratio, Odds Ratio (95% Confidence 
Interval) for  coded allele; and Beta (SE), effect size (standard error) for  coded allele. 
Disease/trait abbreviations: CED indicates Celiac Disease; IBD, Inflammatory Bowel Disease (all types); CD, Crohn's Disease; 
UC, Ulcerative Colitis; PSV, Psoriasis Vulgaris; PSA, Psoriatic Arthritis; PSC, Psoriasis Cutaneous; RA, Rheumatoid Arthritis; 
SLE, Systemic Lupus Erythematosus; SSC, Systemic Sclerosis; T1D, Type 1 Diabetes; KOA, Knee Osteoarthritis; CAD, Coronary 
Artery Disease; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; IS, Ischemic Stroke (all types); IS (CS), Ischemic 
Stroke (Cardioembloic); IS (LVS), Ischemic Stroke (Large Vessel); IS (SVD), Ischemic Stroke (Small Vessel); BMI, Body Mass 
Index; T2D, Type 2 Diabetes; CKD, Chronic Kidney Disease; eGFR, eGFR for creatinine; SA, Serum Albumin Levels; SP, Serum 
Protein Levels; ALS, Amyotrophic Lateral Sclerosis; ALZ, Alzheimer's Disease; PKD, Parkinsons's Disease; AUT, Autism; BPD, 
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Supplementary Figure S1 GRS plots. For each disease / trait we show the plots for two genetic risk scores ; on the left the 
GRSCRP and on the right GRSGWAS. For every graph, the estimated effects on disease risk (log odds) or trait level (vertical axis) are 
plotted against estimated effects on the natural log CRP levels (mg/ml) (horizontal axis), for either the GRSCRP SNPs or GRSGWAS 
SNPs that are associated with CRP levels. The grey vertical lines indicate the 95% confidence interval (CI) for each individual 
SNP. The effect estimate of CRP levels on disease risk or trait level is represented by a solid line with gradient α. The 95% CI of 
this α estimate is represented by dashed lines. 
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plotted against estimated effects on the natural log CRP levels (mg/ml) (horizontal axis), for either the GRSCRP SNPs or GRSGWAS 
SNPs that are associated with CRP levels. The grey vertical lines indicate the 95% confidence interval (CI) for each individual 
SNP. The effect estimate of CRP levels on disease risk or trait level is represented by a solid line with gradient α. The 95% CI of 
this α estimate is represented by dashed lines. 
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Supplementary text S1. Extended methods. 
1.1 Calculation of the Alzheimer’s Disease GWAS summary statistics 
We received summary statistics (SNP, OR, SE, P, Reference Allele, Other Allele, 
OR 95 L ,OR 95 U) from the Genetic and Environmental Risk in Alzheimer's 
Disease (GERAD) consortium for three separate Alzheimer’s datasets; from the 
TGEN consortium, from the ADNI consortium, and from the GERAD 
consortium for up to 4663 cases and 8357 controls. We next performed an inverse 
variance weighted fixed effects analysis using GWAMA1 to calculate combined 
effect sizes and standard errors, which were subsequently used in our genetic risk 
scores. 
1.2 Calculation of the BMI GWAS summary statistics 
We downloaded sex-stratified summary statistics for BMI from Randall et.al 2. 
From: 
https://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files 
We next performed an inverse variance weighted fixed effects analysis using 
GWAMA1 to calculate combined effect sizes and standard errors, which were 
subsequently used in our genetic risk scores. 
 
1 Mägi R, Morris AP. GWAMA: software for genome-wide association meta-
analysis. BMC Bioinformatics. 2010 May 28;11:288.  
2 Randall JC. Sex-stratified genome-wide association studies including 270,000 
individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS 
Genet. 2013 Jun;9(6):e1003500. 
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Supplementary text S2 Additional acknowledgments and consortia related 
information. 
T1D GC study 
This manuscript was not prepared in collaboration with investigators of the 
T1DGC study, except for those listed as authors on the current manuscript, and 
does not necessarily reflect the opinions or views of the T1DGC study, the 
NIDDK Central Repositories, or the NIDDK. The Diabetes Control and 
Complications Trial (DCCT) and its follow-up the Epidemiology of Diabetes 
Interventions and Complications (EDIC) study were conducted by the 
DCCT/EDIC Research Group and supported by National Institute of Health 
grants and contracts and by the General Clinical Research Center Program, NCRR. 
The data from the DCCT/EDIC study were supplied by the NIDDK Central 
Repositories. This manuscript was not prepared under the auspices of the 
DCCT/EDIC study and does not represent analyses or conclusions of the 
DCCT/EDIC study group, the NIDDK Central Repositories, or the NIH. The 
Genetics of Kidneys in Diabetes (GoKinD) Study was conducted by the GoKinD 
Investigators and supported by the Juvenile Diabetes Research Foundation, the 
CDC, and the Special Statutory Funding Program for Type 1 Diabetes Research 
administered by the National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK). The data from the GoKinD study were supplied by the 
NIDDK Central Repositories. This manuscript was not prepared in collaboration 
with investigators of the GoKinD study and does not necessarily reflect the 
opinions or views of the GoKinD study, the NIDDK Central Repositories, or the 
NIDDK. This study makes use of data generated by the Wellcome Trust Case 
Control Consortium. A full list of the investigators who contributed to the 
generation of the data is available from www.wtccc.org.uk. Funding for the project 
was provided by the Wellcome Trust under award 076113. The funders had no role 
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Supplementary text S3 Consortia co-author lists. 
The Genetic and Environmental Risk for Alzheimer’s disease (GERAD1) 
Consortium 
Data used in the preparation of this article were obtained from the Genetic and 
Environmental Risk for Alzheimer’s disease (GERAD1) Consortium. As such, the 
investigators within the GERAD1 consortia contributed to the design and 
implementation of GERAD1 and/or provided data but did not participate in 
analysis or writing of this report. 
Collaborator: Denise Harold1, Rebecca Sims1, Amy Gerrish1, Jade Chapman1, 
Valentina Escott-Price1, Richard Abraham1, Paul Hollingworth1, Marian 
Hamshere1, Jaspreet Singh Pahwa1, Kimberley Dowzell1, Amy Williams1, Nicola 
Jones1, Charlene Thomas1, Alexandra Stretton1, Angharad Morgan1, Kate Williams1, 
Sarah Taylor1,Simon Lovestone2, John Powell2, Petroula Proitsi2, Michelle K 
Lupton2, Carol Brayne3, David C. Rubinsztein4, Michael Gill5, Brian Lawlor5, 
Aoibhinn Lynch5, Kevin Morgan6, Kristelle Brown6, Peter Passmore7, David Craig7, 
Bernadette McGuinness7, Janet A Johnston7, Stephen Todd7, Clive Holmes8, David 
Mann9, A. David Smith10, Seth Love11, Patrick G. Kehoe11, John Hardy12, Rita 
Guerreiro13,33, Andrew Singleton13, Simon Mead14, Nick Fox15, Martin Rossor15, 
John Collinge14, Wolfgang Maier16, Frank Jessen16, Reiner Heun16, Britta 
Schürmann16,17, Alfredo Ramirez16, Tim Becker34, Christine Herold34, André 
Lacour34, Dmitriy Drichel34, Hendrik van den Bussche18, Isabella Heuser19, 
Johannes Kornhuber20, Jens Wiltfang21, Martin Dichgans22,23, Lutz Frölich24, Harald 
Hampel25, Michael Hüll26, Dan Rujescu27, Alison Goate28, John S.K. Kauwe29, 
Carlos Cruchaga28, Petra Nowotny28, John C. Morris28, Kevin Mayo28, Gill 
Livingston30, Nicholas J. Bass30, Hugh Gurling30, Andrew McQuillin30, Rhian 
Gwilliam31, Panagiotis Deloukas31, Markus M. Nöthen32, Peter Holmans1, Michael 
ODonovan1, Michael J.Owen1, Julie Williams1. 
Affiliations: 1Medical Research Council (MRC) Centre for Neuropsychiatric 
Genetics and Genomics, Neurosciences and Mental Health Research Institute, 
Department of Psychological Medicine and Neurology, School of Medicine, Cardiff 
University, Cardiff, UK. 2Kings College London, Institute of Psychiatry, 
Department of Neuroscience, De Crespigny Park, Denmark Hill, London. 
3Institute of Public Health, University of Cambridge, Cambridge, UK. 4Cambridge 
Institute for Medical Research, University of Cambridge, Cambridge, UK. 5Mercers 
Institute for Research on Aging, St. James Hospital and Trinity College, Dublin, 
Ireland. 6Institute of Genetics, Queens Medical Centre, University of Nottingham, 
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UK. 7Ageing Group, Centre for Public Health, School of Medicine, Dentistry and 
Biomedical Sciences, Queens University Belfast, UK. 8Division of Clinical 
Neurosciences, School of Medicine, University of Southampton, Southampton, 
UK. 9Clinical Neuroscience Research Group, Greater Manchester Neurosciences 
Centre, University of Manchester, Salford, UK. 10Oxford Project to Investigate 
Memory and Ageing (OPTIMA), University of Oxford, Department of 
Pharmacology, Mansfield Road, Oxford, UK. 11University of Bristol Institute of 
Clinical Neurosciences, School of Clinical Sciences, Frenchay Hospital, Bristol, UK. 
12Department of Molecular Neuroscience and Reta Lilla Weston Laboratories, 
Institute of Neurology, UCL, London, UK. 13Laboratory of Neurogenetics, 
National Institute on Aging, National Institutes of Health, Bethesda, Maryland, 
United States of America. 14MRC Prion Unit, Department of Neurodegenerative 
Disease, UCL Institute of Neurology, London, UK. 15Dementia Research Centre, 
Department of Neurodegenerative Diseases, University College London, Institute 
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Alexander-University Erlangen-Nürnberg, Germany. 21Department of Psychiatry 
and Psychotherapy, University Medical Center (UMG), Georg-August-University, 
Göttingen, Germany. 22Institute for Stroke and Dementia Reserach, Klinikum der 
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Germany. 28Departments of Psychiatry, Neurology and Genetics, Washington 
University School of Medicine, St Louis, MO 63110, US. 29Department of Biology, 
Brigham Young University, Provo, UT, 84602, USA. 30Department of Mental 
Health Sciences, University College London, UK. 31The Wellcome Trust Sanger 
Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. 
32Department of Genomics, Life & Brain Center, University of Bonn, Bonn, 
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